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Abstract 
Elderly and type 2 diabetes mellitus (T2DM) patients with stable coronary artery 
disease (CAD) have increased risk of atherothrombotic events despite recommended 
secondary prevention therapy. High platelet reactivity drives this risk. Novel 
approaches to antiplatelet therapy are needed. 
Objectives: 
To: 
 determine the effect of age and T2DM on blood thrombogenicity and response 
to dual antiplatelet therapy in stable CAD  
 assess the effect of changes in platelet count on thrombus quantity and quality 
with Rafigrelide 
Methods: 
Study 1: Patients with stable CAD, 4 groups: age<75 non-DM, age≥75 T2DM, age≥75 
non-DM and age<75 T2DM studied at baseline and one week after clopidogrel. I 
performed Badimon chamber study, thromboelastography, VerifyNow® and 
Multiplate® aggregometry, coagulation and inflammatory biomarkers and scanning 
electron microscopy. 
Study 2: Twelve volunteers took Rafigrelide (novel platelet lowering agent) singly and 
then with aspirin. I performed Badimon chamber study and thromboelastography at 
pre-defined intervals. 
Results: 
Study 1: At baseline and after clopidogrel therapy, there was no difference in thrombus 
area between the four groups. Serum TNFα levels were higher in elderly T2DM 
patients. Other coagulation and inflammatory markers were similar between the 
groups. Clopidogrel reduced thrombus area, lowered platelet content of thrombus and 
increased fibrin diameter and density in all four groups. Elderly and T2DM patients 
demonstrated high platelet reactivity and hyporesponsiveness to clopidogrel. 
Significant reduction in thrombus area was demonstrated both in good- and hypo-
responders to clopidogrel. Point of care tests and thrombus area showed no 
correlation. Post chamber blood confirmed release of P selectin, CD40 ligand and PAI-
1 from activated platelets. 
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Study 2: Rafigrelide reduced platelet count and thrombus area, delayed initiation of 
clot formation and reduced over all clot strength. Platelet count positively correlated 
with thrombus area. 
Conclusion: 
Elderly and T2DM patients had similar over all blood thrombogenicity but higher 
platelet reactivity when compared to young and non-diabetic patients. Addition of 
clopidogrel reduced thrombus area with ultrastructural changes in fibrin favouring 
fibrinolysis. Reduction in platelet count with Rafigrelide reduced thrombus formation 
and lowered viscoelastic strength. Dual antiplatelet therapy and novel therapeutic 
strategies may reduce future thrombotic risk in these high risk populations.  
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Chapter 1  Introduction 
1.1  Epidemiology and Pathogenesis of Coronary Artery Disease (CAD) 
1.1.1 Epidemiology of Cardiovascular Disease 
Over the last decade, cardiovascular disease (CVD) has become the single largest 
cause of death worldwide. In 2004, CVD caused an estimated 17 million deaths and 
led to 151 million disability-adjusted life years (DALYs) lost – about 30% of all deaths 
and 14% of all DALYs that year ('World Health Organization: The Global Burden of 
Disease: 2004 Update.,' 2008). During the last century, similar to the high-income 
countries, an alarming increase in the rates of CVD has been observed in low- and 
middle-income countries and this change is accelerating. In approximately 38 % of 
individuals in high-income countries, death is due to CVD. 
In high-income countries, despite the overall increase in CVD burden, the age adjusted 
death rates from CVD are declining, predominantly due to large stroke rate reductions. 
Almost 80% of deaths occur in those older than 60 years compared with 42% in low- 
and middle-income countries (Lopez et al., 2006). 
In Europe, CVD is the main cause of death: accounting for over 4.30 million deaths 
each year. Nearly half (48%) of all deaths are from CVD (54% of deaths in women and 
43% of deaths in men). The main forms of CVD are coronary artery disease (CAD) and 
stroke. CAD by itself is the single most common cause of death in Europe: accounting 
for 1.92 million deaths each year. 20% of deaths before the age of 75 in men and 19% 
of deaths before the age of 75 in women are from CAD (Nichols et al., 2012). In 2001, 
75% of global deaths and 82% of total DALYs lost because of CAD occurred in low- 
and middle-income countries (Lopez et al., 2006). Between 1990 and 2020, CAD 
deaths alone are anticipated to increase by 120% for women and 137% for men in 
developing countries (Leeder et al., 2004). 
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1.1.2 Diabetes and Cardiovascular disease 
Diabetes mellitus (DM) can be described as a metabolic disorder of multiple aetiologies 
characterised by chronic hyperglycaemia with disturbances of carbohydrate, fat, and 
protein metabolism resulting from defects of insulin secretion, insulin action, or a 
combination of both (DeFronzo, 2004). Clinical features include polydipsia, polyuria 
and weight loss. 
The World Health Organisation biochemical diagnostic criteria for diabetes are: 
i. Fasting plasma glucose ≥ 7.0 mmol/L and 
ii. Plasma glucose two hours after ingestion of 75 grams of oral glucose 
load ≥ 11.1 mmol/L 
In the presence of clinical features, one of the above is sufficient to make a diagnosis 
of DM (www.who.int/diabetes/publications/diagnosis_diabetes2006/en/, accessed on 
07th July 2015) 
iii. An HbA1c of 48mmol/mol (6.5%) is recommended as the cut off point 
for diagnosing diabetes. A value of less than 48mmol/mol (6.5%) does 
not exclude diabetes diagnosed using glucose tests.  
(www.who.int/diabetes/publications/diagnosis_diabetes2011/en/, accessed on 07th 
July 2015) 
The world prevalence of diabetes among adults (aged 20-79 years) was approximately 
6.4%, affecting 285 million adults in 2010 and is predicted to rise to 7.7%, affecting 439 
million adults by 2030 (Shaw et al., 2010). Between 2010 and 2030, there will be a 
69% increase in numbers of adults with diabetes in developing countries and a 20% 
increase in developed countries. Type 2 diabetes mellitus (T2DM) accounts for ninety 
percent of patients with diabetes (www.who.int/mediacentre/factsheets, accessed on 
07th July 2015). Insulin resistance usually precedes the onset of T2DM and is 
commonly accompanied by other related metabolic abnormalities such as 
hyperglycaemia, dyslipidaemia, hypertension, and pro-thrombotic factors, all of which 
contribute to the increased cardiovascular risk. This condition is called the metabolic 
syndrome (Hopkins et al., 1996; Gray et al., 1998). It is estimated that there will be 4 
million people in the UK with diabetes by 2025 and the majority will have type 2 
diabetes mellitus (T2DM). (www.diabetes.org.uk, Accessed 03rd Jan 2011) 
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1.1.3 Cardiovascular mortality and morbidity in type 2 diabetes mellitus (T2DM) 
Cardiovascular Disease (CVD), particularly coronary artery disease (CAD) resulting 
from accelerated atherosclerosis, is the leading cause of morbidity and mortality in 
patients with T2DM accounting for 80% of all causes of death (Fox et al., 2007). A 
large body of epidemiological and pathological data documents that diabetes is an 
important independent risk factor for CVD in both men and women (McGill and 
McMahan, 1998; Wilson et al., 1998). Patients with T2DM have a fivefold risk of 
developing CVD compared to non-diabetics (Preis et al., 2009).To make matters 
worse, when patients with diabetes develop clinical CVD, they have a poorer prognosis 
than the CVD patients without diabetes (Smith et al., 1984; Singer et al., 1989; Stone 
et al., 1989). Cardiovascular mortality in patients with DM without a history of prior MI 
is comparable to mortality in non-diabetic subjects with previous MI (Haffner et al., 
1998). Hence, diabetes has been classified as a coronary “risk equivalent” ('Third 
report of the National Cholestrol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholestrol in Adults (Adult 
Treatment Panel III) final report ', 2002). In general, women have lower prevalence of 
cardiovascular disease and age specific cardiovascular mortality. However, pre-
menopausal women with diabetes seem to not only lose most of their inherent 
protection against developing CVD but also have a poorer prognosis for cardiovascular 
illness (Brezinka and Padmos, 1994). Their mortality rates are 50% higher than in men 
(Mulnier et al., 2006; Kautzky-Willer et al., 2010). 
Despite a significant overall reduction in cardiovascular mortality over the last two 
decades due to improved aggressive secondary prevention strategies, the relative risk 
of cardiovascular mortality in patients with diabetes remains around 2.5, unchanged 
over the last fifty years (Hanefeld et al., 1996; Fox et al., 2007). Cardiovascular 
morbidity is difficult to estimate in patients with diabetes. However, cardiovascular 
disease is responsible for significant number of hospitalisations, prolonged in-hospital 
admissions and loss of quality adjusted life years (QALY) in patients with diabetes 
(Sampson et al., 2006). 
Coronary Artery Disease (CAD) accounts for the majority of cardiovascular events in 
patients with T2DM. CAD can present as acute coronary syndrome (unstable angina, 
non ST elevation and ST elevation acute myocardial infarction) and chronic stable 
angina. A significant number of patients with T2DM do not survive their first myocardial 
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event (Cho et al., 2002). Mortality rates for DM patients with acute MI are 1.5 - 2.0 
times those of non-DM patients. In hospital and 6 month mortality rates after an acute 
MI are highest among DM patients receiving insulin therapy. The negative impact of 
DM on the outcomes is maintained across the ACS spectrum, including unstable 
angina and non-ST elevation myocardial infarction (NSTEMI) (Yusuf et al., 2001b), ST 
elevation myocardial infarction (STEMI) treated medically (Mak et al., 1997) and ACS 
undergoing percutaneous coronary intervention (PCI) (Roffi and Topol, 2004). DM 
patients have more progressive, diffuse and multi vessel coronary disease compared 
to non-diabetic patients and have poorer outcomes after both PCI (especially with bare 
metal stent [BMS]) and coronary artery bypass graft surgery (CABG), compared to 
non-diabetic patients (Flaherty and Davidson, 2005). 
Following an acute cardiac event, patients with T2DM demonstrate higher incidence of 
recurrent cardiovascular events despite optimal secondary prevention therapy (Lee et 
al., 2004). For example, the 7 year incidence of recurrent MI in a large population 
based study was 45% in diabetic patients versus 19% in non-diabetic patients. 
Cardiovascular mortality during that period was 42.0% and 15.4% in DM patients with 
and without history of acute MI, respectively (Haffner et al., 1998). T2DM has been 
shown to be a strong independent predictor of mortality and recurrent cardiovascular 
events (Kotseva et al., 2010). The advent of drug eluting stents (DES) has improved 
PCI outcomes but the problem of atherothrombotic complications, including stent 
thrombosis, persists in diabetic patients (Cola et al., 2009). Patients with T2DM 
demonstrated higher rates of stent thrombosis following percutaneous coronary 
intervention (Machecourt et al., 2007). 
1.1.4 Risk factors for coronary artery disease in T2DM 
Increased prevalence of conventional risk factors such as hypertension, dyslipidaemia, 
central obesity, smoking and endothelial dysfunction, all contribute to higher adverse 
cardiovascular events in patients with T2DM (Eberly et al., 2003; Bhatt et al., 2010; 
Griffin et al., 2011) Hyperglycaemia may play an important role in increased 
atherothrombotic risk in DM patients. This has been supported by the Diabetes 
Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) trial. In this 
study, acute intensive glucose lowering therapy with insulin-glucose infusion led to a 
reduction in mortality after 3.4 years follow up in DM patients with acute myocardial 
infarction (Malmberg, 1997). In UKPDS follow up study, tighter control of 
5 
 
hyperglycaemia (HbA1c~7.0 %) reduced cardiovascular mortality over many years 
when begun in individuals with short-duration diabetes (Home, 2008; McGuire and 
Gore, 2009). However, in longstanding T2DM patients, long-term aggressive glucose 
lowering (glycated haemoglobin < 6.0 %) was associated with increased mortality in 
the Action of Control Cardiovascular Risk in Diabetes (ACCORD) study (Gerstein et 
al., 2008). This was supported by ADVANCE trial and VADT trial data (Patel et al., 
2008; Duckworth et al., 2009; Skyler et al., 2009). 
1.1.5 Ageing and Cardiovascular disease 
Ageing is a continuous and extremely complex multifactorial process that involves the 
interaction of genetic and environmental factors, and in which the incidence of 
diseases and the possibility of dying increases (Tosato et al., 2007). Ageing is a major 
cardiovascular risk factor and is a strong predictor of adverse outcomes after acute 
coronary syndrome. Coronary artery disease is the most common cause of death in 
the elderly. Due to increasing longevity and declining fertility, the geriatric population 
is rapidly expanding globally. At present, humans over age 65 years are more likely to 
be active and productive than at any other time in history, and life expectancy, disability 
rates, and health and wealth indicators have all shown significant improvement in the 
last 25 years.  
The US census bureau reported that average life expectancy has gone up from about 
47.3 years in 1900 to 77.9 years in 2004 and is estimated to increase to 79.2 years by 
2015. This increase appears to be largely due to improvements in health care, nutrition, 
and overall standard of living for most people. Population ageing represents a shift in 
the distribution of a country’s population towards greater ages. This shift is partly 
related to increased longevity, as a consequence of improvements in living conditions 
and health care. Considered as one of the most important human achievements, this 
shift is not only seen in the developed countries, but also in developing countries. The 
UN has projected that by 2025 there will be almost 1.2 billion elderly people living in 
the world, 71% of whom are likely to be in developing countries. Between 1950 and 
2025, the “Old” Old (those who are 80 years and above) will grow twice as fast as the 
60-plus-age group (Iliescu and Zanoschi, 2004). By 2030, 20% of the population will 
be aged 65 years or older (Muss, 2001). In 2020, the proportion of the population aged 
80 years and above is expected to range between 3.7% and 7.5% (Anderson and 
Hussey, 2000). 
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Ageing is an inevitable part of life and is an independent risk factor for the development 
of atherosclerosis that plays a significant role in the development of many 
cardiovascular disorders including coronary artery disease (CAD). Given the rapid 
growth of an ageing population worldwide, an increasing proportion of morbidity and 
mortality related to cardiovascular disorders is likely to occur in elderly patients. Both 
the prevalence and severity of atherosclerotic CAD increase with age in men and 
women. Autopsy studies show that more than half of people older than 60 years of age 
have significant CAD with increasing prevalence of left main or triple-vessel disease 
with older age. Estimates from electronic medical records report almost half of men 
older than 80 years of age have CAD, as do one third of women (Steinman et al., 
2012).  
Ageing unfortunately poses the largest risk factor for cardiovascular disease and CAD 
is the most common cause of death in the elderly. In fact, older people are not only 
more likely to develop acute myocardial infarction, but also more likely to die from it. 
Optimizing care for elderly patients with CAD constitutes both a central priority and a 
formidable challenge in contemporary medicine. The cost to treat cardiovascular 
diseases is estimated to get tripled in the next 15 years. Hence it remains vital that we 
understand why age is such a crucial component of CVD etiology. 
1.1.6 Cardiovascular disease mortality and morbidity in elderly  
The CRUSADE National Quality Improvement Initiative investigators 2005 report 
states that persons aged ≥ 75 years constitute <10% of the US population but they 
account for 35% of patients with non-ST segment elevation acute coronary syndromes 
(ACS). As expected, the prevalence of CAD is very high in the elderly population 
(Aronow, 1999). Elderly patients presenting with ACS including unstable angina and 
non-ST segment myocardial infarction (NSTEMI) have a very high prevalence of 
coronary risk factors (Woodworth et al., 2002).  
In the United Kingdom in 2008, more than twice as many individuals >75 years of age 
(n = 55,028) died from IHD compared to younger individuals ˂75 years (n = 25,540) 
(Nichols et al., 2014). According to the UK Myocardial Ischemia National Audit Project 
(MINAP) database annual public report 2011-2012, there were 79,433 admissions with 
a final diagnosis of myocardial infarction (MI). Of these, 41% had ST-elevation 
myocardial infarction (STEMI). The mean age of patients presenting with MI in England 
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and Wales was 65 years in men and 73 years in women (68 years overall). Individuals’ 
˃70 years represented 49% of patients with an MI in the MINAP data. The average 
age for a first STEMI was 65 years, while that of NSTEMI was 70 years (21% of STEMI 
patients and 26% of NSTEMI patients were between 70 and 79 years of age, in 
comparison to 15% of patients with STEMI and 27% of patients with NSTEMI who were 
80–89 years of age). Although cases of STEMI appear to be equally distributed around 
the age-range 60–69 years, for NSTEMI the majority are older than this at presentation 
(Gavalova and Weston, 2012). In the Global Registry of Acute Coronary Events 
(GRACE) (Avezum et al., 2005), increasing age was associated with increased 
incidence of NSTEMI. NSTEMI was diagnosed in just over 30% of patients aged ˂65 
years compared with 41% in those aged ≥85 years. STEMI was more frequent in 
younger patients (36.5% in 45-74 years vs 30.7% in ˃75 years). All in-hospital events 
after ACS were more frequent among elderly patients. Cardiogenic shock was nearly 
6 times more common in the oldest compared with the youngest group (9.8% vs 1.6%, 
respectively). Rates of major bleeding were twice that in patients aged ≥85 years 
compared to ˂65 years (p<0.0001). Each 10-year increase in age resulted in a 75% 
increase in hospital mortality. 
Age ≥75 years constitutes one of the seven prognostic variables in the Thrombolysis 
In Myocardial Infarction (TIMI) risk score (Antman et al., 2000). In general, the 
management of ACS in the elderly patients does not differ a great deal from that the 
younger patients in terms of management according to the current guidelines 
(Braunwald et al., 2002; Smith et al., 2006). 
As a result of higher prevalence of cardiac risk factors and impaired healing processes, 
elderly patients with ACS are at higher risk of recurrent ischaemic events and death, 
as well as treatment-related complications compared with younger patients. It has 
been reported that patients >75 years of age comprise one third of overall ACS 
episodes and that this age group accounts for around 60% of the overall mortality from 
ACS. Further, after allowance for confounding factors, the odds for in-hospital death 
from acute events increases by 70% for each 10-year increase in age (OR: 1.70; 95% 
CI: 1.52 to1.82). Atypical symptoms are more common in elderly patients presenting 
with ACS, dyspnoea, and confusion are relatively common, whereas ischaemic pain is 
less likely to be present or is present in an atypical location.  
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Despite these demographic realities, elderly persons are generally underrepresented 
in randomized controlled trials and recent data have suggested limited success in 
attempts at making cardiovascular trials more inclusive by including the elderly (Lee et 
al., 2001). Current ACS treatment guidelines are based primarily upon studies largely 
comprising younger patients (Roe et al., 2013). Although age may alter the balance of 
risk and benefit of therapeutic strategies, trials data regarding older patients with ACS 
have usually been limited to subgroup analyses rather than derived from dedicated 
age-specific studies. Registries have found that elderly patients presenting with an 
ACS less frequently receive evidence-based therapies highlighting the need for studies 
targeted specifically to the elderly. 
1.1.7 Factors contributing to increased risk of CAD in elderly 
Age dependent alterations of haemostasis suggest that certain coagulation proteins 
such as fibrinogen, factor V, VII, VIII, IX, XIII, high-molecular weight kininogen and 
prekallikrein levels increase with age (Franchini, 2006). Overall, the elderly experience 
a shift of the haemostatic balance towards increased clotting and decreased 
fibrinolysis. Ageing may also lead to intrinsic changes to platelets, thereby increasing 
platelet reactivity. This increased platelet reactivity has been correlated with a higher 
content of platelet phospholipids, suggesting an age related increase in platelet trans-
membrane signalling (Bastyr et al., 1990b). Blood stasis and endothelial dysfunction 
also play a key role contributing to increased platelet activation and arterial thrombosis 
in the elderly (Zahavi et al., 1980; Loscalzo, 2001; Brandes et al., 2005).  
Ageing of the vasculature results in increased arterial thickening and stiffness as well 
as endothelial dysfunction. Clinically, these changes result in increased systolic 
pressure and present major risk factors for development of atherosclerosis, 
hypertension and stroke, and atrial fibrillation. The vasculature undergoes structure 
and function alterations with age that are well documented, such as luminal 
enlargement with wall thickening and a decline in endothelial cell function negatively 
affecting endothelium-dependent dilation and promoting vascular stiffness. In addition, 
endothelial cells lose their ability to proliferate and migrate after tissue injury. 
Furthermore, endothelial barriers become porous and vascular smooth muscle cells 
migrate into sub-endothelial spaces and deposit extracellular matrix proteins that result 
in intimal thickening. At the molecular level, as endothelial cells age, they exhibit a 
reduction in endothelial nitric oxide synthase (eNOS) activity, reducing the abundance 
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of nitric oxide (NO). NO is a critical vasodilator produced by endothelial cells, regulating 
vascular tone, in addition to inhibiting vascular inflammation, thrombotic events, and 
aberrant cellular proliferation. Loss of NO also promotes endothelial cell senescence. 
Numerous mechanisms can modulate eNOS activity. However, hemodynamic shear 
stress, the frictional force acting on endothelial cell surface as a result of blood flow, is 
one of the most potent inducers of eNOS activity. As vessels age, they are exposed to 
less hemodynamic stress due to reduced blood flow caused by decline in heart 
function; in addition, endothelial cells become less responsive to shear stress, resulting 
in a decline in the protective NO. 
1.1.8 Ageing and bleeding 
Age features as a risk factor in many bleeding risk stratifications. Indeed, bleeding risk 
is greater in elderly versus younger patients. In a recent meta-analysis of stroke 
prevention in elderly patients with atrial fibrillation, the risk of serious bleeding 
increased for each decade increase of age (HR: 1.61; 95% CI, 1.47 to 1.77). 
Furthermore, the use of several antiplatelet and anticoagulant therapies is associated 
with increased bleeding risk in the elderly, with a resulting reduction in net clinical 
benefit. For example, age is a predictor of intracranial haemorrhage in patients 
receiving antiplatelet or anticoagulant therapy. In the Assessment of the Safety and 
Efficacy of a New Thrombolytic Regimen (ASSENT)-III PLUS trial, enoxaparin as a 
conjunctive therapy to tenecteplase in patients with ST-segment elevation myocardial 
infarction was associated with an unacceptable risk of intracranial haemorrhage in the 
elderly population, warranting a dose reduction in patients aged >75 years. 
1.1.9 Ageing and Diabetes Mellitus 
The prevalence and incidence of T2DM are greater among elderly individuals 
compared to the younger population. From a study in France, the overall prevalence 
of DM was estimated at 4.4% in 2009. The prevalence increased with age to 14.2% in 
those aged 65-74 years, peaking at 19.7% in men and 14.2% in women aged 75-79 
years (Fagot-Campagna et al., 2005). From 2001 to 2005, the prevalence of DM 
increased by 3.1 % in men aged 70-79 years, 3.8 % in men aged 80-89 years and by 
0.7 % and 3.0 % respectively in women in those age group (Pornet et al., 2011). Elderly 
patients with T2DM are at increased risk of vascular complications, loss of cognitive 
function and mobility and, consequently, of dependency (Bourdel-Marchasson and 
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Berrut, 2005). Hence, the increasing number of older individuals with T2DM will lead 
to a greater public health burden (Bethel et al., 2007; Sloan et al., 2008). Ageing is 
accompanied by increased arterial stiffness and reduced myocardial compliance, 
contributing to adverse cardiovascular events. Patients with T2DM manifests these 
changes at a younger age, suggesting that mechanisms underlying these changes in 
vasculature during ageing is accelerated in diabetes. Advanced glycation end-products 
(AGEs) that form during the Maillard reaction (non-enzymatic reaction between 
glucose and proteins) are implicated in the complications of ageing and diabetes. The 
formation of AGEs on vascular wall collagen causes cross-linking of collagen 
molecules to each other. This leads to the loss of collagen elasticity, and subsequently 
a reduction in arterial compliance. This causes hypertension and might be contributing 
to increased cardiovascular events (Aronson, 2003; Aronson, 2004).  Booth et al 
showed that diabetes confers an equivalent risk to ageing by 15 years. Elderly people 
with diabetes, on average seemed to be at high risk of CVD compared to young 
diabetics or elderly non-diabetics (Booth et al., 2006). 
1.2   Pathophysiology of coronary atherosclerosis 
Pathophysiological mechanisms contributing to atherosclerosis are complex and inter 
linked. The 20th century has witnessed a remarkable evolution in the concepts 
concerning the pathogenesis of atherosclerosis. In the mid-19th century Rudolf Virchow 
viewed atherosclerosis as a proliferative disease whilst Karl Rokitansky believed that 
atheroma was derived from healing and resorption of thrombi (Mayerl et al., 2006). 
Experiments in the early 20th century identified cholesterol as the main culprit 
(Steinberg). In the mid-20th century characterisation of human lipoprotein particles 
promoted the insudation of lipids as a cause of atherosclerosis. In late 20th century, 
studies have revealed significant involvement of inflammation and genetic propensity 
in various stages of atherosclerosis. We now recognise that elements of all these 
mechanisms contribute to atherogenesis with inflammation occupying a significant role 
in the initiation and progression of atherosclerotic lesions. 
Atherosclerosis is a systemic dysfunctional endothelial, focal occurring or diffuse, 
chronic inflammatory, fibro-proliferative, prothrombotic, angiogenic, multifactorial 
disease of the arterial wall caused by the retention of modified low-density lipoproteins 
and hemodynamic and reductive-oxidative stress (Hayden and Tyagi, 2004). 
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Atherosclerosis was viewed as a localised narrowing of arteries secondary to 
cholesterol and smooth muscle cell deposits but this view has change in the last 
decade and atherosclerosis is now considered as a widespread vascular inflammatory 
process with varying clinical manifestations (Libby et al., 2002). Atheroma or an 
atheromatous plaque is a focal atherosclerotic lesion in a coronary artery which is in a 
state of constant flux. It responds to changes mainly mediated by inflammation, 
immune, vasomotor and lipid environment in the intra and extra plaque milieu. 
1.2.1 Coronary artery anatomy 
An appreciation of the ultrastructure of coronary arteries is crucial in understanding the 
complex pathophysiology of atherothrombosis. Knowledge of coronary artery anatomy 
and pathogenesis of atherosclerosis has significantly evolved since the days of Rudolf 
Virchow.   
The normal coronary artery has a well-developed trilaminar structure: 
1. Tunica intima – innermost monolayer of endothelial cells abutting directly on a 
basal lamina containing non-fibrillar collagen types such as type IV collagen, 
laminin, fibronectin and other extra cellular matrix molecules. The internal 
elastic lamina bounds intima abluminally and serves as the border between the 
intimal layer and the underlying tunica media. 
2. Tunica media – lies under the intimal layer and internal elastic lamina. This layer 
is made up of layers of SMCs interleaved with layers of elastin-rich extracellular 
matrix. In a normal artery the extracellular matrix neither accumulates nor 
atrophies due to a fine balance between the rate of matrix synthesis and 
dissolution. The external elastic lamina bounds the media abluminally, forming 
the border with the adventitial layer. 
3. Tunica adventitia – outer layer consisting of collagen fibrils and other cells such 
as fibroblasts and mast cells. This layer also contains the neurovascular bundle 
with the vasa vasorum. Emerging evidence suggests a role of mast cells in 
atheroma in animal models, but their importance in humans remains speculative 
(Libby and Shi, 2007). 
In general the endothelial monolayer forms a continuous sheet as the innermost layer 
of the arterial lumen, remains non thrombogenic and prevents the exposure of highly 
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thrombogenic collagen in tunica media from being exposed to flowing blood (Fuster et 
al., 1992). 
With ageing, human arteries develop a more complex intima, containing arterial 
smooth muscle cells (SMCs) and fibrillary forms of interstitial collagen (type I and III). 
This is termed as diffuse intimal thickening and characterizes most of the adult arteries. 
This does not necessarily go hand in hand with lipid accumulation and may occur in 
individuals without substantial atheroma burden. 
1.2.2 Laminar flow and protection against atherosclerosis 
Atheromatous changes in the coronary arteries are either focal or diffuse. Laminar 
blood flow, has been found to elicit various antiatherogenic homeostatic mechanisms 
(atheroprotective functions) and anti-inflammatory functions such that under usual 
conditions of laminar shear stress in normal coronary arteries, the endothelium is 
atheroprotective. Early atheromatous plaques in proximal segment of the coronary 
arteries at bifurcations or branch points, progresses to significant atherosclerotic 
plaque (Nigro et al., 2011). This results in rapid changes to shear stress on the vessel 
wall and the plaque resulting in non-laminar flow. This triggers endothelial damage and 
dysfunction, mediated via the nuclear factor kappa B (NFKB) pathway (Tegos et al., 
2001; Cunningham and Gotlieb, 2005; Chiu and Chien, 2011). 
1.2.3 Initiation of plaque formation – endothelial dysfunction 
The initial steps in atherogenesis remains inconclusive. However, observations from 
tissues obtained from young humans and from experimental studies in animals points 
towards structural and functional changes in the endothelial layer as a marker of 
initiation of atherosclerosis. 
 All infants have focal thickening of the coronary artery intima due to vascular smooth 
muscle cell (VSMC) proliferation (Milei et al., 2008). Although focal thickening is an 
important hallmark of the developing atherosclerotic plaque, this is considered to be 
an adaptive response to turbulent blood flow rather than to be pathological. 
1.2.4 Fatty streak 
Endothelial dysfunction initiated by risk factors permits the entry of lipids (low density 
lipoprotein - LDL) and inflammatory cells into the artery wall. LDL particles accumulate 
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over a period of time and undergo oxidative modification in the presence of free 
radicals. This oxidised and glycated LDL is more atherogenic and immunogenic (Tegos 
et al., 2001; Kruth, 2002). Leucocyte recruitment and accumulation also occurs early 
in lesion generation (Muller, 2009). Normal endothelial lining generally resists adhesive 
interactions with leukocytes. However, at sites of endothelial dysfunction, the damaged 
endothelial cell responds by expressing adhesion molecules for leucocytes such as 
vascular cell adhesion molecule-1 (VCAM-1) and P-selectin as a repair mechanism.  
Upon continuous insult by endogenous (high cholesterol) and exogenous (smoking) 
factors, these adhesion molecules are over expressed in coronary endothelium 
allowing the circulating leucocytes to adhere to the endothelium. They then move 
between the endothelial cell junctions or penetrate through endothelium (transcytosis) 
to enter the intima (Linton and Fazio, 2003). Once in the artery, monocytes differentiate 
into macrophages which take up the lipid and become foam cell macrophages. This 
results in the formation of lesions termed “fatty streaks”. These are small, slightly raised 
lesions caused by focal collections of foam cell macrophages in the intima. They may 
progress to larger atherosclerotic plaques or may regress. Chemoattractant cytokines 
or chemokines especially monocyte chemoattractant protein 1 (MCP-1) and 
interleukin-8 (IL-8) are involved in the process of leucocyte migration (Libby et al., 
2002; Gleissner et al., 2008). 
Fatty streak progresses to a more complex lesion due to the formation of a necrotic 
core and a fibrous cap. Foam cell macrophages, engorged with LDL, begin to die and 
their contents contributes to the formation of a necrotic core. The release of the 
cytoplasmic contents of the foam cells leads to the accumulation of extracellular lipids, 
cytokines, leukotrienes, prostanoids, histamine like substances and growth factors, all 
of which induce inflammation. These also impair nitric oxide synthesis which in turn 
reduces the functional and regenerating capacity of the endothelium (Stary et al., 1995; 
Virmani et al., 2000).  
The occurrence of VSMC migration and proliferation results in the formation of a fibrous 
cap. VSMCs migrate into the intima where they proliferate and deposit extracellular 
matrix. The increase in cell number and presence of matrix causes augmentation of 
the bulk of the plaque, which now protrudes into the lumen. This is termed a stable 
advanced plaque (George and Dwivedi, 2004; Newby, 2006). The size and 
composition of the plaque determine its outcome.
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Figure 1.1 Progression of coronary atherosclerosis 
Spectrum of representative coronary lesion morphologies seen in a sudden 
death population, forming the basis for the modified American Heart Association 
(AHA) descriptive classification. The 2 non-progressive lesions are intimal 
thickening and intimal xanthomas (foam cell collections known as fatty streaks, 
AHA type II). Pathological intimal thickening (PIT) (AHA type III transitional 
lesions) marks the first of the progressive plaques, as they are the assumed 
precursors to more advanced fibroatheroma (FA). Thin-cap fibroatheromas are 
considered precursors to plaque rupture. Essentially missing from the AHA 
consensus classification are alternative entities that give rise to coronary 
thrombosis, namely erosion and the calcified nodule. Erosions can occur on a 
substrate of PIT or FA, whereas calcified nodules depict eruptive fragments of 
calcium that protrude into the lumen, causing a thrombotic event. Luminal 
thrombi overlie areas lacking surface endothelium and so are in communication 
with the lipid-rich necrotic core. Lastly, healed plaque ruptures are lesions with 
generally smaller necrotic cores and focal areas of calcification where the surface 
generally shows areas of healing rich in proteoglycans. Multiple healed plaque 
ruptures are thought responsible for progressive luminal narrowing. Ca2+ = 
calcium; EL = extracellular lipid; FC = fibrous cap; NC = necrotic core; Th = 
luminal thrombus. From (Virmani et al., 2000)  Arterioscler Thromb Vasc Biol. 
2000; 20(5):1262-75. 
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1.2.5 Progression and evolution of atheromatous lesion 
Innate and adaptive immunity: Mechanisms of inflammation in atherogenesis 
During the last decade, the role of inflammation in atherogenesis has been well 
established (Libby et al., 2002; Hartvigsen et al., 2009). The macrophage foam cells 
serve as the rich source of proinflammatory mediators including proteins such as 
cytokines, chemokines, various eicosanoids and lipids such as platelet activating 
factor. These can also elaborate large quantities of oxidant species such as superoxide 
anion, in the milieu of the atherosclerotic plaque. This ensemble of inflammatory 
mediators can promote inflammation in the plaque and contribute to the progression 
of lesions. The term innate immunity describes this type of amplification of the 
inflammatory response that does not depend on antigenic stimulation. 
In addition to innate immunity, antigen-specific or adaptive immunity in plaque 
progression has also been identified (Andersson et al., 2010). Macrophages and 
dendritic cells in the atherosclerotic lesions can present antigens to the T cells. These 
antigens include modified lipoproteins, heat shock proteins, beta2-glycoprotein 1b and 
infectious agents (Tsimikas et al., 2005; Chou et al., 2008). The antigen presenting 
cells allow the antigen to interact with T cells in a manner that triggers their activation. 
These activated T cells then can secrete copious quantities of cytokines that can 
modulate atherogenesis.    
The helper T cells (bearing CD4) fall in to two general categories: 
i. T helper 1 (Th1) subtype secretes proinflammatory cytokines such as interferon-
y (IFN-y), lymphotoxin, CD40 ligand and tumour necrosis factor-α (TNF-α) 
which in turn activates vascular wall cells leading to plaque destabilization and 
heightened thrombogenicity. 
ii. T helper 2 (Th2) subtype secretes cytokines such as interleukin-10 which can 
inhibit inflammation in the context of atherogenesis (Ait-Oufella et al., 2009). 
The cytotoxic T cells (bearing CD8) can express Fas ligand and other cytotoxic factors 
that can promote cytolysis and apoptosis of target cells, including smooth muscle cells 
(SMCs), endothelial cells and macrophages. The death of these cell types can occur 
in the atherosclerotic lesion and may contribute to plaque progression and 
complication.  
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The regulatory T cells (Treg – bearing CD4 and CD25) can elaborate transforming 
growth factor-β (TGF-β) and interlukin-10. These cytokines can exert anti-inflammatory 
effects. Several experimental studies have suggested an antiatherosclerotic function 
of Treg cells in vivo (Taleb et al., 2008; Andersson et al., 2010). 
Smooth muscle cell migration and proliferation 
Evolution of atheroma into more complex plaques involves SMCs in addition to 
endothelial dysfunction and leucocyte recruitment (Manabe and Nagai, 2003; Mulvihill 
et al., 2004). Intimal SMCs in atheroma contain rougher endoplasmic reticulum and 
fewer contractile fibres than do the normal medial SMCs.  SMCs are recruited from the 
underlying tunica media into the intimal layer in advanced atheroma. This recruitment 
is facilitated by chemoattractants such as platelet-derived growth factor (PDGF) 
secreted by activated macrophages. Although replication of SMCs in the steady state 
appears infrequent in mature atheroma, bursts of SMC replication may occur during 
the life history of a given atheromatous lesion. These can occur during episodes of 
plaque disruption with thrombosis, when the intimal SMCs are exposed to mitogens 
including the coagulation factor thrombin. Thus accumulation of SMCs and their growth 
in the intima does not occur in a continuous linear fashion but bursts of SMC replication 
or migration may occur. 
Smooth muscle cell death during atherogenesis 
In addition to replication, death of these cells also participate in complication of the 
atherosclerotic plaque (Clarke et al., 2006). Some SMCs in advanced atheroma exhibit 
fragmentation of their nuclear DNA that is characteristic of programmed cell death or 
apoptosis. Soluble proinflammatory cytokines act in conjunction with Fas ligand 
expressing T cells in the atheromatous lesion and this leads to SMC apoptosis 
(Kavurma et al., 2008). Thus, SMC accumulation in a progressing atheromatous 
plaque probably results from a tug-of-war between cell replication and cell death (Geng 
and Libby, 2002). Contemporary cell and molecular biologic research has identified 
candidates that mediate replication and attrition of SMCs. 
Arterial extracellular matrix 
Extracellular matrix makes up much of the volume of an advanced atherosclerotic 
plaque. These molecules include interstitial collagens (types I and III) and 
proteoglycans. SMCs produce these matrix molecules and the main stimuli include 
17 
 
PDGF and TGF-β. Elastic fibers may also accumulate in atherosclerotic plaques. 
Similar to accumulation of SMCs, extracellular matrix is also in a state of constant flux. 
The biosynthesis of matrix molecule is counterpoised by catabolic enzymes known as 
matrix metalloproteinases (MMPs). Dissolution of extracellular matrix molecules 
undoubtedly plays a crucial role in the migration of SMCs into the intima from media 
traversing the elastin-rich internal elastic lamina (Dollery and Libby, 2006).  
Extracellular matrix breakdown also is likely to play a role in arterial remodelling that 
accompanies atheroma growth. During the early life of an atheromatous lesion, 
plaques grow outwardly, in an abluminal direction, rather than inwardly. Luminal 
stenosis starts to occur only after the plaque burden exceeds around 40% of the cross-
sectional area of the artery. 
Angiogenesis in plaques 
Atherosclerotic plaques develop their own microvasculature as they grow because of 
endothelial migration and replication. These microvessels probably form in response 
to angiogenic peptides overexpressed in the atheroma. These factors include vascular 
endothelial growth factor (VEGF), placental growth factor (PGF) and oncostatin M. As 
a consequence of the presence of microvessels, there is increased trafficking of 
leucocytes, prominence of adhesion molecules like VCAM-1 and increased growth of 
plaque overcoming diffusion limitations on oxygen and nutritional supply (Dollery and 
Libby, 2006). The plaque microvessels may be friable and prone to rupture. 
Haemorrhage and thrombosis in situ could promote local SMC proliferation and matrix 
accumulation in the area adjacent to the microvascular disruption. This in turn helps 
progression of atheromatous plaque. 
Plaque mineralisation 
Plaques develop areas of calcification as they evolve. Some subpopulation of SMCs 
may foster calcification by enhanced secretion of cytokines such as bone morphogenic 
proteins (BMP), homologues of TGF-β. Receptor activation of NF-kB ligand (RANKL), 
a member of TNF-α family, appears to promote SMC mineral formation through the 
BMP4 dependent pathway. Osteoprotegerin can inhibit plaque mineralisation by 
inhibiting RANKL signalling. Genetic absence of osteoprotegerin augments 
calcification of mouse atheromas and administration of exogenous osteoprotegerin 
limits it (Bennett et al., 2006; Morony et al., 2008). Transcription factor Runx-2, 
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activated by inflammatory mediators and oxidative stress also promote SMC mineral 
formation (Aikawa et al., 2007; Byon et al., 2008). 
1.2.6 Plaque vulnerability and rupture 
Atherosclerotic plaque morphology has been classified into 7 types based on lipid core, 
ratio of fibrous tissue to lipid core, fibrous tissue lining of the plaque and the presence 
of thrombus. This pathological classification is based on the vulnerability and rupture 
of the plaque (Farb et al., 1996; Virmani et al., 2000). This final common end point of 
an atheromatous plaque is plaque rupture and thrombosis (Arai et al., 2010). 
Fracture of the fibrous cap, accounts for two thirds of acute myocardial infarctions. 
Another mechanism involves superficial erosion of intima. The rupture of the fibrous 
cap reflects an imbalance between the forces that impinge on the cap and the 
mechanical strength of the fibrous cap. Interstitial collagen provide most of the 
biomechanical resistance to disruption of the fibrous cap and hence collagen 
metabolism is thought to participate in regulating the propensity of plaque rupture 
(Libby, 2008). T cell derived cytokine INF-y potently inhibits SMC collagen synthesis, 
thereby impairing the ability of the plaque to repair and maintain the fibrous cap. On 
the other hand, certain mediators released from platelet granules during activation, 
including TGF-β and PDGF, increase collagen synthesis and reinforce the plaque’s 
fibrous structure. 
Increased catabolism of extracellular matrix macromolecules that compose the fibrous 
cap can also contribute to weakening of this structure, rendering it susceptible to 
rupture and hence thrombosis. Macrophages in advanced atheroma overexpress 
MMPs and elastolytic cathepsins that can breakdown the collagen and elastin of the 
arterial extracellular matrix (Dollery and Libby, 2006; Libby, 2008). The strength of the 
fibrous cap undergoes dynamic regulation, linking the inflammatory response in the 
intima with the molecular determinants of plaque stability and hence thrombotic 
complications of atheroma. 
Another feature of vulnerable plaque is a relative lack of SMCs. As describe earlier, 
inflammatory mediators, can produce apoptosis of SMCs. Loss of SMCs from regions 
of local inflammation within plaques probably explains the relative lack of SMCs at 
places where plaque ruptures. Due to lack of SMCs there is reduced collagen 
production that is needed to repair and maintain the matrix of the fibrous cap. This 
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contributes to the weakening of the fibrous cap and increases the propensity for plaque 
rupture (Clarke et al., 2008). 
A prominent accumulation of macrophages and a large lipid milieu is a third micro-
anatomical feature of the so-called vulnerable atherosclerotic plaque. The activated 
macrophages produce cytokines and matrix degrading enzymes thought to regulate 
matrix catabolism and SMC apoptosis. These macrophages and SMCs can generate 
particulate tissue factor, a potential instigator for microvascular thrombosis after plaque 
disruption.  
The success of lipid lowering therapy in reducing the incidences of acute myocardial 
infarction or unstable angina in patients at risk may result from a reduced accumulation 
of lipid and decrease in inflammation and plaque thrombogenicity. Plaque rupture 
exposes thrombogenic lipids and collagen to flowing blood and can result in either 
occlusive or non-occlusive thrombus leading to myocardial necrosis (Lafont, 2003). 
The pathobiology of superficial erosion is much less well understood. Most of the 
superficial erosions do not result in clinically apparent myocardial infarction but are 
responsible for bursts in growth of atheromatous plaques (Fuster et al., 2005; Virmani 
et al., 2006). In humans, superficial erosion appears more likely to cause fatal acute 
myocardial infarction in women and in individuals with hypertriglyceridemia and 
diabetes mellitus but the underlying molecular mechanisms remain obscure. Apoptosis 
of endothelial cells contributing to desquamation of endothelial cells and the role of 
MMPs in degrading the nonfibrillar collagen in the basement membrane have been 
postulated for superficial erosion (Kramer et al., 2010).   
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Figure 1.2 Schematic of the evolution of the atherosclerotic plaque.  
1: Accumulation of lipoprotein particles in the intima. The modification of these 
lipoproteins is depicted by the darker colour. Modifications include oxidation and 
glycation.  
2: Oxidative stress, including products found in modified lipoproteins, can induce 
local cytokine elaboration.  
3: The cytokines thus induced increase expression of adhesion molecules for 
leukocytes that cause their attachment and of chemoattractant molecules that 
direct their migration into the intima.  
4: Blood monocytes, upon entering the artery wall in response to chemoattractant 
cytokines such as MCP-1, encounter stimuli such as macrophage colony 
stimulating factor (M-CSF) that can augment their expression of scavenger 
receptors. 
 5: Scavenger receptors mediate the uptake of modified lipoprotein particles and 
promote the development of foam cells. Macrophage foam cells are a source of 
mediators such as further cytokines and effector molecules such as hypochlorous 
acid, superoxide anion (O2-), and matrix metalloproteinases.  
6: Smooth muscle cells in the intima divide other smooth muscle cells that migrate 
into the intima from the media.  
7: Smooth muscle cells can then divide and elaborate extracellular matrix, 
promoting extracellular matrix accumulation in the growing atherosclerotic plaque. 
In this manner, the fatty streak can evolve into a fibrofatty lesion.  
8: In later stages, calcification can occur (not depicted) and fibrosis continues, 
sometimes accompanied by smooth muscle cell death (including programmed cell 
death, or apoptosis) yielding a relatively acellular fibrous capsule surrounding a 
lipid-rich core that may also contain dying or dead cells and their detritus. 
Abbreviation: IL-1 = interleukin-1; LDL = low-density lipoprotein. Adapted from 
(Libby et al., 2010). 
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Figure 1.3 Interplay between adaptive and innate immunity during 
atherogenesis. 
The principal effector cell of innate immunity, the macrophage (MF), secretes 
cytokines that critically regulate many functions of atheroma-associated cells 
involved with disease initiation, progression, and complication, as well as 
thrombosis. IFN-γ, a product of the activated T cell, activates a number of these 
functions of the macrophage. In turn, the activated macrophage expresses high 
levels of MHC class II antigens, needed for antigen-dependent activation of T cells.  
Abbreviation: IFN-γ = interferon- γ; MF = macrophages; Th = T helper cell 
From (Hansson et al., 2002) 
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1.3 Blood Haemostasis and thrombus formation 
Thrombus formation is the most effective protective mechanism by which haemostasis 
is maintained in a closed, high pressure circulatory system after vessel wall damage. 
Haemostasis is nature’s first and most efficient response to control bleeding and 
preserve the integrity of the circulatory system. This process remains inactive but 
readily gets activated following vascular injury to minimise extravasation of blood from 
the vasculature. Following this activation, it is critical to contain this thrombus formation 
so that it is localised to the site of injury and to modulate thrombus size to be 
appropriate to the injury. Thus, there exists a very fine balance between pathways that 
initiate thrombus formation and that regulate / modulate thrombus formation (Furie, 
2009). 
1.3.1 Mechanisms of thrombosis 
At sites of vascular injury, platelets rapidly adhere to the exposed sub-endothelial 
extracellular matrix, gets activated and together with the coagulation system form a 
thrombotic plug that seals the lesion (Furie and Furie, 2008). A highly specified and 
efficient haemostatic system consisting of cellular (platelets) and non-cellular 
(coagulation factors) components is responsible for three main steps in thrombus 
formation as listed below: 
i. Initiation of thrombosis 
ii. Propagation of thrombus 
iii. Autolysis of thrombus 
Initiation of thrombosis 
The vessel wall with intact endothelium is crucial to the maintenance of a patent 
vasculature. The endothelium contains three thromboregulators — nitric oxide, 
prostacyclin and the ectonucleotidase CD39 — which together provide a defence 
against thrombus formation.  Collagen and tissue factor facilitate the maintenance of a 
closed circulatory system. When the vessel wall is injured or the endothelium is 
disrupted, collagen and tissue factor gets exposed to the flowing blood, thereby 
initiating thrombus formation.  
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Two distinct pathways act in parallel to activate platelets. In one, exposed collagen 
triggers the accumulation and activation of platelets, whereas in the other exposed 
tissue factor initiates thrombin generation, which not only converts fibrinogen to fibrin 
but also activates platelets. 
The interactions of platelet glycoprotein VIb with the collagen of the exposed vessel 
wall and of platelet glycoprotein Ib-V-IX with collagen-bound von Willebrand factor 
(vWF) result in adhesion of platelets to the site of injury (Ruggeri, 2000). In addition to 
its role in the adherence of platelets to collagen, glycoprotein VIb is the major agonist 
for initial platelet activation and granule release. The platelet integrin α2β1 plays a 
supportive but not essential role in the interaction between platelets and collagen 
(Nieswandt et al., 2001). 
Tissue factor (TF) triggers a second independent pathway that initiates platelet 
activation. Tissue factor forms a complex with coagulation factor VIIa, the 
enzymatically active form of factor VII, and this tissue factor–factor VIIa complex 
activates coagulation factor IX, thereby initiating a proteolytic cascade that generates 
thrombin (Steffel et al., 2006). Thrombin cleaves protease-activated receptor 1 (PAR 
1) on the platelet surface, thereby activating platelets and causing them to release 
adenosine diphosphate (ADP), serotonin, and thromboxane A2 (Vu et al., 1991). In 
turn, these agonists activate other platelets, and in doing so, amplify the signals for 
thrombus formation. 
Von Willebrand factor synthesised by endothelial cells and megakaryocytes, 
promotes platelet adhesion to subendothelium. Elevated levels of vWF indicates 
endothelial damage and correlates with cardiovascular risk factors including T2DM and 
dyslipidaemia (Kessler et al., 1998). vWF plays a crucial role in thrombosis by binding 
to fibrillar and non-fibrillar collagen, heparin and sulfatide in the sub endothelium. vWF 
interacts with platelet GPIb receptor and initiates platelet adhesion. It also triggers the 
expression of GPIIb/IIIa and binds to it, thereby promoting irreversible adhesion and 
aggregation of platelets (Kessler et al., 1998; Reininger et al., 2006) 
Propagation of thrombus formation 
A developing thrombus recruits unstimulated platelets and within the thrombus, 
activation occurs only in a subgroup of the recruited platelets (Dubois et al., 2007). 
Other platelets remain loosely associated with the thrombus but do not undergo 
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activation and may ultimately disengage from the thrombus. In short, thrombus 
formation is a dynamic process in which some platelets adhere to and others separate 
from the developing thrombus, and in which shear, flow, turbulence, and the number 
of platelets in the circulation greatly influence the architecture of the clot. 
Following adhesion and platelet activation, cyclooxygenase-1 (COX-1)-dependent 
synthesis and release of thromboxane A2 (TXA2) and release of ADP from storage 
granules occur. TXA2 is a potent vasoconstrictor and it locally activates platelets and 
recruits them to the site of injury. This results in expansion of the platelet plug. To 
activate platelets, TXA2 and ADP binds to their respective receptors on the platelet 
membrane. The role of ADP receptors in platelet function and the pharmacology of 
drugs directed against these receptors are described in detail later. Activated platelets 
promote assembly of coagulation factor complexes. These complexes trigger a burst 
of thrombin generation and subsequent fibrin formation. In addition to converting 
fibrinogen to fibrin, thrombin amplifies platelet activation further and helps anchor the 
platelet aggregates at the site of injury.  
This is followed by platelet aggregation, the final step in the formation of the platelet 
plug. Platelet aggregation links platelets to each other to form clumps. Glycoprotein 
IIb/IIIa (GP IIb/IIIa) mediates these platelet to platelet linkages. On nonactivated 
platelets, GP IIb/IIIa exhibits minimal affinity for its ligands (Lefkovits and Topol, 1995). 
On platelet activation it undergoes a conformational transformation, which reflects 
transmission of signals from its cytoplasmic domain to its extracellular domain. This 
transformation enhances the affinity of GP IIb/IIIa for its ligands, fibrinogen under low 
shear and vWF under high shear conditions (Italiano et al., 2008). Fibrinogen and vWF 
serve as bridges and bind adjacent platelets together. Fibrin, the final end product of 
the coagulation cascade, tethers the platelet aggregates together and anchors them 
to the site of injury. The viscoelastic property of thrombus is derived from fibrin to fibrin 
cross linkage and overlapping of longitudinal fibrin fibres. By forming a mesh-like 
structure due to crosslinking of individual fibres, cellular elements in the blood are 
trapped in thrombus resulting in cellular thrombus (Collet et al., 2003; Weisel, 2005). 
Circulating monocytes are attracted towards this organising thrombus. Leukocyte-
platelet adhesion is mediated by inflammatory cytokines, microparticles and P-selectin 
from activated platelets (Zarbock et al., 2007). 
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Figure 1.4 Mechanism of thrombus formation. 
Plaque rupture exposes subendothelial components. Platelet adhesion is mediated by 
interactions between vWF and GP Ib/V/IX receptor complexes located on the platelet 
surface, and between platelet collagen receptors (GP VI and GP Ia) and collagen 
exposed at the site of vascular injury. Binding of collagen to GP VI induces the release 
of activating factors (ADP, thromboxane A2, serotonin, epinephrine, and thrombin), 
which promote interactions between adherent platelets, as well as further recruitment 
and activation of circulating platelets. Platelet activation leads to changes in platelet 
shape, expression of proinflammatory molecules, platelet procoagulant activity, and 
activation of platelet integrin GP IIb/IIIa. Activated GP IIb/IIIa binds to the extracellular 
ligands fibrinogen and vWF, leading to platelet aggregation and thrombus formation. 
Vascular injury also exposes subendothelial tissue factor, which forms a complex with 
factor VIIa and sets off a chain of events that results in formation of the prothrombinase 
complex. Prothrombin is converted to thrombin, which subsequently converts 
fibrinogen to fibrin, generating a fibrin-rich clot. Abbreviations: GP, glycoprotein; vWF, 
von Willebrand factor. From (Franchi and Angiolillo, 2015) 
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Autolysis of formed thrombus 
Autolysis is a natural mechanism by which haemostasis is regulated and maintained 
by removal of excess thrombus formation. An early but weaker thrombus retraction 
mediated by platelets is followed by a stronger fibrinolysis mediated by fibrinolytic 
enzymes. Thrombus retraction involves rearrangement of internal actin cytoskeletons 
in the platelet cell wall resulting in platelet contraction (Carroll et al., 1981). 
Thrombus retraction is followed by fibrinolysis where plasminogen activators convert 
plasminogen to plasmin, which then degrades insoluble fibrin into soluble fibrin 
degradation products. Two immunologically and functionally distinct plasminogen 
activators, namely endothelial tissue plasminogen activator (t-PA) and hepatic 
urokinase-type plasminogen activator (u-PA) (Cesarman-Maus and Hajjar, 2005) are 
present in the circulation. Tissue plasminogen activator mediates intravascular fibrin 
degradation and u-PA mediates both proteolysis and tissue remodelling and repair 
(Medcalf, 2007). 
Regulation of fibrinolysis occurs at two levels. Plasminogen activator inhibitor-1 (PAI-
1) and to a lesser extent PAI-2, inhibits plasminogen activator whereas α2-antiplasmin 
inhibits plasmin. Endothelial cells synthesise PAI-1 which inhibits both t-PA and u-PA. 
Monocytes and placental cells synthesise PAI-2 which specifically inhibits u-PA. A 
dynamic equilibrium is maintained between t-PA and PAI-1 on the luminal surfaces of 
the vessels to determine net local fibrinolytic activity. Either increased expression of 
PAI-1 or decreased expression of t-PA or both can lead to decreased fibrinolytic activity 
predisposing to thrombosis (Vaughan, 2005). The other fibrinolysis inhibitors include 
α2-antiplasmin, α2-macroglobulin and thrombin-activated fibrinolysis inhibitor (TAFI).  
Macrophages are also involved in thrombus resolution. Following completion of 
fibrinolytic process, platelets and other cellular elements of thrombus are resorbed by 
macrophages. Some of these cellular components undergo calcification resulting in 
giant cell formation. Macrophage induced calcification is the hallmark of old and 
recurrent thrombus (Fuster et al., 2005; Medcalf, 2007). 
1.3.2 Platelets in thrombogenesis 
Platelets are anucleate particles released into the circulation after fragmentation of 
bone marrow megakaryocytes. Once they enter the circulation, they have a life span 
of 7 to 10 days (Kaushansky, 2005). Platelets are involved in haemostasis, wound 
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healing and inflammation. They contribute to haemostasis by activation, adhesion and 
aggregation. Under physiological conditions, platelets circulate in a quiescent state, 
protected from untimely activation by inhibitory mediators released from intact 
endothelial cells, mainly NO and prostaglandin I2 (PGI2, prostacyclin) which increase 
the platelet content of cyclic AMP (cAMP) and cyclic GMP (cGMP) respectively. 
Endothelial dysfunction and changes in release of antiplatelet factors may lead to 
increased platelet activation followed by their interaction with neutrophils and 
monocytes, and increased platelet adhesion and aggregation (Frenette et al., 1995; 
Frenette et al., 1998). 
Upon activation by thrombin, ADP or TXA2, platelets undergo shape change, and 
secrete the contents of α- and dense granules (Holmsen, 1994). Rearrangement of 
cytoskeletal proteins, including the disassembly of a microtubule ring, occurs as one 
of the very first steps and results in a shape change from a disc shaped cell into an 
intermediate spherical shape cell. This is followed by actin polymerization and 
extension of pseudopodia (Bearer, 1995).  
Platelet secretion 
Activated platelets secrete a number of potent inflammatory and mitogenic substances 
into the local microenvironment. These mediators modulate functions of other platelets, 
leukocytes, and endothelial cells. Platelets secrete: 
i. chemokines (CCL3, 5, 7, 17, CXCL1, 4, 5, 7, and 8)  
ii. cytokines (e.g., IL-1b, CD40 ligand, b-thromboglobulin)  
iii. growth factors (e.g., PDGF, TGF-b, EGF, VEGF, bFGF), 
iv. coagulation factors (e.g., factor V, factor XI, PAI-1, plasminogen, protein S).  
These factors participate in cell survival, proliferation, coagulation and fibrinolysis, 
chemotaxis, and cell adhesion. 
Platelet chemokines play a key role in the activation of different cell types and can 
induce adhesion by activating integrins (Carveth et al., 1989; Detmers et al., 1990). 
Most of the platelet chemokines are stored in α-granules and can be released upon 
platelet activation. CXCL4 (platelet factor 4) is a chemokine that is constitutively and 
abundantly expressed in platelets.  
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The platelet cytokine CD40 ligand (CD40L), a transmembrane protein, was originally 
described on stimulated CD4+ T cells and also found on stimulated mast cells as well 
as basophils (Vishnevetsky et al., 2004). Preformed CD40L is stored in platelets and 
rapidly translocated to the cell surface upon activation. CD40L, surface-expressed or 
secreted by platelets, can bind to endothelial CD40 and induces chemokine secretion 
and up-regulation of adhesion molecules. This process leads to recruitment to and 
extravasation of leukocytes at the site of injury and thereby immediately links 
haemostasis to the inflammatory system. 
Activated platelets secrete IL-1β, a major activator of endothelial cells (Hawrylowicz et 
al., 1991). Interaction of activated platelets with endothelial cells induces an IL-1β 
dependent secretion of IL-6, CXCL8, CCL2 (monocyte chemoattractant protein-1) from 
endothelial cells. In addition to the induction and release of these inflammatory 
mediators, IL-1β induces increased expression of adhesion molecules, such as E-
selectin, VCAM-1, ICAM-1, alpha2b/beta3 integrin and others (Kaplanski et al., 1994; 
Gawaz et al., 2000). Two other important platelet agonists released upon activation 
are ADP and serotonin. ADP acts through P2Y1 receptor and produces calcium 
mobilisation, shape changes and initial transient activation. It also interacts with the 
P2Y12 receptor, which mediates potentiation of platelet secretion and irreversible 
aggregation. Serotonin is an agonist of the Gαq-coupled 5HT2A-receptor and amplifies 
the platelet response (Gachet, 2001a). 
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Figure 1.5 Platelet components implicated in coagulation and atherosclerotic 
process.  
 
ADP, adenosine diphosphate; bFGF, fibroblast growth factor; EGF, endothelial 
growth factor; ENA, neutrophil-derived peptide activator of epithelial cells; GP, 
glycoproteins; IGF, insulin-like growth factor; IL, interleukin; MIP-1, macrophage 
inflammation protein 1; PAI-1, plasminogen activator inhibitor 1; PDGF, platelet-
derived growth factor; PECAM, platelet and endothelial cell adhesion molecule; 
PF4, platelet factor 4; TGFb, transforming growth factor b; VEGF, vascular 
endothelial growth factor; vWF, von Willebrand factor. From (Badimon et al., 2009) 
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1.3.3 Platelet-neutrophil interaction 
Polymorphonuclear leukocytes (PMN) play an important role in host defence and in 
the pathogenesis of various diseases. The recruitment of PMN into inflammatory tissue 
follows a distinct recruitment pattern. During these different recruitment steps, PMN 
become activated and subsequently release mediators into the surrounding tissue 
(Zarbock et al., 2007). In many experimental animal models, blockade of PMN 
recruitment or PMN depletion leads to attenuation of organ damage. In addition to 
observations in animal models, clinical studies show a positive correlation between the 
number of PMNs and the risk of acute myocardial infarction as well as recurrence 
(Ernst and Matrai, 1987; Danesh et al., 1998). 
In addition to classical neutrophil recruitment, platelets bound to activated endothelial 
cells can interact with leukocytes, and induce ‘secondary capture’ which induces 
interactions of neutrophils with platelets first, followed by neutrophil-endothelial 
interaction (Mine et al., 2001). Under high shear stress as may be encountered in 
arterioles or stenotic arteries, platelets can adhere to subendothelial vWF. The 
interaction of platelets with vWF is mediated by the GPIb/IX/V complex. These 
interactions induce the activation of GPIIb/IIIa with a subsequent binding of GPIIb/IIIa 
to immobilized vWF, fibrinogen, and other ligands (Yuan et al., 1999; Zaffran et al., 
2000). The binding of integrin α5β1 to fibronectin can also mediate stable adhesion. 
Neutrophil rolling on platelets is mostly mediated by platelet P-selectin binding to P-
selectin glycoprotein ligand (PSGL) on leukocytes. Firm adhesion of leukocytes to 
platelets is achieved by CD11b/CD18 and CD11a/CD18. Further mechanisms involved 
in firm adhesion include the simultaneous binding of fibrinogen to GPIIb/IIIa on 
platelets and CD11b/CD18 on leukocytes and the binding of GPIbα to CD11b/CD18. 
Hence, GPIIb/IIIa antagonists do not prevent the formation of platelet-neutrophil-
aggregates in patients (Zhao et al., 2003). Upon adhesion of PMN to platelets, 
activation of PMN is induced through PSGL-1 and chemokine and lipid mediators 
presented by platelets.  
In addition to interacting with neutrophils, platelets interact with other leukocyte 
subpopulations. Platelets present chemokines to and thereby activate monocytes (Huo 
et al., 2001). Activated platelets increase monocyte binding to inflamed endothelium, 
which is important in atherosclerosis. The interaction between endothelial cells, 
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platelets, and monocytes leads to increased monocyte recruitment and accelerates the 
development of atherosclerotic lesions (Huo et al., 2003). 
The end result of platelet activation is conversion of soluble fibrinogen into insoluble 
fibrin and also activation and recruitment of other platelets. Platelets along with other 
cells such as erythrocytes and monocytes are trapped in the fibrin mesh formed by 
fibrin polymerisation resulting in growth and stabilisation of thrombus. 
1.3.4 Platelet procoagulant activity 
Activated platelets further activate other resting platelets and interact with other 
coagulant factors, eventually promoting thrombogenesis (Ilveskero et al., 2001). This 
inherent property of platelets is known as platelet procoagulant activity (PPA). 
Activated platelet adhesion is mediated by vWF and GPIb interaction as described 
earlier. This interaction also initiates PPA which comprises of changes in platelet 
membrane architecture, intra cytoplasmic enzyme activation and release of powerful 
procoagulants from the platelets.  
The plasma membrane of activated platelets provides this surface for the assembly of 
the "tenase" and "prothrombinase" complexes that activate factor X and prothrombin, 
respectively. Activation of factor X and conversion of prothrombin to thrombin are the 
most powerful steps in the coagulation cascade. Platelet plasma membrane 
asymmetry is maintained by two enzymatic activities: a "flippase" directing the inward 
transport of lipids and a "floppase" that directs the transport of choline- and amino-
phospholipids to the outer leaflet. Following an agonist-stimulated rise in intraplatelet 
calcium (Ca2+), membrane asymmetry is lost with exposure of anionic phospholipids 
on the platelet surface. Platelets then round off to balloon-like structures as well as 
developing membrane blebs termed membrane vesicles or microparticles. The 
significance of microparticles is described elsewhere.  
High shear forces can increase PPA. In high shear conditions, despite blocking vWF 
and GPIb receptors platelet activation was present. Increased release of ADP and 
intraplatelet accumulation of Ca2+ in activated platelets under high shear conditions 
help sustain further procoagulant activity thereby enhancing thrombogenesis (Goto et 
al., 2003; Chen et al., 2010). Activated platelets contribute to coagulation activity by 
releasing several compounds including thrombin, factor V, factor XIII, fibrinogen, vWF, 
calcium ions and ADP from their α-granules and dense granules. These in turn activate 
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the resting platelets and this vicious cycle helps to maintain and increase platelet 
procoagulant activity (Jennings, 2009). 
1.3.5 Coagulation physiology and factors 
The coagulation system, together with endothelial cells and platelets, is responsible for 
maintaining blood in a fluid state, but when activated rapidly results in the development 
of a fibrin clot by conversion of the fibrinogen to the insoluble polymer fibrin by the key 
enzyme, thrombin (Mann, 1999; Dahlback, 2000). The coagulation system comprises 
of proenzymes that typically reside in the intravascular space in an inactivated state 
together with cofactors, cations and cell-associated phospholipids. Coagulation can be 
activated by two principal mechanisms, the intrinsic and the extrinsic pathways that 
converge to produce thrombin by the common pathway through a series of inter-related 
enzymatic reactions (Davie and Ratnoff, 1964; Macfarlane, 1964).  
The intrinsic pathway 
One mechanism of coagulation activation is the intrinsic pathway, so called because 
its components, factors XII, XI, IX, VIII, prekallikrein (PK), and high molecular weight 
kininogen (HMWK), are all plasma proteins and are “intrinsic” to the lumen of the blood 
vessel. The intrinsic pathway can be activated when factor XII undergoes auto-
activation to factor XIIa on a negatively charged surface through a process called 
“contact activation” (Gailani and Renne, 2007) (Figure 1.6). Negatively charged 
surfaces include the artificial reagents in the APTT assay, such as kaolin, celite, and 
silica, which explains the dependence of the APTT on the contact activation factors. 
However, the intrinsic pathway can be activated in vivo by substances such as articular 
cartilage, endotoxin, L-homocysteine, and the developing thrombus (Schmaier and 
McCrae, 2007). Activation of factor XII leads to conversion of PK to kallikrein, facilitated 
by the cofactor HMWK, with kallikrein further stimulating the activation of factor XII. 
Activated factor XII subsequently activates factor XI, with factor XIa activating factor 
IX. Factor IXa, together with factor VIIIa, phospholipids, and calcium from the tenase 
complex that activates factor X. The intrinsic pathway can also be activated in a cell-
based process, as the components can assemble on endothelial cells, platelets, and 
granulocytes. HMWK-PK binds to a cell-based receptor complex, which includes a 
binding protein for the globular head domains of complement component C1q, 
designated gC1qR, cytokeratin 1 (CK1) and urokinase plasminogen activator receptor 
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(u-PAR) (Schmaier and McCrae, 2007). Prolylcarboxypeptidase (PRCP) bound to the 
complex activates PK to form plasma kallikrein, resulting in factor XII activation. Apart 
from activation of factor XI, this complex is involved in other physiological activities 
through formation of bradykinin, which participates in fibrinolysis activation and the 
production of antiplatelet molecules, nitric oxide and prostacyclin, from endothelial 
cells. 
The Extrinsic Pathway  
The so-called Extrinsic Pathway of coagulation, comprising tissue factor (TF) and 
factor VII, is activated by tissue injury or cellular activation and is likely the primary 
mechanism for in vivo haemostasis (Dahlback, 2000; Mackman et al., 2007). TF is an 
intrinsic membrane glycoprotein expressed on many vascular wall cells, such as 
endothelial cells, vascular smooth muscle cells, pericytes, fibroblasts (Day et al., 2005) 
and blood borne cells including platelets and monocytes (Giesen et al., 1999; Steffel 
et al., 2006). TF is a 236-residue membrane-bound glycoprotein which is not normally 
present in or exposed to the circulation. Constitutively expressed cell-based tissue 
factor can be exposed to the blood following vascular injury, but tissue factor 
expression can also be induced on vascular endothelial cells and leukocytes by 
thrombin and inflammatory stimuli. This induction is well described for monocytes, but 
also may occur in neutrophils and eosinophils. Activation of many cells leads to 
production of minute membrane-bound microparticles, which may be a source of 
circulating tissue factor activity (Aras et al., 2004). Recent studies have shown that 
platelets can be stimulated to produce TF mRNA and synthesize TF protein (Panes et 
al., 2007). 
Fibrin Formation and Common Pathway Activation  
The purpose of coagulation is the formation of an insoluble fibrin polymer as a 
hemostatic plug. To this end, the transformation of plasma-based fibrinogen to cross-
linked insoluble fibrin is accomplished by several mechanisms and is tightly regulated. 
Fibrinogen is a plasma protein synthesised by liver which helps blood thrombogenesis 
and platelet aggregation. This is also an acute phase reactant and a marker of 
inflammation. It is present in blood at a concentration of 2.0 to 5.0 g/dl. Fibrinogen 
binds with high affinity to the α2b/β3a integrin receptor on activated platelets, and acts 
as a bridge to link platelets. Fibrinogen dimer is composed of two mirror-image groups 
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of three polypeptide chains, the Aα, Bβ, and γ chains which are held together by a 
group of central disulfide bonds (McKee et al., 1966). Fibrinogen has a trinodular 
structure, with the central disulfide bonded area forming the central E domain, and the 
flanking polypeptides forming two lateral D domains (Yang et al., 2000) (Figure 1.7). 
Serum fibrinogen level is a well-known independent risk factor for coronary artery 
disease. In a longitudinal observational study over 13 years, elevated plasma 
fibrinogen was associated with higher rates of subclinical cardiovascular disease 
(Danesh et al., 1998).  
Fibrin is formed by polymerisation of fibrinopeptides. Thrombin cleaves off small 
fibrinopeptides from the Aα and Bβ chains, converting fibrinogen to fibrin monomer. 
Binding sites in the central region of the fibrin monomer, termed A-knobs and B-knobs, 
are exposed. This allows the “knobs” on one monomer to bind to γC and βC “holes” in 
the D domains in another monomer in a half-staggered overlap pattern, facilitating non-
covalent assembly into a fibrin protofibril polymer (Weisel, 1986; Yang et al., 2000). 
The protofibrils then associate laterally into bundles that form thicker fibers. Concurrent 
with the conversion of fibrinogen to fibrin, thrombin catalyses the activation of factor 
XIII, a transglutaminase enzyme that stabilizes the fibrin polymer by forming covalent 
crosslinks between γ chains in the D domains of adjacent fibrin molecules (Chen and 
Doolittle, 1969). After reaching a sufficient length (600-800 nm) protofibrils elongate 
laterally by binding to their adjacent fibrils to form mesh like fibrin network (Cohen et 
al., 1983; Weisel, 1986; Ryan et al., 1999). Twisting of individual fibrin fibres limits its 
length and lateral growth thereby reducing the available binding sites for fibrinolytic 
agonists. Increased thickness of fibrin strands in this way limits the growth of fibre 
(Wolberg, 2007). Fibrin is characterised by stiffness (representing its elastic properties) 
and compliance (representing its inelastic properties). 
Thrombin, which plays a key role in the formation of fibrin and its crosslinking, is a 
serine protease that is formed from prothrombin by the action of factor Xa and the 
prothrombinase complex, a phospholipid membrane-based complex consisting of 
factors Xa and Va together with calcium (Lane et al., 2005). Apart from fibrin formation, 
thrombin is associated with propagation of coagulation through activation of factors V 
and VIII, thus accelerating the activity of the prothrombinase and tenase complexes, 
respectively (Brummel et al., 2002) (Figure 1.8). Thrombin also exhibits direct 
activation of factor XI. Thrombin also activates platelets and other cells, such as 
endothelial cells and monocytes via G-coupled protease-activated receptors (PARs) 
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(Martorell et al., 2008). Upregulation of PARs in smooth muscle cells play a key role in 
the pathogenesis of atherosclerosis (Barnes et al., 2004). Due to its wide-ranging 
effects, thrombin activity is closely regulated. The activation of thrombin requires the 
action of factor Xa, in the prothrombinase complex resulting in cleavage of a peptide 
fragment, prothrombin fragment F1 + 2, from prothrombin (Tracy et al., 1985).  
The formation of active factor Xa from the proenzyme factor X is considered the start 
of the common pathway and can be triggered by both TF/factor VIIa from the extrinsic 
pathway and by the tenase complex (factors IXa, VIIIa, calcium, and phospholipids) 
from the intrinsic pathway (Dahlback, 2000). Having two separate mechanisms for 
factor Xa activation is thought to be associated with two temporal stages of blood 
coagulation (Butenas et al., 1997; Butenas et al., 2007), the initiation and propagation 
stages. In the initiation stage, factor X is initially activated by TF/factor VIIa. This 
produces small amounts of thrombin, which activates factors V and VIII, leading to 
further thrombin production (Brummel et al., 2002).  
1.3.6 Regulation of coagulation 
The major regulation of TF/factor VIIa activity is through an inhibitor, tissue factor 
pathway inhibitor (TFPI). TFPI, a serine protease then downregulates the ability of 
tissue factor/VIIa to activate factor X (Broze et al., 1993; Lu et al., 2004). TFPI may 
also further downregulate coagulation by causing TF-expressing cells to internalise 
surface TF/factor VIIa complexes (Iakhiaev et al., 1999). Coagulation then enters the 
propagation phase, directing the activity of tissue factor/VIIa toward activation of factor 
IXa, resulting in a switch of the primary activation of factor X to be via the intrinsic 
pathway tenase complex. Further thrombin production leads to the activation of factor 
XIa, which amplifies the propagation phase further.  
Levels of TFPI correlate positively to levels of TF in patients with dyslipidaemia 
(Hansen et al., 2001) and acute coronary syndrome (Falciani et al., 1998; Gori et al., 
2002). Hyperactivation of the coagulation system in ischaemic heart disease patients 
may, in part be compensated for by TFPI but may not be sufficient to attenuate the 
elevation of TF (Viles-Gonzalez and Badimon, 2004).  A rise in TFPI is a marker of 
hyperactivation of the coagulation system and offers some but not full protection 
against future thrombotic events (Leurs et al., 1997; Badimon et al., 1999a). 
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Figure 1.6 The coagulation cascade.  
Subendothelial collagen and tissue factor, both released during vessel intimal 
injury, initiate the intrinsic and extrinsic pathways, respectively, of the cascade. 
Ca++ = calcium, HMWK = high-molecular-weight kininogen, PK = prekallikrein 
 
 
 
Figure 1.7 Schematic diagram of the three pairs of polypeptide chains 
of fibrinogen.  
The Aα, Bβ, and γ chains are represented by bars with lengths proportional to 
the number of amino acid residues in each chain and the N- and C-terminal ends 
of the chains are labelled. The coiled-coil regions are indicated by the diagonally 
striped boxes, while the intra- and inter- chain disulfide bonds are indicated by 
solid lines. Carbohydrate attachment sites are labelled with CHO, while thrombin 
and major plasmin cleavage sites are indicated by T and P, respectively. From 
(Weisel, 2005) 
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Figure 1.8 Schematic diagram of fibrin polymerization.  
Fibrinopeptide A is cleaved from fibrinogen, producing desA fibrin monomers, 
which aggregate via knob-hole interactions to make oligomers. Fibrinopeptide B 
is cleaved primarily from polymeric structures. The oligomers elongate to yield 
protofibrils, which aggregate laterally to make fibers, a process enhanced by 
interactions of the αC domains. Factor XIIIa crosslinks or ligates γ chains more 
rapidly than α chains. Plasmin cleaves the αC domains and Bβ1-42 and then 
cuts across the fibrin in the middle of the coiled coil. At the bottom of the diagram, 
a branch point has been initiated by the divergence of two protofibrils. From 
(Weisel, 2005). 
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1.4 Blood thrombogenicity in Diabetes and Ageing 
Higher cardiovascular mortality has been attributed to higher thrombogenicity in 
patients with T2DM (Osende et al., 2001; Berry et al., 2007). In vitro studies have 
demonstrated an inherent prothrombotic state in patients with T2DM. Endothelial 
dysfunction, coagulation factors, hyperactive platelets, inflammatory milieu and 
impaired fibrinolysis results in higher blood thrombogenicity in patients with T2DM 
(Balasubramaniam et al., 2012). Antiplatelet therapy reduces this thrombogenicity but 
less so in those with T2DM compared to those without (Natarajan et al., 2008a). Hypo-
responsiveness to current antiplatelet therapy may also be contributing towards excess 
mortality seen in patients with T2DM (Angiolillo, 2009b).  
The incidence of thrombotic cardiovascular disease dramatically increases with age 
(Tracy and Bovill, 1992), and recent studies have begun to address the important 
clinical problem of “ageing and thrombosis” (Wilkerson and Sane, 2002). Age-related 
changes may occur in the vascular and hemostatic systems, which includes platelets, 
coagulation, and fibrinolytic factors as well as endothelial changes. Ageing-associated 
sclerotic changes in the vascular wall may also contribute to the increased incidence 
of thrombosis in the elderly (Kiechl et al., 1999). The hypercoagulability of the blood in 
the elderly may be yet another cause of the increased thrombotic tendency. For 
example, platelet activity is enhanced with advancing age, and ageing is associated 
with increased plasma levels of several blood coagulation factors (e.g., factor VII, 
factor VIII, and fibrinogen) (Balleisen et al., 1985), all of which have been shown to be 
risk factors for thrombotic diseases (Koster et al., 1994). Advanced age is associated 
with elevated interleukin-6 (IL-6) and C-reactive protein (CRP) levels, indicating an 
inflammatory state that may also be an important stimulus for thrombus formation in 
the elderly. On the other hand, a proportional increase in natural anticoagulant factors 
(e.g., protein C, protein S, antithrombin, tissue factor pathway inhibitor, etc.) has not 
been observed in the elderly (Sagripanti and Carpi, 1998). The fibrinolytic system is 
impaired by ageing since a progressive prolongation of the lysis time (Abbate et al., 
1993) and an increase in plasminogen activator inhibitor-1 (PAI-1), a principal regulator 
of fibrinolysis (Loskutoff, 1988), have been observed with ageing (Hashimoto et al., 
1987). Thus, increases in coagulation factors without a proportional increase in 
anticoagulant factors is the likely contributing factor for increased thrombotic events in 
the elderly. As the population ages, further studies are warranted to define the 
mechanisms for thrombosis in the elderly. 
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1.4.1 Platelets in Diabetes - “Angry Diabetic” platelets and Ageing platelets 
ACS is precipitated by the ischaemic effect of an occlusive intra-coronary thrombus 
that develops over a ruptured atheromatous plaque as a result of platelet adhesion and 
aggregation (Badimon et al., 1999b). Platelet function is significantly altered favouring 
a thrombotic tendency in patients with T2DM (Vinik et al., 2001; Natarajan et al., 2008b; 
Ferroni et al., 2009). Platelets in patients with T2DM constantly remain in a state of 
hyperactivation and hence have been referred to as ‘angry platelets’ (Bhatt, 2008). 
Platelet synthesis is also enhanced in patients with T2DM. As diabetic platelets 
respond more frequently to sub-threshold stimuli, they soon become exhausted, 
consumed and finally incorporated into thrombus. This relative excess consumption of 
platelets results in accelerated thrombopoiesis in the bone marrow mediated by 
thrombopoietin and the release of ‘fresh’ hyper-reactive platelets (Watala et al., 1999; 
Watala et al., 2005). 
Among diabetic individuals increased platelet aggregation and adhesion are due to: 
 Reduced platelet membrane fluidity due to changes in the lipid composition or 
glycation of membrane proteins (Papanas et al., 2004)  
 Increased production of thromboxane A2 (TXA2) which increases platelet 
sensitivity (Halushka et al., 1981) 
 Increased expression of platelet adhesion molecules such as CD31, CD36, 
CD49b, CD62P and CD63 (Eibl et al., 2004) 
 Upregulation of platelet ADP P2Y12 receptor signalling leading to increased 
adhesion, aggregation and pro-coagulant activity 
 Increased expression of platelet surface receptors such as P-selectin, 
Glycoprotein (GP) Ib and GP IIb/IIIa (Lefkovits et al., 1995)  
 Increased generation of platelet dependent thrombin 
 Decreased sensitivity to the effects of PGI2 and NO (Ferroni et al., 2004) 
 Disorder in calcium and magnesium haemostasis. Increased intracellular 
calcium and decreased intracellular magnesium have been linked to platelet 
hyperaggregability and adhesiveness (Gawaz et al., 1994; Lee et al., 2001) 
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 Increased platelet content of cytokines and chemokines such as platelet factor-
4, interleukin-1β and CD40L contribute to inflammation and atherogenesis 
alongside a pro-coagulant milieu (Ross, 1999; Lindemann et al., 2001; 
Cipollone et al., 2002; Weyrich et al., 2003) 
 Accelerated platelet turnover results in the presence of ‘young’ activated 
platelets in the circulation which demonstrate reduced responsiveness to 
antiplatelet agents and augment their response to naturally circulating agonists 
(Ferreiro and Angiolillo, 2011) 
These platelet characteristics may contribute to the poorer outcomes observed in DM 
patients despite compliance with the recommended secondary prevention therapy. 
A significant age related elevation in the markers of platelet activation such as β 
thromboglobulin and platelet factor 4 has been observed (Zahavi et al., 1980). Platelets 
of individuals aged 60 years showed greater aggregation in response to ADP and 
collagen than did the platelets from younger individuals (Kasjanovova and Balaz, 
1986). A significant reduction in the bleeding time and an increase of eicosanoid 
biosynthesis has been reported in older individuals, suggesting that platelet activation 
increases with age (Reilly and Fitzgerald, 1986). The increase of platelet activity with 
age is also correlated with higher content of platelet phospholipids, suggesting an age 
related increase in platelet transmembrane signalling (Bastyr et al., 1990a).      
1.4.2 Microparticles in Diabetes and Ageing 
In addition to platelets, microparticles (MPs) are also involved in diabetic 
atherothrombosis. MPs are small membrane coated vesicles (size: 0.02 to 0.10 µm) 
that emerge by exocytosolic budding from their parental cells upon activation or 
apoptosis and which carry procoagulant activity (Burnier et al., 2009). They retain at 
least some functions of their cells of origin, which can include platelets, endothelial 
cells and various leukocytes.  MPs have the ability to activate the coagulation cascade 
with consequent thrombosis formation (Morel et al., 2010). Platelet-derived MPs 
(PMPs) expose negatively charged phospholipids which act as binding sites for 
activated coagulation factors (George, 2008). Platelet MPs also bind to the sub 
endothelial matrix and act as a substrate for further platelet adhesion via GP IIb/IIIa 
fibrinogen bridging (Morel et al., 2008). Monocyte-derived MPs (MMPs) exposing TF 
have P-selectin glycoprotein ligand-1 which interacts with P-selectin on the surface of 
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activated platelets and helps in further stabilization of thrombus. Other possible 
pathways regulated by MPs include production of lysophosphatidic acid (a strong 
platelet agonist), endothelial and leukocyte activation, recruitment of monocytes within 
the plaque, stimulation of neoangiogenesis, induction of apoptosis in endothelial or 
smooth muscle cells and increase in T XA2 release which in turn causes 
vasoconstriction (Ardoin et al., 2007; Leroyer et al., 2008).  
Increased levels of platelet-derived MPs and their role in macrovascular complications 
have been reported in patients with T2DM patients (Nomura et al., 1995). Elevated 
levels of endothelial cell-derived MPs (EMPs) are predictive for the presence of 
coronary artery lesions, and are a more significant independent risk factor than the 
duration of DM, lipid levels and history of hypertension (Nomura et al., 2004). In 
patients with T2DM and ACS, increased EMPs have been linked to non-calcified 
atheromatous lesions as detected by multi-detector computed tomography (Bernard et 
al., 2009). Increased levels of procoagulant TF positive MPs have been demonstrated 
within the occluded coronary artery of patients with STEMI (Morel et al., 2009). 
Beneficial effects of statins in T2DM and atherothrombosis are possibly due to their 
effects on MPs (Sommeijer et al., 2005; Koh et al., 2007; Diamant et al., 2008; Nomura 
et al., 2009). All this evidence indicates that MPs are not only a reliable marker for 
vascular injury but they also actively participate in promoting atherothrombotic 
complications in T2DM (Morel et al., 2010). 
Age was shown to be associated with reduced basal levels of EMP but with 
preservation of MP procoagulant potential (Forest et al., 2010). In stable conditions, 
despite a reduction in EMP, procoagulant activity was maintained using PMP, RBC-
MP, TF-bearing MP or annexin V MP in the elderly (Forest et al., 2010). These results 
suggest that MP still carry their procoagulant activity with age, possibly due to reduced 
ability to maintain energy consuming plasma membrane phospholipid asymmetry, 
resulting in increased exposure of the anionic procoagulant phospholipid 
phosphatidylserine on the external layer. 
In this context, drugs that may reduce the release of MPs and/or their thrombogenicity 
may have the potential to improve the effects of current antiplatelet therapy, resulting 
in lower adverse event rates in elderly patients and those with T2DM. 
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1.4.3 Platelet leukocyte aggregates (PLA) in Diabetes and Ageing 
Platelets and leukocytes from patients with DM are hyperreactive and express more 
adhesion molecules. P-selectin is one of the markers of platelet activation and is the 
main link for platelet adhesion to circulating leukocytes (Vandendries et al., 2004). 
Platelet P-selectin interacts with leukocyte P-selectin glycoprotein ligand (PSGL-1) 
leading to the formation of PLA (Rinder et al., 1991; Hidari et al., 1997). Consequently, 
activated leukocytes secrete several pro-inflammatory cytokines and express a pro-
thrombotic membrane phenotype. Elevated levels of circulating PLA have been 
reported in DM population, thereby suggesting their involvement in the pathogenesis 
of atherothrombosis. Elevated circulating PLA levels are linked with vascular injury in 
DM patients (Vandendries et al., 2004). A significant increase in circulating platelet-
polymophonuclear aggregates (PPA) and platelet-monocyte aggregates (PMA) 
percentages was demonstrated in DM patients (Elalamy et al., 2008). Interestingly, 
levels of circulating PPA and PMA were significantly higher in DM with vascular injury 
compared to DM without vascular injury, suggesting the involvement of inflammatory 
leukocytes in vascular damage (Hu et al., 2004; Elalamy et al., 2008). 
Platelet aggregation in platelet-rich plasma (PRP) is increased in the elderly, relative 
to young individuals, in response to the agonists ADP, epinephrine, collagen and 
arachidonic acid. Platelet reactivity, aggregation, adherence to thrombogenic surfaces 
and plasma levels of the secreted platelet α-granule protein thromboglobulin are 
increased in elderly. However, there are no published data comparing circulating PLA 
levels among older and younger individuals. 
1.4.4 Coagulation in Diabetes and Ageing 
TF and Factor VII (F VII) initiate the thrombotic process, resulting in the generation of 
thrombin. This subsequently helps in the conversion of fibrinogen into a three-
dimensional network of fibrin fibres which forms the skeleton of the blood clot 
(Alzahrani and Ajjan, 2010). TF is an integral prothrombotic transmembrane protein 
expressed by both vascular and non-vascular cells, including monocytes, 
macrophages and platelets (Breitenstein et al., 2010). In T2DM, TF expression is 
upregulated due to the presence of low grade inflammation. Levels of TF in 
atherosclerotic plaques in patients with unstable angina are higher compared with 
those who have stable angina (Annex et al., 1995). Plasma TF levels are raised in 
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subjects with CAD, particularly ACS, further emphasising the role of TF in 
atherothrombosis (Suefuji et al., 1997; Soejima et al., 1999). Patients with T2DM have 
higher circulating TF levels which are directly modulated by glucose and insulin, and 
the two appear to have an additive effect (Boden et al., 2007). In T2DM, increased 
levels of advanced glycation end products and reactive oxygen species activate NFκB 
which in turn leads to increased TF production (Breitenstein et al., 2010). 
Factor VII is a vitamin-K dependent coagulation factor synthesised in the liver. F VII 
coagulant activity (F VII: c) has been associated with fatal cardiovascular events 
(Folsom et al., 1991; Heinrich et al., 1994; Scarabin et al., 1998). T2DM subjects have 
elevated F VII: c levels (Heywood et al., 1996). An association between triglyceride 
levels and F VII: c levels has been demonstrated; this appears to be independent of 
obesity and insulin resistance (Karatela and Sainani, 2009). 
Thrombin concentration influences fibrin clot formation and also determines the clot 
structure and stability (Wolberg and Campbell, 2008). High thrombin concentration 
results in denser and less permeable clots which are more resistant to lysis. Thrombin 
generation is enhanced in T2DM secondary to low grade coagulation system activation 
(Boden et al., 2007; Ceriello et al., 2009).  
Plasma fibrinogen is a well-known independent CVD risk factor and is used as a 
surrogate marker for CVD risk (Corrado et al., 2010). High fibrinogen levels predict 
silent myocardial ischaemia in patients with T2DM (Guardado-Mendoza et al., 2009). 
High levels of IL-6 in T2DM stimulate fibrinogen synthesis by hepatocytes, 
representing a link between inflammation and the prothrombotic state (Ajjan and Grant, 
2006). Insulin resistance is also associated with increased hepatocyte fibrinogen 
synthesis (Barazzoni et al., 2003; Tessari et al., 2006). Overall, in patients with T2DM 
there is increased TF production, increased F VII: c levels, increased thrombin 
generation, high levels of IL-6 and fibrinogen. 
Fibrinogen levels increase with advancing age from approximately 18 to 85 years old 
(Tracy et al., 1992). Plasma concentrations of IL-6, F VII, factor VIII, factor IX activation 
peptide, factor X activation peptide, prothrombin fragments 1+2, thrombin-antithrombin 
(TAT) complex and fibrinopeptides A (FPA) were found to positively correlate with 
advancing age (Bauer et al., 1987; Mari et al., 1995).  
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1.4.5 Fibrinolysis in Diabetes and Ageing 
Fibrinolysis is initiated by the conversion of plasminogen to plasmin and this is largely 
mediated by tissue plasminogen activator (tPA). Plasminogen activator inhibitor-1 
(PAI-1) is the main inhibitor of fibrinolysis by binding to tPA and forming PAI-1/tPA 
complex. In a long term 18 year study, glycated haemoglobin (HbA1C) correlated 
positively with PAI-1 and negatively with tPA. This demonstrates an association 
between hyperglycaemia and elevated PAI-1 levels (Seljeflot et al., 2006). 
Hyperinsulinaemia also has been shown to increase PAI-1 levels, which may account 
for elevated PAI-1 levels in insulin resistant states (Alessi and Juhan-Vague, 2008; 
Stegenga et al., 2008). 
A study indicated that clots derived from fibrinogen purified from plasma from 150 
subjects with T2DM had a more compact structure characterised by smaller pore size, 
increased fibrin thickness and number of branch points than that from 50 healthy 
controls (Dunn et al., 2005). Clot lysis from diabetic patients was slower when 
compared to controls due to elevated PAI-1 levels. 
There is strong evidence that PAI-1 increases with ageing (Wilkerson and Sane, 2002). 
A significant age related decrease in fibrinolytic activity, documented by an increase in 
PAI-1 levels has been reported (Mehta et al., 1987). Age related increase of plasmin-
antiplasmin complex, D-dimer and thrombin activatable fibrinolysis inhibitor (TAFI) 
have also been reported (Mari et al., 1995; Sakkinen et al., 1999; Schatteman et al., 
1999).
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Figure 1.9  Fibrinolytic system and its regulation. 
Plasminogen activators convert plasminogen to plasmin. Plasmin then degrades 
fibrin into soluble fibrin degradation products. The system is regulated at two 
levels. PAI-1 regulates the plasminogen activators, whereas α2-antiplasmin 
serves as the major inhibitor of plasmin. From Jeffrey I, Haemostasis, 
thrombosis, fibrinolysis and cardiovascular disease, Braunwald’s Heart Disease. 
9th edition.  
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1.4.6 Inflammation and thrombosis in Diabetes and Ageing 
The presence and extent of inflammation, procoagulant state and composition of the 
atherosclerotic plaque have been strongly associated with an increased risk of future 
cardiovascular events. Thus, the perpetuation of the inflammatory response likely 
plays a pivotal role in the pathobiology and vulnerability of the atherosclerotic plaque. 
Inflammatory markers once thought to be passive observers are now being 
investigated as active participants in the progression of atherosclerosis and therefore 
targets for future pharmacological intervention. Inflammation up-regulates 
procoagulants and down-regulates anticoagulants and fibrinolysis. 
Subclinical chronic low-grade inflammation is linked to insulin resistance and is 
involved in the pathogenesis of type 2 diabetes (Stern, 1995; Herder et al., 2005). 
Inflammatory and insulin signalling pathways are tightly linked, both of which lead to 
insulin resistance and endothelial dysfunction, contributing to cardiovascular 
complications including coronary events (Hotamisligil, 2006). As mentioned earlier, it 
is possible that inflammation is the hidden but potent ‘common soil’ for the 
prothrombotic state in T2DM (Omoto et al., 2002; Koga et al., 2005).  
 Adipose tissue is an active endocrine and paracrine organ that releases a large 
number of cytokines and bioactive mediators, such as leptin, adiponectin, IL-6 and 
TNF-α that influence insulin resistance, inflammation and atherosclerosis (Hauner, 
2005; Halberg et al., 2008). Obesity is also associated with more generalized, systemic 
inflammation involving circulating inflammatory proteins such as CRP, IL-6, PAI-1, P-
selectin, VCAM-1, and fibrinogen. Adhesion molecule expression is induced by 
proinflammatory cytokines such as IL-1β, TNF-α, and CRP produced by the liver in 
response to IL-6 (Szmitko et al., 2003). A study was performed in offspring of patients 
with T2DM who are at high risk of developing diabetes and CVD. This demonstrated 
the presence of insulin resistance, an excess of intra-abdominal fat mass, 
hypoadiponectinemia, and multiple defects in glucose and energy metabolism in these 
individuals (Salmenniemi et al., 2004). This study also demonstrated high levels of 
high-sensitivity CRP (hsCRP), IL-6, IL-1β, IL-1 receptor antagonist, and adhesion 
molecules (P-selectin, ICAM-1) among these pre-diabetic subjects, indicating that low-
grade inflammation and markers of endothelial dysfunction are characteristic findings 
in subjects at high risk of T2DM and CVD (Ruotsalainen et al., 2008). 
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Tumour necrosis factor α (TNFα) is a pleiotropic proinflammatory cytokine present 
in atherosclerotic lesions. This appears to be one of the most important influences on 
the progression of atherosclerosis. Its upregulation is known to mediate and amplify a 
multitude of interactions resulting in progressive inflammation, plaque destabilisation 
and prothrombotic tendencies (Rus et al., 1991). Plasma TNFα levels are higher in 
T2DM and have been linked to insulin resistance and complications of T2DM such as 
retinopathy and nephropathy (Mavridis et al., 2008). Suppression of TNFα either by 
biological antagonists or by physical measures such as weight reduction and exercise 
improves glycaemic control in T2DM. Treatment with biological antagonists to TNFα 
has been shown to suppress inflammation in patients with rheumatoid arthritis and has 
also been proven to be associated with the rapid down-regulation of a spectrum of 
cytokines (IL-6), cytokine receptors and acute phase proteins (amyloid A, haptoglobin 
and fibrinogen) (Charles et al., 1999). This potent suppression of markers and 
mediators of inflammation may have tremendous potential in preventing progression 
of atherosclerosis. 
Interleukins, especially IL-6 and IL-8 circulating levels are significantly higher in 
patients with T2DM compared to those without even after adjustment for confounding 
factors including visceral obesity. IL-6 increases platelet production and indirectly 
increases thrombogenicity since young platelets are more thrombogenic compared to 
the old platelets (Lim et al., 2004). IL-6 increases fibrinogen and PAI-1, promotes 
adhesion of neutrophils and myocytes during myocardial reperfusion (Miyao et al., 
1993). Elevated levels of IL-6 in subjects with unstable angina were associated with 
higher 6- and 12- month mortality which was independent of troponin levels (Lindmark 
et al., 2001). IL-8 is a powerful trigger for firm adhesion of monocytes to vascular 
endothelium. In addition, it may play a potential atherogenic role by inhibiting local 
inhibitors of metalloproteinases in atherosclerotic plaques and by stimulating smooth 
muscle cell migration (Yue et al., 1993; Gerszten et al., 1999). Inflammatory mediators 
induce expression of protease activated receptors (PARs) on the endothelium of 
patients with T2DM which in turn increases leukocyte adhesion molecules on the cell 
surface (Dangwal et al., 2011). 
Adipokines, such as leptin, adiponectin, TNF-α, IL-6, resistin, visfatin, and retinol-
binding protein 4, have been suggested to be associated with insulin resistance (Van 
Gaal et al., 2006). Adiponectin has important anti-atherogenic, antidiabetic, and anti-
inflammatory properties and is expressed abundantly in adipocytes. In subjects with 
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an excess of intra-abdominal fast mass, adiponectin levels are low, which might be 
explained by an increase in TNF-α secretion from visceral fat. High adiponectin level 
correlates with high insulin sensitivity (Kadowaki et al., 2008). Adiponectin inhibits the 
expression of ICAM-1, VCAM-1, and E-selectin through the inhibition of nuclear factor-
κB (NF-κB) activation and has several antiatherogenic and anti-inflammatory 
properties (Kadowaki et al., 2008). 
Ageing is associated with increased inflammatory activity in the blood, including 
increased circulating levels of TNF-α (Bruunsgaard et al., 1999), IL-6 (Ershler et al., 
1993; Cohen et al., 1997), cytokine antagonists, acute-phase proteins and neopterin 
(Ballou et al., 1996). Increased inflammatory activity in the elderly may reflect age-
related pathological processes. Thus, atherosclerosis is an age-related inflammatory 
disease reflected by secretion of cytokines such as TNF-α, IL-1, IL-6, and IFN-γ and 
the presence of large numbers of macrophages and activated CD4+ T cells within 
inflammatory atherosclerotic plaques. 
High TNF-α levels in centenarians are associated with a low ankle-brachial arterial 
pressure index, indicating peripheral atherosclerosis. Furthermore, atherosclerosis 
and increased risk of thromboembolic complications have been associated with 
several parameters which are related to TNF α, e.g. increased circulating levels of IL-
6, acute-phase proteins such as C-reactive protein (CRP) and fibrinogen, intercellular 
adhesion molecule-1 (ICAM-1), leucocytes, and a lipid profile including increased 
levels of triglycerides, total cholesterol (TC), and low-density lipoproteins (LDL), 
decreased concentrations of high-density lipoproteins (HDL), and a low HDL/TC ratio. 
Thus, TNF-α is an early mediator of the acute-phase response and involved in the 
production of chemokines, IL-6, and CRP as well as the recruitment of leucocytes 
during inflammatory reactions. TNF-α is also known to induce smooth muscle 
proliferation and to increase adherence of leucocytes to endothelial cells by inducing 
the expression of cell adhesion molecules such as ICAM-1 and vascular cell adhesion 
molecule-1 (VCAM-1). Furthermore, TNF-α induces the expression of a wide range of 
cytokines, including chemokines and IL-6 by endothelial cells. TNF-α also has an 
important role in lipid metabolism by decreasing the activity of 7 α-hydroxylase and 
lipoprotein lipase and by stimulating the liver production of triglycerides. 
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1.4.7 Markers of inflammation 
Previous studies have shown that high levels of CRP, IL-6, and TNF-α predict 
subsequent development of T2DM (Schmidt et al., 1999). In one study, hsCRP levels 
were measured in 1,045 subjects with T2DM. Subjects with hsCRP >3 mg/l had a 
higher risk for CHD death than patients with hsCRP ≤3 mg/l, even after the adjustment 
for confounding factors (Soino et al., 2006). This study confirmed hsCRP as an 
independent risk factor for CHD deaths in patients with T2DM. In another recent study, 
hsCRP was independently associated with short-term mortality risk in individuals with 
T2DM and in those without a previous diagnosis of CVD (Bruno et al., 2009). The 
American Heart Association suggested in their guidelines on cardiovascular risk 
factors that higher levels of CRP are a hallmark of T2DM and may warrant preventive 
therapy for cardiovascular events even in patients with pre-diabetes (Sabatine et al., 
2007). 
CRP has been suggested to play a more direct role in atherothrombosis involving the 
endothelium, platelets, and leukocytes as well as vascular smooth muscle cells (Mazer 
and Rabbani, 2004; Paffen and Demaat, 2006). Evidence now suggests that CRP may 
possess procoagulant activity, as it has been shown to decrease tPA activity while 
increasing PAI-1 levels in human aortic endothelial cells (Devaraj et al., 2003; Singh 
et al., 2005). CRP also inhibits endothelial nitric oxide synthase and prostacyclin 
activity, thus promoting a prothrombotic state. CRP increases TF synthesis on 
monocytes, promotes platelet adhesion via up-regulation of P-selectin, promotes 
monocyte-platelet aggregation, increases vascular smooth muscle cell migration and 
proliferation, as well as neointima formation (Danenberg et al., 2007). 
 
. 
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1.5 Antiplatelet therapy in patients with CAD 
Platelets play a central role in thrombosis and hence anti-platelet agents are vital in 
prevention of acute coronary events in high risk patients. A clear benefit of antiplatelet 
agents in the prevention of atherothrombotic events in those at high risk is well 
established. Multiple genetic, iatrogenic and environmental factors influence platelet 
responsiveness to these agents. Three different classes of antiplatelet agents are 
approved for treatment and/or prevention of ACS:  
i. Cyclooxygenase-1 (COX-1) inhibitors (Aspirin)  
ii. ADP P2Y12 receptor antagonists (thienopyridines – Clopidogrel, Prasugrel and 
Ticagrelor) 
iii. Platelet GP IIb/IIIa inhibitors (Figure 1.10).  
Commonly used antiplatelet agents in patients with CAD and T2DM have been aspirin 
and clopidogrel. Prasugrel and Ticagrelor is being used more often than clopidogrel in 
ACS setting. Clopidogrel is still being used in patients who have contraindications to 
prasugrel or ticagrelor, elderly population or patients at high risk of bleeding. 
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Figure 1.10 Schematic representation of mechanisms of action of 
antiplatelet agents. 
PAR-1: Protease activated thrombin receptor – 1. Adapted from (Schafer, 1996) 
 
 
 
Figure 1.11 Structure of aspirin 
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1.5.1 Structure of aspirin 
Aspirin is the most widely used antiplatelet for prevention of atherothrombotic events. 
Low dose aspirin (e.g. 75mg daily) has been used as an antiplatelet therapy since 1960 
(Spectre and Varon, 2009). Aspirin (acetyl salicylic acid) is prepared from salicylic acid, 
by acetylation with acetic anhydride (Figure 1.11) (Vane and Botting, 2003). 
1.5.2 Pharmacokinetics of aspirin 
After oral intake, non-dissociated acetylsalicylic acid passively diffuses across the 
gastric and intestinal mucosa. Enteric coated aspirin has delayed absorption time 
(peak plasma levels in 3-4 hours) as compared to uncoated aspirin (peak plasma levels 
in 30-40 minutes). In the liver, it is hydrolysed by esterases. Aspirin has a half-life of 
about 15-20 minutes in human circulation but its antiplatelet effects last for the entire 
lifespan of platelets due to irreversible inhibition of COX-1, allowing the use of a once 
a day regimen despite the very short half-life of the drug (Reilly and Fitzgerald, 1987). 
The mean life span of human platelets is approximately 10 days. About 10% of 
circulating platelets are replaced each day and 5-6 days following aspirin ingestion 
approximately 50% of the platelets function normally. Aspirin thus exhibits a 
dissociation of pharmacokinetics and pharmacodynamics. Platelet function recovers 
after stopping aspirin faster than the predicted 10 days due to a non-linear relationship 
between thromboxane A2 (TXA2) biosynthesis and COX-1 inhibition (Perneby et al., 
2006). 
1.5.3 Mechanism of action of aspirin 
After rapid absorption from the stomach and upper small intestine, aspirin first comes 
in contact with platelets in the portal circulation, where it leads to irreversible 
inactivation of the cyclooxygenase activity of prostaglandin H synthase 1 and synthase 
2, referred to as COX-1 and COX-2 respectively. These enzymes catalyse the 
conversion of arachidonic acid to prostaglandin H2, which is then converted to 
prostaglandins, prostacyclin and TXA2 by tissue-specific isomerases. TXA2 induces 
potent platelet aggregation and vasoconstriction, whereas prostaglandins inhibit 
platelet aggregation and induces vasodilatation. In addition, TXA2 augments the 
actions of platelet agonists, is pro-atherogenic and a potent stimulus for vascular 
smooth muscle cells to express adhesion molecules (Vane and Botting, 2003).  
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After diffusing through the cell membrane, aspirin enters the COX channel, first binds 
to an arginine 120 residue, and then acetylates the serine 529 residue in COX-1 and 
serine 516 residue in COX-2. This prevents access of arachidonic acid to the COX site. 
As the anuclear platelets cannot synthesise new enzymes, this aspirin effect remains 
for the rest of their life span. In contrast, the inhibition of COX-2 dependent 
pathophysiological processes such as hyperalgesia and inflammation, mediated by 
nucleated cells, require higher doses of aspirin and frequent dosing because higher 
levels of aspirin are required to inhibit COX-2 than to COX-1 (Patrono et al., 2005a). 
In addition, unlike platelets, nucleated cells can repeatedly synthesise fresh COX-2, 
explaining the approximate 100-fold variation in daily doses of aspirin when it is used 
for anti-inflammatory rather than antithrombotic purposes. 
1.5.4 Dosage of aspirin for coronary artery disease 
Aspirin is commonly used at doses 75mg to 100mg for primary and secondary 
prevention of cardiovascular diseases. At this dose, it has maximal antiplatelet effect 
and reduces major cardiovascular events without excessively increasing the bleeding 
risk. Complete suppression of COX-1 mediated platelet activity has been shown to be 
achieved at doses 50 to 81mg (Patrono et al., 2005b; Lordkipanidze et al., 2007; 
Qayyum et al., 2008). Doses higher than 100mg have not been shown to provide 
additional benefit but increase bleeding risk. 
Low dose aspirin is effective as antiplatelet therapy in patients with CAD due to the 
following reasons: 
i. Complete suppression of COX-1 mediated platelet activity at low doses 
ii. Lack of significant clinical benefits at higher doses  
iii. Dose dependent side effects as explained below  
1.5.5 Side effects of aspirin 
In a sex-specific meta-analysis of the six primary prevention trials, aspirin use was 
associated with 70% increased risk of major bleeding events in men and women; this 
translated into causing one major bleeding event per 400 women and per 303 men 
over 6.4 years of aspirin use (Berger et al., 2006). Gastrointestinal tract ulceration, 
bleeding and perforation are expected adverse effects, in that, they are at least partly 
explained by inhibition of prostaglandin synthesis produced by aspirin. Gastrointestinal 
bleeding risk is dose-dependent; higher doses are associated with higher bleeding 
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rates. Concomitant use of NSAIDs, steroids, Helicobacter pylori infection, history of 
previous gastric ulcer and age more than 70 years increase the risk of gastrointestinal 
side effects of aspirin (Dutch, 1991; Farrell et al., 1991). A case-control study has 
suggested that proton pump inhibitors are more effective than H2 receptor antagonists 
in preventing upper gastrointestinal bleeding associated with aspirin use (Lanas et al., 
2007). Enteric-coated aspirin has been shown to be associated with endoscopically 
documented decreased risk of gastric mucosal injury in at least five randomised 
controlled trials (Walker et al., 2007). Meta-analysis by Antithrombotic Trialists’ 
Collaboration (ATC) found an odds ratio of 1.6 for major extracranial bleeding, e.g. 
gastric bleeding, in patients taking aspirin (Antithrombotic et al., 2009). 
Aspirin hypersensitivity is an uncommon adverse effect and desensitisation therapy 
may be successful in permitting the continued use of aspirin.  
1.5.6 Aspirin resistance 
The term “aspirin resistance” suffers from lack of consensus definition and validity. It 
has been varyingly defined as recurrence of major thrombotic events such as acute 
coronary events, stroke or peripheral vascular acute ischaemic events despite 
prescription of a regular therapeutic dose of aspirin (“clinical aspirin resistance”) or 
persistent ex vivo platelet activation and aggregation, measured by platelet function 
tests, despite aspirin use (“biochemical” or “laboratory aspirin resistance”). The 
reported prevalence of biochemical aspirin resistance ranges widely from 1% to 61% 
(Hankey and Eikelboom, 2006). A recent meta-analysis showed that patients with 
laboratory aspirin resistance have higher risk of clinical aspirin resistance (Snoep et 
al., 2007). Three studies followed individuals with failure to suppress thromboxane 
production by aspirin and found they were 2.2 to 4.3 times at risk of developing 
cardiovascular events (Sciulli et al., 2006; Santilli et al., 2009; Dragani et al., 2010). No 
study has shown clear benefit from routine screening for aspirin resistance. There is 
some indication that genetic factors such as polymorphism PLA1/A2 of the gene 
encoding for glycoprotein IIIa might be associated with altered platelet function and 
increased risk of cardiovascular events.  
In addition, non-compliance to aspirin intake is more common (up to 40%) than true 
aspirin resistance and hence any laboratory or clinical assessment of aspirin 
resistance should be adjusted for compliance to aspirin therapy (Cotter et al., 2004; 
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Schwartz et al., 2005). Other factors like cigarette smoking, concomitant use of 
NSAIDs including ibuprofen and indomethacin have been shown to antagonise the 
antiplatelet effect of aspirin.  
1.5.7 Aspirin and T2DM 
Patients with T2DM and CAD, have an increased risk of atherothrombotic events 
despite being on aspirin. Genetic variations, increased platelet activation, enhanced 
thrombopoiesis, increased thromboxane production and persistent thromboxane-
dependent activation of platelets have all contributed to aspirin unresponsiveness. This 
warrants the need for intensive platelet-inhibiting strategies in these high risk groups 
to reduce further ischaemic risk. Low dose aspirin at doses ranging from 75mg to 
325mg is currently the preferred antiplatelet agent for secondary prevention in 
individuals with T2DM and CAD. Low dose aspirin as a primary prevention measure in 
T2DM is controversial (Antithrombotic et al., 2009; De Berardis et al., 2009). Although 
in vitro studies demonstrate that doses of aspirin  less than 75mg  daily are sufficient 
to achieve full COX-1 inhibition, ex vivo pharmacodynamic studies have suggested 
that patients at high risk, such as those with T2DM, may have improved 
pharmacodynamic responses with higher doses of aspirin. Hence, it has been argued 
that patients with T2DM may need higher doses of aspirin for secondary prevention 
therapy.  
Mortensen et al demonstrated that patients with T2DM and CAD on aspirin 75mg OD 
had higher platelet reactivity compared to non-diabetic patients with CAD, as 
measured by two different point of care tests (Mortensen et al., 2010). T2DM is a 
significant risk factor for residual platelet reactivity in patients treated with aspirin after 
adjusting for confounding factors, and residual platelet activity positively correlates with 
clinical cardiovascular events (Geisler et al., 2010). 
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1.5.8 Aspirin and acute coronary syndrome  
Benefits of aspirin in the early management of ACS patients including unstable 
angina/NSTEMI (Lewis et al., 1983; Theroux et al., 1988; Group, 1990) and STEMI 
(Investigators, 1988; Roux et al., 1992) have been demonstrated consistently in 
various studies. Aspirin should be given as early as possible at an initial dose of 162 
to 325 mg followed by a daily maintenance dose of 75 to 162 mg (Antman et al., 2004; 
Anderson et al., 2007). Withdrawal of aspirin can lead to recurrence of ACS (Senior, 
2003). Two large meta-analyses performed by the Antiplatelet Trialists’ Collaboration 
included 287 studies and involved 212000 high risk patients (with acute or previous 
vascular disease or other predisposing condition increasing the risk of occlusive 
vascular disease) ('Collaborative overview of randomised trials of antiplatelet therapy: 
Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy 
in various categories of patients. Antiplatelet Trialists' Collaboration,' 1994; 
'Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention 
of death, myocardial infarction, and stroke in high risk patients,' 2002). Aspirin was the 
most frequently used antiplatelet agent at doses ranging from 75 to 325 mg daily in 
these trials. The incidence of vascular events on aspirin was reduced from 22.3% to 
18.5% in the DM cohort (P<0.002) and from 16.4% to 12.8% (P<0.00001) in non-DM 
cohort. The incidence of vascular events was much higher in DM patients but the 
benefit of antiplatelet therapy was consistent regardless of the DM status 
('Collaborative overview of randomised trials of antiplatelet therapy: Prevention of 
death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various 
categories of patients. Antiplatelet Trialists' Collaboration,' 1994). Low dose aspirin (75 
to 150 mg) was as effective as higher daily doses but with significantly lower bleeding 
complications ('Collaborative overview of randomised trials of antiplatelet therapy--I: 
Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy 
in various categories of patients. Antiplatelet Trialists' Collaboration,' 1994; 
'Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention 
of death, myocardial infarction, and stroke in high risk patients,' 2002). The Clopidogrel 
Optimal Loading Dose Usage to Reduce Recurrent Events – Organisation to Assess 
Strategies in Ischaemic Syndromes (CURRENT/OASIS-7) trial is the first large scale 
randomised study comparing high and low dose aspirin. This study randomised ACS 
patients who were scheduled to undergo angiography within 72 hours of hospital arrival 
(Mehta et al., 2010a; Mehta et al., 2010b). With a 2x2 factorial design, patients were 
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randomised (double blinded) to high or standard dose clopidogrel for a month and in 
open label fashion to high dose (300 to 325 mg daily) or low dose (75 to 100 mg daily) 
aspirin. There was no significant difference in the rates of the primary outcome 
(cardiovascular death, MI or stroke after 30 days) between high and low dose aspirin 
(4.1% versus 4.2%; hazard ratio [HR] =0.98; p=0.76) in DM and non-DM patients. A 
trend towards higher gastrointestinal bleeding rates (0.38% versus 0.24%; p=0.051) in 
the high dose group was observed (Mehta et al., 2010a).  
1.5.9 Aspirin and elderly population 
Although a clear excess of adverse events has been shown with aspirin even at lower 
dosage in elderly patients when compared to the young (Naschitz et al., 1990; Segal 
et al., 2003), only very few primary and secondary prevention trials have specifically 
addressed the benefit-risk ratio of aspirin in the elderly population and these are 
frequently derived from large clinical trials in which data are stratified by age. The 
magnitude of absolute benefits and risks with aspirin for primary prevention is not fully 
known. Although patients with high baseline atherothrombotic risk are more likely to 
benefit from aspirin, bleeding complications including intracranial and gastrointestinal 
bleeding are common in the elderly and this might counteract the small benefit from 
aspirin in those at lower risk (Capodanno and Angiolillo, 2010). 
1.5.10 Structure and metabolism of clopidogrel 
Clopidogrel is a thienopyridine and acts by inhibition of P2Y12 receptors on platelet 
membranes. It is one of the most widely used and carefully studies antithrombotic 
agents. It is estimated that more than 100,000 patients have been enrolled in various 
randomised trials involving clopidogrel. Platelet ADP signalling pathways mediated by 
P2Y1 and P2Y12 play an important role in platelet activation and aggregation. P2Y12 
activation leads to sustained platelet aggregation and stabilisation of the aggregated 
platelets (Gachet, 2001b; Storey et al., 2001). Thienopyridines are non-direct, 
irreversible P2Y12 antagonists.  
Clopidogrel is well absorbed from the upper small intestine and enters the portal 
circulation. It is inactive in vitro, but is converted to its active metabolite by the 
Cytochrome P450 pathway in the liver. When platelets come in contact with this active 
metabolite, their P2Y12 receptors are blocked irreversibly and they become 
permanently inactivated. Only about 15% of the absorbed drug is metabolised by 
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cytochrome P450 (CYP450) into its active metabolite. About 85% of the drug is 
hydrolysed by an esterase to create an inactive carboxylic acid derivative.  
Clopidogrel is converted to its active metabolite by cytochrome enzymes in the liver by 
a two-step process: 
i. CYP450 oxidises the thiophene ring of clopidogrel to 2-oxoclopidogrel (Lau et 
al., 2004) 
ii. Thiophene ring opens to form a thiol and carboxyl group. The thiol derivative of 
clopidogrel binds with cysteine residues (cys17 and cys20) of P2Y12 receptors 
resulting in irreversible platelet inhibition (Savi et al., 2000; Ding et al., 2003) 
Platelet inhibition prevents expression of GPIIb/IIIa receptors on platelet membranes 
and thereby inhibits fibrin mediated platelet aggregation. Collagen- and thrombin-
induced platelet aggregation are also inhibited by clopidogrel. Clopidogrel reduces 
platelet-leukocyte aggregate formation, levels of CRP, p-selectin and CD40L, and also 
the rate of thrombin formation (Gurbel et al., 2007). 
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Figure 1.12 Structure and metabolism of clopidogrel 
Clopidogrel is a prodrug, and its activation is complex. Some 85% of the dose 
administered is hydrolyzed in the liver, where it is converted into an inactive 
metabolite (SR 26334); the remainder is metabolized by CYP2C19 and to a 
lesser degree by CYP1A2 and CYP2B6 to 2-oxo-clopidogrel. Around half of this 
metabolite, which is also inactive, is hydrolyzed and converted into an inactive 
thiolactone, while the other half is metabolized by the 3A4, 3A5, 2B6, 2C9 and 
2C19 isoenzymes, finally producing the active metabolite (R-130964). The fact 
that a significant proportion of the absorbed drug is wasted (converted to inactive 
metabolites), the complex activation of the prodrug requiring two oxidation steps, 
and its heavy dependence on the function of the CYP2C19 isoenzyme (whose 
reduced-function genetic variants have a prevalence of around 25%), are the 
main pharmacokinetic factors affecting the variability of response to clopidogrel. 
From (Aguiar, 2012) 
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1.5.11 Clinical studies of clopidogrel in coronary artery disease 
Clopidogrel has been studied in several disease areas including CAD, cerebrovascular 
disease, PVD either separately or in combination, ACS, PCI and atrial fibrillation. 
The Clopidogrel versus aspirin in patients’ at risk of ischaemic events (CAPRIE) trial 
was the first study to show safety and efficacy of clopidogrel. This study randomised 
19,185 patients with a history of prior stroke, MI or PVD to either clopidogrel 75mg or 
aspirin 325mg. The annual rates of death, stroke, or MI over the average 2 years of 
follow-up were 5.3% and 5.8% respectively (HR: 0.91; 95% CI: 0.83 – 0.97; p=0.04). 
The overall incidence of haemorrhagic events did not differ between treatment groups 
(Gent et al., 1996) (CAPRIE steering committee, 1996). Although there was a slight 
benefit of clopidogrel over aspirin, there was no change in practice. Importantly 
CAPRIE established the efficacy and safety of clopidogrel as a useful antiplatelet agent 
and an alternative if patients cannot tolerate aspirin. 
The next major trial was Clopidogrel in Unstable Angina to Prevent Recurrent Events 
(CURE) study which enrolled 12,562 patients with non ST elevation acute coronary 
syndrome (NSTE-ACS) and randomised them to clopidogrel plus aspirin (loading dose 
clopidogrel 300mg followed by 75mg daily or aspirin alone (75 – 300mg). After a mean 
duration of treatment of 9 months, the risk of cardiovascular death, stroke or MI was 
9.3% and 11.4% respectively (HR: 0.80; 95% CI: 0.72 – 0.90; p<0.001). There was an 
increase in major bleeding events in the clopidogrel group (OR: 1.39; 95% CI: 1.14 to 
1.70). This was a landmark study and established clopidogrel along with aspirin as 
standard of care antiplatelet therapy in patients after NSTE-ACS (Yusuf et al., 2000). 
The Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) – Thrombolysis in 
Myocardial Infarction (TIMI) 28 trial and ClOpidogrel and Metoprolol in Myocardial 
Infarction Trial (COMMIT) also known as Second Chinese Cardiac Study (CCS-2) were 
complimentary trials evaluating clopidogrel plus aspirin for management of patients 
with ST elevation acute coronary syndrome (STE-ACS). CLARITY was an 
angiographic study in patients treated with thrombolysis as the method of reperfusion 
and enrolled 3491 patients randomised to clopidogrel plus aspirin and aspirin alone. 
Rates of occluded arteries (TIMI flow grade 0 or 1) were 11.7% and 18.4% respectively 
(HR: 0.59; 95% CI: 0.48 to 0.72; p<0.001). This was the main driver of the primary 
outcome composite assessed at angiography occluded infarct related artery, death or 
MI. There was no difference in bleeding between the two groups. Clopidogrel plus 
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aspirin improved patency of the infarct related artery compared to aspirin alone (OR: 
1.36; 95% CI: 1.18 to 1.57) (Sabatine et al., 2005a). 
COMMIT was a large pragmatic study of 45,852 patients with mainly STE-ACS 
enrolled in China, randomised to clopidogrel 75mg plus aspirin 162mg or aspirin alone 
for 4 weeks. The primary outcome of death, stroke or MI occurred in 9.2% in clopidogrel 
plus aspirin group and 10.1% in aspirin alone group (HR: 91; 95% CI: 0.86 to 0.97; 
p=0.002), and there was a significant reduction in all-cause mortality (HR: 0.93; 95% 
CI: 0.83 to 0.99; p=0.03). There were no excess major bleeding events or cerebral 
haemorrhage in the clopidogrel group (COMMIT collaborative group) (Chen et al., 
2005a).  These two trials established clopidogrel as a standard approach for patients 
with STE-ACS treated with thrombolysis. Previous smaller trials had shown benefits of 
clopidogrel in patients undergoing PCI and therefore clopidogrel usage became 
standard practice for patient with STE-ACS undergoing primary PCI. 
 The Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, 
Management, and Avoidance trial (CHARISMA) compared combination of clopidogrel 
and aspirin to aspirin alone in providing greater vascular protection in a wide range of 
stable patients in at risk of vascular events. Eligibility criteria included patients who had 
a clear diagnosis of coronary, cerebrovascular or peripheral arterial disease (without a 
definite prior stroke or MI), or if they had a combination of risk factors such as diabetes, 
hypertension, hypercholesterolemia or smoking (without a clear prior history of 
vascular disease). The trial enrolled 15,603 patients randomised either to clopidogrel 
(75mg daily) plus aspirin (75 to 162mg daily) or to placebo plus aspirin. There was a 
non-significant reduction in the primary end point of MI and death from cardiovascular 
cause (OR: 0.92; 95% CI: 0.81 to 1.04). There was a non-significant increase in major 
bleeding (OR: 0.92; 95% CI: 0.81 to 1.04) (Chen et al., 2005a). 
The Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-
Seventh Organization to Assess Strategies in Ischaemic Syndromes (CURRENT-
OASIS 7) trial was a complex design study and showed that there was no difference 
in the primary outcome (cardiovascular death, stroke and MI) in patients assigned to 
double dose clopidogrel (150mg) as compared to standard dose (75mg) (HR: 0.94; 
95% CI: 0.83 to 1.06). Major bleeding occurred at similar rates in both the groups and 
150mg of clopidogrel was associated with a significant reduction in stent thrombosis 
(CURRENT-OASIS7 Investigators, 2010) (Mehta et al., 2010b). 
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1.5.12 Dosage of clopidogrel 
Without a loading dose, clopidogrel 75 mg daily induces inhibition of ADP-induced 
platelet aggregation as early as 2 hours after the first dose but requires 3 to 7 days to 
achieve maximal inhibition of platelet aggregation (Thebault et al., 1999). The 3- to 7-
day delay can be shortened to 5 to 6 hours with a loading dose of 300mg and can be 
maintained for 24 hours. Doubling the loading dose from 300 to 600mg achieves 
platelet inhibition at 2 to 3 hours and a further increase in platelet inhibition is reported 
at this dose (L'Allier et al., 2008). Doses higher than 600mg are not recommended for 
loading since only a limited increase in platelet inhibition occurs at higher doses.  
Dosage regimes differ based on the timing and clinical indication of PCI 
Current guidelines for clopidogrel loading dose are as follows: 
i. Patients undergoing elective PCI – 300mg is recommended, to be administered 
at least 24 hours before PCI 
ii. Patients who have acute coronary syndrome – 300mg loading dose is 
recommended 
iii. Patients undergoing non elective PCI and have never had clopidogrel 
(clopidogrel naïve), 600mg loading dose is recommended. If they have already 
been preloaded with 300mg, a further 300mg dose is recommended 
iv. Doses higher than 600mg are not currently recommended 
Following this, a daily dose of 75mg is recommended for maintenance therapy. The 
antiplatelet response to clopidogrel is highly heterogeneous. Variability in clopidogrel 
response is widely recognised and well documented, and is associated with higher 
adverse clinical events as described later. 
1.5.13 Side effects of clopidogrel  
Clopidogrel in general was well tolerated in clinical trials and fatal complications have 
not been reported. Serious side effects at loading dose of 300mg or 600mg or 
maintenance dose of 75mg are rare in clinical practice.  
Several clinical trials (CAPRIE, CURE, CREDO, CLARITY TIMI-28, COMMIT, ISAR-
CHOICE, MATCH and others) focused mainly on bleeding as a major side effect of 
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clopidogrel. Some studies reported an increase in the incidence of bleeding following 
dual clopidogrel and aspirin therapy compared to aspirin alone (CURE study, 1.6% vs. 
1.0%) (Yusuf et al., 2001b), while others did not. Gastrointestinal haemorrhage 
requiring hospitalisation was less frequent with clopidogrel compared to aspirin in 
CHARISMA trial (2.0% vs 2.7%) (Berger et al 2010). In the large CAPRIE trial (1996), 
major haemorrhage occurred in 1.4% of clopidogrel treated patients; this percentage 
was not significantly different from that seen in aspirin-treated patients (1.6%).  
Other important but less frequent side effects include severe neutropenia as observed 
in CAPRIE trial, thrombocytopenia in CURE trial (Yusuf et al., 2000), severe 
multisystem thrombotic microangiopathy, thrombotic thrombocytopenic purpura (TTP) 
(Bennett et al., 2000; Hankey, 2000), drug-associated thrombotic thrombocytopenic 
purpura-haemolytic uremic syndrome (Medina et al., 2001). Clopidogrel in rare 
instances has been associated with many other life threatening side effects such as 
severe bone-marrow suppression manifested as toxic bone marrow failure, aplastic 
anaemia (Meyer et al., 2001), thrombocytopenia, neutropenia or even pancytopenia 
(Trivier et al., 2001). Furthermore, Meyer et al. reported another case of fatal aplastic 
anaemia, which led to the patient's death from septicaemia (Meyer et al., 2001). Non-
haematological side effects of clopidogrel treatment have also been reported. These 
include, membranous nephropathy, a major cause of nephrotic syndrome in adults 
(Tholl et al., 1999), gastroenteritis (e.g., abdominal pain, dyspepsia, gastritis, diarrhoea 
and constipation), acute arthritis (Garg et al., 2000), angioedema (Fischer et al., 2003), 
urticarial rash (Khambekar et al., 2004) and hepatocellular and cholestatic liver injury 
(Goyal, 2009). Dyspeptic symptoms were more frequent in clopidogrel therapy in 
CAPRIE study (27.1%) but resulted in drug withdrawal only in very few cases (3.2%) 
(1996).  
1.5.14 Variability of clopidogrel response 
The antiplatelet effect of clopidogrel varies significantly from one person to another. 
The mechanisms leading to variability in clopidogrel responsiveness are not fully 
elucidated and similar to aspirin, are multifactorial. The variability is attributable to 
patient related clinical factors, genetic factors and cellular factors (Figure 1.13). 
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Figure 1.13  Proposed Mechanisms Leading to Variability in Individual 
Responsiveness to Clopidogrel 
ADP = adenosine diphosphate; CYP = cytochrome P450; GP = glycoprotein 
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1.5.15 Pharmacogenomics of clopidogrel 
The response to clopidogrel is influenced by pharmacokinetic variables such as 
intestinal absorption and metabolic activation in the liver, both of which are affected by 
genetic polymorphisms (Giusti and Abbate, 2010). Three different types of genetic 
polymorphisms of clinical interest in patients taking clopidogrel include gene series 
involved in modulating intestinal absorption of clopidogrel (ABCB1 gene), metabolic 
activation of clopidogrel (CYP3A5 and CYP2C19), and biologic activity 
(P2RY12 and ITGB3). Although the active metabolite of clopidogrel arises from 
complex biochemical reactions that involves a number of different hepatic CYP 
enzymes, there is accumulating evidence that CYP2C19 plays a dominant role in 
clopidogrel activation (Mega et al., 2010). The CYP2C19 gene is located on 
chromosome 10 (10q24.1-q24.3) and consists of 490 amino acid residues. At least 25 
genetic variants in CYP2C19 have been identified. Hulot et al. conducted a 
pharmacogenomics study using young healthy volunteers who were treated with 
clopidogrel and provided novel evidence that loss-of-function CYP2C19*2 allele was 
associated with marked decrease in platelet responsiveness and hence proposed that 
this gene was an important contributor to clopidogrel resistance in clinical setting (Hulot 
et al., 2006). In a systematic meta-analysis of 10 studies involving 11,959 patients, 
Hulot et al. demonstrated that carriers of the loss-of-function CYP2C19*2 allele were 
at 30% higher risk of major adverse clinical events compared to non-carriers (9.7% vs. 
&.8%; OR: 1.29; 95% CI: 1.12 to 1.49; P<0.001). CYP2C19*2 alone was also 
associated with increased mortality (1.8% vs. 1.0%; OR: 1.79; 95% CI: 1.10 to 2.91; 
P=0.019; n=6225) and stent thrombosis (2.9% vs. 0.9%; OR: 3.45; 95% CI: 2.14 to 
5.57; P<0.001; n=4905). This increased risk was apparent in both heterozygotes and 
homozygotes and was independent of the baseline cardiovascular risk (Hulot et al., 
2010). 
The US Food and Drug Administration (FDA) has added a boxed warning to the 
clopidogrel label which suggests that individuals with poor metabolizer genotypes (i.e., 
CYP2C19*2 and *3 carriers) may be at increased risk for adverse cardiovascular 
outcomes and should consider other antiplatelet medications or alternative dosing 
strategies (Holmes et al., 2010). 
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Figure 1.14 Pharmacogenomics of clopidogrel. 
Representation of the candidate genes involved in the metabolism of clopidogrel 
and its primary mechanism of action. Intestinal absorption of the prodrug 
clopidogrel is limited by an intestinal efflux pump P-glycoprotein coded by the 
ABCB1 gene. The majority of the prodrug is metabolized into inactive 
metabolites by ubiquitous esterases. The minority is bio-activated by various 
cytochrome P450 (CYP) isoforms into active metabolites. These metabolites 
irreversibly antagonize the adenosine diphosphate (ADP) receptor (coded by the 
P2RY12 gene), which in turn inactivates the fibrinogen receptor (the glycoprotein 
[GP] IIb/IIIa receptor coded by the ITGB3 gene) involved in platelet aggregation. 
From (Simon et al., 2009; Beitelshees et al., 2011) 
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1.5.16 Clopidogrel and T2DM 
There is plenty of evidence to support the superiority of clopidogrel compared to aspirin 
in patients with diabetes mellitus (DM). CAPRIE trial included 3837 patients with DM. 
The primary end point (combined incidence of CV death, stroke or MI) occurred less 
frequently in the clopidogrel group compared to the aspirin group (15.6% vs 17.7%; 
RR: 0.87; 95% CI: 0.76 to 0.99; p=0.042). For every 1000 DM patients treated with 
clopidogrel, 21 vascular events were prevented (Bhatt et al., 2002). CURE study sub 
group analysis of patients with T2DM showed that addition of clopidogrel to aspirin 
resulted in fewer adverse clinical cardiovascular events (14.2% vs. 16.7%; RR: 0.84; 
95% CI: 0.70 to 1.02) (Yusuf et al., 2000). CHARISMA trial found no benefit of dual 
aspirin and clopidogrel therapy in the long term in a wide range of non-ACS patients 
(n=15 603) with risk factors for, and established atherothrombotic disease including 
DM patients (n=6555; 42% of the study population) (Bhatt et al., 2007). 
Nevertheless, clinical benefits of clopidogrel are lower in T2DM compared to those 
without diabetes (Angiolillo, 2009a). Elevated plasma fibrinogen levels, presence of 
DM and BMI ≥ 25 kg/m2 are associated with lower platelet inhibition with clopidogrel 
therapy in subjects with CVD. A significant interaction between elevated plasma 
fibrinogen and DM exists, identifying elevated plasma fibrinogen as a unique factor 
associated with lower platelet inhibition in diabetic patients. Increased BMI also 
remains independently associated with lower platelet inhibition after clopidogrel 
therapy. 
The aetiology of clopidogrel resistance in T2DM is multifactorial, and insulin resistance 
and systemic inflammation play a significant role. Patients with T2DM show lower 
response to clopidogrel both in the loading phase and in the maintenance phase. 
Patients who are on insulin have the highest degree of platelet reactivity whilst on dual 
antiplatelet therapy.  Impaired response to clopidogrel in T2DM has been shown to be 
an independent marker of cardiovascular mortality after adjusting for confounding 
factors (El Ghannudi et al., 2011). Persistent high platelet activity in DM patients 
despite current recommended antiplatelet therapy has raised interest in identifying 
strategies to optimise platelet inhibition in this high risk population. 
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1.5.17 Antiplatelet therapy in the elderly 
The physiological changes accompanying ageing have an important impact on the 
effects of therapeutic agents including antithrombotic medications. Given that 
atherothrombotic disease processes increase with age and that prevalence of the 
elderly population is continuously growing, understanding the effects of antithrombotic 
therapy in this high risk cohort is of key importance (Capodanno and Angiolillo, 2010). 
This is further emphasized by the fact that antithrombotic therapy used to reduce 
ischaemic events in the elderly is counterbalanced by their increased risk of bleeding. 
Numerous factors influence the effect of antiplatelet therapy in the elderly. These 
include renal function, hepatic metabolism, body mass distribution, platelet 
dysfunction, coagulation disorders and drug-drug interaction due to polypharmacy. 
Lack of dedicated research studies in the elderly, who are excluded from many large 
scale clinical trials, often leads to either no recommendations or arbitrary assumptions 
regarding the most appropriate antithrombotic therapy. Hence more data from large 
scale clinical trials and dedicated studies in the elderly assessing the safety and 
efficacy of antithrombotic agents are strongly warranted. 
1.5.18 Dose modification of antiplatelet agents 
Suboptimal responsiveness to clopidogrel is a well-established clinical entity and this 
phenomenon has been associated with recurrence of ischaemic events including stent 
thrombosis. Stent thrombosis may lead to severe consequences and has become a 
major concern in the era of drug-eluting stents. Diabetes mellitus has been identified 
as an independent predictor of stent thrombosis. 
The Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study was the 
first study which showed marked improvement in platelet inhibition when 150 mg 
maintenance dose of clopidogrel was used in DM patients with CAD (Angiolillo et al., 
2007). This study was not powered to evaluate the risk of bleeding with the use of high-
dose clopidogrel in association with aspirin and the study was not designed to measure 
clinical outcomes. 
In the Gauging Responsiveness With Verify Now Assay: Impact on Thrombosis and 
Safety (GRAVITAS) trial, high clopidogrel dose (600mg loading dose followed by 
150mg daily maintenance dose for 6 months) was given to patients with inadequate 
response to standard clopidogrel dose. At six months of follow-up, the composite end 
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point of cardiovascular death, MI or stent thrombosis was identical in both groups, at 
2.3% (HR=1.01; 95% CI, 0.58-1.76; p=0.97). Stent thrombosis occurred in 0.5% of the 
high-dose group and 0.7% of the standard-dose group, a non-significant difference. 
There was also no difference in bleeding (Price et al., 2011b). The results of 
GRAVITAS did not support a uniform treatment strategy of high-dose clopidogrel in 
patients with high on-treatment platelet reactivity. Thus, at present there is no evidence 
that increasing the dose of clopidogrel will improve the outcomes in patients with 
T2DM. Alternative treatment strategies incorporating platelet function testing merit 
further investigation.  
1.5.19 Dual antiplatelet therapy in stable coronary artery disease 
There is little clear evidence to routinely add a thienopyridine to aspirin in patients with 
stable coronary, cerebrovascular or symptomatic PVD and no evidence for this 
regimen for primary prevention in patients without evidence of vascular disease. 
CAPRIE data clearly supports the use of clopidogrel in patients who need vascular 
protection but cannot tolerate aspirin.  
The CHARISMA trial was designed to examine the effect of DAPT on vascular 
protection compared to aspirin monotherapy in patients with stable CAD (n=15 603). 
Patients with diabetes comprised 42% of the study population (n=6555). Data on the 
effects of clopidogrel plus aspirin in the subgroup of patients with CAD have not been 
published from the CHARISMA trial, but presentations of these data and interpretation 
from the available publications suggest that an expected proportional reduction of 
about 15% for CAD patients is consistent with the CAPRIE like cohort subgroup. In the 
main publication of CHARISMA, a separate subgroup analysis was performed on 
patients with previous myocardial infarction, ischaemic stroke or symptomatic 
peripheral arterial disease (PAD). In this cohort, DAPT decreased the rate of 
cardiovascular death, myocardial infarction or stroke (7.3% vs. 8.8%; HR, 0.83; 95%CI, 
0.72 to 0.96; p=0.01), and the risk of hospitalisations for ischaemia (11.4% vs. 13.2%; 
HR, 0.86; 95%CI, 0.76 to 0.96; p=0.008) when compared with aspirin and placebo. 
This benefit was associated with increased risk of GUSTO defined moderate (2.0% vs. 
1.3%; HR, 1.60; 95%CI, 1.16 to 2.20; p=0.004), but not severe bleeding (1.7% vs. 
1.5%; HR, 1.12; 95%CI 0.81 to 1.53; p=0.50). This analysis suggested that high risk 
patients with history of previous MI, ischaemic stroke or symptomatic PAD may benefit 
from intensified antithrombotic therapy (dual antiplatelet therapy with aspirin and 
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clopidogrel). Those without prior MI did not demonstrate any significant benefit (Bhatt 
et al., 2006). 
A CHARISMA subgroup analysis comparing patients with age<75 years and age≥75 
years did not demonstrate any significant difference in clopidogrel response both in 
terms of primary outcomes and bleeding complications. Another subgroup analysis of 
the CHARISMA trial also showed that the benefits of clopidogrel are greater in the 
population with T2DM and a previous cardiovascular event (relative risk reduction: 
17.1%; 95% CI: 4.4 – 28.1). Overall, the CHARISMA trial demonstrated a small but 
significant benefit in the subgroup of patients with known atherothrombosis and a 
potential role for intensification of antithrombotic therapy beyond aspirin alone (long-
term dual antiplatelet therapy) in certain high-risk groups. 
The REACH registry (n=68,000), which ran concurrently with the CHARISMA trial with 
similar eligibility criteria but an observational study design, demonstrated that patients 
with vascular disease in more than one territory (coronary, cerebrovascular or 
peripheral) have a greater risk of adverse outcomes than patients with either no 
documented vascular disease or disease in a single territory (Steg et al., 2007). Annual 
average risk of death, stroke or MI in the REACH registry was between 4% and 5% 
compared to 3% overall risk in CHARISMA, suggesting that future studies on dual 
antiplatelet therapy for secondary prevention should focus on patients with a prior 
vascular event, symptomatic PVD or patients with evidence of disease in more than 
one territory. MATCH trial, one of the largest secondary prevention stroke trials, did 
not confirm the benefits of dual antiplatelet therapy compared to clopidogrel alone 
(Diener et al., 2004). 
From all the above discussion, it is clear that in elderly patients and in patients with 
T2DM, rates of recurrent cardiovascular events remain higher compared to younger 
individuals and in those without T2DM. Despite being aware of these increased risks 
in high risk population group, the current guidelines from international societies 
recommend similar antiplatelet and antithrombotic therapy for all patients in ACS 
setting and after coronary stent insertion. These increased risks persist in elderly and 
T2DM patients even in stable CAD setting but the current recommended antiplatelet 
therapy is aspirin monotherapy for stable CAD and clopidogrel monotherapy if the 
patients are intolerant or allergic to aspirin. Thus further work to reduce the risk of 
further adverse cardiovascular events in these high risk groups is essential. As 
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discussed in detail above, CHARISMA trial did demonstrate modest benefit of DAPT 
in selected population (previous MI, ischaemic stroke or symptomatic PAD) but cost-
effectiveness might have been one of the reasons for not adapting DAPT in those high 
risk patients. Because of increased platelet reactivity in elderly and T2DM, It is possible 
that these groups of patients may benefit from DAPT when continued long-term. 
Proportion of hyporesponders to aspirin and clopidogrel are much higher in elderly and 
in T2DM. Hence other ways of inhibiting platelet functions also need to be developed 
to improve outcomes in these high risk groups. 
1.5.20 Introduction to Rafigrelide – a novel platelet lowering agent 
Successful antithrombotic therapy is a balancing act between maximising efficacy that 
yields reduction in adverse outcomes, and minimising bleeding risk that would lead to 
adverse events. Persistent high platelet activity in elderly and T2DM patients despite 
current recommended antiplatelet therapy has raised interest in identifying strategies 
to optimise platelet inhibition in these high-risk population groups. 
 
Hence in my second study, in healthy volunteers I assessed the effects of Rafigrelide, 
a novel, highly selective platelet lowering agent, on platelet count, platelet dependent 
thrombus formation and viscoelastic strength of the clot. Rafigrelide is a chemical 
analogue of anagrelide, which is currently used to reduce the platelet count in patients 
with myeloproliferative disorders. Rafigrelide has two distinct pharmacological 
activities similar to anagrelide: inhibition of megakaryocyte maturation and 
differentiation which gives rise to the platelet lowering effect (4 to 6 fold less effect than 
anagrelide) and inhibition of cyclic adenosine monophosphate (cAMP) 
phosphodiesterase III (PDE III) characterised by positive inotropic and chronotropic 
effects resulting in vasodilation. The clinical symptoms of PDE III inhibition manifest 
mainly as headaches and cardiovascular side-effects including tachycardia and 
palpitations. Rafigrelide is stated to be better tolerated than anagrelide since the PDE 
III inhibition is 200 fold less effect than anagrelide. 
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Chapter 2 Hypothesis and Objectives 
2.1 Study 1: Elderly stable CAD study 
2.1.1 Hypothesis 
Dual antiplatelet therapy with aspirin (75mg) and clopidogrel (75mg) inhibit platelet-
dependent thrombus formation more powerfully in subjects aged ≥75 years than in 
younger individuals. In the presence of T2DM, the effect of age is reduced.  
2.1.2 Primary Objectives 
i. To determine the effect of age and age plus T2DM on the inhibition of platelet-
dependent thrombus formation by dual oral antiplatelet therapy in patients with 
stable CAD. 
2.1.3 Secondary Objectives 
i. To identify platelet hyporesponsiveness to dual antiplatelet therapy (DAPT) and 
effect of age and T2DM on platelet hyporesponsiveness 
ii. To evaluate the effect of age and T2DM on viscoelastic properties of thrombus 
role in patients after initiation of DAPT  
iii. To study the role of inflammation in thrombogenicity and effect of age and T2DM 
on  
a. platelet reactivity upon stimulation with platelet agonists  
b. inflammation 
c. platelet activation markers 
iv. To assess the ultrastructural changes to thrombus after initiation of DAPT 
v. To evaluate the relationship between platelet reactivity measured by “point of 
care” platelet function assays and platelet dependant thrombus  
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2.2 Study 2: Rafigrelide (new platelet lowering agent) study – Phase 1 study 
2.2.1 Hypothesis 
1. Rafigrelide induced reduction in the platelet count will inhibit platelet dependent 
thrombus formation 
2. Thrombus characteristics alter with the change in the platelet count 
2.2.2 Primary Objectives 
i. To assess the relationship between platelet count and platelet dependent 
thrombus formation with and without aspirin; using rafigrelide administration to 
lower platelet counts 
ii. To evaluate the effect of platelet count on viscoelastic properties of thrombus  
2.2.3 Secondary Objectives 
i. To assess the safety and tolerability of rafigrelide administered with and without 
aspirin in healthy volunteers
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Chapter 3 Methods 
3.1 General methods 
I conducted two hypothesis led clinical studies namely, Study 1: Elderly stable CAD 
study (a non-randomised, open labelled study) and Study 2: Rafigrelide study (an 
open-label, phase 1, single-sequence crossover study) 
3.2 Study 1: Elderly stable CAD study design 
This was a single-centre, non-randomised, open-labelled study assessing the efficacy 
of clopidogrel in patients with established CAD, with and without T2DM and over a 
wide age range. Patients who had stable, established CAD were recruited in three 
groups as below: 
i. Age ≥ 75 years with type 2 diabetes mellitus (T2DM)  
ii. Age ≥ 75 years without diabetes 
iii. Age < 75 years without diabetes 
Briefly, eligible patients with stable CAD were studied on day 1 to assess baseline 
blood thrombogenicity. They all were treated with clopidogrel 75mg once daily for 7 
days and studied again on the eighth day. All patients took their routine prescribed 
medications as per standard practice. 
The 4th group used for comparison included patients aged<75 years with T2DM and 
stable CAD. This group was recruited as a part of a previous research study by my 
senior research associate, Dr G Viswanathan. Similar inclusion / exclusion criteria 
were used to enrol patients in that study. They underwent Badimon chamber study, 
thromboelastography (TEG®) and platelet mapping™, VerifyNow® and Multiplate® 
assays at baseline and 1 week after clopidogrel therapy, using procedures identical to 
mine. For thrombus area from Badimon chamber study, I analysed all the images and 
recalculated the thrombus area for consistency and comparison with my data. I used 
the results from all three point of care platelet function assays for comparison 
(Viswanathan et al., 2012b).  
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3.2.1 Patient selection 
Eligibility criteria 
Inclusion criteria  
1. Patients with CAD and T2DM as defined below:  
CAD: Presence of any one of the following: history of angina and positive 
exercise tolerance test, history of (enzyme and/or Q wave) positive myocardial 
infarction, angiographic evidence (>50% stenosis of one vessel) or prior history 
of percutaneous or surgical coronary revascularisation 
T2DM: Diagnosed according to the WHO criteria, and on treatment 
2. Patients who were taking aspirin 75mg once daily. 
3. Patients who could provide written informed consent for participation in the trial 
prior to any study-specific procedures or requirements.  
Exclusion criteria  
1. Contraindications to clopidogrel, as per Summary of Product Characteristics 
(http://www.medicines.org.uk/emc/medicine/24207, accessed August 8th 2015) 
such as history of hypersensitivity, severe hepatic impairment and major / active 
pathological bleeding   
2. Current smokers  
3. Malignancy (currently diagnosed or under investigation) 
4. Haematological disorders (Anaemia, malignancy, bleeding disorders)  
5. Women of child-bearing potential as clopidogrel is contraindicated in pregnancy 
6. Use of corticosteroids or non-steroidal anti-inflammatory drugs as it could 
increase bleeding risks and might affect the thrombotic milieu 
7. Chronic liver disease (Cirrhosis, malignancy and patients with abnormal liver 
function tests, as clopidogrel bio-availability will be unpredictable)  
8. End stage renal disease on dialysis as clopidogrel can be removed from the 
blood by haemodialysis 
9. Patients who were already on clopidogrel for other clinical indications such as  
stroke and coronary intervention 
10. Patients who were taking aspirin at doses other than 75mg once daily 
11. Patients who were taking other antithrombotic agents such as dipyridamole, 
warfarin, low molecular weight heparin and newer oral anti-coagulants 
12. Unable to consent  
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13. Use of other investigational study drugs within 1 year prior to entry into our study  
3.2.2 Screening and recruitment 
The study was approved by Regional Ethics Committee, Sunderland. All the 
appropriate approvals for recruitment from various centres list below where obtained. 
All participants were recruited from the Cardiology outpatient clinics in the Newcastle 
upon Tyne Hospitals NHS Foundation Trust, Newcastle Diabetes Centre, Gateshead 
Diabetes centre, Diabetes clinics in general practice of Tyneside primary care trusts 
and cardiovascular community rehabilitation centres in Newcastle and Gateshead. 
Potential participants were identified by me and eligibility was verified from information 
documented in their clinical records.  The patient information sheet, consent form and 
a letter of invitation were all posted at least 1 week prior to their planned outpatient 
appointments. Eligible patients were then approached in person at a suitable time point 
during their visit and I provided detailed verbal information regarding the study and 
answered any questions.  Patients who provided written consent were given a further 
minimum of 24 hours to reflect on their agreement to participate in the study. 
Participants voluntarily agreed to participate in the study and no financial 
reimbursements were offered to them. Participants attended two appointments, visit 1 
(Day 1) and visit 2 (Day 8) at Clinical Research Facility. 
Visit 1 (Day 1) 
Patients attended the research facility in the morning of Day 1. They fasted overnight 
and delayed taking their usual medications until study specific procedures were 
completed.  
All subjects underwent the following assessments: 
 Eligibility, understanding and consent to participate in the study were 
reconfirmed 
 Subject number was assigned to each participant sequentially starting from 601 
 Demographic data including height, weight, waist and hip circumference, resting 
heart rate and blood pressure were recorded 
 Participant’s medical history and routine prescription was checked 
 Rose angina questionnaire was completed 
 Badimon perfusion chamber experiment was then performed as described.  
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o An 18G cannula was inserted in the antecubital fossa.  
o The first 2ml of blood was discarded to avoid activated platelets by 
venepuncture.  
o Ten ml blood was then collected for serum separation and Badimon 
perfusion chamber experiment was performed.  
o Effluent blood sample (5ml) from the chamber was collected for serum 
separation.  
o Another 5ml of venous blood was collected using the same cannula after 
disconnecting the chamber. This was used for platelet function assays 
and biomarker analysis.  
o The cannula was then removed.  
 Participants were provided with breakfast 
 Participants were observed to swallow the first dose of their IMP with at least 
100ml of water under supervision  
 Prior to discharge from the facility, subjects were given instructions for at-home 
self-administration of IMP 
 A wallet sized card with information regarding the IMP, emergency contact 
details of myself and principal investigator, subject number and sponsors of the 
study was provided to the participants 
Visit 2 (Day 8) 
Participants returned to the research facility having fasted overnight and delayed taking 
their usual medications until study specific procedures were completed. All subjects 
underwent the following assessments: 
 Returned investigational medicinal product collected to determine compliance 
 Assessment of AEs and concomitant medications 
 Badimon perfusion chamber experiment was then performed exactly as 
performed in Visit 1 
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3.2.3 Study specific procedures 
Demographic data 
Demographic data were collected during visit 1 to Clinical research facility. They were 
collected in a clinical research proforma and then stored electronically in a password 
protected computer. The following details were recorded: 
 Participant’s age was calculated as total number of completed years on the day of 
chamber study 
 Height was measured in centimetres (cm) 
 Weight in kilograms (kg) 
 Body mass index (BMI) was calculated as body weight (kg) divided by height 
squared (m2) 
 Waist circumference (cm) was measured at midpoint between the lower rib margin 
and the iliac crest 
 Hip circumference (cm) was measured at level of the widest circumference over 
the greater trochanters 
 Waist hip ratio (WHR) was calculated as waist circumference divided by hip 
circumference 
Vital signs 
Blood pressure and pulse were measured in the sitting position after the participants 
rested for at least 5 minutes. The left arm was used for blood pressure measurements. 
General Biochemistry 
Patient’s blood samples were analysed at the nationally accredited clinical 
biochemistry laboratory at Royal Victoria Infirmary, Newcastle upon Tyne Hospitals 
NHS Foundation Trust, Newcastle upon Tyne. Samples were identified by study 
number, participants name and date of birth. Quality control and quality assurance 
were in keeping with local laboratory protocols. 
The following parameters were assessed: 
Fasting plasma glucose, mmol/L  HbA1c (DCCT aligned), % 
Blood urea mmol/L    Serum creatinine, µmol/L 
Serum high sensitivity C reactive protein, mg/dl 
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Lipid profile (fasting) including total cholesterol, HDL cholesterol, LDL cholesterol and 
triglycerides, mmol/L      
General Haematology 
Patient’s blood samples were analysed at nationally accredited general haematology 
and coagulation laboratories at Royal Victoria Infirmary, Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne. Quality control and quality 
assurance were in keeping with local laboratory protocol. Blood was drawn into a tube 
containing potassium ethylene diamine tetra acetic acid (EDTA) anticoagulant for full 
blood count analysis and the following parameters were assessed: 
Haemoglobin , g/L      Haematocrit, % 
Red blood cells (RBC), 1012/L Platelet count, 109/L 
Prothrombin time, sec  Activated partial thromboplastin time, sec 
Plasma fibrinogen was measured using the von Clauss quantitative method. Citrated 
tubes were preferred over heparinised tubes for coagulation analysis including 
fibrinogen as citrate preserves labile coagulation factors thus ensuring better 
reproducibility. The von fibrinogen assay is the most reliable method for use in 
laboratories according to the British Society of Haematology guidelines (Mackie et al., 
2003).  
3.2.4 Investigational Medicinal Product 
This was a non-randomised, open labelled study. Hence there was no randomisation 
or blinding involved. 
Clopidogrel bisulphate 75mg (Plavix®, Sanofi-Aventis) was used as the investigational 
medicinal product (IMP). This was provided by the pharmacy production unit at Royal 
Victoria Infirmary, Newcastle upon Tyne (MHRA Unit IMP license number 17736), as 
individual subject dose packs. These supplies were open-label, packaged as a 
commercial pack containing 8 blistered tablets. 
All supplies were labelled with the study name, subject number, medication 
identification number, dosage form (including product name and quantity in pack), 
directions for use, storage conditions, expiry date, batch number or packing reference 
number, the statements ‘For clinical trial use only’, “’Keep out of reach of children’, and 
the Sponsor's name and address. 
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As per the protocol, participants took IMP from Day 1 to Day 7 (Seven tablets in total), 
but I chose to provide them with 8 tablets for two reasons: 1) pill counting to monitor 
compliance 2) additional spare IMP to be used by participants if they lose one tablet. 
3.2.5 Pharmacovigilance and data monitoring 
An adverse event (AE) was defined as any untoward medical occurrence which does 
not necessarily have a causal relationship with the treatment. “Treatment” includes all 
investigational products administered during the course of the study.  Medical 
conditions/diseases present before starting study treatment are only considered 
adverse events if they worsened after starting study treatment.  
Any serious adverse event was deemed to be recorded throughout the duration of the 
trial until 5 days after cessation of study drug. Non-serious adverse reactions were 
recorded and monitored throughout duration of trial until 5 days after cessation of study 
drug. Participants were provided with a wallet sized card with contact details of myself 
and principal investigator if they experienced any further adverse events after the final 
visit.  
I was responsible for monitoring and reporting all adverse events. The intensity (mild, 
moderate, severe), relationship to investigational product, and outcome were recorded 
for all AEs.  All AEs were followed to closure, and reviewed, confirmed, and classified 
by myself. I was also delegated the task of informing MHRA and REC of all serious 
adverse events / reaction [SAE/SAR including Suspected Unexpected Serious 
Adverse Reaction (SUSAR)] occurring during the study. A study data monitoring 
committee and adverse event monitoring committee oversaw the safety of the study. 
3.2.6 Statistical methods 
Statistical analyses were performed using SPSS version 17.0 (SPSS Inc, NY, USA) 
and Graphpad prism version 6 (Graphpad software, CA, USA). Graphs were 
constructed after data analyses using Graphpad software.  
Elderly stable CAD study was a non-randomised open labelled study comparing four 
study groups. For continuous variables, mean and standard deviations were 
calculated; for dichotomous variables number and percent are shown. For variables 
that were normally distributed with equal variances, one way analysis of variance 
(ANOVA) was performed to measure statistical significance across the four groups and 
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post hoc test was performed with Bonferroni correction to determine which pairs of 
groups were significantly different. For variable that were not normally distributed, 
Kruskal-Wallis H Test was performed to determine statistical differences across the 
four groups and Mann-Whitney U test was performed to determine which groups were 
significantly different. 
To assess the effect of age at baseline and after the addition of clopidogrel, patients 
were divided into two groups (age<75 vs. age≥75). Age category was the grouping 
variable and all the other data from the study such as thrombus area, platelet function 
test indices, coagulation and inflammatory biomarker levels were the test variables. I 
performed analysis adjusting for sex, body mass index, waist-hip ratio and basic 
laboratory tests (creatinine, lipids). Independent sample t test (normally distributed 
variables) and Mann-Whitney U test (non-parametric) were used to look for statistical 
differences between the groups. Similar test were repeated for T2DM vs. Non-DM, 
using Diabetes category as the grouping variable. 
The volunteers in each group were carefully chosen and were well matched except for 
the difference in age and diabetic status. Hence I analysed the effect of the intervention 
in each group without including covariates in the analysis. For continuous variables 
mean and standard deviations were calculated and paired sample t test was used to 
measure statistical significance. For dichotomous variables, the percentage in each 
group was measured and chi-square estimates were used to calculate statistical 
significance. For highly skewed variables, I used non-parametric paired t test and 
repeated the analysis with log-transformation. 
For correlation analysis, Pearson’s method and linear regression analysis were 
employed for normal data and Spearman’s method and non-linear regression analysis 
method were employed for non-normally distributed data. 
Data from our previous study were used to estimate the sample size needed for this 
study. In order to detect a 20% reduction in thrombus area from baseline 1 week after 
clopidogrel therapy with 80% power, we estimated that a sample size of 45 patients 
per group was required.  
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Figure 3.1 Participant Pathway for Elderly stable CAD study
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Figure 3.2 Elderly stable CAD study – Flow chart
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3.3 Study 2: Rafigrelide study design 
This study used a Phase 1, non-randomised, open-label, single-sequence, crossover 
design to investigate the effect of rafigrelide with or without aspirin on thrombus 
formation and clot kinetics.  This study was conducted in healthy subjects and 
comprised of 2 treatment periods where subjects received rafigrelide for 14 days either 
alone (Treatment Period 1) or in combination with aspirin (Treatment Period 2).  In 
each period, subjects underwent blood thrombogenicity studies which included the ex-
vivo Badimon perfusion chamber and thromboelastography (TEG) along with tests for 
plasma drug concentrations, and platelet count assessments. 
Upon qualifying for the study, subjects were alternately assigned to 1 of 2 schedules 
(Panel A or Panel B) (Figure 3.3), for the assessment of pharmacokinetic (PK) and 
pharmacodynamic (PD) measures.  The subjects followed the same panel assignment 
for both treatment periods. 
In both treatment periods, subjects received 4mg/day of rafigrelide for 14 consecutive 
days starting on the morning of Day 1.  In treatment period 2, subjects also received 
75mg/day of aspirin administered from Day 1 until Day 20 (Panel A) or Day 17 (Panel 
B). 
In both treatment periods, subjects returned to the clinical research facility for 6 visits.  
For 4 of these visits subjects underwent pharmacokinetic and/or pharmacodynamic 
assessments.  For these visits, subjects were admitted to the clinical research facility 
on the evening prior to the assessment day and were discharged the next day (the visit 
day), following the completion of all assessments.  On the other 2 visit days, subjects 
undergo “haematology” assessments on an outpatient basis.  The day of each visit 
varied according to the assigned test panel.  An overview of visit days is outlined in 
Table 1. 
During the remainder of the treatment period (when not confined in the Clinical 
Research Facility), subjects self-administered investigational product at home, and 
recorded daily dosing information (dates/times), adverse events (AEs), and any 
concomitant medications in subject diary cards. 
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3.3.1 Patient selection 
Eligibility criteria 
Inclusion Criteria 
Subjects meeting all of the criteria listed below were included in the study: 
1. Male volunteers aged between 18-50 years willing to fully comply with study 
procedures and restrictions 
2. Satisfactory medical assessment as determined by medical history, physical 
examination, vital signs, 12-lead ECG, and clinical laboratory evaluation 
(haematology, biochemistry, urinalysis) 
3. Ability to provide written informed consent 
4. Body Mass Index (BMI) between 18.5-30.0 kg/m² 
5. Haemoglobin of 12.0g/dL or greater and platelet count between 200-400x109/L 
6. Ability to swallow all investigational medicinal products 
Exclusion Criteria 
Subjects were excluded from the study if any of the following criteria were met at 
Screening or at baseline (Day –1 [or Day 1 when specified] of treatment period 1) (if 
reassessed): 
1. Current or recurrent disease that could affect the action, absorption or 
disposition of rafigrelide, aspirin, or clinical laboratory assessments 
2. Current or relevant history of physical or psychiatric illness, any medical 
disorder that may require treatment or make the subject unlikely to fully 
complete the study, or any condition that presents undue risk from the 
investigational medicinal product (IMP) or study procedures 
3. Use of any prescription medication, non-prescription medication or over-the-
counter medicine (including multivitamin, herbal or homeopathic preparations) 
within 14 days prior to the first dose of investigational medicinal product 
4. Use of anti-aggregant, anti-platelet or anti-coagulant therapy, including aspirin, 
non-steroidal anti-inflammatory drugs (NSAIDs), and paracetamol within 14 
days prior to the first dose of investigational medicinal product 
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5. Abnormal clotting parameters as assessed by both TEG® and platelet mapping 
on initial Screening and Day 1 of Treatment Period 1 
6. Known or suspected intolerance or hypersensitivity to the investigational 
medicinal product(s), including aspirin, closely related compounds, or any of the 
stated ingredients 
7. History of alcohol or other substance abuse within the last year 
8. A positive screen for alcohol or drugs of abuse 
9. Consumption of more than 21 units of alcohol per week or 3 units per day 
10. Use of an investigational medicinal product within 30 days prior to receiving the 
first dose of investigational medicinal product or active enrolment in another 
drug or vaccine clinical trial 
11. A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B 
surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen 
12. Donation of blood or blood products (e.g. 450mL or more of plasma or platelets) 
within 60 days prior to receiving the first dose of investigational medicinal 
product 
13. Prior screen failure, participation, or enrolment in this study 
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Figure 3.3 Overview of study design 
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Subject Restrictions 
Reproductive Potential 
All subjects, including those who were sterilised (vasectomy), were strongly advised to 
use a condom.  I also suggested that their female partners used at least one of the 
following medically acceptable forms of contraceptives: Intrauterine devices, hormonal 
contraceptives (oral, depot, patch, injectable, or vaginal ring), double barrier methods 
(e.g. condoms or diaphragms with spermicidal gel or foam). 
Male subjects were not permitted to donate sperm and were advised against 
unprotected sex during the study or during the 84 days after the last dose of 
investigational product. 
Other Restrictions 
During confinement in the Clinical Research Facility, subjects were fasted for at least 
2 hours before, until 1 hour after, taking investigational product, and abstained from 
tobacco use until discharge. 
From the first dose of investigational product until the completion of the follow-up visit, 
subjects were requested not to engage in any activities associated with the potential 
for bruising or bleeding, and were advised to refrain from taking any prescription or 
over the counter medication, and alcohol use. 
3.3.2 Screening and recruitment 
Screening procedures were completed within 28 days prior to receiving the first dose 
of investigational product.  Eligibility criteria were confirmed and informed consent was 
obtained prior to the initiation of any study-related procedures. Subjects who failed to 
meet all inclusion/exclusion criteria were not permitted to be rescreened. 
Screening procedures included: 
 Demographics (including date of birth, gender, ethnicity and race) 
 Height and weight  
 Medical history and concomitant medications 
 Complete physical examination, vital signs and 12-lead electrocardiogram 
(ECG) 
90 
 
  clinical laboratory assessments including biochemistry, haematology, 
urinalysis, screen for drugs of abuse and alcohol and virology screen (HIV, 
HBsAg, and HCV antibody) 
  Thromboelastography (TEG) 
Treatment Periods 1 and 2 
This was a 2-period, single-sequence, crossover study in which each subject was 
scheduled to receive rafigrelide at a dose of 4mg/day administered alone (Treatment 
Period 1) and in combination with aspirin at a dose of 75mg/day (Treatment Period 2).   
In both treatment periods, eligible subjects returned to the Clinical Research Facility 
on Day -1.  Subjects who completed pre-admission assessments were then admitted 
to the clinical research facility overnight. 
Admission to the Clinical Research Facility (Day –1): 
Eligible subjects returned to the Clinical Research Facility on Day –1. The following 
pre- admission assessments were performed:  
 Review/confirm eligibility criteria (Treatment Period 1 only) 
 Medical and drug history 
 Complete physical examination, vital signs, 12-lead ECG 
 Clinical laboratory assessments (biochemistry, haematology, and urinalysis) 
and Drug and alcohol screen 
 Review AEs and concomitant medications since Screening 
Subjects who successfully completed the pre-admission assessments and procedures 
were then admitted to the Clinical Research Facility overnight in order to complete the 
study related assessments and procedures on Day 1. 
Visit 1 (Day 1) 
On the morning of Day 1, following at least a 2 hour fast, all subjects underwent the 
following assessments, prior to dosing: 
 Vital signs 
 Blood sample for haematology panel 
 Blood sample for TEG, PK assessment and Badimon perfusion chamber 
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 Assessment of AEs and concomitant medications (if applicable) 
Treatment Period 1 only: Upon completion and analysis of the TEG assessment, final 
eligibility was determined. Subjects were then assigned a subject number, prior to the 
first dose of investigational medicinal product. Investigational medicinal product was 
administered in the Clinical Research Facility under supervision (following completion 
of all other assessments). 
Prior to discharge from the facility, subjects were given instructions for at-home self-
administration of investigational medicinal product and the use of Subject Diary Cards. 
Subjects returned to the Clinical Research Facility for Visits 2, 3 and 4 according to the 
schedule of their panel assignment. 
Panel A: Visits 3, 5, and 6 / Panel B: Visits 2, 4, and 6 
Subjects returned to the Clinical Research Facility in the evening for check-in 
according to the following schedule: 
Panel A: Day 6, Day 13, Day 20, respectively (for testing the following morning on Day 
7, Day 14, and Day 21, respectively) 
Panel B: Day 3, Day 9, Day 17, respectively (for testing the following morning on Day 
4, Day 10, and Day 18, respectively) 
Upon admission to the Clinical Research Facility, all subjects underwent the following 
assessments: 
 Returned investigational medicinal product and Subject Diary Cards collected 
from preceding visit, and compliance determined 
 Vital signs 
 Assessment of AEs and concomitant medications 
The next morning, following at least a 2 hour fast, the following assessments were 
performed: 
 Vital signs 
 Blood sample for haematology panel 
 Blood sample for TEG, PK assessment, Badimon perfusion chamber 
 Physical examination (Visit 4 only) 
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 Investigational medicinal product administered in the Clinical Research Facility, 
following completion of all other assessments (does not apply to Visit 6) 
 Assessment of AEs and concomitant medications  
Prior to discharge from the facility, subjects were given instruction on at-home self- 
administration of investigational medicinal product and the use of Subject Diary Cards. 
Panel A: Visits 2 and 4 / Panel B: Visits 3 and 5 
Subjects returned to the Clinical Research Facility as an outpatient and a blood sample 
for haematology panel was obtained. 
Washout Period: 
There was a washout period of at least 6 weeks between the last dose in Treatment 
Period 1 and the first dose in Treatment Period 2.  Subjects only received 
investigational product in Treatment Period 2 if their platelet counts had returned to 
within their baseline pre-treatment levels. 
Follow-up Period: 
Approximately 14 days after the last dose of rafigrelide in Treatment Period 2 (which 
corresponds to 8 days after the last dose of aspirin for subjects in Panel A, and 11 
days after the last dose of aspirin for subjects in Panel B), subjects returned for a 
follow-up visit. During this visit, the following assessments were performed: 
 Vital signs and 12-lead ECG 
 Clinical laboratory assessments (biochemistry, haematology, and urinalysis) 
 Follow-up of any concomitant medications that are new and/or on-going since 
the last visit 
 Follow-up of any AEs and/or SAEs that are new and/or on-going since the last 
visit 
Removal of subjects from study treatment or assessment: 
A subject was permitted to stop (in full or in part), taking investigational product or to 
withdraw from the study at any time for any reason without prejudice to their future 
medical care by the physician or at the institution.  All discontinued subjects underwent 
the protocol specified follow-up visit.  
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If platelet count fell below 100x109/L, subjects were to be immediately discontinued 
from investigational product, but continued to be monitored and to complete all 
scheduled study assessments for that treatment period.  Subjects were also to be 
removed from treatment (but continued all study procedures) if platelet count fell below 
150x109/L and decreased by more than a 20x109/L per day on average (e.g., 60x109/L 
over 3 days). 
If a subject was removed from investigational product in treatment period 1 due to a 
drop in platelet count, the subject was permitted to complete treatment period 2 
receiving rafigrelide at a reduced dose of 3 mg/day.   
3.3.3 Study specific procedures: 
Safety: 
Safety was evaluated by collecting reported AEs at scheduled intervals throughout the 
study and by the assessment of physical examination findings, vital signs, clinical 
laboratory parameters, and 12-lead ECGs. 
Medical history and concomitant medications 
A complete medical and medication history, as well as demographic information were 
recorded including: 
 Date of Birth, Sex, Race and ethnicity 
 Recent ingestion of medication (within 30 days prior to Screening) 
 History of respiratory, cardiovascular, renal, gastrointestinal (GI), hepatic, 
endocrine, haematological, neurological, psychiatric and other diseases 
Physical Examination 
A complete physical examination was performed at screening, Day -1 and the final day 
after the last dose of investigational product (Day 21 for Panel A and Day 18 for Panel 
B). This included the following: General appearance, skin, Head, Eyes, Ears, Nose and 
Throat (HEENT), Spine/Neck/Thyroid, Musculoskeletal, Respiratory, Cardiovascular, 
Neurological and Abdominal (including liver and kidneys) examination. 
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Electrocardiogram 
A 12-lead ECG was performed at screening, Day -1 and at follow-up. Subjects rested 
in a supine position for at least 5 minutes prior to collecting the 12-lead ECG. Date, 
time, assessment of ‘normal’ or ‘abnormal’, and the heart rate (RR, PR, QT [corrected 
values where applicable]) and QRS were collected. The eligibility of the subject was 
based on ‘normal’ 12-lead ECG at Screening and Day –1. The determination of 
normal/abnormal results and the clinical significance was performed by me. 
Vital Signs 
Measurements of vital signs (blood pressure and pulse) were performed according at 
screening, on the days of admission to the Clinical Research Facility, and on the 
inpatients assessment days. 
Height and Weight 
Height and weight were collected at screening. Height was measured in centimetres 
(cm) and weight in kilograms (kg). Body Mass Index was calculated at screening in 
order to determine subject eligibility to enrol in the study. 
Clinical Laboratory Measurements 
All laboratory assays were performed according to the laboratory’s normal procedures. 
Reference ranges were supplied by the laboratory and used to assess the laboratory 
data for clinical significance and out-of-range pathological changes. If a subject’s 
laboratory values were out of normal range and deemed to be ‘clinically significant’, 
this was recorded as an AE. Clinical laboratory evaluations were performed at 
Screening, Day -1, and at follow-up. 
The following laboratory assessments were performed: 
Biochemistry 
Patient’s blood samples were analysed at nationally accredited clinical biochemistry 
laboratory at Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation 
Trust, Newcastle upon Tyne. Fasting blood samples (6.0mL) for serum biochemistry 
were collected and the following parameters were assessed: 
Sodium     Potassium 
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Calcium     Urea 
Creatine kinase (total)   Albumin 
Total protein     Troponin I mg/dl 
Creatinine µmol/L 
Changes from Screening were recorded as an AE if clinically significant. 
Haematology 
Patient’s blood samples were analysed at nationally accredited general haematology 
and coagulation laboratories at Royal Victoria Infirmary, Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne. A 3.0mL sample of blood was 
drawn into a tube containing potassium ethylene diamine tetra acetic acid (EDTA) 
anticoagulant at screening, at Day  1, at all inpatient and outpatient visits (as outlined 
in Table 1 for each panel), and at follow-up. The following parameters were assessed: 
Haemoglobin , g/L      Haematocrit, % 
Red blood cells (RBC), 1012/L Mean corpuscular volume 
Platelet volume   Platelet count 
Mean corpuscular haemoglobin Mean corpuscular haemoglobin concentration 
White blood cell (WBC) count – total and differential 
Neutrophils    Lymphocytes 
Monocytes    Eosinophils 
Basophils 
Changes from Screening were recorded as an AE if clinically significant. 
Thromboelastography 
A 4.0mL sample of blood was drawn into a syringe for performing thromboelastography 
(TEG) at screening and on the days when subjects were inpatients at the Clinical 
Research Facility. TEG was used to assess blood coagulation, clot kinetics and platelet 
function. This was performed by me. 
Urinalysis 
A 10mL midstream urine sample was collected at screening, Day -1, and at follow-up. 
The following parameters were assessed: Specific Gravity, Protein, Ketones, Bilirubin, 
pH, Glucose, Blood. Microscopic examination was conducted if protein and/or blood 
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is/are detected during urinalysis. This consisted of RBC, WBC, casts and bacteria. 
Changes from screening were recorded as an AE if clinically significant. 
Drug and Alcohol Screen 
A urine drug screen was performed at Screening and Day –1 of each treatment period. 
Urine sample was collected in a polystyrene (10mL) tube. 
Urine samples were tested for the following: Methadone, Benzodiazepine, Cocaine, 
Amphetamine/Methamphetamine, Barbiturates, Tricyclic Antidepressants (TCA), 
Opiates, Tetrahydrocannabinol (THC) 
An alcohol breath test was performed at Screening and on Day –1 of each treatment 
period. 
Virology Screen 
At Screening, a blood sample of approximately 15mL was drawn into a serum 
separator tube to test for the presence of HIV, HBsAg, and HCV antibody. The test 
results were confirmed negative prior to enrolment in the study. 
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3.3.4 Investigational Medicinal Product(s) 
 Rafigrelide: supplied as 0.5mg oral capsules (open-label) 
 Aspirin: supplied as 75mg oral enteric-coated tablets (open-label) 
Labelling 
Rafigrelide was provided by Shire Pharmaceuticals Development Ltd., Basingstoke, 
UK, to the pharmacy production unit at Royal Victoria Infirmary, Newcastle upon Tyne 
(MHRA Unit IMP license number 17736), as labelled individual subject dose bottles. 
These supplies were open-labelled and presented as 0.5mg Swedish orange size 0 
capsules packaged in 30ml high-density polyethylene (HDPE) bottles. The batch 
number of Rafigrelide was PR100103-001. 
Aspirin (75mg enteric-coated tablets) was provided as individual subject dose packs. 
These supplies were also open-label, packaged as a commercial pack containing 28 
blistered tablets. The batch number of Aspirin was PR100103-002. Labels for both 
rafigrelide and aspirin were multi-part computer-generated labels. 
One part adhered to the supplies container and the other tear-off part was removed at 
the time the investigational medicinal product was dispensed to the subject and 
adhered to the drug accountability form. All supplies were labelled with the protocol 
number, subject number, medication identification number, dosage form (including 
product name and quantity in pack), directions for use, storage conditions, expiry date, 
batch number or packing reference number, the statements ‘For clinical trial use only’, 
“’Keep out of reach of children’, and the Sponsor's name and address. 
Storage 
As the Investigator, I had the overall responsibility for ensuring that investigational 
medicinal product is stored in a secure, limited-access location. Limited responsibility 
was delegated to the pharmacy or member of the study team, but this delegation was 
documented. Investigational medicinal products were distributed by the pharmacy or 
nominated member of the study team. 
Investigational medicinal products were stored in accordance with labelled storage 
conditions. Temperature monitoring was strictly adhered to at the site’s storage 
location to ensure that the investigational medicinal product was maintained within an 
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established temperature range. I was responsible for ensuring that the temperature 
was monitored throughout the total duration of the study and that records were 
maintained; the temperature was monitored continuously by using a calibrated 
mechanical recording device and minimum and maximum thermometric values over a 
specific time period were recorded and retrieved as required. The device was manually 
reset upon each recording. 
Allocation of Subjects to Treatment 
Screening numbers were assigned sequentially to all subjects as they consent to take 
part in the study. This was a 4-digit number starting at 0001. This number was assigned 
to subjects according to the sequence of presentation for study participation. For 
screen failures, the Screening Number was the identifying number used throughout 
the CRF. 
A 4-digit subject number was allocated to the subject on Day 1 of Treatment Period 1, 
after reconfirming eligibility. Subjects were assigned subject numbers starting at 1001. 
This number was the identifying number used throughout the CRF. All odd-numbered 
subjects (e.g. 1001, 1003, 1005, etc.) who were eligible for dosing on Day 1 of 
Treatment Period 1 were assigned to Panel A. All even-numbered subjects (e.g. 1002, 
1004, 1006, etc.) who were eligible for dosing on Day 1 of Treatment Period 1 were 
assigned to Panel B. 
Replacement subjects were assigned a subject number that corresponded to the same 
panel assignment (Panel A or Panel B) of the subject that they replaced. 
3.3.5 Pharmacovigilance and data monitoring 
All AEs, including those associated with the protocol, were collected from the time 
written informed consent was obtained until the defined follow-up period and were 
recorded on the appropriate AE pages in the CRF and in source documents. All AEs 
were followed to closure (the subject’s health had returned to his baseline status or all 
variables had returned to normal), an outcome was reached, stabilisation (the 
Investigator does not expect any further improvement or worsening of the event), or 
the event was otherwise explained regardless of whether the subject continued to 
participate in the study. The intensity (mild, moderate, severe), relationship to 
investigational product, and outcome were recorded for all AEs.  All AEs were followed 
to closure, and reviewed, confirmed, and classified by myself. When appropriate, 
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medical tests and examinations were performed so that resolution of event(s) could be 
documented. 
All initial and follow-up SAE reports were reported by myself to the sponsors within 1 
business day of the first awareness of the event. I completed, verified the accuracy of 
information recorded with the corresponding source documents, signed, and dated the 
Clinical Trial Serious Adverse Event Form, and sent the form to the sponsor’s 
Pharmacovigilance Department.  
The Sponsor took the responsibility to notify the relevant regulatory authorities, 
European Union (EU) central IECs of related and unexpected SAEs. The principal 
investigator and I were responsible for notifying the local Institutional Review Board 
(IRB), local Independent Ethics Committee (IEC), and the relevant local regulatory 
authority of all SAEs that occurred. 
An electronic case report form (eCRF) was used to permit consistent collection of data; 
source-verified data were subjected to both manual and electronic checks to ensure 
data integrity and accuracy. Quality control and data validation procedures were 
applied to ensure the validity and accuracy of the clinical database. 
3.3.6 Statistical methods 
Statistical analyses were performed using SPSS version 17.0 (SPSS Inc, NY, USA) 
and Graphpad prism version 6 (Graphpad software, CA, USA). Graphs were 
constructed after data analyses using Graphpad software. Baseline characteristics 
were summarised using descriptive statistics. Platelet count, mean platelet volume, 
thrombus area, standard TEG® parameters and Platelet mapping™ was compared 
between and within the treatment panel using repeated measures analysis of variance 
(ANOVA) with time and panel as fixed factors. Separate analysis was performed for 
Panel A and Panel B in both the treatment periods. All results are expressed as 
mean±SD unless specified otherwise. A p value of less than 0.05 with two tailed 
measurement was considered statistically significant.  
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Figure 3.4 Rafigrelide study – Flow chart
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3.4 Special methods 
3.4.1 Badimon perfusion chamber – platelet dependent thrombus formation 
Principles of the Badimon perfusion chamber 
The Badimon perfusion chamber system is a well validated model of deep arterial injury 
and thrombosis (Napoli et al., 2006), and has previously been used to evaluate the 
effects of novel antithrombotic agents in human participants in different disease states 
for over fifteen years (Lev et al., 2001; Osende et al., 2001; Sarich et al., 2003). This 
model enables the measurement of thrombus formation in native (non-anticoagulated) 
whole blood triggered by exposure to physiologically relevant substrate (e.g. collagen 
in tunica media), and under different rheological conditions mimicking flow in stenosed 
coronary arteries. The chamber has been designed to “retain the cylindrical shape 
typical of the vasculature, to be flexible enough to accept a variety of biologic and 
prosthetic materials, and to simulate a broad range of physiologic flow conditions” in 
either an ex vivo or in vitro perfusion system (Badimon et al., 1987). The consistency 
and reproducibility of the chamber system has been re-validated again recently in a 
cohort of 24 healthy volunteers (Lucking et al., 2010). 
The Badimon chamber in our study is an ex vivo model that mimics: 
i. the flow conditions in normal and moderately stenosed arteries 
ii. atherothrombotic plaque rupture 
Platelet dependent thrombus (PDT) formation in Badimon chamber experiments 
involves two basic physiological principles of arterial thrombosis. These include: 
i. collagen mediated thrombus generation 
ii. shear induced platelet activation 
Freshly slaughtered pig’s aorta was used as a source of collagen in our experiments. 
The tunica intima (endothelial layer) was surgically dissected and the tunica media, 
which is rich in collagen, was used as the substrate (simulating an atherothrombotic 
plaque rupture) in the Badimon chamber. This layer was exposed to the flowing blood. 
Platelet activation occurs in the coronary circulation at the site of luminal narrowing 
produced by atheromatous plaques. At these sites the laminar flow is disrupted and 
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converted to turbulent flow, thereby increasing the shear rate of flowing blood. In the 
Badimon chamber system, reduction of luminal diameter increases the velocity of 
flowing blood within the chamber. This also disrupts the laminar flow of blood. As a 
result there is re-distribution of platelets in a moving column of blood, with more 
platelets accumulating in the periphery than in the centre of the flow. This enables 
activation of the platelets when they come into contact with the tunica media and 
aggregation of platelets when they come into contact with each other (Ahlqvist, 2001). 
Standardisation of the Badimon perfusion chamber 
Our reference laboratory at Mount Sinai Medical School, New York, USA, performed a 
series of experiments to assess thrombus generation at varying shear rates, flow rates 
and duration of blood flow through the Badimon chamber. Iridium 111 labelled platelets 
were used to assess PDT burden at time intervals from 1 minute to 20 minutes; flow 
rates at 5 to 20 ml/minute (blood velocity of 2.65 to 42.3 cm/sec) and shear rates from 
106 per sec to 3380 per sec (Badimon et al., 1986). 
This experiment demonstrated a steep increase in thrombus generation from 1 to 5 
minutes but reached a plateau after 10 minutes.  Thrombus generation increased with 
increase in flow rates from 5ml/minute to 10 ml/minute but not at higher rates. Effects 
of shear rates on thrombus generation were studied both by radio labelled platelets 
and by image analysis. At low shear states (inner luminal diameter: 2.0mm; vessel wall 
shear rate: 100-200s-1, mean blood velocity: 5.3 cm/sec; Reynolds number: 30), fibrin 
rich thrombus was formed and at high shear rates (inner luminal diameter: 1.0mm; 
vessel wall shear rate: 1500-3000s-1, mean blood velocity: 21.2 cm/sec; Reynolds 
number: 60) platelet rich thrombus was formed. Assessment of thrombus quantity, as 
measured by total thrombus area (platelet and fibrin content combined), showed higher 
thrombus generation at high shear states compared to low shear states. 
In our laboratory, we standardised our chamber experiments to obtain adequate 
amount of thrombus but using the lowest possible volume of blood. Hence, I used two 
chambers with inner diameter of 1.0 mm (high shear chambers) and one chamber with 
inner diameter of 2.0 mm (low shear chamber) to generate high shear rates [Reynolds 
number 60 (measure of non-laminar flow), shear rate of 1920 per sec] and low shear 
rates [Reynolds number 30, shear rate of 500 per sec] respectively. I used a flow rate 
of 10 ml/min for a duration of 5 minutes (total of 50 mls of blood).  
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An 18 G cannula (inner diameter 1.2mm, maximum flow rates 90-100 ml/min) and 
Tygon tube (number 14.0, inner diameter 1.6mm) were used in all subjects in order to 
maintain the same shear force within the Chamber. The same peristaltic pump 
(Masterflex® pump, Thermo-Fisher Scientific Inc, MA, USA) was used in all the 
experiments at a fixed flow rate of 10ml/min. Quality control experiments were 
performed at fixed time intervals to check for consistency as detailed elsewhere. 
Technique of Badimon perfusion chamber system 
The system consisted of: 
i. three small plexi glass chambers – one low shear and two high shear chambers 
ii. three plexi glass over-chambers with a screw to secure the substrate inside the 
chambers 
iii. a plexi glass container designed to accommodate the chambers connected in 
series and which easily sits in a water bath 
iv. four plastic connectors – connects the chambers in series 
Each of the chambers contain two split individual units, called the upper lid unit and 
the lower core unit. The lower core unit has cylindrical channels carved out in the 
rectangular plexi glass block – dimension of 1.0mm×25.0mm and 2.0mm×25.0mm for 
high shear and low shear chamber respectively. The upper lid unit has a rectangular 
raised central projection which is 25.0 mm long with a thickness of 1.0mm and 2.0mm 
for high shear and low shear respectively. 
A piece of porcine aorta stripped of its intimal layer to expose the underlying 
thrombogenic tunica media (substrate for thrombus formation) was placed between 
the upper lid and lower core unit with the exposed medial layer forming the roof of the 
cylindrical flow channel in the chambers. The chambers were then placed in the over 
chamber and were held in position by the screw that opposed the upper lid and lower 
core units together, sandwiching the substrate between them (Badimon et al., 1986).  
This enabled the flowing blood to come in contact with the exposed media, thereby 
initiating platelet activation and thrombus formation. The flow channels of the chamber 
were then connected in series by plastic connectors with matching diameters. For all 
my chamber studies, I arranged the chambers in the following order, proximal to distal, 
low shear unit followed by first high shear unit followed by second high shear unit. This 
whole assembly was then placed inside the plexi glass container which was in turn 
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placed in a circulating water bath maintained at 37 degrees Celsius (body temperature) 
(Figure 3.5). 
18 G cannula in participant’s antecubital fossa was connected to a three way tap. The 
other end of the tap was connected to the proximal end of the chamber system using 
14.0 Tygon® tubing (Cole Palmer, IL, USA). The third end of the tap was connected to 
a container that contained 0.01M phosphate buffer solution (PBS) using the same 
Tygon tubing.    
The output of the chamber system was connected to a peristaltic pump (Masterflex, 
model 7013) using similar Tygon tubing. Initially, to flush and prime the perfusion 
system, 0.01 M PBS was drawn through the system at a flow rate of 150mL/min for 
about 10 seconds. Then, the peristaltic pump drew blood (native, non-anticoagulated) 
directly from the intravenous cannula over the substrate at a constant rate of 10 mL/min 
for 5 min. The effluent blood was collected between the 3rd and the 5th minute into plain 
and 3.2N sodium citrate tubes. After 5 minutes, PBS was again drawn through the 
chamber for 30 seconds by turning the three way connector (flow rate 10mL/min). This 
was to remove all the unattached cells and blood overlying the formed thrombus on 
the substrate. The switch from buffer to blood then to buffer were achieved manually 
by turning the three way valve without any stasis of flow within the chambers. 
Connectors and Tygon tubing used in the chamber system are non thrombogenic, fits 
air tight in to the peristaltic pump and maintains constant flow and shear rate during 
the study.   
The aortic tissues with formed thrombi were then removed from the chamber units, 
with extreme care to prevent any dislodgement of fresh thrombus. Individual aortic 
segments were then fixed in 10% buffered formalin. After a minimum of 72 hours of 
fixing, the aorta segments (one low shear and two high shear) were sectioned into 
eight pieces, each approximately 1mm in width (Natarajan et al., 2008a) and placed in 
pre-labelled histocassettes, one for each aorta segment. The segments were labelled 
as below: 
i. Low shear aorta segment: A1, A2, A3, A4, B1, B2, B3, B4 
ii. High shear aorta segment 1: C1, C2, C3, C4, D1, D2, D3, D4 
iii. High shear aorta segment 2: E1, E2, E3, E4, F1, F2, F3, F4 
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The histocassettes were placed in formalin and taken to Cellular Pathology 
department, Royal Victoria Infirmary where sectioning, mounting and staining 
processes were carried out. The aorta segments were embedded in liquefied wax. The 
tissue blocks in the wax were then sectioned using a microtome to smaller sections of 
0.4µm width. These were then mounted on glass slides and stained using modified 
Masson trichrome stain (described below).  
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Figure 3.5 Set up of the Badimon chamber 
Blood from patients’ antecubital fossa is drawn directly and allowed to flow through the 
Badimon chamber using Tygon tubing. Aorta with stripped intima is used as the 
substrate in Badimon chamber. The chamber is in a circulating water bath maintained 
at body temperature. The three chamber units are connected in series – low shear unit 
then high shear unit 1 followed by high shear unit 2. Uniform flow condition was 
maintained during the study. 
High shear chamber has an inner diameter of 1.0 mm and generates a shear rate of 
1920 per sec and Reynold number of 60. 
Low shear chamber has an inner diameter of 2.0 mm and generates a shear rate of 
500 per sec and Reynold number of 30. 
Effluent blood sample was collected from minute 3 to minute 5 and the serum and 
plasma samples were stored for coagulation and inflammatory biomarkers analysis. 
Rest of the effluent blood was safely discarded.  
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Staining of the thrombus 
The sections of aorta segment on glass slides were stained using modified Masson 
trichrome method. This is a three colour stain protocol where after staining, the 
thrombus with fibrin appears red, the elastin of the aorta substrate appears green and 
the aortic smooth muscle appears pink. The original Masson trichrome staining was 
first described in 1929 (Bancroft and M, 2002). The technique was modified to enhance 
the thrombus staining over the aortic substrate and also to clearly delineate the stained 
thrombus and tunica media. This modification has been validated by Thrombosis 
Research Laboratory at Mount Sinai Hospital, New York (Osende et al., 2001). Step 
by step staining protocol is described below. 
Image acquisition 
The stained thrombi were viewed using a Leica DM2000 microscope (Leica 
Mikrosysteme Vertrieb GmbH, Weltzler, Germany). The microscope was calibrated 
according to manufacturer’s recommendations. It was cleaned and quality control 
checked twice a year. The thrombus was identified (pink to red) on the top of the raised 
section of tunica media of the aortic substrate (green) under 10X magnification. A high 
definition digital camera with resolution of 1360x1024 (KY-F1030, JVC, Japan) was 
connected to the microscope and a computer using an IEEE1396 electronic link and 
an inbuilt TWAIN driver. The captured image of thrombus and substrate was digitalised 
and stored without losing its precision using special software (What You See Is What 
You Get Software (WYSIWYG) ®, JVC, Japan). 
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Modified Mason trichrome staining protocol 
1. 150 ml of Weigart’s haematoxylin solutions A and B are mixed 
together. 
2. Slides were taken and serially exposed to solutions – Xylene x2, 
99% alcohol x2, 95% alcohol and 75% alcohol. 
3. The slides were then left in Weigart’s solution (A and B) for 10 
minutes. 
4. Following this the slides were run in tap water. 
5. The slides were dipped in acid alcohol and then run in tap water 
again. 
6. The slides were then dipped in Scotts tap water and then run in 
tap water again. 
7. Then dipped in 2% Poncaeu Red in acetic acid for 10 minutes. 
8. The slides were then washed in distilled water. 
9. The slides were then left in 2% light green for 40 seconds. 
10. Following this the slides were dipped in distilled water then in 
2% acetic acid. 
11. The slides were then run in tap water and then dehydrated 
quickly, 70% alcohol, 95% alcohol, 99% alcohol x2, Xylene x2. 
12. The slides were then placed in holder and cover slips are 
pasted. 
13. The slides were then blot with tissue and are arranged in boxes 
safely. 
 
Table 3.1 Stepwise protocol for modified Mason trichrome staining.  
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Thrombus area measurement 
Image ProPlus®, Version 4.0 software (Media Cybernetics, Bethesda, MD, USA) was 
used for image analysis and total thrombus area measurement. Standard micron 
calibration scale supplied by the manufacturer was used for calibration prior to image 
analysis. Acquired images that were stored in .jpeg format were opened using this 
software. Automated best fit algorithm was used to adjust the brightness and contrast 
of the images. The thrombus outline was precisely traced with the cursor using 
‘irregular area of interest (AOI)’ in the software. Utmost care was taken to make sure 
tunica media was not included in the area of interest. Once the area of interest was 
delineated from the rest of the aortic tissue, the thrombus area was measured using 
the dark object identification algorithm. This algorithm identifies thrombus as multiple 
individual dark objects separating it from the background image. The area of the 
thrombus was quantified as the sum of area of the multiple dark objects. Thrombus 
areas of each of the 24 sections of aorta (8 low shear and 16 high shear) were counted. 
Total thrombus area (TTA) was calculated as mean of individual thrombus areas for 
high shear and low shear sections and expressed as micrometres squared per 
millimetre (µm2/mm) of aorta. 
Images were checked by two observers, myself and the senior experienced 
investigator Prof Azfar Zaman. After reviewing all the images we excluded the aorta 
sections that were deemed unsuitable for analysis as listed below: 
i. Sections with flaps: may lead to sluggish flow and increased red cell 
thrombus may overestimate the thrombus area 
ii. Sections which were damaged by microtome: may underestimate thrombus 
area 
iii. Sections with artefacts from dye or coverslip: may overestimate thrombus 
area 
iv. Sections with negligible thrombus formation (<500 µm2/mm): falsely low 
thrombus area due to wash artefact 
v. Sections with red cell thrombi: due to sluggish flow may overestimates 
thrombus area 
We excluded 4.9% of thrombus images from final analysis (538/10880 images) due to 
one of the above listed reasons. 
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Quality Control 
Before every chamber study, I ensured the integrity of the chamber circuit by priming 
with 0.01 M PBS at 10mL/min (standard laminar flow) and 150mL/min (high shear, 
non-laminar flow).  
I performed quality control chamber study once every four months. I used 30g of coffee 
powder mixed with 50 ml of 4% cream and 50ml of water (1:1) to mimic the consistency 
of viscous blood. Deposition of the coffee powder particles was examined using a 
magnifying glass (X4). Presence of coffee powder in places other than the central three 
fourths of aorta was considered non uniform flow. A full chamber study with a volunteer 
(myself) was also performed every year, exactly similar to a patient study. Mean 
thrombus area was similar in all the three studies (total thrombus area µ2/mm, 12453, 
13124, 12221). 
Quality control for image analysis was also performed. Two independent observers 
(myself and Prof Azfar Zaman) analysed 5% of randomly chosen images in a blinded 
fashion. Inter-observer co-efficient of variation was 6.2%. I also analysed the same set 
of images on three different occasions on three consecutive days, with an intra-
observer co-efficient of variation of 4.2%. 
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3.4.2 Scanning electron microscopy (SEM) – Ultrastructural assessment of 
thrombus 
Introduction 
Studying the architecture of platelets and fibrin fibres is done using scanning electron 
microscopy. Fibrin fibre structural arrangement in thrombus was first demonstrated in 
1981 using electron microscopy (Weisel et al., 1981). Thrombus structure was later 
described using iridium labelled platelets in a small cohort of patients (Badimon et al., 
1987). Microscopic mechanical properties of thrombus were first described by Collet 
et al using electron microscopy (Collet et al., 2005). This was found to be time 
consuming and error prone, hence the current focus is mainly on fibrin structure 
derived from platelet poor plasma. However, the quantitative assessment of thrombus 
using SEM is still in early stages of development and is not yet formally standardised. 
From our laboratory, we have recently published ultrastructural differences in fibrin 
fibres of formed thrombus using scanning electron microscopy comparing T2DM and 
non-DM patients following NSTE-ACS (Viswanathan et al., 2014). 
Principles and technique of scanning electron microscopy 
Light microscopes cannot generate images of magnification higher than 1000x. Hence 
scanning electron microscopy (SEM) was used. SEM is a type of electron microscope 
that produces images of a sample by scanning it with a focused bean of electrons. 
SEM uses the principles of signal generation when high voltage electron beams are 
focused on a smaller area on the surface of the solid biological sample. The electrons 
interact with atoms in the sample, producing various signals that can be detected and 
that contain information about the sample's surface topography / external morphology, 
composition, crystalline structure and orientation of individual subunits of the sample. 
The electron beam is generally scanned in a raster scan pattern, and the beam's 
position is combined with the detected signal to produce an image. SEM can achieve 
resolution better than 1 nanometer. Specimens can be observed in high vacuum, in 
low vacuum, in wet conditions (in environmental SEM), and at a wide range of 
cryogenic or elevated temperatures. The electron beam receiver collects data over a 
selected area of the surface of the sample, and a 2-dimensional image is generated 
that displays spatial variations in these properties. Areas ranging from 1 cm to 5 
microns in width can be imaged using conventional SEM techniques (magnification 
ranging from 20x to approximately 30,000x, spatial resolution of 50 to 100 nm). 
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Components of SEM include: 
i) electron optical column - source to produce electrons 
ii) electromagnetic coils to control and modify the beam  
iii) vacuum systems - “holds” vacuum to minimise artefacts  
iv) Signal detection & display unit - consists of detectors that collect the signal 
and electronics to produce an image from the signal. 
Detailed principles and capacities involved in the image acquisition and analysis are 
beyond the scope of this thesis. Basically, in SEM accelerated electrons carry 
significant amounts of kinetic energy, and when these focused electrons hit and 
decelerate from the surface of the sample, the energy is dissipated as various signals. 
The types of signals include secondary electrons (SE), back-scattered electrons 
(BSE), characteristic X-rays, cathodoluminescence (CL), specimen current and 
transmitted electrons. Back-scattered electrons (BSE) are beam electrons that are 
reflected from the sample by elastic scattering. A backscatter electron detector covers 
the trajectory of the backscattered electrons. Secondary electrons and backscattered 
electrons can be efficiently detected separately at a low accelerating voltage and the 
detector is placed in such a way to avoid the pathway of the primary electron beam. 
Images from backscattered and secondary electrons can be of high resolution can be 
obtained. 
Transmission EM (TEM) is another high resolution EM and can achieve magnification 
of up to 450,000x. I decided to use SEM rather than TEM for the following reasons: 
i. SEM is better suited to study the thrombus formed in Badimon 
chamber as TEM may focus only on a very small area of the thrombus 
ii. thrombus preparation on a very thin slice of aorta will be technically 
challenging for TEM 
iii. fibrin to fibre interactions are better studied using SEM 
iv. cross sectional imaging of thrombus by TEM will be very time  
consuming and less likely to yield more information 
SEM study protocol 
With the help of the senior operators at Electron Microscopy services, Newcastle 
University, I performed a series of pilot image acquisition under supervision as a part 
of my training. For better reproducibility and to improve processing speed, the pilot 
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image was standardised at approximately 60x magnification using an 8 kilo Voltage 
electron beam and the sample kept at 6mm distance from the electron gun. For high 
power 3,200x magnification and for ultrahigh power 15,000x magnification were 
chosen as standard for this study.  
I decided to analyse 60 random patient samples (20 in each group) on both visits. The 
samples were identified by the study identification numbers, chosen randomly by an 
independent member of our team. This kept me blinded to the group the particular 
study identification number belonged to during the analysis. In order to detect a 10% 
change in fibrin diameter from baseline 1 week after clopidogrel therapy with 80% 
power, we estimated that a sample size of 17 patients per group was required. Hence, 
I chose my sample size as 20 per group. Each patient had two high shear aorta 
specimens.  
Thrombus laden aorta samples from the Badimon chambers were fixed in 2% 
glutaraldehyde. A sample of 1mm width was taken from each chamber (1x low shear 
and 2x high shear) at the median point of the aorta. Only high shear thrombus 
specimens were used for analysis. After 72 hours of fixing, the thrombus specimens 
were serially treated with varied concentration of ethyl alcohol. After critical point 
drying, the samples were mounted using silver adhesive. They were then gold coated 
in a specialised chamber and the samples were loaded to SEM. Standard pilot images 
were taken at 60x magnification. Six images were taken at high power 3.2x103 
magnification and further six images were taken at 15x103 magnification. The areas of 
interest were identified using a validated random grid model using 2x3 squares (Silvain 
et al., 2011). Total numbers of fibres were counted in a square grid model with area of 
36sq.microns. All the images were analysed by me and I was blinded from which group 
the study identification number belonged to. 
The images were analysed using Image ProPlus® software 4.0.1 (Media Cybernetics 
Inc, MD, USA). I first focused on the standard pilot image (60x magnification) and 
identified platelet rich areas and fibrin areas using a simple grid analysis model and 
calculated proportional content of each of them. This did not provide the absolute value 
of platelet or fibrin content of thrombus but percentage area occupied by each of the 
components. Internal validation was performed and intra observer CV (KB) was 12.4% 
and inter-observer CV (KB vs KW) was 16.5% for platelet-fibrin content of thrombus. 
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I then proceeded with high power images of 3.2x103 magnification and focused on two 
distinct structures, platelets (disc shaped) and fibrin (filament shaped) 
Platelets in the sample were identified by the following validated structural features, 
Figure 3.6 (Williams text book of Haematology, 8th edition, McGraw Hill, New York, 
USA): 
i. disc shaped structure 
ii. presence of pseudopodia 
iii. Presence of filaments 
iv. Presence of exosomal globular structures (exocytosis of 
golgi apparatus and granules) 
v. Presence of clumping 
Fibrin fibres were identified by the following validated features, Figure 3.7: 
i. Long filamentous architecture 
ii. Presence of interlinkage between filaments 
iii. Twisting of filaments 
iv. Attachment to platelets 
v. Entrapment of platelets 
The “hub and spokes” model of thrombus assessment was created following the 
discussion with the senior laboratory technicians. It was hypothesised in our previous 
work that the presence of higher number of “hub and spokes” would limit the energy to 
be used in individual fibrin fibre polymerisation and thus make them more susceptible 
for autolysis. 
Dendrite identification algorithm of Image Proplus® version 4.0 was used to analyse 
the fibrin to fibrin interlinkage. This software identified fibrin filaments in the thrombus 
and was used to count the numbers and measure the size of individual fibres. The 
dendrite function algorithm specifically identifies fibrin-fibrin interlinkage in a predefined 
area of thrombus. The “hub and spokes model” was applied on the image to study 
individual fibrin to fibrin interaction.  
“Hub” was defined as presence of three or more individual fibrin fibres intersecting 
each other at three different angles with at least 20 degrees in between. Those with 
angles less than 20 were defined as parallel fibrin fibres. This model helped us to study 
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the compactness of the thrombus. Individual fibrin fibres were known as “spokes”. As 
the thrombus was heterogeneous in any given field in SEM, I also measured clusters 
of hub and spokes per square micron of the field. This provided a quantitative 
assessment of compactness of the thrombus.  
For quality control, every fourth sample was re-analysed and if the differences in fibrin 
diameter or platelet diameter were more than 10%, analysis was performed for the 
third time and the results of the third analysis was included in the analysis. 
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Figure 3.6 Electron microscopy appearance of platelets 
Electron microscopy appearance of platelets in various stages of activation was seen 
at high power magnification (x3600) and at 8kV energy. Activated platelets were 
characterised by the presence of pseudopodia seen as an “end on” appearance. 
Granules were seen as small projections on the surface of the platelets. The platelets 
were seen here at various stages of changes in shape. The fibrin filaments are seen 
bridging the adjacent platelets, thereby resulting in platelet clumps. 
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Figure 3.7 Electron microscopic appearance of fibrin fibres 
Fibrin fibres viewed at ultra-high power magnification by scanning electron microscopy. 
Fibrin fibres were arranged in longitudinal pleated structure with trapped RBC’s and 
platelets. The presence of hub and spoke appearance is shown in this section with 
lateral fibrin fibre interlinkages. 
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Step by step SEM analysis protocol 
SEM analysis of the thrombus consisted of three distinct stages (sample preparation, 
image acquisition and image analysis), as describe below: 
Sample preparation 
1. After completion of Badimon chamber study, the aorta substrate was carefully 
removed from the chamber 
2. The middle 1mm width of aorta laden with thrombus was dissected using a 
precision blade/scalpel. Care was taken not to disturb freshly formed thrombus. 
The same was repeated for the two other chambers, so that three specimens 
were obtained (1x low shear, 2x high shear). The samples were immediately 
fixed in 2% glutaraldehyde in Sorensons phosphate buffer 
3. The specimens were then stored at 5°C for at least 72 hours  
4. The fixed thrombus samples were then rinsed twice for 15 minutes using 0.01M 
phosphate buffer solution 
5. This was followed by step by step dehydration using various strengths of 
ethanol as follows: (gradual increase in concentration to minimise artefacts): 
a) 25% ethanol for 30 minutes 
b) 50% ethanol for 30 minutes 
c) 75% ethanol for 30 minutes 
d) 100% ethanol one hour 
e) 100% ethanol for one hour 
6. This was followed by critical point drying using Baltec critical point dryer.  
7. Samples were then mounted on an aluminium stub with sample number written 
on the bottom surface and Acheson silver Electrodag was used as an adhesive 
on the adventitial side of the aorta 
8. Using Poloron SEM coating unit, with argon vapour, colloid gold was spray 
coated (up to 15nm thickness) on the surface of the thrombus 
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Image acquisition 
1. Maximum of six gold coated samples in the aluminium stubs were loaded in the 
SEM tray 
2. One tray was then loaded in to the holder and the door is closed 
3. Electron detector was then adjusted 
4. SEM machine was then switched on to generate vacuum 
5. The green flicker from tungsten filament was adjusted to sharpen the image 
6. Image detector was switched on and the sample image appeared on the screen 
7. Recommended settings used to obtain a magnification of 60-72x times as a basal 
image 
8. Image was acquired to the folder in the PC using Olympus software 
9. This image was the pilot image and used to check patients ID number 
10. Major grid was used and the image was divided to 6 squares. One image was 
obtained from each major grid 
11. Image was refocused to the square of interest starting with left top square 
12. This focused square was then divided to 4 squares using a high power grid. One 
square was again chosen at random and focused at 3,200 to 3,600x magnification. 
Further fine tuning of the image was performed to obtain better contrast. Image was 
then acquired and stored in the PC 
13. The high power image was further divided into 4 squares using ultra power grid. 
One square was chosen at random and focused at approximately 15,000x 
magnification. The image was fine-tuned, acquired and stored in PC as in step 8  
14. Then returned back to low power at 60-70x magnification and moved to the next 
square in pilot grid, bottom left corner. Steps repeated as above 
15. Image acquisition was repeated from middle top, middle bottom, right top and right 
bottom squares. One high power and one ultra-high power image for each major 
square in the pilot grid was available 
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16. Returned back again to low power at 60-70x magnification and moved to the next 
square in pilot grid, bottom left corner. Steps repeated as above 
17. Image acquisition was repeated from middle top, middle bottom, right top and right 
bottom squares. One high power and one ultra-high power image for each major 
square in the pilot grid was available 
18. In total each sample had six high power (x3200 magnification) and six ultra-high 
power (x15000 magnification). There were four samples for each patients (2 from 
visit 1 and 2 from visit 2) generating 24 samples for each patient 
19. Once completed, images were backed up in the portable hard drive 
20. Filament was turned down, and SEM left under vacuum 
Image analysis 
The images were analysed using Image ProPlus® software 4.0.1 (Media Cybernetics 
Inc, MD, USA) as explained in the previous section. 
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Figure 3.8 Image acquisition in SEM – Major Grid 
The sample was divided into 6 squares using major grid. One square was chosen at 
random and further divided into four high power grid (squares). One square was 
chosen again at random from the high power grid, for high power image (3200x - 3600x 
magnification). One high power image per one major grid of the pilot image. Similar 
steps were repeated for acquiring ultra-power images (15000x magnification) per one 
major grid of pilot image. Solid arrows indicate the area of interest in the pilot image of 
high power grid and ultra-high power grid. 
 
122 
 
3.4.3 Thromboelastography® and Platelet Mapping™ - assessment of 
viscoelasticity 
Principles and technique 
Thromboelastography (TEG®) is a non-invasive diagnostic instrument designed to 
measure the viscoelastic property of the whole blood. The analyser is intended to be 
used to provide a quantitative and qualitative measurement of haemostatic system and 
hence can be used to identify defects in thrombus formation and autolysis. TEG® 
monitors the thrombodynamic properties of blood as it is induced to clot under a low 
shear environment. The patterns of change in shear-elasticity enable the determination 
of the kinetics of clot formation and growth as well as the strength and stability of the 
formed clot. The strength and stability of the clot provide information about the ability 
of the clot to perform the work of haemostasis, while the kinetics determine the 
adequacy of quantitative factors available to clot formation. TEG® is used to assess 
clinical conditions such as post-operative haemorrhage and/or thrombosis during and 
following cardiovascular surgery, hepatobiliary surgery, organ transplantation, trauma 
and other cardiology procedures. TEG® provides a dynamic and real time assessment 
of viscoelastic property of the thrombus (Reikvam et al., 2009).  
The TEG® consists of two mechanical parts as demonstrated in Figure 3.9: 
i. a heated (37 ºC) oscillating cuvette or cup 
ii. a stationary pin which is suspended in the centre of the cup and connected to a 
torsion wire 
Blood is placed in the cuvette and is oscillated through an angle of 4.45 degrees with 
each rotation cycle lasting for 10 seconds. Whilst the blood remains unclotted the 
motion of the cuvette does not affect the pin. The torque of the rotating cuvette is 
transmitted to the immersed pin only after fibrin-platelet bonding has linked the cuvette 
and pin together. The strength of these fibrin-platelet bonds affects the magnitude of 
the pin motion, such that strong clots move the pin directly in phase with cuvette 
motion. Thus, the magnitude of the output is directly related to the strength of the 
formed clot. As the clot retracts or lyses, these bonds are broken and the transfer of 
cuvette motion to the pin is diminished. The rotational movement of the pin is converted 
by a mechanical-electrical transducer to an electrical signal which is monitored by a 
computer and displayed as a graph. The resulting haemostasis profile is a measure of 
123 
 
the time it takes for the first fibrin strand to be formed, the kinetics of clot formation, the 
strength of the clot (in shear elasticity units of dyn/sq.cm) and dissolution of clot (Figure 
3.10). By measuring the tensile strength of the thrombus continuously, TEG® results 
reflect the dynamic property of whole blood thrombosis which includes platelet 
adhesion, aggregation, fibrin-platelet bonds and fibrin polymerization. TEG® also 
measures the velocity at which the thrombus forms and this is known as clot kinetics. 
TEG® measurements are displayed in the form of a graph and various parameters 
measured are explained in the table below. Initiation of thrombus formation begins with 
the activation of coagulation cascade and results in formation of fibrin polymers (R 
time). This is calculated from the graph as the time from initiation of the trace until the 
amplitude of the clot reaches 2 mm. This is functionally related to plasma clotting and 
inhibitor activity. The next parameter measures the speed at which the thrombus forms 
(K time) and is calculated as the time from R until the amplitude of the clot reaches 20 
mm. The next parameter α-angle (the slop between R and K valves of the graph), 
measures the rate of clot formation and this reflects the rapidity of fibrin polymerization. 
Maximum amplitude of the thrombus (MA) measures the maximum strength of the 
fibrin clot and represents a direct function of the maximum dynamic properties of fibrin 
and platelet bonding. This correlates more to platelet function and to a lesser extent to 
fibrinogen. Early autolysis also known as thrombus retraction is mainly contributed by 
rearrangement of fibrin to fibrin linkage. This is measured as percentage (%) of lysis at 
30 minutes and 60 minutes respectively (CL30 and CL60). This is calculated as 
percentage decrease in amplitude 30 minutes and 60 minutes post maximum 
amplitude. The rate of loss of thrombus strength is measured by lysis parameter (L 
mm/min). L parameter is calculated using a complex first derivative integral calculus 
equation by continuously measuring loss of maximum amplitude in mm per minute. 
Platelet Mapping™, an advancement of TEG® technique, was used to measure 
platelet inhibitory effect of individual antiplatelet agents such as aspirin, clopidogrel and 
glycoprotein IIb/IIIa inhibitor. Heparin was used in Platelet Mapping™ to neutralise the 
effect of thrombin and this enabled us to measure the effects of particular platelet 
agonists such as arachidonic acid and ADP. Commercially available activator F (A-P1) 
was used to bypass the effect of heparin. This stimulates conversion of fibrinogen to 
fibrin and activation of Factor XIIIa to crosslink the fibrin network. Platelet agonists, 
arachidonic acid (AA 1 mM) and ADP (2 µM) were used alongside A-P1 to study the 
effect of aspirin and clopidogrel respectively in separate cuvettes. Platelet inhibitory 
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effect of clopidogrel and aspirin were calculated by measuring the maximum amplitude 
using the formula: 
Percentage reduction in maximum amplitude, MA reduction =  
100 - (([MAAA or ADP – MAactivator] / [MAthrombin - MAactivator]) x 100) 
There are published data to validate the above formula (Zmuda et al., 2000; Wasowicz 
et al., 2008). 
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Figure 3.9 Thromboelastography 
The first image shows the stationary pin which is suspended in the centre of the cuvette 
and connected to a torsion wire. Blood is placed in the cuvette and is oscillated through 
an angle of 4.45 degrees with each rotation cycle lasting for 10 seconds.  As blood 
begins to clot the torque to the inner central pin is transmitted and the elastic force is 
recorded digitally and displayed as a graph as depicted in the second image. The 
bottom image shows a 4 channel TEG® analyser and the final image shows close-up 
of the pins. 
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Figure 3.10 Normal TEG® tracing as displayed digitally.  
TEG values with normal limits of all the parameters are depicted at the bottom of the 
graph.  
 
 
 
Figure 3.11 TEG® Platelet Mapping™ tracings 
Platelet mapping tracings depict the changes in viscoelastic strength of the thrombus 
upon activation by kaolin (MA thrombin), ADP or arachidonic acid (MA ADP/MA AA) 
and activator F (MA A). The greater the reduction in MA ADP, the better is the 
antiplatelet response to clopidogrel.
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Name of the 
parameter 
Definition Clinical relevance Normal 
values 
R time, min Time from the beginning of the TEG® trace 
until an amplitude of 2 mm is reached  
This is the time of latency from the time the blood 
sample was placed in the cuvette until the initial fibrin 
formation. It shows the rate at which thromboplastin is 
generated and the function of intrinsic pathway, 
especially factors XII, XI and VIII 
 
2-8  
K time, min Time from the end of R to the point where 
TEG amplitude reaches 20 mm 
This measures the time taken to form a firm thrombus 
and is also a measure of intrinsic pathway, platelets 
and fibrinogen. This is a measure of the rapidity to 
reach certain level of clot strength 
 
1-3  
α- angle (thrombus 
formation rate) 
The angle formed from the horizontal to a 
point on the trace until amplitude is 20 mm 
This measures the rapidity of fibrin polymerisation and 
fibrin - platelet interaction, thereby assessing the rate 
at which a solid thrombus is formed. It is an indicator 
of the quality of platelet and fibrinogen 
 
55-78 
MA, maximum 
amplitude, mm 
Measures the maximum distance between 
the two arms of the graph at their peak 
amplitude 
This measures maximum viscoelastic strength of the 
formed thrombus. This has been the most studied and 
consistent measurement among all the TEG® indices. 
MA is a direct function of the maximum dynamic 
properties of fibrin and platelet bonding and 
represents the ultimate strength of the fibrin clot. 
Using the modification of TEG® assay in Platelet 
51-69 
128 
 
Name of the 
parameter 
Definition Clinical relevance Normal 
values 
Mapping™ assay individual effects of aspirin and 
clopidogrel are studied. 
G, dynes/cm2 Measure of the shear elastic force of the 
thrombus, G = 5000 MA / (100-MA) 
G value is very sensitive to small changes in MA. G 
value is an indicator of how firm a formed thrombus is 
and is reported in absolute numbers. 
4,600 – 
10,900 
CI, Coagulation 
Index / Clot Index 
Dimensionless parameter calculated using 
the formula, CI = - (0.6516) R - (0.3772) K + 
(0.1224) MA + (0.0759) α – 7.7922. 
It is a composite measure derived from the R, K, MA 
and angle (α). It is a dimensionless index. CI 
measures the combined effect of fibrinogen and 
platelets on thrombus and  
-3 to 3 
LY30 Measures the area under the curve 30 
minutes after MA has been achieved (rate of 
amplitude reduction 30 mins after MA) 
Indicative of thrombus retraction at 30 mins, signifies 
early autolysis. This measurement gives an indication 
of the stability of the clot 
0-8 
LY60 Measures the area under the curve 60 
minutes after MA has been achieved (rate of 
amplitude reduction 60 mins after MA)  
Indicative of thrombus retraction at 60 mins. 0-15 
L parameter, 
mm/min 
This is a thrombus lysis parameter, 
calculated as the average reduction in 
amplitude per unit of time. This is the first 
derivative calculus measurement of thrombus 
strength and is calculated for 90 minutes in 
standard TEG® tracings. 
This represents the changes in viscoelastic property 
due to ongoing clot retraction or autolysis.  
30-60 
 
Table 3.2 Thromboelastography parameters
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In addition to standard TEG® parameters, an additional set of parameters is generated 
from the mathematical first derivative values of TEG® and is displayed as a real time 
graph known as velocity curve (V curve). V curve provides dynamic information about 
the velocity of both thrombus formation as well as lysis. The positive curve above the 
horizontal axis represents thrombus generation. Inherent thrombin activity has a strong 
influence on clot development. During thrombogenesis, the elastic force of the 
generated thrombus is directly proportional to the speed of thrombin generation. Thus, 
measured velocity changes based on the V curve can be used to indirectly quantify 
thrombin generation (Rivard et al., 2004). 
The following parameters are calculated.  
i. L parameter, the composite measure of autolysis has been described 
before.  
ii. Maximum rate of thrombus generation, (MRTG, mm/min) measures the 
maximum velocity reached when the viscoelastic strength develops within a 
developing thrombus.  
iii. Time to maximum rate of thrombus generation (TMRTG, seconds) 
measures the time taken from the initiation of thrombus formation to the time 
it takes for the thrombus to reach its maximum strength.  
iv. Total thrombus generated (TG, mm/min) is measured as the area under 
the curve (AUC) is an indirect measure of clot strength. Thrombus formation 
is followed by autolysis.  
v. Time to maximum rate of clot lysis (TMRL, seconds) measures the time 
from the start of the coagulation cascade until the maximum rate of clot lysis 
is reached. This indirectly reflects clot stability. 
vi. Maximum rate of lysis (MRL, mm/min) represents the maximum rate of 
clot breakdown. The standard V curve graph is shown in Figure 3.12 
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Figure 3.12 V curve parameters of TEG® 
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My study protocol 
My step by step study protocol, as per manufacturer’s guidelines is as described below 
(Haemoscope, CA, USA). Patients were identified only by their study numbers and the 
data were stored anonymously in the dedicated computer attached to the TEG® 
machine. 
Quality control for TEG® Platelet Mapping™ 
I performed electronic quality control every time before starting the test. This is to 
ensure equilibrium of the central pin and torsion wire. This was recorded and stored 
automatically. I performed quality control using the control samples provided by the 
manufacturer once every other week. This was repeated prior to start of each new 
batch of reagents and for every 30 studies performed (which ever was earlier). These 
results were also stored.  
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TEG study protocol 
1. After switching on the TEG® analyser, electronic QC was performed and 
participants’ study ID was entered. 
2.  The plain disposable cups & pins were loaded into all 4 channels of the 
TEG® analyser.  
3. The lyophilised vials containing activator F (A-P1), adenosine diphosphate 
(ADP-P2) and arachidonic acid (AA-P3) were taken out from storage (6 
deg C) and gently brought to room temperature.  
4. Blood samples were collected in  
i. sodium citrate tube (1.75 mls of blood into the tube containing 0.25 mls 
of sodium citrate)  
ii. lithium heparin tube (2 mls of blood into the tube containing 100 units 
of heparin). 
5. After waiting for 30 minutes, 20 μl 0.2M of calcium chloride (supplied by 
the manufacturer) was pipetted into the plain cup in CHANNEL 1.  
6. One mL of citrated blood was pipetted into the kaolin vial (supplied by 
Haemoscope) by gently letting it run down the side of the vial until it 
reaches the 1 mL mark. The vial was re-stoppered and mixed by gentle 
inversion five times without shaking the sample. 
7. 340 μl of blood from the kaolin vial was pipetted into the cuvette in 
CHANNEL 1. 
8. Immediately the carrier was slid up, the lever was moved to Test position 
and the Start button in the software main toolbar was clicked to begin 
sample analysis. 
9. One ml of distilled water (supplied by manufacturer) was added to each 
vial containing reagents A-P1, ADP-P2 and AA-P3. The vials were gently 
mixed by rolling between the hands and avoiding foam formation. 
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10. 10 μL of prepared A-P1 was pipetted out into each plain cup in 
CHANNELS 2, 3 and 4. 
11. 10 μL of ADP-P2 was added to A-P1 in plain cup in CHANNEL3 (for ADP 
assay). 
12. 10 μL of AA-P3 was added to A-P1 in plain cup in CHANNEL 4 (for AA 
assay). 
13. 360 μL of heparinised whole blood was pipetted into A-P1 cup in 
CHANNEL 2. The blood sample was pipetted up and down three times in 
cup to mix with the reagent whilst avoiding foam formation. The carrier 
was slid up, the lever was moved to test position and start button was 
clicked. 
14. 360 μL of heparinised whole blood was pipetted into ADP-P2 cup in 
CHANNEL 2. The blood sample was pipetted up and down three times in 
cup to mix with the reagent whilst avoiding foam formation. The carrier 
was slid up, the lever was moved to test position and start button was 
clicked. 
15. 360 μL of heparinised whole blood was pipetted into AA-P3 cup in 
CHANNEL 2. The blood sample was pipetted up and down three times in 
cup to mix with the reagent whilst avoiding foam formation. The carrier 
was slid up, the lever was moved to test position and start button was 
clicked. 
16. The TEG® analyser now started showing graphs from all the four channels 
in four different colours.  
17. Recording automatically stopped once the graph lines reached a steady 
state. It usually takes up to 90 minutes for plain kaolin added sample and 
60 minutes for other channels. Once the study was completed, a print out 
of the tracings was taken.  
18. The results were digitally stored in the computer that was attached to the 
TEG® analyser. 
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19. After the study was over, percentage inhibition was obtained by selecting 
the Multi button located in the software Main toolbar to select tracings 
needed for computation of this variable. 
20. For the ADP assay, the tracings for A (A-P1), ADP (ADP-P2), and kaolin 
(K) sample types were selected. The Done button located in the software 
main toolbar was clicked to display the percentage inhibition.  
21. For the AA assay, the tracings for A (A-P1), AA (AA-P3), and kaolin (K) 
sample types were selected. The Done button located in the software main 
toolbar was clicked to display the percentage inhibition.  
22. After noting the results, the levers were brought back to neutral position 
and the cups and pins were gently removed and discarded. 
23. The device was switched off and the surface was cleaned with 70% 
alcohol wipes. 
 
Table 3.3 TEG® step by step protocol 
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3.4.4 VerifyNow® optical aggregometry – Measurement of platelet aggregation 
Principles and technique 
VerifyNow® (Accumetrics, CA, USA) is a whole blood point of care platelet function 
assay which measures platelet aggregation as an increase in light transmittance using 
the principles of optical aggregation and turbimetry. VerifyNow® is a microprocessor-
controlled, cartridge-based, software driven automated assay that measures the 
antiplatelet effect of aspirin, P2Y12 antagonists and glycoprotein IIb/IIIa antagonists in 
whole blood. The results are displayed in a digitised format. VerifyNow® uses 
turbimetric principles to measure platelet induced aggregation in response to various 
agonists such as ADP, prostacyclin E1 and thrombin receptor activating peptide 
(TRAP). It uses similar principles employed in “gold standard” light transmission 
aggregometry (LTA).  
The VerifyNow® System uses disposable assay devices to conduct the test. There are 
three types of assay device relating to the appropriate platelet function test: Aspirin, 
P2Y12 and GP IIb/IIIa inhibitors. Each assay device consists of a sample well, staging 
well and four detection wells. The instrument automatically draws blood into the assay 
device from a sample collection tube in the sample well. It then heats the blood to 37 
degree Celsius for a period of time specific to each assay, and proceeds with the 
analysis of the blood in the detection wells. The detection wells of an assay device 
contains a lyophilized preparation of human fibrinogen-coated beads and a platelet 
agonist, either arachidonic acid or adenosine di phosphate (ADP). Fibrinogen-coated 
beads bind to available platelet receptors in the blood sample. When the activated 
platelets are exposed to fibrinogen-coated beads, agglutination occurs in proportion to 
the number of available platelet receptors. After activation, the GP IIb/IIIa receptors on 
platelets will bind to the fibrinogen-coated microbeads and cross link to other 
microbeads resulting in a clearing of the beads and platelets within the detection well. 
The instrument uses light transmittance to measure the rate at which this clearing 
occurs. The instrument measures this agglutination as an increase in light 
transmittance through the detection wells. The effective platelet inhibition with 
antiplatelet therapy is measured by the changes in light transmittance using arbitrary 
(dimensionless) units.  The greater the effect of antiplatelet therapy, the greater the 
platelet inhibition. This will lead on to less platelet aggregation and less light 
transmittance and thereby will record lower reactive units. 
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I used two different types of cartridges to measure aspirin induced platelet inhibition 
and clopidogrel induced platelet inhibition respectively. Cartridges were purchased 
from the manufacturer and the whole assay has been performed according to the 
manufacturer’s instruction.  
In one channel of the assay device, prostaglandin E1 (PGE1) (22 nM) is incorporated 
with ADP (20 μM). The values measured are reported by the device as P2Y12 Reaction 
Units – activated (PRUz).  In a separate channel iso-thrombin receptor-activating 
peptide (iso-TRAP) is used as an agonist to measure platelet aggregation independent 
of the effects of P2Y12 receptors; this value is regarded as baseline or PRUb.  The 
VerifyNow® P2Y12 assay reports the results as P2Y12 Reaction Units (“PRUz”), “% 
Inhibition” and “baseline PRUb”. Percentage inhibition due to clopidogrel (P2Y12 
antagonist), “% Inhibition” is calculated using the equation ([PRUb-PRUz] 
X100)/PRUb. If clopidogrel has produced significant platelet suppression, the PRUz 
values will be lower and the percentage inhibition will be higher. There is no universal 
agreement on the cut-offs used to measure platelet inhibition. Hence, I have chosen 
PRUz of 240 and percentage inhibition of less than 40% as a cut off for high on 
treatment platelet hyperactivity to clopidogrel (“hypo responders”) based on a paper 
published by Marcucci et al (Marcucci et al., 2009). The sample result for the Aspirin 
assay is interpreted based on the rate of platelet aggregation measured and is reported 
in Aspirin Reaction Units (ARU). Patients with ARU ≥495 were classified as high on 
treatment platelet reactivity to aspirin (“hyporesponders”) (Paniccia et al., 2007). 
My study protocol 
Blood was collected in 2 ml partial-fill sodium citrate blood collection tubes (0.105M, 
3.2% sodium citrate + citric acid, pH 5.2, Catalogue number 367691, BD Vacutainer®) 
and gently mixed by inverting 5 times. After leaving the sample static for 30 minutes, 
the assay device was taken out of the sealed pouch and inserted into the device port 
on the VerifyNow® instrument. The citrated blood sample tube was inverted gently 
again 5 times and was then inserted into the sample well of the assay device with the 
rubber stopper facing downward so that the needle pierces the stopper. The cover to 
the assay port was then closed. The instrument automatically draws sample from the 
vacuum collection tube into the assay device. It then heats the blood to 37 degree 
Celsius for a time specific to each assay, and proceeds with the analysis. It typically 
takes 3 to 6 minutes for the assay to complete and the results were displayed as 
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respective units (PRU or ARU). Two assay device, one for aspirin and other for P2Y12 
was used to measure ARU and PRU respectively. 
Quality Control for VerifyNow® 
VerifyNow® comes with its own manufacturer specified quality control. I performed an 
electronic quality control (EQC) every day using the standard assay device supplied 
by the manufacturer. This verifies that instrument components are functioning properly 
including optics, reagent mixing, and pneumatics. It also confirms correct calibration 
parameters and checks for correct data acquisition and calculations. An automatic 
error message would be displayed as “attention” with a diagnostic code, if the results 
fall outside the wider range for ARU or PRU. I performed a wet quality control assay 
(supplied by the manufacturer, Level 1 and 2) for both aspirin and clopidogrel assay 
devices once a month and at every time a new batch of assay devices was used. In 
addition, I tested reproducibility annually using 10 healthy volunteers measured twice 
on the same day. The coefficient of variation of ARU was 3.9% and for PRUz 4.1% 
and the results of ARU were (median, IQR) 606, 599 - 621 and PRUz were 318, 302-
334. 
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Figure 3.13 VerifyNow® assay 
Assay cartridge used in VerifyNow® assay contains fibrinogen coated beads in the 
four chambers at its bottom. The cartridge is inserted in to its slot as shown in the 
middle picture and the needle cover is removed. The blood sample vacutainer is gently 
inverted 5 times and is then inserted into the sample slot and the cover is closed. Blood 
is drawn into the cartridge and it mixes with these beads and produces platelet 
aggregation as stimulated by specific agonists like ADP or arachidonic acid. The 
amount of aggregation depends on the level of residual antiplatelet activity and will 
result in different light transmittance. The emitted light is read by a sensor and the 
result will be displayed as a dimensionless unit (ARU, PRU). 
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3.4.5 Multiplate® impedance aggregometry – Measurement of platelet 
aggregation 
Principles and technique 
Multiplate® analyser evaluates whole blood platelet aggregation by measuring the 
changes in impedance / electrical resistance in the Multiplate sensor wires during 
thrombogenesis. Impedance aggregometry was developed by Cardinal and Flower 
(Cardinal and Flower, 1980) and has been used since the 1980’s for the assessment 
of platelet function in whole blood. This is based on the principle that platelets are non-
thrombogenic in their resting state, but expose receptors on their surface when they 
are activated, which allow them to attach to sites of vascular injury and artificial 
surfaces. The main disadvantages of the earlier devices used in various coagulation 
laboratories were poor reproducibility due to short life of the electrodes and the 
presence of residual thrombi attached to the electrode after each test. This problem 
has been overcome by the Multiplate® analyser by using single use disposable test 
cells, which incorporate a dual sensor unit and a teflon-coated stirring magnet.  
Platelets become sticky upon activation, and therefore have a tendency to adhere and 
aggregate on metal sensor wires in the Multiplate test cell. When platelets stick on the 
Multiplate sensor wires they form a sheet over the electrodes and this enhances the 
electrical resistance between them. With increasing thrombus formation there is a 
proportionate increase in electrical impedance which indirectly reflects platelet 
aggregation. This is measured as a continuous variable over time. The maximum 
increase in the impedance reflects platelet activity and this is plotted as a graph. Adding 
a specified quantity of platelet agonist to the whole blood from patients taking 
antiplatelet agents will demonstrate changes in impedance. This change in impedance 
reflects residual platelet reactivity and this can be used to assess the response of 
platelets to these agents. 
In my study whole blood impedance aggregometry was measured using the novel 
Multiplate® analyser (Dynabyte medical, Munich, Germany) in accordance with 
manufacturer’s guidelines. Blood samples from patients were collected in hirudin 
tubes.  The test cell was placed into the measurement position and the sensor cable 
was attached to it.  Each test cell has a pipetting inlet and a cup portion with the twin 
sensor wires which extend into the blood sample. There is a teflon-coated magnet in 
the cup portion which stirs the blood at 800 rpm. The sensor wires are made of highly 
140 
 
conductive copper which are silver-coated. The test cell is connected to the 
instrument using a sensor cable and the electrical resistance between the sensor wires 
is recorded during the test. When activated, platelets adhere to the sensor wires and 
the electrical resistance between the wires increases. The Multiplate® analyser records 
platelet aggregation at approximately 0.5 second intervals. The study was continued 
for 6 minutes until steady state electrical impedance was reached. The increase in 
impedance by the attachment of platelets onto the Multiplate® sensors is transformed 
to aggregation units (AU) and plotted against time. Results are displayed as a graph. 
Three parameters that are calculated includes:  
i. Platelet aggregation (AU, maximal aggregation)  
ii. Area under curve (AUC) 
iii. Aggregation velocity (slope of the curve)  
AUC is recorded as Units or U. It is affected by the total height of the aggregation curve 
as well as by its slope and is best suited to express the overall platelet activity. Maximal 
aggregation (AU) is the maximum height of the curve during the measurement period 
and the Velocity (AU/min) is the maximum slope of the curve. Maximal aggregation 
has been used in various clinical contexts as it is the most reproducible parameter and 
hence I also chose to use the same parameter for analysis (Sibbing et al., 2010a; Kim 
et al., 2011). 
Each test cell incorporates two independent sensor units. The increase of impedance 
due to the attachment of platelets to the electrodes is detected for each sensor unit 
separately and transformed to arbitrary aggregation units (AU) that are plotted against 
time. The duplicate sensors serve as an internal control. The correlation coefficient of 
the individual measurements is determined and the analysis is accepted when the 
correlation coefficient is greater than 0.98. Additionally, the difference of each curve 
from the mean curve is calculated and is accepted when the difference is less than 
20%.  
Whole blood samples of 1.2 mls from each patient were used to study the effects of 
four agonists, namely arachidonic acid, ADP, collagen and thrombin in my study. 
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Figure 3.14 Multiplate® assay: Based on impedance aggregometry 
Schematic diagram of Multiplate test cell, electrodes, reagents and platelet 
aggregation inside the cuvette is presented here. Electricity is transmitted across the 
electrodes which are immersed in the whole blood. When the blood is in fluid state it is 
a good conductor of electricity and electrical resistance is almost negligible. However, 
as the thrombus forms, platelet-fibrin interaction forms a sheet over the electrodes, 
thereby increasing the resistance to the flow of electrons from cathode to anode plates. 
As thrombus formation increases, the electrical impedance increases proportionately 
to the platelet aggregation. A change in electrical impedance is a reflection of platelet 
aggregation and is measured as a continuous variable over time. The maximum 
increase in electrical impedance represents platelet activity and is displayed as a 
graph.  
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Figure 3.15 Platelet function tests performed by Multiplate® aggregometry 
Schematic diagram explaining various platelet function tests that can be performed 
using Multiplate® aggregometry. Most commonly used test include:  
ASPItest – measures aspirin effect using arachidonic acid as a stimulus 
ADPtest – measures effects of P2Y12 antagonist such as clopidogrel 
COLtest – measures platelet inhibitory effects of either of the agents upon stimulation 
with collagen 
TRAPtest – measures the platelet activity upon stimulation by thrombin receptor 
activating peptide 
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Multiplate® study protocol 
1. 2mls of blood was drawn in hirudin vacutainer tube supplied by the manufacturer. 
2. The blood sample was gently mixed and was left to stand for 35 minutes before 
analysis. 
3. Multiplate® analyser was switched on and allowed 20 minutes to warm up to 37 
degree C. 
4. Electronic quality control was performed. 
5. Patient ID was entered and the following tests were selected - ADPtest, ASPtest, 
COLtest, TRAPtest.  
6. Lyophilised vials of the reagents ADP, ASP (aspirin), COL (collagen) and TRAP 
(thrombin) are brought to room temperature. 
7. Each vial was mixed with 1 ml of distilled water, gently swirled for through mixing 
and left for 10 minutes. 
8. The reagents were then divided into small aliquot tubes each 200 µl, labelled and 
dated. AA, ADP and thrombin aliquots were stored at -40 deg C and collagen 
mixture was stored at 5-6 deg C. Expiry date for the reagents stored at -40 deg C 
and 5-6 deg C were 4 weeks and one week respectively from the date of 
preparation. 
9. Four test cells were inserted into the machine and were connected to the sensor 
cable firmly. 
10. Using autopippette 300 µl of blood from hirudin tube was pipetted in to the test cell 
cup. 
11. Following this 300 µl of normal saline pre-heated to 37 deg C was added. 
12. This was followed by 3 minutes of incubation. 
13. 20 µl of respective stock reagents were added to the specified test cells. 
14. The reaction started and platelet aggregation was displayed as a graph with two 
lines (from two independent sensor units that act as internal control). 
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15. The test ran for 6 minutes and final results were printed out. 
16. After completion, the test cells were removed after disconnecting the cables and 
safely disposed in the sharps container. 
If the COV between the recorded curves was more than 2% or there was >20% 
difference in AUC readings, the results were discarded and the test was repeated 
again.
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3.4.6 Coagulation and Inflammatory biomarker assay – serum and plasma 
samples 
Serum and plasma samples were collected and stored for specific biomarker assays 
at the end of each Badimon chamber study. Both venous blood and effluent blood from 
chamber were collected and stored for these assays. 
Following listed biomarkers were assayed: 
Coagulation biomarkers: 
i. Soluble P selectin (sP-selectin) 
ii. Soluble CD40 ligand (sCD40L) 
iii. Plasminogen activating factor inhibitor 1 (PAI-1) 
Inflammatory biomarkers (cytokines): 
i. Interferon gamma (IFN γ) 
ii. Interleukin 1 (IL 1) 
iii. Interleukin 6 (IL 6) 
iv. Tumour necrosis factor alpha (TNF α) 
Sample collection, processing and storage 
Serum samples were needed for all biomarker assays except for PAI-1 which was 
measured using plasma samples. Hence plain glass tubes were used for serum 
collection and 3.2N sodium citrate blood collection tubes (Grainer-bio one, GmbH) 
were used for plasma collection. 
Pre-chamber venous samples 
Venous blood (10mls) was collected from the antecubital vein following Badimon 
chamber study using the same cannula in plain glass tubes and 3.2 N sodium citrate 
tube. The samples were allowed to settle for 10 minutes. They were then centrifuged 
at 1550g (3000 rpm) for 10 minutes. The serum was separated and stored in four 
aliquots (1ml each) at -80 deg C. 
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Activated serum samples (post chamber activated effluent blood) 
Effluent blood samples were collected between 3rd and 5th minute of the chamber 
study. Effluent blood samples were collected both in plain glass tubes and 3.2 N 
sodium citrate tubes. Serum and plasma were separated and stored in exactly similar 
fashion to pre-chamber venous samples. 
The rationale behind doing this is, the chamber experiment simulates a deep arterial 
injury model and hence there is both shear induced and collagen induced platelet 
activation. My hypothesis was that the effluent blood consists of coagulation and 
inflammatory biomarkers that were released from platelet activation and thrombus 
formation. By measuring the levels of these biomarkers before and after platelet 
activation we might be able to reflect on their involvement in thrombus generation. 
Measurement of soluble P selectin 
Soluble P selectin was measured using Human sP-selectin/CD62P, SBBE6, R&D 
systems, Abington, UK (lot number 300846, part number 890272). The ELISA 
procedure was followed step by step according to manufacturer’s instructions. Quality 
control for P selectin was performed using the standards supplied by the manufacturer.  
I used 4 parameter logistic curve fitting method (SoftMax Pro 5.3, Molecular Devices 
Corporation Sunnyvale, CA, USA) to derive soluble P selectin levels from optical 
density values. Duplicate samples and samples from normal controls were used in 
each plate to ensure assay precision. 20 quality control volunteer samples were 
assayed with a mean Co-efficient of variation (COV) of 5.2%. 
Measurement of soluble CD40 ligand 
Soluble CD40 ligand was measured using Human CD40 Ligand/TNFSF5 
immunoassay, DCDL40, R&D systems, Abington, UK (lot number 298718, part 
number 890989). I used 4 parameter logistic curve fitting method (SoftMax Pro 5.3, 
Molecular Devices Corporation Sunnyvale, CA, USA) to derive soluble CD40 ligand 
levels from optical density values. Quality control was performed using the standards 
supplied by the manufacturer. Duplicate samples and samples from normal controls 
were used in each plate to ensure assay precision. 20 quality control volunteer samples 
were assayed with a mean COV of 6.3%.  
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Measurement of Plasminogen activator inhibitor – 1 (PAI - 1)  
Plasma samples were used to measure PAI-1 levels. I performed PAI – 1 antigen 
ELISA assay using Technozym® PAI-1 antigen ELISA kit, TC12075, Technoclone 
GmbH. I performed all the PAI – 1 assay in the nationally accredited laboratory at 
Freeman Hospital, Newcastle upon Tyne. My performance was supervised by the chief 
technician. Quality control was performed using the standards provided by the 
manufacturer. Duplicate samples and samples from normal controls were used in each 
plate to ensure assay precision. 20 quality control volunteer samples were assayed 
with a mean COV of 4.2%. 
Measurement of inflammatory biomarkers (serum cytokines) 
To measure inflammatory cytokines, I used a novel multi array platform which 
implements electrochemiluminescence (ECL) technology (MesoScale Devices, 
Gaithersburg, MD, USA). Electrochemiluminescence (ECL) has a lot of advantages 
over conventional ELISA, a few are as listed below: 
i. High sensitivity: Multiple excitation cycles can amplify signals to enhance 
light levels 
ii. Broad dynamic range: this helps to measure high and low expression levels 
without multiple sample dilutions 
iii.  Low background: the stimulation mechanism (electrical) is decoupled from 
the detection signal (light) allowing only labels near the electrode surface to 
be detected 
iv. Carbon electrode plate surface has a 10X greater binding capacity than 
conventional ELISA microplates 
v. Multiple analytes can be run in a single well, reducing required sample 
volume (Toedter et al., 2008; Fu et al., 2010) 
vi. Greater flexibility: Labels are stable, non-radioactive, conveniently 
conjugated to biological molecules and quicker than conventional ELISA 
MSD platform that I used was a 96-well plate-based assay that incorporated ECL 
technology. MSD wells contains spotted / capture antibody, specific cytokines are 
captured by these antibodies after the study samples are added, labelled detection 
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antibodies are added and they bind to the cytokines in a sandwich manner. The 
detection antibodies are attached to electrochemiluminescent labels that emitted light 
when electrochemically stimulated via carbon-coated electrodes in the bottom of the 
array wells. A detection buffer is added prior to the reading of the assay to enhance the 
electrochemical signal. The resulting signal was read using a photo detector in a 
charge-coupled device (sector reader) available in Institute of Cellular Medicine, 
Newcastle University.  
Duplicates were run as 1:4 and the reproducibility of the results were excellent with a 
COV of 3.2% in 20 volunteer samples tested in all the six plates. Five volunteer 
samples were repeated on three different days and the results showed a COV of 3.4%. 
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Figure 3.16 MSD Electrochemiluminescence technology 
Carbon-coated working electrodes are in the bottom of the array wells. Cytokines from 
the sample are captured by the spotted antibodies following which the addition of 
detection antibodies sandwiches the cytokines between these two antibodies.  
Detection antibodies are attached to electrochemiluminescent labels that emit light 
when stimulated by the electrodes. Addition of a detection buffer enhanced the 
electrochemical signal and the resulting signal was read using a photo detector in a 
charge-coupled device. 
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Chapter 4 Results and discussion 
4.1 Platelet dependant thrombus formation – Elderly stable CAD study 
4.1.1 Results 
Elderly stable CAD study was a non-randomised, open-labelled study assessing the 
efficacy of clopidogrel as a second antiplatelet agent alongside aspirin in patients with 
established CAD, with and without T2DM and over a wide age range. A total of 172 
patients were included in this analysis and they were classified into four groups based 
on age and diabetic status as listed below: 
iv. Age < 75 years with type 2 diabetes mellitus (T2DM); n = 41 
v. Age < 75 years without diabetes; n = 45 
vi. Age ≥ 75 years with T2DM; n = 41 
vii. Age ≥ 75 years without diabetes; n = 45 
Baseline demographic data comparing all four groups are shown in table 4.1.  
Body mass index (BMI) in patients with age < 75+T2DM was significantly higher when 
compared to elderly patients with and without T2DM. Total cholesterol was significantly 
lower in the age<75 with T2DM group when compared to the Non DM population.  This 
could be due to effective high dose statin therapy in this group. HDLc levels were lower 
in T2DM population when compared to the non-diabetic population. Systolic BP as 
expected was significantly higher in patients with age≥75 compared to the younger 
population. Haemoglobin levels were significantly lower in the patients with age≥75 
when compared to younger population. The lowest haemoglobin was in patients with 
age≥75 with T2DM. 
Thrombus measurements at baseline (aspirin alone, visit 1) and 1 week after 75mg 
daily clopidogrel therapy as a second antiplatelet agent alongside aspirin (visit 2) are 
shown in (Table 4.2, Figure 4.1) 
At baseline all the four groups had similar high shear thrombus area (thrombus area in 
µ2/mm, mean±SD, 14623± 5333 vs. 15633± 5425 vs. 15838± 6383 vs. 17725± 7186, 
p = 0.143). After treatment with 1 week of clopidogrel all the four groups demonstrated 
a significant reduction in thrombus area (thrombus area in µ2/mm, mean±SD; Group 1: 
14623±5333 vs. 11615±4313, p=0.002; Group 2: 15633±5425 vs. 12918±4663, 
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p<0.001; Group 3: 15838± 6383 vs. 13204±4924, p=0.001; Group 4: 17725±7186 vs. 
14127±4958, p<0.001). The mean change in thrombus area was similar in all the four 
groups (µ2/mm, 95% confidence interval; 3008, 1210-4805 vs. 2716, 1483-3949 vs. 
2285, 700-3869 vs. 2903, 2145-3662; p=0.672) Table 4.3. 
Similar findings were seen in low shear thrombus measurements as shown in table 
4.3, figure 4.1. Low shear thrombus area was similar between the groups at baseline 
(thrombus area in µ2/mm, mean±SD, 9204±1802 vs. 9651± 2323 vs. 9839± 2641 vs. 
9773± 2273, p=0.671). One week of clopidogrel therapy demonstrated a significant 
reduction in low shear thrombus area (Group 1: 9204±1802 vs. 7756±1376, p<0.001; 
Group 2: 9651± 2323 vs. 7573± 2082, p<0.001; Group 3: 9839± 2641 vs. 8717± 1705, 
p=0.001; Group 4: 9773± 2273 vs. 8483± 1776, p<0.001). The mean change in 
thrombus area was similar in all the four groups (µ2/mm, 95% confidence interval; 
1806, 1069-2542 vs. 1821, 998-2645 vs. 1485, 776-2193 vs. 1072, 389-1756; 
p=0.405).  
There were moderate but significant correlations between platelet count and high 
shear thrombus area (rho=0.197, p=0.012) and platelet count and low shear thrombus 
area (rho=0.264, p=0.001) at baseline (Figure 4.2).
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Age < 75 + T2DM 
(n = 41) 
 
Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 63.7 ± 7.9 63 ± 7.3 78.6 ± 3.2 79.0 ± 3.7  
Male gender, % ( n ) 82.9 (34) 68.9 (31) 80.5 (33) 71.1 (32) 0.346 
Body mass index, kg/m2 31.7 ± 4.4 29.6 ± 3.7 29.1 ± 5.0 27.8 ± 3.6 0.000 
Waist to hip ratio 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 0.9 ± 0.1 0.090 
Heart rate, beats  per minute 70 ± 13* 62 ± 11* 68 ± 14 64 ± 10 0.005 
Systolic BP, mmHg 143 ± 19.2 137 ± 17 156 ± 22.5 152 ± 22.4 0.000 
Diastolic BP, mmHg 77 ± 10.4 77 ± 7.8 76 ± 10 75± 9.0 0.675 
Risk profile: % ( n ) 
Angina 68.3 (28) 77.8 (35) 80.5 (33) 60 (27) 0.131 
Previous MI 43.9 (18) 48.9 (22) 46.3 (19) 66.7 (30) 0.130 
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Previous PCI 29.3 (12) 40 (18) 34.1 (14) 28.9 (13) 0.655 
Previous CABG 31.7 (13) 11.1 (5) 39.0 (16) 26.7 (12) 0.026 
H/o Hypertension 36.6 (15) 51.1 (21) 68.3 (28) 66.7 (30) 0.610 
H/o CKD 9.8 (4) 0 (0) 14.6 (6) 2.2 (1) 0.020 
H/o PVD 9.8 (4) 0 (0) 26.8 (11) 11.1 (5) 0.002 
H/o CVA 9.8 (4) 4.4 (2) 14.6 (6) 8.9 (4) 0.447 
Medications: % ( n ) 
Sulphonylurea 29.3 (12)  19.5 (8)   
Metformin 63.4 (26)  47.5 (19)   
Insulin 24.4 (10)  48.8 (20)   
Beta-blocker 78 (32) 82.2 (37) 68.3 (28) 66.7 (30) 0.343 
ACE inhibitor / ARB 70.7 (29) 73.3 (33) 87.8 (36) 84.4 (38) 0.152 
Statin 100 (41) 93.3 (42) 92.7 (38) 95.6 (43) 0.380 
Laboratory data: Mean ± SD 
Haemoglobin, g/dl 13.7 ± 1.1 13.6 ± 1.2 12.6 ± 1.3 12.9 ± 1.2 0.000 
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Platelets x 1000 cells/mm3 223 ± 53.5 238 ± 63.6 211 ± 48.8 232 ± 66.2 0.182 
Fibrinogen, g/ml 3.4 ± 0.6 3.2 ± 0.6 3.4 ± 0.7 3.3 ± 0.6 0.302 
HbA1c, mmol/mol 58.8 ± 14.1 39.3 ± 7.0 61.2 ± 15.1 41.3 ± 3.4  
Fasting plasma glucose, 
mmol/L 
8.4 ± 4.6 5.2 ± 0.6 8.3 ± 4.3 5.2 ± 0.7  
Creatinine, micromol/L 100 ± 25.7 83 ± 25.2* 110 ± 53.5* 100 ± 27.7 0.004 
Total cholesterol, mmol/L 3.6 ± 0.7 4.2 ± 1.0 4.0 ± 0.9 4.2 ± 0.8 0.005 
LDLc, mmol/L 1.9 ± 0.7 2.2 ± 0.9 2.1 ± 0.9 2.1 ± 0.7 0.369 
HDLc, mmol/L 1.1 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.4 ± 0.3 0.000 
Triglyceride, mmol/L 1.6 ± 0.8 1.4 ± 0.8 1.5 ± 0.7 1.3 ± 0.6 0.303 
HsCRP, mg/L 4.1 ± 4.0 1.8 ± 1.8 4.3 ± 6.6 4.4 ± 7.7  0.095 
 
Table 4.1 Baseline characteristics for Elderly stable CAD study. 
LDLc – Low density lipoprotein cholesterol; HDLc – High density lipoprotein cholesterol; HsCRP – high-sensitive C-reactive protein; H/o – 
History of 
The p value in the table ANOVA p across all four groups. Significant individual pair differences are as follows: 
Body mass index: Age<75+T2DM vs. Age≥75+T2DM, p=0.039; Age<75+T2DM vs. Age≥75+Non DM, p<0.001 
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Systolic BP: Age<75+T2DM vs. Age≥75+T2DM, p=0.023; Age<75+Non DM vs. Age≥75+T2DM, p<0.001; Age<75+Non DM vs. 
Age≥75+Non DM, p=0.003 
Haemoglobin: Age<75+T2DM vs. Age≥75+T2DM, p<0.001; Age<75+T2DM vs. Age≥75+Non DM, p=0.006; Age<75+Non DM vs. 
Age≥75+T2DM, p=0.001; Age<75+Non DM vs Age≥75+Non DM, p=0.024 
Total cholesterol: Age<75+T2DM vs. Age<75+Non DM, p=0.007, Age<75+T2DM vs. Age≥75+Non DM, p=0.016 
HDLc: Age<75+T2DM vs. Age<75+Non DM, p=0.001; Age<75+T2DM vs. Age≥75+Non DM, p<0.001; Age≥75+T2DM vs. Age≥75+Non 
DM, p=0.002 
*p<0.05 
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Mean 
thrombus 
area 
 
Age < 75 + T2DM 
(n = 41) 
 
 
Age < 75 + Non T2DM 
(n = 45) 
 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
 
Mean ± SD, 
µ2/mm Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value Visit 1 Visit 2 
P 
Value 
High shear 
chamber 
14623± 
5333 
11615± 
4313 0.002 
15633± 
5425 
12918± 
4663 0.000 
15838± 
6383 
13204± 
4924 0.001 
17725± 
7186 
14127± 
4958 0.000 
Low shear 
chamber 
9204± 
1802 
7756± 
1376 0.000 
9651± 
2323 
7573± 
2082 0.000 
9839± 
2641 
8717± 
1705 0.001 
9773± 
2273 
8483± 
1776 0.000 
 
Table 4.2 Mean thrombus area - Elderly stable CAD study. 
  
158 
 
 
 
 
Age < 75 + T2DM 
(n = 41) 
 
Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
 Mean thrombus area: Mean ± SD 
High shear chamber, µ2/mm 
14623± 5333 15633± 5425 15838± 6383 17725± 7186 0.143 
Low shear chamber, µ2/mm 
9204± 1802 9651± 2323 9839± 2641 9773± 2273 0.671 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
 Mean thrombus area: Mean ± SD 
High shear chamber, µ2/mm 
11615± 4313 12918± 4663 13204± 4924 14127± 4958 0.127 
Low shear chamber, µ2/mm 
7756± 1376 7573± 2082* 8717± 1705 8483± 1776* 0.013 
Difference in thrombus area between Visit 1 and Visit 2 
Mean change in thrombus area, 95% CI 
High shear chamber, µ2/mm 
3008, 1210-4805 2716, 1483-3949 2285, 700-3869 2903, 2145-3662 0.672 
Low shear chamber, µ2/mm 
1806, 1069-2542 1821, 998-2645 1485, 776-2193 1072, 389-1756 0.405 
 
Table 4.3 Comparison of mean thrombus area. 
Post hoc analysis to compare the mean thrombus area and difference in thrombus area between visit 1 and visit 2 among the four groups. 
The p value is the ANOVA p across all four groups 
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Figure 4.1 High shear thrombus area in elderly stable CAD study. 
After treatment with 1 week of clopidogrel all the four groups demonstrated a significant 
reduction in thrombus area (µ2/mm, mean±SD; Group 1: 14623±5333 vs. 11615±4313, 
p=0.002; Group 2: 15633±5425 vs. 12918±4663, p<0.001; Group 3: 15838± 6383 vs. 
13204±4924, p=0.001; Group 4: 17725±7186 vs. 14127±4958, p<0.001).  
Mean difference in thrombus area was similar in all the four groups (µ2/mm, 95% 
confidence interval; 3008, 1210-4805 vs. 2716, 1483-3949 vs. 2285, 700-3869 vs. 
2903, 2145-3662; p=0.672). 
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Figure 4.2 Correlation of platelet count with high shear (A) and low shear 
thrombus (B) 
There a significant positive correlation between high shear thrombus area and platelet 
count (rho=0.197, p=0.012). Low shear thrombus area also demonstrated a significant 
positive correlation with platelet count (rho=0.264, p=0.001).  
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Age<75 years vs. Age≥75 years 
I then classified the study population as young (age<75 years) and elderly (age≥75 
years) to assess the effect of age on clopidogrel response and platelet dependent 
thrombus formation.  
Demographic data between these two groups is shown in Table 4.4. The elderly group 
had significantly higher number of participants with history of hypertension and 
peripheral vascular disease (PVD). Mean systolic BP was higher in the elderly 
population. Laboratory data demonstrated significantly higher serum creatinine and 
HDLc levels and lower haemoglobin levels in the elderly group. Though the absolute 
value of mean HsCRP was higher in the elderly group, it was not statistically significant. 
Significantly higher number of patients in the elderly group were on ACE-inhibitor 
therapy. Though the number of participants with diabetes was similar in the younger 
and older groups, a significantly higher number of older individuals were prescribed 
Insulin therapy (Table 4.4). 
At baseline, though the absolute numerical value of mean high thrombus area was 
slightly higher in the elderly population this was not statistically significant (thrombus 
area in µ2/mm, mean±SD, 15171±5374 vs. 16804±6831, p=0.088).  
After treatment with 1 week of clopidogrel there was a significant reduction in thrombus 
area in both the groups (Age<75: 15171± 5374 vs. 12321± 4526, p<0.001; Age≥75: 
16804± 6831 vs. 13677± 4934, p<0.001). The mean change in the thrombus area was 
similar between the groups (µ2/mm, 95% confidence interval; 2967, 2013-3921 vs. 
3168, 2011-4324, p=0.889) (Table 4.5, Figure 4.3, Figure 4.6). 
Low shear thrombus area demonstrated a similar response pattern as shown in Table 
4.5 and Table 4.6. 
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Age < 75 
(n = 87) 
 
Age ≥ 75  
(n = 86) 
 
 
    P Value 
Demographic data: Mean ± SD or % (n) 
 
Age, years 
 
63.4±7.5 78.9±3.5  
Male gender, % ( n ) 
 
75.9 (66) 75.6 (65) 0.966 
Body mass index, kg/m2 
 
30.8±4.4 28.4±4.3 0.001 * 
Waist to hip ratio 
 
0.97±0.10 0.95±0.07 0.079 
Heart rate, beats  per minute 
 
66±12 66±12 0.959 
Systolic BP, mmHg 
 
140±18.2 154±22.4 0.000 * 
Diastolic BP, mmHg 
 
77±9 76±9.5 0.296 
Risk profile: % ( n ) 
 
Angina 
 
73.6 (64) 69.8 (60) 0.580 
Previous MI 
 
46 (40) 57 (49) 0.148 
Previous PCI 
 
35.6 (31) 31.4 (27) 0.555 
Previous CABG 
 
20.7 (18) 32.6 (28) 0.077 
Diabetes Mellitus 
 
48.3 (42) 47.7 (41) 0.937 
Hypertension 
 
44.8 (39) 67.4 (58) 0.003 
CKD 
 
4.6 (4) 8.1 (7) 0.340 
PVD 
 
4.6 (4) 18.6 (16) 0.004 
CVA 
 
6.9 (6) 11.6 (10) 0.283 
Medications: % ( n ) 
 
Sulphonylurea 
 
13.8 (12) 9.3 (8) 0.356 
Metformin 
 
31 (27) 22.4 (19) 0.198 
Insulin 
 
12.6 (11) 24.4 (21) 0.046 
Beta-blocker 79.3 (69) 67.4 (58) 0.198 
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ACE inhibitor / ARB 
 
72.4 (63) 86 (74) 0.027 
Statin 
 
96.6 (84) 94.2 (81) 0.459 
Laboratory data: Mean ± SD 
 
Haemoglobin, g/dl 
 
13.6±1.2 12.7±1.2 0.000 
Platelets x 1000 cells/mm3 
 
233±60.5 222±59.2 0.248 
Fibrinogen, g/ml 
 
3.3±0.6 3.3±0.6 0.748 
HbA1c, mmol/mol 
 
48.6±14.6 50.8±14.6 0.319 
Fasting plasma glucose, mmol/L 
 
6.7±3.5 6.7±3.4 0.943 
Creatinine, micromol/L 
 
91±26.5 105±42 0.010 
Total cholesterol, mmol/L 
 
3.9±0.9 4.1±0.9 0.272 
LDLc, mmol/L 
 
2.1±0.8 2.1±0.8 0.890 
HDLc, mmol/L 
 
1.2±0.3 1.3±0.3 0.018 
Triglyceride, mmol/L 
 
1.5±0.8 1.4±0.7 0.343 
HsCRP, mg/L 
 
2.9±3.2 4.3±7.2 0.093 
 
Table 4.4 Baseline characteristics (age<75 years vs. age≥75 years) 
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Mean 
thrombus 
area 
Age < 75 
(n = 87) 
 
Age ≥ 75 
(n = 86) 
 
Mean ± SD, 
µ2/mm Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
High shear 
chamber 
15171± 
5374 
12321± 
4526 0.000 
16804± 
6831 
13677± 
4934 0.000 
Low shear 
chamber 
9481± 
2114 
7666± 
1822 0.000 
9803± 
2411 
8589± 
1737 0.000 
 
Table 4.5 Mean thrombus area (age<75 years vs. age≥75 years) 
 
 
  
Age < 75 
(n = 87) 
 
 
Age ≥ 75  
(n = 86) 
 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean thrombus area: Mean ± SD 
High shear chamber, µ2/mm 
 
15171±5374 16804±6831 0.088 
Low shear chamber, µ2/mm 
 
9481± 2114 9803± 2411 0.347 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean thrombus area: Mean ± SD 
High shear chamber, µ2/mm 
 
12321± 
4526 
13677± 4934 0.066 
Low shear chamber, µ2/mm 
 
7666± 1822 8589± 1737 0.001* 
Change in thrombus area between Visit 1 and Visit 2 
Mean change in thrombus area, 95% CI 
High shear chamber, µ2/mm 
 
2967,  
2013-3921 
3168,  
2011-4324 
0.889 
Low shear chamber, µ2/mm 
 
1799,  
1229-2369 
1227,  
734-1719 
0.132 
 
Table 4.6 Comparison of thrombus area (age<75 years vs. age≥75 years) 
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Figure 4.3 High shear thrombus area (age<75 and age≥75) 
At baseline, there was no difference in thrombus area between elderly and young 
(thrombus area in µ2/mm, mean±SD, 15171±5374 vs. 16804±6831, p=0.088).  
After treatment with 1 week of clopidogrel there was a significant reduction in thrombus 
area in both the groups (Age<75: 15171± 5374 vs. 12321± 4526, p<0.001; Age≥75: 
16804± 6831 vs. 13677± 4934, p<0.001).  
The mean difference in the thrombus area was similar between the groups (µ2/mm, 
95% confidence interval; 2967, 2013-3921 vs. 3168, 2011-4324, p=0.889). 
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T2DM vs. Non DM 
I assessed the effect of T2DM on clopidogrel response and platelet dependant 
thrombus formation. For this, I classified the study population in to patients with T2DM 
and non-diabetic patients.  
Demographic data between the two groups are shown in the Table 4.7. The T2DM 
group demonstrates significantly higher BMI, waist to hip ratio (WHR), resting heart 
rate, history of chronic kidney disease (CKD), coronary artery bypass graft (CABG) 
and PVD. Laboratory data demonstrated significantly higher serum creatinine levels 
but lower total cholesterol and HDLc levels in T2DM group. Absolute values of 
fibrinogen and HsCRP were high in the T2DM group but the differences were not 
statistically significant (Table 4.7). 
At baseline, the mean high shear thrombus area was similar in patients with T2DM and 
non DM group (thrombus area in µ2/mm, mean±SD, 15254±5895 vs. 16656±6397, 
p=0.142).  
After treatment with 1 week of clopidogrel there was a significant reduction in thrombus 
area in both the groups (T2DM: 15254± 5895 vs. 12440± 4679, p<0.001; Non DM: 
16656± 6397 vs. 13509± 4820, p<0.001). The mean change in the thrombus area was 
similar between the groups (µ2/mm, 95% confidence interval; 2771, 1625-3917 vs. 
3312, 2305-4318, p=0.508) (Figure 4.4, Table 4.8, Table 4.9).  
Low shear thrombus area demonstrated a similar response pattern as shown in Table 
4.8 and Table 4.9. 
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 T2DM 
(n = 83) 
Non DM 
(n = 90) 
P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 
 
71±9.6 71±9.9 0.985 
Male gender, % ( n ) 
 
81.9 (68) 70 (63) 0.068 
Body mass index, kg/m2 
 
30.1±5.1 28.7±3.7 0.006 * 
Waist to hip ratio 
 
0.98±0.07 0.95±0.10 0.006 * 
Heart rate, beats  per minute 
 
69±13 63±11 0.001 * 
Systolic BP, mmHg 
 
150±21.7 145±21.3 0.118 
Diastolic BP, mmHg 
 
77±10 76±8 0.579 
Risk profile: % ( n ) 
Angina 
 
74.7 (62) 68.9 (62) 0.397 
Previous MI 
 
45 (37) 58 (52) 0.083 
Previous PCI 
 
32.5 (27) 34.4 (31) 0.790 
Previous CABG 
 
34.9 (29) 18.9 (17) 0.017 * 
Hypertension 
 
53 (44) 58.9 (53) 0.437 
CKD 
 
12 (10) 1.1 (1) 0.003 * 
PVD 
 
18.1 (15) 5.6 (5) 0.010 * 
CVA 
 
12 (10) 6.7 (6) 0.222 
Medications: % ( n ) 
Sulphonylurea 
 
24.1 (20) 0  
Metformin 
 
56.1 (46) 0  
Insulin 
 
37.3 (31) 0  
Beta-blocker 72.3 (60) 74.4 (67) 0.154 
ACE inhibitor / ARB 
 
79.5 (66) 78.9 (71) 0.919 
Statin 
 
96.4 (80) 94.4 (85) 0.544 
Laboratory data: Mean ± SD 
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Haemoglobin, g/dl 
 
13.1±1.3 13.2±1.2 0.593 
Platelets x 1000 cells/mm3 
 
218±53 235±64.6 0.077 
Fibrinogen, g/ml 
 
3.4±0.6 3.2±0.6 0.060 
HbA1c, mmol/mol 
 
60.1±14.5 40.3±5.5  
Fasting plasma glucose, mmol/L 
 
8.3±4.4 5.2±0.6  
Creatinine, micromol/L 
 
105±41.9 91±27.7 0.014 * 
Total cholesterol, mmol/L 
 
3.8±0.9 4.2±0.9 0.003 * 
LDLc, mmol/L 
 
2.0±0.8 2.2±0.8 0.190 
HDLc, mmol/L 
 
1.1±0.3 1.4±0.3 0.000 * 
Triglyceride, mmol/L 
 
1.6±0.7 1.4±0.7 0.109 
HsCRP, mg/L 
 
4.2±5.4 3.1±5.7 0.196 
 
Table 4.7 Baseline characteristics (T2DM vs. Non-DM) 
*p<0.05 
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Mean 
thrombus 
area 
 
T2DM 
(n = 83) 
 
 
Non DM 
(n = 90) 
 
Mean ± SD, 
µ2/mm Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
High shear 
chamber 
15254± 
5895 
12440± 
4679 0.000 * 
16656± 
6397 
13509± 
4820 0.000 * 
Low shear 
chamber 
9573± 
2303 
8295± 
1641 0.000 * 
9714± 
2265 
8050± 
1970 0.000 * 
 
Table 4.8 Mean thrombus area. (T2DM vs. Non-DM) 
 
  
T2DM 
(n = 83) 
 
Non DM 
(n = 90) 
 
 
    P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean thrombus area: Mean ± SD 
High shear chamber, µ2/mm 
 
15254± 
5895 
16656± 6397 0.142 
Low shear chamber, µ2/mm 
 
9200± 2476 9939± 2666 0.076 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean thrombus area: Mean ± SD 
High shear chamber, µ2/mm 
 
12440± 
4679 
13509± 4820 0.148 
Low shear chamber, µ2/mm 
 
7601± 1880 8505± 2240 0.007 * 
Change in thrombus area between Visit 1 and Visit 2 
Mean change in thrombus area, 95% CI 
High shear chamber, µ2/mm 
 
2771,  
1625-3917 
3312,  
2305-4318 
0.508 
Low shear chamber, µ2/mm 
 
1613,  
1096-2131 
1409,  
872-1945 
0.575 
 
Table 4.9 Comparison of mean thrombus area (T2DM vs. Non-DM) 
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Figure 4.4 High shear thrombus area (T2DM vs. Non-DM) 
At baseline, the thrombus area was similar in patients with T2DM and non DM 
(thrombus area in µ2/mm, mean±SD, 15254±5895 vs. 16656±6397, p=0.142).  
After treatment with 1 week of clopidogrel there was a significant reduction in thrombus 
area in both the groups (T2DM: 15254± 5895 vs. 12440± 4679, p<0.001; Non DM: 
16656± 6397 vs. 13509± 4820, p<0.001).  
The mean difference in the thrombus area was similar between the groups (µ2/mm, 
95% confidence interval; 2771, 1625-3917 vs. 3312, 2305-4318, p=0.508). 
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4.1.2 Discussion 
Elderly patients are at increased risk of atherothrombosis and coronary artery disease. 
However, these patients also encounter an increased risk of bleeding during 
antiplatelet therapy. Thus, we face a challenging treatment dilemma in these patients. 
This is further complicated by frequent co-morbid diseases and polypharmacy. 
Knowledge about the risk/benefit relationship of dual antiplatelet therapy is poorly 
understood in the elderly population since they are under-represented in all the major 
clinical trials (9 – 17%) (Alexander et al., 2007). The current ACS treatment and stable 
CAD treatment guidelines are based primarily upon these studies largely comprising 
of younger patients. Newer P2Y12 antagonists such as prasugrel and ticagrelor have 
demonstrated superior platelet inhibition when compared to clopidogrel, with better 
ischaemic outcomes but at the expense of increased bleeding risk especially in the 
elderly study population. Although age may alter the risk benefit balance of dual 
antiplatelet therapy, data from various trials regarding elderly patients with ACS have 
usually been limited to subgroup analyses rather than derived from age-specific 
studies. Hence, despite increased usage of these agents in younger patients with 
NSTE-ACS / unstable angina, their usage in the elderly population remains 
controversial.  
The elderly population with CAD has never been extensively studied as far as 
thrombus formation and antiplatelet therapies are concerned.  
The findings from this elderly stable CAD study are important as: 
i. This is the first study assessing and comparing platelet dependent thrombus 
formation using the Badimon chamber, in stable CAD patients with age<75 
years and age≥75 years, with and without T2DM 
 
ii. All participants were on appropriate secondary prevention therapy including 
aspirin (75mg daily); clopidogrel (75mg daily) was added for 1 week as dual 
antiplatelet therapy (DAPT) 
 
iii. The data describe the effect of dual antiplatelet therapy on thrombus formation 
and platelet function in stable CAD patients with age≥75 years and age˂75 
years, with and without T2DM 
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The aim of our study was to compare the effect of clopidogrel on thrombus formation, 
when added to aspirin 75mg daily, in elderly and young patients with stable CAD, in 
the presence and absence of T2DM. Our study demonstrated a significant reduction 
in thrombus area when clopidogrel was added to aspirin 75mg daily. This reduction 
was consistently seen in both elderly (age≥75 years) and young (age˂75 years) 
patients with and without T2DM. When elderly patients were compared with the young, 
there was no difference in thrombus area between the groups at baseline. The 
reduction in thrombus area with clopidogrel were similar between the groups. When 
T2DM patients were compared with non-diabetic patients, baseline thrombus area and 
the reduction in thrombus area after a week of clopidogrel therapy were similar 
between the groups. 
This is the first study that evaluates the effect of “age” (an established cardiovascular 
risk factor) on platelet dependent thrombus formation, platelet reactivity, coagulation 
and inflammatory biomarkers and response to dual antiplatelet therapy. The findings 
from this stable CAD study have significant implications in the management of elderly 
patients with CAD. To achieve a significant reduction of thrombus area with DAPT in 
all the 4 groups of patients with stable CAD and good secondary prevention therapy 
(good lipid control, good hypertension control and good glycaemic control) is clinically 
very important. The reduction in thrombus area was also similar in all the four groups. 
This reduction in thrombus formation was not associated with any increase in bleeding 
complications during and one week after the study period. If DAPT is continued beyond 
the study duration the benefits are likely to be sustained and whether any long term 
benefits might outweigh the bleeding risk remains to be ascertained. 
My findings complement the results from the Clopidogrel for High Atherothrombotic 
Risk and Ischaemic Stabilization, Management and Avoidance (CHARISMA) trial and 
support the use of clopidogrel added to aspirin therapy in stable CAD groups. The 
CHARISMA trial was designed to examine whether DAPT provided greater vascular 
protection than aspirin alone in patients with stable CAD. In the final analysis, there 
was a suggestion of marginally significant reduction of the cumulative risk of 
myocardial infarction, stroke or cardiovascular death in the subset of patients with 
symptomatic atherothrombotic disease (6.9% vs. 7.9%; relative risk, 0.88; 95%CI, 0.77 
to 0.998; p=0.046). This marginal benefit of DAPT came at the expense of an increased 
risk of Global Utilization of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries (GUSTO) defined moderate bleeding (2.1% vs. 1.3%, 
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p<0.001) (Bhatt et al., 2006). A separate subgroup analysis of patients with previous 
myocardial infarction, ischaemic stroke or symptomatic peripheral arterial disease 
(PAD) also demonstrated similar results. In this cohort, DAPT decreased the rate of 
cardiovascular death, myocardial infarction or stroke (7.3% vs. 8.8%; HR, 0.83; 95%CI, 
0.72 to 0.96; p=0.01), and the risk of hospitalisations for ischaemia (11.4% vs. 13.2%; 
HR, 0.86; 95%CI, 0.76 to 0.96; p=0.008) when compared with aspirin and placebo. 
This benefit was associated with increased risk of GUSTO defined moderate (2.0% vs. 
1.3%; HR, 1.60; 95%CI, 1.16 to 2.20; p=0.004), but not severe bleeding (1.7% vs. 
1.5%; HR, 1.12; 95%CI 0.81 to 1.53; p=0.50). This analysis demonstrated the potential 
benefit from intensification of antithrombotic therapy beyond aspirin alone, especially 
in patients with risk factors such as documented prior MI, ischaemic stroke or 
symptomatic PAD. A subgroup analysis comparing patients with age<75 years and 
age≥75 years did not demonstrate any significant difference in clopidogrel response 
both in terms of primary outcomes and bleeding complications. Another subgroup 
analysis of the CHARISMA trial also showed that the benefits of clopidogrel are greater 
in the population with T2DM and a previous cardiovascular event (relative risk 
reduction: 17.1%; 95% CI: 4.4 – 28.1). Overall, the CHARISMA trial demonstrated a 
small but significant benefit in the subgroup of patients with known atherothrombosis 
and a potential role for intensification of antithrombotic therapy beyond aspirin alone 
(long-term dual antiplatelet therapy) in certain high-risk groups. My study has 
demonstrated a significant reduction in overall thrombus formation in both the younger 
and older cohorts, in both patients with and without T2DM, highlighting the fact that 
clopidogrel might still have a significant role in selected groups of patients, despite the 
availability of prasugrel and ticagrelor. Though the current study has been performed 
in patients with stable coronary artery disease, the results from this study will certainly 
help in assessing the way patients might respond to dual antiplatelet therapy in the 
setting of an acute coronary event.  
In the management of acute coronary syndrome, current cardiovascular society 
guidelines (AHA/ACC/ESC) do not recommend prasugrel in elderly patients (age≥75 
years) and recommend ticagrelor over clopidogrel even in elderly population unless 
there is a specific contraindication to ticagrelor (Amsterdam et al., 2014; Roffi et al., 
2015). 
In TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by 
Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction 38) 
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study, Prasugrel has been shown to reduce the risk of ischaemic events when 
compared with clopidogrel in ACS patients undergoing PCI with a 60mg loading dose 
followed by 10mg daily maintenance dose (Wiviott et al., 2007a). However, no net 
benefit was observed in elderly patients (≥75 years) due to increased occurrence of 
intracranial and fatal bleeding. Hence prasugrel 10mg daily is not recommended in 
patients with age ≥ 75 years. GENERATIONS (comparison of prasugrel and 
clopidogrel in very elderly and non-elderly patients with stable coronary artery disease) 
trial recruited aspirin treated patients with stable CAD, to compare pharmacodynamic 
(PD) and pharmacokinetic effects of adding prasugrel 5mg in patients aged ≥ 75 years 
with prasugrel 10mg in patients aged ≥ 45 and ˂ 65 years. Prasugrel 5mg attenuated 
platelet inhibition while meeting pre-specified non inferiority criteria versus prasugrel 
10mg in younger patients. Prasugrel 5mg also demonstrated significantly better PD 
response with fewer poor responders compared to clopidogrel 75mg in patients aged 
≥ 75 years (Erlinge et al., 2012).    
The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage 
Acute Coronary Syndromes (TRILOGY ACS) study demonstrated a steep increase in 
risks of ischaemic and bleeding events with increasing age among ACS patients 
managed medically without revascularisation. Prasugrel was not shown to be superior 
to clopidogrel in reducing the primary end point during 2.5 years of follow-up, even 
though signs of intensified platelet inhibition were observed in the prasugrel group. 
There was no difference in the risks of both ischaemic and bleeding outcomes with 
reduced-dose prasugrel (5mg daily) versus clopidogrel in elderly patients (age ≥ 75 
years) (Gurbel et al., 2012).  
The PLATelet inhibition and patient Outcomes (PLATO) trial demonstrated the 
superiority of ticagrelor as compared with clopidogrel in 18,624 patients with STEMI or 
NSTE-ACS. The trial showed a significant reduction in the primary composite end point 
(death from vascular causes, myocardial infarction, or stroke) with ticagrelor compared 
to clopidogrel (9.8% vs. 11.7%, HR: 0.84, 95% CI: 0.77–0.92, p < 0.001). There were 
also significant reductions of the individual endpoints of total death, cardiovascular 
death, myocardial infarction and stent thrombosis. There were no differences in overall 
major bleeding but a significant increase in non-procedure related major bleeding 
(James et al., 2009; Wallentin et al., 2009). A substudy from PLATO trial investigated 
the effect and treatment related complications of ticagrelor versus clopidogrel in elderly 
patients (age ≥ 75 years) with ACS compared with those ˂  75 years of age. The clinical 
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benefit of ticagrelor over clopidogrel was not significantly different between patients 
aged ≥ 75 years (n=2878) and those aged < 75 years (n=15744) with respect to 
composite endpoint of CV death, myocardial infarction, or stroke (interaction p=0.56), 
MI (p=0.33), CV death (P=0.47), definite stent thrombosis (p=0.81) or all-cause 
mortality (p=0.76). No increase in overall major bleeding with ticagrelor versus 
clopidogrel was observed in patients aged ≥ 75 years (HR: 1.02, 95% CI: 0.82-1.27) 
or patients aged < 75 years (HR: 1.04, 95% CI: 0.94-1.15) (Husted et al., 2012). 
Dyspnoea and ventricular pauses were more common with ticagrelor with no evidence 
of an age-by-treatment interaction.  Over all, ticagrelor is preferred over clopidogrel in 
ACS setting with or without coronary revascularisation in elderly and young patients. 
The optimal treatment duration and intensity of P2Y12 inhibition after a coronary event 
in patients who do not undergo revascularization remain uncertain. In a recent study 
conducted by Mauri et al, a total of 9961 patients who underwent coronary 
revascularisation with drug-eluting stent were randomly assigned to continue DAPT or 
to receive placebo alongside aspirin after 1 year of DAPT and were followed up to 30 
months. 65 percent of patients received clopidogrel and 35% received prasugrel. The 
patients in DAPT group were continued on the same P2Y12 inhibitor that they were on 
initially. This study demonstrated that DAPT as compared to aspirin alone, beyond 1 
year reduced the risks of stent thrombosis and further ischaemic events. Although 
longer duration of DAPT was associated with greater risk of bleeding, severe or fatal 
bleeding was uncommon and the rate did not differ significantly between the groups 
(Mauri et al., 2014). 
Our findings in stable CAD patients highlight the fact that clopidogrel is effective in 
reducing platelet dependent thrombus in older and younger patients, in individuals with 
and without diabetes. Clopidogrel has the least bleeding risk when compared to 
prasugrel or ticagrelor and is much cheaper. With more and more data being published 
about the need for extended DAPT following an acute coronary event and 
revascularisation, this study reinforces the potential usage of clopidogrel in certain high 
risk group especially in the elderly. 
Despite the currently recommended aggressive secondary prevention therapy, 
patients with T2DM experience more thrombotic events and have poorer prognosis 
compared to people without diabetes, both in NSTE-ACS setting and stable CAD 
setting (Bartnik et al., 2005). In my study, platelet dependent thrombus (measured as 
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total thrombus area) was similar in patients with and without T2DM. Addition of 
clopidogrel to aspirin resulted in a significant reduction in thrombus formation in stable 
CAD patients with and without T2DM. This reduction in thrombogenicity was not 
associated with any increase in bleeding complications during and one week after the 
study period. 
Our research group has previously demonstrated higher thrombus area in patients with 
T2DM and stable CAD compared to people without diabetes and without CAD. 
Thrombus area was similar in patients with T2DM without CAD and patients with CAD 
without T2DM suggesting T2DM as “Coronary artery disease equivalent” (Natarajan et 
al., 2007; Natarajan et al., 2008a). We have also demonstrated that in NSTE-ACS 
setting, patients with T2DM demonstrated significantly higher blood thrombogenicity 
despite the current recommended antithrombotic therapy (Viswanathan et al., 2012a). 
A subgroup analysis of the CHARISMA study demonstrated greater beneficial effects 
of clopidogrel in patients with T2DM and a previous cardiovascular event (relative risk 
reduction: 17.1%; 95% CI: 4.4-28.1) (Bhatt et al., 2007). Despite the availability of 
newer antiplatelet agents, outcomes in patients with T2DM have not improved to the 
levels seen in non-diabetic patients. In PLATO and TRITON-TIMI 38 trials in which 
ticagrelor and prasugrel were compared with clopidogrel, one year mortality rate in the 
diabetic cohort still remained at 7.0% and 12.2% respectively (Wiviott et al., 2008; 
James et al., 2010). 
My findings strengthen the argument that dual antiplatelet therapy might be able to 
provide better platelet inhibition without overtly increasing the bleeding risk in stable 
CAD patients with T2DM and/or elderly who are at high risk of future thrombotic events. 
Large scale studies are needed to further validate the role of long term dual antiplatelet 
therapy in providing clinical benefits with reduction in future thrombotic events without 
significant increase in bleeding in this population.
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4.2 Thromboelastography® (TEG) and Platelet Mapping™ - Elderly stable CAD 
study 
4.2.1 Results – Viscoelastic properties of thrombus 
I undertook TEG® and platelet mapping in the same cohort in whom thrombus area 
was measured. However, in the young T2DM cohort TEG and Platelet Mapping were 
performed in only 33 participants due to non-availability of equipment at the beginning 
of the previous study. The demographic and biochemical data characteristics are 
similar to the whole cohort (Table 4.10). Baseline TEG® parameters (e.g. R, K, MA to 
kaolin, G, clot index) were similar across all the four groups.  
After one week of clopidogrel therapy, there was a significant reduction in high shear 
thrombus area (age<75+T2DM: 14020± 4580 vs. 11151± 4445, p=0.029; age<75+non 
DM: 15633± 5425 vs. 12918± 4663, p<0.001; age≥75+T2DM: 15577± 6511 vs. 12733± 
4387, p<0.001; age≥75+non DM: 17725± 7186 vs. 14127± 4958, p<0.001). A similar 
response was seen in low shear thrombus area as well (Table 4.12). 
In thromboelastography parameters, elderly non diabetic patients demonstrated a 
reduction in clot index (CI) and prolongation of R time. All the other parameters 
remained unchanged. All the standard TEG® parameters (e.g. R, K, MA to kaolin, G, 
clot index) did not change after one week of clopidogrel therapy in the other groups 
(Table 4.11, Table 4.13Figure 4.5). 
Baseline platelet mapping™ tests were compared between the groups. Maximum 
viscoelastic strength of thrombus as measured by maximum amplitude upon 
stimulation with 10µl of arachidonic acid (MA-AA, in mm) was significantly lower in the 
non-diabetic elderly group compared to the non-diabetic younger population 
(29.6±17.2 vs. 40.4±18.6, p=0.025). Percentage aggregation to arachidonic acid (% 
aggregation to AA, %) was also significantly lower in the elderly nondiabetic group 
when compared to the young diabetic population (32.7±31.3 vs. 55.0±37.7, p=0.007). 
This demonstrates good platelet inhibition with aspirin in the elderly non-diabetic group 
(Table 4.11). 
After one week of clopidogrel therapy, there was a significant reduction in the maximum 
viscoelastic strength of thrombus (MA, mm) upon stimulation by 10µl of ADP. This 
reduction was consistently seen across all the four groups (MA, mm; age<75+T2DM: 
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59.9±7.4 vs. 54.0±10.8, p=0.007; age<75+non DM: 60.8±10.2 vs. 55.8±9.4, p=0.004; 
age≥75+T2DM: 61.5±6.3 vs. 54.5±11.2, p<0.001; age≥75+non DM: 59.8±12.7 vs. 
55.6±11.7, p<0.001). Percentage aggregation to ADP demonstrated similar reduction 
in all the four groups (Figure 4.6). 
An interesting finding was that even though participants had been on long term aspirin 
therapy, there was a significant improvement in aspirin induced platelet inhibition as 
measured by MA-AA in 3 out of 4 groups after the addition of clopidogrel (MA-AA, mm; 
age<75+T2DM: 34.7±19.2 vs. 25.9±15.7, p=0.002; age<75+non DM: 40.4±18.6 vs. 
26.1±17.1, p<0.001; age≥75+T2DM: 29.6±17.2 vs. 20.9±12.1, p=0.001). This 
improvement was not demonstrated in the elderly T2DM group (31.4±14.9 vs. 
27.4±16.4, p=0.125). A similar reduction was seen in the percentage aggregation to 
AA, further establishing the fact that clopidogrel therapy potentiated the platelet 
inhibitory effect of aspirin. This potentiation effect was maximum in the young non-
diabetic group and the change in viscoelastic strength was significantly higher when 
compared to the elderly T2DM group as measured by MA-AA, in mm (mean, 95% CI; 
14.3, 9.6-18.9 vs. 4.1, -1.2-9.3, p=0.033) (Table 4.13). 
Moderate but statistically significant correlations were demonstrated between 
thrombus area and various TEG® parameters on aspirin alone, as shown in Table and 
figure. After one week of clopidogrel therapy, MA-ADP demonstrated a significant 
positive correlation with both high shear thrombus area (rho=0.219, p=0.007) and low 
shear thrombus area (rho=0.176, p=0.034) (Figure 4.7).
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Age < 75 + T2DM 
(n = 33) 
 
Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 63.6 ± 7.2 63 ± 7.3 78.9 ± 3.1 79.0 ± 3.7  
Male gender, % ( n ) 84.8 (28) 68.9 (31) 81.6 (31) 71.1 (32) 0.275 
Body mass index, kg/m2 32.5 ± 4.9 29.6 ± 3.7 29.1 ± 5.1 27.8 ± 3.6 0.000 
Waist to hip ratio 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 0.9 ± 0.1 0.079 
Heart rate, beats  per minute 71 ± 12 62 ± 11 68 ± 14 64 ± 10 0.003 
Systolic BP, mmHg 142 ± 19.9 137 ± 17 158 ± 22.9 152 ± 22.4 0.000 
Diastolic BP, mmHg 77 ± 10.5 77 ± 7.8 76 ± 10.1 75± 9.0 0.679 
Risk profile: % ( n ) 
Angina 75.8 (25) 77.8 (35) 81.6 (31) 60 (27) 0.114 
Previous MI 48.5 (16) 48.9 (22) 50 (19) 66.7 (30) 0.258 
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PCI 30.3 (10) 40 (18) 36.8 (14) 28.9 (13) 0.664 
CABG 27.3 (9) 11.1 (5) 42.1 (16) 26.7 (12) 0.016 
Hypertension 36.4 (12) 51.1 (23) 73.7 (28) 66.7 (30) 0.006 
Heart failure 9.1 (3) 0 (0) 13.2 (5) 8.9 (4) 0.128 
CKD 6.1 (2) 0 (0) 13.2 (5) 2.2 (1) 0.036 
PVD 12.1 (4) 0 (0) 28.9 (11) 11.1 (5) 0.001 
CVA 12.1 (4) 4.4 (2) 13.2 (5) 8.9 (4) 0.523 
Medications: % ( n ) 
Sulphonylurea 24.2 (8)  21.1 (8)   
Metformin 60.6 (20)  44.7 (17)   
Insulin 33.3 (11)  52.6 (20)   
Beta-blocker 75.8 (25) 82.2 (37) 71.1 (27) 66.7 (30) 0.401 
ACE inhibitor / ARB 75.8 (25) 73.3 (33) 89.5 (34) 84.4 (38) 0.224 
Statin 100 (33) 93.3 (42) 92.1 (35) 95.6 (43) 0.438 
Laboratory data: Mean ± SD 
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Haemoglobin, g/dl 13.7 ± 1.1 13.6 ± 1.2 12.6 ± 1.3 12.9 ± 1.2 0.000 
Platelets x 1000 cells/mm3 223 ± 53.5 238 ± 63.6 211 ± 48.8 232 ± 66.2 0.171 
Fibrinogen, g/ml 3.4 ± 0.6 3.2 ± 0.6 3.4 ± 0.7 3.3 ± 0.6 0.466 
HbA1c, mmol/mol 58.8 ± 14.1 39.3 ± 7.0 61.2 ± 15.1 41.3 ± 3.4  
Fasting plasma glucose, 
mmol/L 
8.4 ± 4.6 5.2 ± 0.6 8.3 ± 4.3 5.2 ± 0.7  
Creatinine, micromol/L 100 ± 25.7 83 ± 25.2* 110 ± 53.5* 100 ± 27.7 0.005 
Total cholesterol, mmol/L 3.6 ± 0.7 4.2 ± 1.0 4.0 ± 0.9 4.2 ± 0.8 0.039 
LDLc, mmol/L 1.9 ± 0.6 2.2 ± 0.9 2.0 ± 0.9 2.1 ± 0.7 0.459 
HDLc, mmol/L 1.1 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.4 ± 0.3 0.000 
Triglyceride, mmol/L 1.6 ± 0.8 1.4 ± 0.8 1.5 ± 0.7 1.3 ± 0.6 0.306 
HsCRP, mg/L 4.1 ± 4.0 1.8 ± 1.8 4.3 ± 6.6 4.4 ± 7.7  0.114 
 
Table 4.10 Baseline characteristics of participants who underwent TEG® and platelet mapping™ 
LDLc – Low density lipoprotein cholesterol; HDLc – High density lipoprotein cholesterol; HsCRP – high-sensitive C-reactive protein 
Body mass index: Age<75+T2DM vs. Age<75+Non DM, p=0.026; Age<75+T2DM vs. Age≥75+T2DM, p=0.007; Age<75+T2DM vs. 
Age≥75+Non DM, p<0.001 
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Heart rate: Age<75+T2DM vs. Age<75+Non DM, p=0.004; Age<75+T2DM vs. Age≥75+Non DM, p=0.047 
Systolic BP: Age<75+T2DM vs. Age≥75+T2DM, p=0.009; Age<75+Non DM vs. Age≥75+T2DM, p<0.001; Age<75+Non DM vs. 
Age≥75+Non DM, p=0.004 
Haemoglobin: Age<75+T2DM vs. Age≥75+T2DM, p=0.003; Age<75+T2DM vs. Age≥75+Non DM, p=0.034; Age<75+Non DM vs. 
Age≥75+T2DM, p=0.001; Age<75+Non DM vs. Age≥75+Non DM, p=0.022 
Total cholesterol: Age<75+T2DM vs. Age<75+Non DM, p=0.007, Age<75+T2DM vs. Age≥75+Non DM, p=0.016 
HDLc: Age<75+T2DM vs. Age<75+Non DM, p=0.004; Age<75+T2DM vs. Age≥75+Non DM, p<0.001; Age≥75+T2DM vs. Age≥75+Non 
DM, p=0.001 
  
183 
 
 
 
Age < 75 + T2DM 
(n = 33) 
 
Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
Mean ± SD Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
R, min 6.1±1.5 6.4±1.5 0.442 6.5±1.7 6.6±1.5 0.721 6.6±1.9 6.0±1.4 0.013* 6.0±1.6 6.5±1.7 0.033* 
K, min 1.8±0.5 1.8±0.5 0.646 1.9±0.6 1.8±0.4 0.076 1.8±0.4 1.7±0.4 0.048* 1.7±0.5 1.8±0.5 0.434 
MA, mm 65.2±4.0 64.3±5.7 0.226 62.9±4.6 63.0±4.9 0.828 63.6±3.6 64.1±5.0 0.468 64.3±4.3 63.6±4.9 0.157 
G 
Kdynes/sec 
9.6±1.7 9.3±2.0 0.283 8.7±1.6 8.8±1.8 0.722 8.9±1.4 9.2±2.1 0.222 9.2±1.8 9.0±2.0 0.240 
CI 0.5±2.0 0.1±2.0 0.377 -0.2±2.1 -0.1±1.7 0.788 0±1.8 0.6±1.4 0.016* 0.5±1.8 0.1±2.0 0.039* 
MA-A, mm 11.4±6.6 11.8±4.1 0.703 15.9±14.7 16.1±14.2 0.892 14.7±7.5 16.4±10.2 0.151 13.8±8.1 12.1±4.5 0.074 
MA-AA, mm 34.7±19.2 25.9±15.7 0.002* 40.4±18.6 26.1±17.1 0.000* 31.4±14.9 27.4±16.4 0.125 29.6±17.2 20.9±12.1 0.001* 
MA-ADP, 
mm 
59.9±7.4 54.0±10.8 0.007* 60.8±10.2 55.8±9.4 0.004* 61.5±6.3 54.5±11.2 0.000* 59.8±12.7 55.6±11.7 0.000* 
% 
aggregation 
to AA 
44.7±35.5 26.9±32.1 0.000* 55.0±37.7 23.8±38.1 0.000* 32.5±30.0 23.7±32.6 0.124 32.7±31.3 16.9±24.1 0.001* 
% 
aggregation 
to ADP 
90.0±14.0 80.7±20.1 0.002* 97.7±21.0 85.0±23.5 0.002* 96.9±14.2 81.1±22.9 0.000* 92.1±21.1 84.3±20.2 0.000* 
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Thrombin 
generation 
 
739±295.2 741±269.3 0.954 763±55.7 764±59.7 0.778 772±42.5 777±58.4 0.476 781±54.4 771±57.3 0.066 
Maximum 
rate of 
thrombin 
generation, 
min 
16.8±27.3 12.7±3.9 0.391 11.5±2.9 11.8±2.5 0.419 12.3±2.5 12.9±2.5 0.065 12.9±3.6 12.8±3.8 0.814 
Thrombus 
retraction, 
L 
parameter 
mm/min 
74.2±32.8 78.4±17.7 0.521 84.8±26.4 83.7±21.8 0.746 87.5±22.9 88.6±36.9 0.119 83.1±16.5 80.4±23.2 0.511 
Maximum 
rate of 
thrombus 
retraction, 
min 
0.26±0.17 0.44±0.58 0.868 0.27±0.16 0.29±0.17 0.429 0.34±0.26 0.32±0.19 0.920 0.25±0.13 0.24±0.11 0.627 
 
Table 4.11 Standard TEG® parameters, Platelet Mapping™ and V-curve data  
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Mean 
thrombus 
area 
 
Age < 75 + T2DM 
(n = 33) 
 
Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + T2DM 
(n = 38) 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
Mean ± SD, 
µ2/mm Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value Visit 1 Visit 2 
P 
Value 
High shear 
chamber 
14020± 
4580 
11151± 
4445 0.029 
15633± 
5425 
12918± 
4663 0.000 
15577± 
6511 
12733± 
4387 0.000 
17725± 
7186 
14127± 
4958 0.000 
Low shear 
chamber 
9173± 
1624 
7660± 
1242 0.046 
9651± 
2323 
7573± 
2082 0.000 
9771± 
2648 
8710± 
1729 0.000 
9773± 
2273 
8483± 
1776 0.000 
 
Table 4.12 Thrombus area in patients who underwent TEG® measurements 
*p<0.05  
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Age < 75 + T2DM 
(n = 33) 
 
Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + T2DM 
(n = 38) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
R, min 6.1±1.5 6.5±1.7 6.6±1.9 6.0±1.6 
0.264 
K, min 1.8±0.5 1.9±0.6 1.8±0.4 1.7±0.5 
0.279 
MA, mm 65.2±4.0 62.9±4.6 63.6±3.6 64.3±4.3 
0.102 
G dynes/sec 9.6±1.7 8.7±1.6 8.9±1.4 9.2±1.8 
0.101 
CI 0.5±2.0 -0.2±2.1 0±1.8 0.5±1.8 
0.205 
MA-A, mm 11.4±6.6 15.9±14.7 14.7±7.5 13.8±8.1 
0.308 
MA-AA, mm 34.7±19.2 40.4±18.6 * 31.4±14.9 29.6±17.2 * 
0.025 * 
MA-ADP, mm 59.9±7.4 60.8±10.2 61.5±6.3 59.8±12.7 
0.854 
% aggregation to AA 43.2±35.9 55.0±37.7 * 33.1±29.8 32.7±31.3 * 
0.007 * 
% aggregation to ADP 90.0±13.8 95.0±27.1 96.9±14.2 92.1±21.1 
0.503 
Thrombin generation 739±295.2 763±55.7 772±42.5 781±54.4 
0.605 
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Maximum rate of thrombin 
generation, min 
16.8±27.3 11.5±2.9 12.3±2.5 12.9±3.6 
0.291 
Thrombus retraction, L parameter 
mm/min 
74.2±32.8 84.8±26.4 87.5±22.9 83.1±16.5 
0.388 
Maximum rate of thrombus 
retraction, min 
0.26±0.17 0.27±0.16 0.34±0.26 0.25±0.13 
0.238 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
R, min 6.4±1.5 6.6±1.5 6.0±1.4 6.5±1.7 
0.244 
K, min 1.8±0.5 1.8±0.4 1.7±0.4 1.8±0.5 
0.372 
MA, mm 64.3±5.7 63.0±4.9 64.1±5.0 63.6±4.9 
0.709 
G dynes/sec 9.3±2.0 8.8±1.8 9.2±2.1 9.0±2.0 
0.639 
CI 0.1±2.0 -0.1±1.7 0.6±1.4 0.1±2.0 
0.272 
MA-A, mm 11.8±4.1 16.1±14.2 16.4±10.2 12.1±4.5 
0.054 
MA-AA, mm 25.9±15.7 26.1±17.1 27.4±16.4 20.9±12.1 
0.228 
MA-ADP, mm 54.0±10.8 55.8±9.4 54.5±11.2 55.6±11.7 
0.873 
% aggregation to AA 26.9±32.1 23.8±38.1 19.2±42.5 16.9±24.1 
0.610 
% aggregation to ADP 80.7±20.1 91.1±47.1 88.1±22.9 84.3±20.2 
0.405 
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Thrombin generation 741±269.3 764±59.7 777±58.4 771±57.3 
0.689 
Maximum rate of thrombin 
generation, min 
12.7±3.9 11.8±2.5 12.9±2.5 12.8±3.8 
0.333 
Thrombus retraction, L parameter 
mm/min 
78.4±17.7 83.7±21.8 88.6±36.9 80.4±23.2 
0.530 
Maximum rate of thrombus 
retraction, min 
0.44±0.58 0.29±0.17 0.32±0.19 0.24±0.11 
0.079 
Difference in variables between Visit 1 and Visit 2 
Mean difference, 95% CI 
Delta MA-AA, mm 9.5, 3.8-15.2 14.3, 9.6-18.9 * 4.1, -1.2-9.3 * 8.7, 4.0-13.4 
0.033 * 
Delta MA-ADP, mm 5.9, 1.8-10.0 5.0, 1.7-8.3 6.9, 3.7-10.1 4.2, 2.3-6.2 
0.614 
Delta % aggregation to AA 17.9, 7.4-28.3 31.2, 19.3-43.1 * 8.8, -2.5-20.0 * 15.7, 6.5-25.0 
0.023 * 
Delta % aggregation to ADP 9.3, 1.5-17.0 12.6, 4.9-20.3 15.8, 8.7-22.8 7.8, 4.0-11.5 
0.307 
 
Table 4.13 Comparison of TEG® parameters, Platelet Mapping™ and V-curve data 
Post hoc analysis (One way ANOVA) 
*p<0.05 
Visit 1 % aggregation to AA: Age<75+Non DM vs. Age≥75+T2DM, p=0.022; Age<75+Non DM vs. Age≥75+Non DM, p=0.012
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Figure 4.5 Changes in TEG® parameters after clopidogrel therapy 
*p<0.05 
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Figure 4.6 Changes in Platelet Mapping™ after clopidogrel therapy 
*p<0.05   
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Figure 4.7 Correlation between TEG®-Platelet mapping™ and thrombus 
area  
R time negatively correlated with high shear thrombus area (rho= -0.212, p=0.008). K 
time again demonstrated negative correlation with high shear (rho= -0.182, p=0.023). 
Standard Maximum amplitude of the thrombus using Kaolin activated citrated sample 
did not correlate with thrombus area (rho=0.049, p=0.541). Clot index (CI) also 
demonstrated positive correlation with high shear (rho=0.169, p=0.035). Maximum 
amplitude of the thrombus formed in TEG®- Platelet mapping™ upon stimulation by 
ADP (MA-ADP, mm) demonstrated positive correlation with high shear thrombus 
(rho=0.219, p=0.007). Percentage aggregation of ADP demonstrated a similar 
correlation with high shear thrombus. 
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Age<75 years vs. Age≥75 years 
The baseline characteristics and demographic details between these groups have 
already been described earlier (Table 4.4).  
Standard TEG® parameters (R, K, MA, G and CI) were similar between the groups. 
After one week of clopidogrel therapy, all the standard TEG® parameters remained 
unchanged 
Baseline platelet mapping™ tests were compared between the groups. Maximum 
viscoelastic strength of thrombus as measured by maximum amplitude upon 
stimulation with 10µl of arachidonic acid (MA-AA, in mm) was significantly lower in the 
elderly group compared to the younger population in the study (30.5±16.2 vs. 
38.4±18.9, p=0.007). Percentage aggregation to arachidonic acid (% aggregation to 
AA, %) was also significantly lower in the elderly when compared to the young 
(32.6±30.5 vs. 51.0±37.0, p=0.002). This demonstrates good platelet inhibition with 
aspirin in elderly when compared to the young. 
After one week of clopidogrel, there was a significant reduction in the maximum 
viscoelastic strength of thrombus upon stimulation by 10µl of ADP. This reduction was 
consistently seen in both the groups (Age<75: 60.5±9.2 vs. 55.1±10.0, p<0.001; 
Age≥75: 60.6±10.3 vs. 55.1±11.4, p<0.001). Percentage aggregation to ADP also 
demonstrated similar reduction in both the groups (Age<75: 94.6±18.8 vs. 83.3±22.2, 
p<0.001; Age≥75: 94.3±18.3 vs. 82.9±21.4, p<0.001) (Figure 4.8, Table 4.15).  
Despite being on long term aspirin, there was a significant improvement in aspirin 
induced platelet inhibition as measured by MA-AA in both the groups after the addition 
of clopidogrel (Age<75: 38.4±18.9 vs. 26.0±16.5, p<0.001; Age≥75: 30.5±16.2 vs. 
23.9±14.5, p<0.001). Similar reduction was seen in percentage aggregation to AA 
establishing the fact that clopidogrel potentiated the platelet inhibitory effect of aspirin. 
Though this potentiation was seen in both the groups, it was significantly greater in the 
young when compared to the elderly. This was demonstrated by comparing the change 
in viscoelastic strength as measured by MA-AA, in mm (mean, 95% CI; 12.6, 8.9-16.2 
vs. 6.5, 3.0-10.1, p=0.021) between the groups (Table 4.15, Table 4.16). 
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Age < 75 
(n = 78) 
 
Age ≥ 75  
(n = 83) 
 
 
    P Value 
Demographic data: Mean ± SD or % (n) 
 
Age, years 
 
63.3±7.2 79.0±3.4  
Male gender, % ( n ) 
 
75.6 (59) 75.9 (63) 0.969 
Body mass index, kg/m2 
 
30.8±4.5 28.4±4.4 0.001 * 
Waist to hip ratio 
 
0.97±0.13 0.95±0.07 0.085 
Heart rate, beats  per minute 
 
66±12 66±12 0.949 
Systolic BP, mmHg 
 
139±18.4 155±22.6 0.000 * 
Diastolic BP, mmHg 
 
77±9 75±9.5 0.264 
Risk profile: % ( n ) 
 
Angina 
 
76.9 (60) 69.9 (58) 0.313 
Previous MI 
 
48.7 (38) 59 (49) 0.189 
Previous PCI 
 
35.9 (28) 32.5 (27) 0.653 
Previous CABG 
 
20.7 (18) 33.7 (28) 0.017 * 
Diabetes Mellitus 
 
42.3 (33) 45.8 (38) 0.657 
Hypertension 
 
44.9 (35) 69.9 (58) 0.001 * 
CKD 
 
2.6 (2) 7.2 (6) 0.173 
PVD 
 
5.1 (4) 19.3 (16) 0.007 * 
CVA 
 
7.7 (6) 10.8 (9) 0.492 
Medications: % ( n ) 
 
Sulphonylurea 
 
10.3 (8) 9.6 (8) 0.896 
Metformin 
 
25.6 (20) 20.5 (17) 0.437 
Insulin 
 
14.1 (11) 25.3 (21) 0.075 
Beta-blocker 79.5 (62) 68.7 (57) 0.219 
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ACE inhibitor / ARB 
 
74.4 (58) 86.7 (72) 0.046 
Statin 
 
96.2 (75) 94.0 (78) 0.525 
Laboratory data: Mean ± SD 
 
Haemoglobin, g/dl 
 
13.6±1.2 12.7±1.2 0.000 * 
Platelets x 1000 cells/mm3 
 
234±61.0 222±59.8 0.191 
Fibrinogen, g/ml 
 
3.3±0.6 3.3±0.6 0.710 
HbA1c, mmol/mol 
 
47.1±13.9 50.7±14.8 0.122 
Fasting plasma glucose, mmol/L 
 
6.6±3.7 6.7±3.4 0.958 
Creatinine, micromol/L 
 
91±26.6 105±42.6 0.008 * 
Total cholesterol, mmol/L 
 
4.0±0.9 4.0±0.9 0.631 
LDLc, mmol/L 
 
2.1±0.8 2.1±0.8 0.698 
HDLc, mmol/L 
 
1.2±0.3 1.3±0.3 0.061 
Triglyceride, mmol/L 
 
1.5±0.8 1.4±0.7 0.406 
HsCRP, mg/L 
 
2.9±3.3 4.2±7.2 0.112 
 
Table 4.14 Baseline characteristics - TEG® substudy (Age<75 vs. Age≥75) 
*p<0.05 
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Age < 75 
(n = 78) 
 
Age ≥ 75 
(n = 83) 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
R, min 6.3±1.6 6.5±1.5 0.428 6.3±1.7 6.2±1.6 0.844 
K, min 1.9±0.5 1.8±0.4 0.406 1.7±0.5 1.7±0.5 0.540 
MA, mm 64.0±7.2 64.8±5.2 0.499 64.0±4.0 63.9±4.9 0.742 
G Kdynes/sec 9.1±1.7 9.0±1.9 0.696 9.1±1.6 9.1±2.0 0.776 
CI 0.1±2.1 0±1.8 0.655 0.3±1.8 0.3±1.8 0.848 
MA-A, mm 14.1±12.4 14.4±11.5 0.771 14.2±7.8 14.1±7.9 0.842 
MA-AA, mm 38.4±18.9 26.0±16.5 0.000 * 30.5±16.2 23.9±14.5 0.000 * 
MA-ADP, mm 60.5±9.2 55.1±10.0 0.000 * 60.6±10.3 55.1±11.4 0.000 * 
% 
aggregation to 
AA 
51.0±37.0 25.0±35.6 0.000 * 32.6±30.5 20.0±28.3 0.001 * 
% 
aggregation to 
ADP 
94.6±18.8 83.3±22.2 0.000 * 94.3±18.3 82.9±21.4 0.000 * 
Thrombin 
generation 
752±196.5 755±178.3 0.947 777±49.3 774±57.5 0.505 
Maximum rate 
of thrombin 
generation, 
min 
13.8±18.0 12.2±3.2 0.511 12.6±3.2 12.8±3.3 0.299 
Thrombus 
retraction, L 
parameter 
mm/min 
84.4±26.0 84.9±19.6 0.031 88.2±19.9 95.1±30.0 0.088 
Maximum rate 
of thrombus 
retraction, min 
0.25±0.14 0.26±0.13 0.240 0.27±0.15 0.27±0.17 0.892 
 
Table 4.15 Changes in TEG®, Platelet Mapping™ and V-curve data (Age<75 
vs. Age≥75) 
*p<0.05 
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Figure 4.8 Changes in Platelet Mapping™ (Age<75 vs. Age≥75) 
*p<0.05 
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Age < 75 
(n = 78) 
 
Age ≥ 75 
(n = 83) 
 
 
    P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
R, min 6.3±1.6 6.3±1.7 0.830 
K, min 1.9±0.5 1.7±0.5 0.157 
MA, mm 64.0±7.2 64.0±4.0 0.895 
G Kdynes/sec 9.1±1.7 9.1±1.6 0.997 
CI 0.1±2.1 0.3±1.8 0.486 
MA-A, mm 14.1±12.4 14.2±7.8 0.925 
MA-AA, mm 38.4±18.9 30.5±16.2 0.007 * 
MA-ADP, mm 60.5±9.2 60.6±10.3 0.938 
% aggregation to AA 51.0±37.0 32.6±30.5 0.002 * 
% aggregation to ADP 94.6±18.8 94.3±18.3 0.930 
Thrombin generation 752±196.5 777±49.3 0.281 
Maximum rate of thrombin 
generation, min 13.8±18.0 12.6±3.2 0.590 
Thrombus retraction, L 
parameter mm/min 84.4±26.0 88.2±19.9 0.426 
Maximum rate of thrombus 
retraction, min 0.25±0.14 0.27±0.15 0.477 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
R, min 6.5±1.5 6.2±1.6 0.289 
K, min 1.8±0.4 1.7±0.5 0.202 
MA, mm 64.8±5.2 63.9±4.9 0.710 
G Kdynes/sec 9.0±1.9 9.1±2.0 0.722 
CI 0±1.8 0.3±1.8 0.219 
MA-A, mm 14.4±11.5 14.1±7.9 0.841 
MA-AA, mm 26.0±16.5 23.9±14.5 0.389 
MA-ADP, mm 55.1±10.0 55.1±11.4 0.996 
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% aggregation to AA 25.0±35.6 20.0±28.3 0.335 
% aggregation to ADP 83.3±22.2 82.9±21.4 0.894 
Thrombin generation 
755±178.3 774±57.5 
0.368 
Maximum rate of thrombin 
generation, min 
12.2±3.2 12.8±3.3 
0.172 
Thrombus retraction, L 
parameter mm/min 
84.9±19.6 95.1±30.0 
0.582 
Maximum rate of thrombus 
retraction, min 
0.26±0.13 0.27±0.17 
0.228 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta MA-AA, mm 12.6, 8.9-16.2 6.5, 3.0-10.1 0.021 * 
Delta MA-ADP, mm 5.4, 2.9-8.0 5.3, 3.5-7.1 0.942 
Delta % aggregation to AA 28.2, 21.1-35.3 12.6, 5.5-19.6 0.015 * 
Delta % aggregation to ADP 11.3, 5.8-16.8 11.2, 7.4-15.1 0.962 
 
Table 4.16 Comparison of TEG®, Platelet Mapping™ and V-curve data 
(age<75 vs. age≥75) 
*p<0.05 
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T2DM vs. Non DM 
The baseline characteristics and demographic details between T2DM and Non DM 
groups have already been described earlier (Table 4.17).  
Standard TEG® and Platelet mapping™ parameters were similar between the groups. 
After one week of clopidogrel therapy, all the standard TEG® parameters remained 
unchanged 
After one week of clopidogrel therapy, there was a significant reduction in the maximum 
viscoelastic strength of thrombus upon stimulation by 10µl of ADP. This reduction was 
consistently seen in both the groups (T2DM: 60.8±6.8 vs. 54.3±10.9, p<0.001; Non 
DM: 60.3±11.5 vs. 55.7±10.6, p<0.001). Percentage aggregation to ADP also 
demonstrated similar reduction in both the groups (T2DM: 93.9±14.5 vs. 81.0±21.6, 
p<0.001; Non DM: 43.8±36.3 vs. 20.3±31.9, p<0.001) (Table 4.18, Figure 4.9).  
Treatment with clopidogrel for one week also demonstrated significant improvement in 
aspirin induced platelet inhibition as measured by MA-AA in both the groups (T2DM: 
33.1±16.8 vs. 26.7±16.0, p<0.001; Non DM: 35.0±18.7 vs. 23.5±15.0, p<0.001). 
Similar reduction was seen in percentage aggregation to AA further establishing the 
fact that clopidogrel therapy potentiated platelet inhibitory effect of aspirin. Though this 
potentiation effect was demonstrated in both the groups, it was significantly lower in 
T2DM group when compared to non-diabetic group. This was demonstrated by 
comparing the change in viscoelastic strength as measured by MA-AA, in mm (mean, 
95% CI; 6.4, 2.5-10.3 vs. 11.6, 8.3-14.9, p=0.048) and change in percentage 
aggregation to AA between the groups (Table 4.18, Table 4.19). 
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 T2DM 
(n = 71) 
Non DM 
(n = 90) 
 
 
    P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 
 
72±9.4 71±9.9 0.625 
Male gender, % ( n ) 
 
83.1 (59) 70 (63) 0.054 
Body mass index, kg/m2 
 
30.7±5.3 28.7±3.7 0.008 * 
Waist to hip ratio 
 
0.98±0.07 0.95±0.12 0.046 
Heart rate, beats  per minute 
 
69±13 63±11 0.001 * 
Systolic BP, mmHg 
 
150±22.9 145±21.3 0.121 
Diastolic BP, mmHg 
 
76±10 76±8 0.757 
Risk profile: % ( n ) 
Angina 
 
78.9 (56) 68.9 (62) 0.155 
Previous MI 
 
49.3 (35) 57.8 (52) 0.284 
Previous PCI 
 
33.8 (24) 34.4 (31) 0.932 
Previous CABG 
 
35.2 (25) 18.9 (17) 0.019 
Hypertension 
 
56.3 (40) 58.9 (53) 0.745 
CKD 
 
9.9 (7) 1.1 (1) 0.011 
PVD 
 
21.1 (15) 5.6 (5) 0.003 
CVA 
 
12.7 (9) 6.7 (6) 0.193 
Medications: % ( n ) 
Sulphonylurea 
 
22.5 (16) 0  
Metformin 
 
52.1 (37) 0  
Insulin 
 
43.7 (31) 0  
Beta-blocker 73.2 (52) 74.4 (67) 0.528 
ACE inhibitor / ARB 
 
83.1 (59) 78.9 (71) 0.501 
Statin 
 
95.8 (68) 94.4 (85) 0.700 
Laboratory data: Mean ± SD 
Haemoglobin, g/dl 
 
13.0±1.3 13.2±1.2 0.409 
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Platelets x 1000 cells/mm3 
 
217±53 235±64.6 0.066 
Fibrinogen, g/ml 
 
3.4±0.6 3.2±0.6 0.119 
HbA1c, mmol/mol 
 
60.3±14.7 40.3±5.5  
Fasting plasma glucose, mmol/L 
 
8.5±4.7 5.2±0.6  
Creatinine, micromol/L 
 
105±44.1 91±27.7 0.019 * 
Total cholesterol, mmol/L 
 
3.8±0.9 4.2±0.9 0.009 * 
LDLc, mmol/L 
 
2.0±0.8 2.2±0.8 0.219 
HDLc, mmol/L 
 
1.1±0.3 1.4±0.3 0.000 * 
Triglyceride, mmol/L 
 
1.6±0.7 1.4±0.7 0.098 
HsCRP, mg/L 
 
4.2±5.6 3.1±5.7 0.232 
 
Table 4.17 Baseline characteristics - TEG® substudy (T2DM vs. Non-DM) 
*p<0.05 
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T2DM 
(n = 71) 
 
Non DM 
(n = 90) 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
R, min 6.4±1.7 6.1±1.4 0.288 6.2±1.6 6.5±1.6 0.098 
K, min 1.8±0.5 1.7±0.4 0.513 1.8±0.5 1.8±0.5 0.421 
MA, mm 64.4±3.9 64.2±5.3 0.690 63.6±4.5 63.4±4.9 0.521 
G Kdynes/sec 9.2±1.6 9.3±2.1 0.833 8.9±1.7 8.9±1.9 0.720 
CI 0.2±1.9 0.4±1.7 0.488 0.2±2.0 0±1.9 0.298 
MA-A, mm 13.2±7.3 14.4±8.4 0.170 14.8±11.9 14.1±10.6 0.433 
MA-AA, mm 33.1±16.8 26.7±16.0 0.001 * 35.0±18.7 23.5±15.0 0.000 * 
MA-ADP, mm 60.8±6.8 54.3±10.9 0.000 * 60.3±11.5 55.7±10.6 0.000 * 
% 
aggregation to 
AA 
37.9±32.8 25.1±32.2 0.002 * 43.8±36.3 20.3±31.9 0.000 * 
% 
aggregation to 
ADP 
93.9±14.5 81.0±21.6 0.000 * 94.8±21.1 84.7±21.8 0.000 * 
Thrombin 
generation 
756±204.1 761±186.4 0.888 772±55.6 768±58.3 0.428 
Maximum rate 
of thrombin 
generation, 
min 
14.5±18.8 12.8±3.2 0.468 12.2±3.4 12.3±3.3 0.639 
Thrombus 
retraction, L 
parameter 
mm/min 
84.3±26.0 94.2±33.1 0.087 87.9±20.6 88.1±20.5 0.949 
Maximum rate 
of thrombus 
retraction, min 
0.29±0.19 0.28±0.18 0.858 0.24±0.11 0.26±0.13 0.350 
 
Table 4.18 Changes in TEG®, Platelet Mapping™ and V-curve data (T2DM 
vs. Non-DM) 
*p<0.05 
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Figure 4.9 Changes in Platelet Mapping™ (T2DM vs. Non-DM) 
*p<0.05 
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T2DM 
(n = 71) 
 
Non DM 
(n = 90) 
 
 
    P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
R, min 
6.4±1.7 6.2±1.6 
0.558 
K, min 
1.8±0.5 1.8±0.5 
0.429 
MA, mm 
64.4±3.9 63.6±4.5 
0.239 
G Kdynes/sec 
9.2±1.6 8.9±1.7 
0.321 
CI 
0.2±1.9 0.2±2.0 
0.850 
MA-A, mm 
13.2±7.3 14.8±11.9 
0.301 
MA-AA, mm 
33.1±16.8 35.0±18.7 
0.448 
MA-ADP, mm 
60.8±6.8 60.3±11.5 
0.768 
% aggregation to AA 
37.9±32.8 43.8±36.3 
0.254 
% aggregation to ADP 
93.9±14.5 94.8±21.1 
0.736 
 
Thrombin generation 756±204.1 772±55.6 0.541 
Maximum rate of thrombin 
generation, min 
14.5±18.8 12.2±3.4 0.323 
Thrombus retraction, L 
parameter mm/min 
84.3±26.0 87.9±20.6 0.749 
Maximum rate of thrombus 
retraction, min 
0.29±0.19 0.24±0.11 0.212 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
R, min 
6.1±1.4 6.5±1.6 
0.098 
K, min 
1.7±0.4 1.8±0.5 
0.371 
MA, mm 
64.2±5.3 63.4±4.9 
0.311 
G Kdynes/sec 
9.3±2.1 8.9±1.9 
0.257 
CI 
0.4±1.7 0±1.9 
0.127 
MA-A, mm 
14.4±8.4 14.1±10.6 
0.826 
MA-AA, mm 
26.7±16.0 23.5±15.0 
0.205 
MA-ADP, mm 
54.3±10.9 55.7±10.6 
0.420 
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% aggregation to AA 
25.1±32.2 20.3±31.9 
0.365 
% aggregation to ADP 
81.0±21.6 84.7±21.8 
0.293 
Thrombin generation 
761±186.4 768±58.3 
0.754 
Maximum rate of thrombin 
generation, min 
12.8±3.2 12.3±3.3 
0.315 
Thrombus retraction, L 
parameter mm/min 
94.2±33.1 88.1±20.5 
0.592 
Maximum rate of thrombus 
retraction, min 
0.28±0.18 0.26±0.13 
0.073 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta MA-AA, mm 6.4, 2.5-10.3 11.6, 8.3-14.9 0.048 * 
Delta MA-ADP, mm 6.3, 3.8-8.8 4.7, 2.8-6.6 0.236 
Delta % aggregation to AA 12.8, 5.1-20.4 25.2, 18.5-32.0 0.050 * 
Delta % aggregation to ADP 12.7, 7.5-17.9 10.2, 6.0-14.4 0.406 
 
Table 4.19 Comparison of TEG®, Platelet Mapping™ and V-curve data 
(T2DM vs. Non-DM) 
*p<0.05 
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4.2.2 Discussion - viscoelastic properties of thrombus 
In this study at baseline, kaolin stimulated TEG® parameters (standard TEG®) were 
similar in elderly and young patients, with and without diabetes. The conventional 
TEG® parameters remained unaltered in elderly T2DM, young T2DM and young non 
DM group, after addition of clopidogrel 75mg OD for a week. In elderly non DM group, 
there was a reduction in clot index (CI) and prolongation of R time, after clopidogrel 
therapy. When standard TEG® parameters where compared between young and older 
patients, there was no difference in values both at baseline and after one week of 
clopidogrel therapy. These findings probably demonstrate a stronger response to 
clopidogrel among elderly non-diabetic patients when compare to younger patients and 
patients with T2DM.  
It is not surprising that standard TEG® parameters remained unaltered after addition 
of clopidogrel in all the groups except for elderly non-DM group. Kaolin stimulates 
thrombus formation by activating thrombin which acts in the final common pathway of 
coagulation cascade, thereby bypassing the effect of ADP inhibition. Clopidogrel 
therapy has been shown to reduce thrombin generation in small studies, but no study 
has been performed using kaolin stimulated TEG assay to support this finding (Wegert 
et al., 2002).  
In CLEAR PLATELET-2 study (Clopidogrel With Eptifibatide to Arrest the Reactivity of 
Platelets), TEG was used to assess platelet reactivity in patients who received 
clopidogrel, bivalirudin and eptifibatide. There was an immediate and marked reduction 
in maximum amplitude as measured by TEG, following the addition of eptifibatide to 
bivalirudin therapy. The values correlated with peri-procedural myonecrosis. This study 
demonstrated the usefulness of TEG in assessing platelet reactivity (Gurbel et al., 
2009). Various studies have demonstrated the usefulness of TEG parameters post 
cardiac surgery, as a guide to decide on blood products transfusion (Hertfelder et al., 
2005; Ak et al., 2009). Even these studies did not report any difference in TEG 
parameters in patients who were on clopidogrel. Gurbel et al in PREPARE POST-
STENTING study measured standard TEG parameters in patients treated with dual 
antiplatelet therapy following elective coronary stenting. Patients with higher MA and 
shorter R time had more ischaemic events (Gurbel et al., 2005). Unfortunately this 
study did not report any pre and post clopidogrel TEG values. It is possible that DAPT 
with aspirin and clopidogrel is not powerful enough to demonstrate changes in kaolin 
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stimulated standard TEG parameters. The other explanation could be that the sample 
size in my study was too small to demonstrate any significant changes in TEG 
parameters. Despite that, significant difference in CI and R time was demonstrated in 
elderly non-diabetic patients. Effect of prasugrel and ticagrelor on standard TEG 
parameters remains to be seen. 
The results from modified TEG assay namely platelet mapping (PM), demonstrated a 
significantly lower maximum viscoelastic strength of thrombus upon stimulation with 
10µl of arachidonic acid (MA-AA) in elderly patients (age≥75) when compared to the 
young (age<75), thereby demonstrating better platelet inhibition with aspirin in the 
elderly group. There was a significant reduction in maximum viscoelastic strength of 
thrombus upon stimulation by ADP (MA-ADP), in elderly and young patients, with and 
without diabetes. The other interesting finding was a significant reduction in MA-AA in 
young people with and without diabetes, and in the elderly non-diabetic participants, 
after the addition of clopidogrel to aspirin. This suggests the possibility of a potentiating 
effect of clopidogrel on the antiplatelet effect of aspirin. This reduction was not 
demonstrated in elderly patients with T2DM.  
Previous studies which employed modified TEG percentage inhibition to measure the 
response to aspirin and clopidogrel have used cut-off values of <50% and <30% to 
define hypo-responsiveness to aspirin and clopidogrel respectively. Using the same 
cut-off values, results from my PM assay showed inadequate response to clopidogrel 
(ADP inhibition) in the following percentage of patients: 76% (young T2DM), 84% 
(young non DM), 79% (elderly T2DM) and 89% (elderly non DM). Percentage of 
patients with inadequate response to aspirin (AA inhibition) at baseline and after one 
week of clopidogrel treatment: 43% vs. 24% (age<75+T2DM), 53% vs. 20% 
(age<75+non DM), 32% vs. 24% (age≥75+T2DM) and 24% vs. 7% (age≥75+non DM). 
There was a significant variability in individual clopidogrel responses at all ages and 
with and without diabetes, ranging from 0% to 95%.  
Roeloffzen et al demonstrated a tendency towards hypercoagulability in both the sexes 
with increasing age using standard TEG parameters. Cut off age 50 was used to divide 
the study population but in my study, I used 75 as the cut off age to divide patients as 
young and elderly. Weak to moderate correlations between age and most TEG 
variables were observed but the strongest correlation was between age and MA (in 
normal controls thromboelastography) (Roeloffzen et al., 2010).  
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When comparing elderly and young stable CAD patients, standard TEG® parameters 
were similar between the groups. After one week of clopidogrel therapy, all the 
standard TEG® parameters remained unchanged. From TEG-PM data, elderly 
patients demonstrated better platelet inhibition with aspirin, compared to the young. 
After one week of clopidogrel therapy, there was a significant and similar reduction in 
the maximum viscoelastic strength of thrombus upon stimulation by 10µl of ADP (MA-
ADP) suggesting good response to clopidogrel in elderly and young. Despite being on 
long term aspirin therapy, addition of clopidogrel enhanced aspirin induced platelet 
inhibition in both the groups, but this potentiation effect was significantly greater in the 
young compared to the elderly group. 
Standard TEG® parameters were similar between T2DM and non-DM patients at 
baseline (on aspirin alone). All the standard TEG® parameters remained unchanged 
after addition of clopidogrel for one week. From TEG-PM data, T2DM and non-DM 
patients demonstrated similar antiplatelet effect with aspirin. After one week of 
clopidogrel therapy, there was a significant and similar reduction in the maximum 
viscoelastic strength of thrombus upon stimulation by 10µl of ADP (MA-ADP) 
suggesting good response to clopidogrel in both T2DM and non-DM patients. Despite 
being on long term aspirin therapy, addition of clopidogrel enhanced aspirin induced 
platelet inhibition in both diabetic and non-diabetic participants, but this potentiation 
effect was significantly greater in the non-diabetic group. 
Swallow et al demonstrated that TEG-PM (MA-AA and MA-ADP) could be used as a 
reliable bedside test to measure the effects of aspirin and clopidogrel therapy, alone 
or in combination, both in an individual and between different groups (Swallow et al., 
2006). Bliden et al measured platelet reactivity and percentage aggregation in patients 
who were on prescribed DAPT with aspirin and clopidogrel and who underwent elective 
coronary stent insertion. In this study 87% of the patients displayed high on-treatment 
platelet reactivity and this was the only variable that significantly predicted future 
ischaemic events (Bliden et al., 2007). Collyer et al performed a prospective 
observational study in three groups of preoperative acute surgical patients to assess 
the ability of TEG-PM in detecting platelet inhibition. This study demonstrated that 
TEG-PM was able to identify statistically significant inhibition of platelet ADP and TXA2 
receptor after clopidogrel and aspirin therapy respectively (Collyer et al., 2009). 
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In a  3 year follow up study of patients who underwent coronary stent insertion and 
were treated with DAPT, Gurbel et al identified MA-ADP of >47 mm to be the best 
predictor of long-term ischaemic events and MA-ADP <31 mm to be the predictor of 
bleeding (Gurbel et al., 2010b). In another study, Hobson and colleagues 
demonstrated greater baseline MA-ADP, reduced response to clopidogrel and higher 
post treatment platelet reactivity while on aspirin and clopidogrel treatment in young 
women with previous stent thrombosis, when compared to healthy volunteers (Hobson 
et al., 2009). In a subgroup of patients enrolled in the Optimizing anti-Platelet Therapy 
In diabetes MellitUS (OPTIMUS) study, Angiolillo and colleagues demonstrated T2DM 
patients with suboptimal clopidogrel response to have enhanced platelet procoagulant 
activity compared to patients with optimal response. This procoagulant activity can be 
down-regulated by more potent platelet P2Y12 inhibition using high clopidogrel 
maintenance dosing. This study highlighted the usefulness of TEG® in monitoring 
platelet function from patients who are on long term antiplatelet therapy (Angiolillo et 
al., 2009). 
It is well known that aspirin resistance is rare in compliant patients with established 
CAD and that the occurrence of aspirin resistance is overestimated in published 
reports (Tantry et al., 2005). This may explain the higher than expected aspirin 
resistance at baseline in my cohort of patients. The platelet inhibitory effect was 
enhanced after the addition of clopidogrel in all the groups but was highest in young 
non-diabetic group and was lowest in elderly T2DM group. The mechanisms 
underlying this enhanced antiplatelet effect of aspirin measured using pathway specific 
agonist arachidonic acid (MA-AA) remains to be explained. There is a possibility that 
after recruitment in the study, compliance to aspirin improved along with clopidogrel 
treatment resulting in significantly enhanced antiplatelet effect of aspirin. Alstrom et al 
demonstrated a similar finding in a small TEG-PM study (Alstrom et al., 2007). 
The Badimon chamber is predominantly a measure of platelet dependent thrombus 
formation in both high shear and low shear conditions and TEG® evaluates the 
viscoelastic property of clot formation under low shear condition, with fibrinogen levels 
and platelet counts having a major influence on its parameters. Badimon chamber is 
used to evaluate the area of formed thrombus when whole blood is exposed to collagen 
for 5 minutes under different rheological conditions whereas TEG® measures 
viscoelastic properties of thrombus continuously over 90 minutes.  
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Time to initial fibrin formation (R time) negatively correlated with high shear thrombus 
area. Time taken from initial fibrin formation to formation of a firm thrombus (K time) 
also demonstrated negative correlation with both high shear and low shear thrombus 
area. Maximum viscoelastic strength of the thrombus (MA mm) and the elastic force of 
the clot (G dynes/m2) had a positive correlation with low shear thrombus area. Overall 
measure of thrombus strength, clot index (CI) also demonstrated positive correlation 
with high shear and low shear thrombus area. Thrombin generation and maximum rate 
of thrombin generation also correlated positively with low shear thrombus area. These 
interesting correlations between TEG® parameters and platelet dependent thrombus 
formation highlights the potential role of TEG® in evaluation of novel antithrombotic 
agents that might interact in different stages of coagulation cascade. My findings have 
also demonstrated that TEG-PM assay can be helpful in assessing response to 
antiplatelet therapy in CAD patients, both elderly and young and in the presence and 
absence of T2DM. 
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4.3 VerifyNow® (Optical aggregometry) - Elderly stable CAD study 
4.3.1 Results – Platelet reactivity indices 
Baseline characteristics of the patients in all the four groups who had their platelet 
reactivity indices measured are as in the earlier section (Table 4.1). PRUz cut-off value 
of ≥240 was used to classify patients as on treatment high platelet reactivity 
(hyporesponders). Patients with PRUz<240 were classified as good responders to 
clopidogrel. 
Young T2DM group had the least number of good responders to clopidogrel, 12 
patients (36.4%) and the young non-diabetic group had the highest number of good 
responders, 27 patients (67.5%). The elderly T2DM group had 12 good responders 
(36.4%) compared to 22 patients (52.4%) of good responders in elderly non-diabetic 
group. The young T2DM group had the least number of hyporesponders to aspirin, 7 
patients (17.1%) and elderly non-DM had the highest number of hyporesponders to 
aspirin, 17 patients (37.8%) (Figure 4.11, Table 4.20). 
The absolute mean PRUz value was significantly reduced in all the four groups after 
one week of clopidogrel therapy (young T2DM: 322±38.5 to 260±59.4, p<0.001; old 
T2DM: 303±39.4 to 257± 68.8, p<0.001; young non-diabetic: 305± 47.1 to 211± 76.4, 
p<0.001; old non-diabetic: 313± 58.8 to 224± 68.1, p<0.001). Despite significant 
reduction in PRUz, the mean PRUz in the T2DM group: young (260±59.4) and old 
(257± 68.8) remained ≥240, confirming high platelet reactivity in the diabetic 
population. Similar trends were seen with percentage platelet inhibition to clopidogrel. 
Mean difference in PRUz from visit 1 and visit 2 was lowest in Age≥75+T2DM group 
(Mean, 95%CI: 55, 40.4-69.4) and highest in Age<75+Non DM group (105, 82.8-126.8) 
and this difference was significant (p=0.013) (Figure 4.10, Table 4.21). 
Despite being on long term aspirin therapy, there was a numerical reduction in ARU 
from visit 1 to visit 2 in the younger population both in T2DM and non DM group. This 
reduction was significant in T2DM group (mean±SD, 458±55.5 to 430±76.5; p=0.027) 
demonstrating improved platelet inhibition to aspirin after the addition of clopidogrel as 
a second antiplatelet agent. There was no change in ARU value in the elderly 
population (both T2DM and non DM group) after the addition of clopidogrel.  
Good responders to clopidogrel: 
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I compared all the good responders to clopidogrel (mean PRUz < 240) from all the four 
groups. There was a consistent reduction both in high shear (age<75+T2DM: 15579± 
4650 vs. 11338± 4228, p=0.024; age<75+non DM: 15629± 4968 vs. 12422± 4521, 
p<0.001; age≥75+T2DM: 18217± 6227 vs. 14332± 5073, p=0.027; age≥75+non DM: 
17069± 7575 vs. 13537± 4718, p=0.011) and low shear thrombus area following one 
week of clopidogrel therapy. PRUz was lower in non-diabetic group compared to T2DM 
group: both in the young (mean±SD; 164±54.4 vs. 202±37.9) and in the elderly 
(mean±SD; 166± 41.2 vs. 177±30.1). There was no significant change in ARU values 
at baseline and one week after clopidogrel therapy in all the four groups (Table 4.22, 
Table 4.23). 
Hyporesponders to clopidogrel: 
When hyporesponders to clopidogrel (mean PRUz ≥ 240) were compared, patients 
with age<75, both the T2DM group and the non-diabetic group demonstrated 
numerical reduction in high shear thrombus area but this was not statistically significant 
(age<75+T2DM: 14321± 5899 vs.12269± 4164, p=0.063; age<75+non DM: 16113± 
1820 vs. 14809± 1442, p=0.370). In patients with Age≥75, both T2DM and non-diabetic 
group demonstrated significant reduction in thrombus area after one week of 
clopidogrel therapy (age≥75+T2DM: 15113± 6561 vs. 12440± 4637, p=0.007; 
age≥75+non DM: 17596± 6101 vs. 14484± 5024, p=0.012). All the four groups 
demonstrated significant reduction in PRUz but the mean PRUz remained ≥ 240 (Table 
4.24, Table 4.25). 
At baseline when patients were on aspirin alone, there was a significant negative 
correlation between haemoglobin level and PRUz (rho= -0.684; p<0.001). Parameters 
which measured aspirin induced platelet inhibition using TEG®, MA-AA and percentage 
aggregation to AA, correlated positively with ARU (aspirin induced platelet inhibition 
measurement using VerifyNow®) (rho=0.246; p=0.002 and rho=0.248; p=0.002 
respectively). After a week of clopidogrel therapy, significant negative correlation 
between haemoglobin level and PRUz persisted (rho= -0.649; p<0.001). Parameters 
which measured clopidogrel induced platelet inhibition using TEG®, MA-ADP and 
percentage aggregation to ADP correlated positively with PRUz (clopidogrel induced 
platelet inhibition measurement using VerifyNow®) (rho=0.181; p=0.024 and   
rho=0.225; p=0.005 respectively). Positive correlation between MA-AA and ARU 
persisted (rho=0.186; p=0.020) (Table 4.26, Table 4.27).
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Age < 75 + T2DM 
(n = 41) 
 
 
Age < 75 + Non T2DM 
(n = 45) 
 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
ARU 458± 55.5 
430± 
76.5 
0.027 
483± 
78.8 
458± 
81.1 
0.114 
476± 
62.8 
470± 
78.0 
0.399 475± 58 
481± 
87.0 
0.690 
PRUz 322± 38.5 
260± 
59.4 
0.000 
305± 
47.1 
211± 
76.4 
0.000 
303± 
39.4 
257± 
68.8 
0.000 
313± 
58.8 
224± 
68.1 
0.000 
Platelet 
inhibition, 
% 
2.3± 6 
19.6± 
16.0 
0.000 
2.3± 
4.5 
29.6± 
23.7 
0.000 
2.6± 
4.2 
19.5± 
15.6 
0.000 3.8± 5.5 
29.0± 
20.1 
0.000 
 
Table 4.20 VerifyNow ® indices in Elderly stable CAD study 
*p<0.05 
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Age < 75 + T2DM 
(n = 41) 
 
Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
ARU 458±55.5 483±78.8 476±62.8 475±58 0.371 
PRUz 322±38.5 305±47.1 303±39.4 313±58.8 0.249 
Platelet inhibition, % 2.3±6 2.3±4.5 2.6±4.2 3.8±5.5 0.493 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
ARU 430±76.5 * 458±81.1 470±78.0 481±87 * 0.037 * 
PRUz 260±59.4 211±76.4 257±68.8 224±68.1 0.002 * 
Platelet inhibition, % 19.6±16.0 29.6±23.7 19.5±15.6 29.0±20.1 0.015 * 
Good responders, % 42.1 (16) 67.5 (27) * 36.4 (12) * 52.4 (22) 0.039 * 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 28, 3.4-53.1 25, -6.3-56.2 10, -14.1-34.7 -5.4, -33.0-22.0 0.273 
Delta PRUz  69, 52.7-85.6 105, 82.8-126.8 55, 40.4-69.4 96, 71.7-120.2 0.002 * 
Delta Platelet inhibition, % 17.8, 12.1-23.5 26.9, 20.2-33.6 14.6, 9.3-19.9 24.4, 18.2-30.7 0.016 * 
Table 4.21 Comparison of VerifyNow® platelet reactivity indices 
Post hoc analysis (One way ANOVA); *p<0.05 
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PRUz (Visit 2):  Age<75+Non T2DM vs Age<75+T2DM, P=0.008; Age<75+Non T2DM vs Age≥75+T2DM, P=0.013 
Platelet inhibition, %: Age<75+T2DM vs Age≥75+Non T2DM, p=0.039; Age≥75+T2DM vs Age≥75+Non T2DM, p=0.026 
Delta PRUz: Age<75+Non T2DM vs Age≥75+T2DM, p=0.005; Age≥75+T2DM vs Age≥75+Non T2DM, p=0.029 
Delta Platelet inhibition, %: Age<75+Non T2DM vs Age≥75+T2DM, p=0.028
216 
 
 
 
Figure 4.10 Changes in VerifyNow® indices 
*p<0.05 
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Figure 4.11 Percentage of good and hyporesponders to clopidogrel 
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Good 
responders to 
clopidogrel 
 
Age < 75 + T2DM 
(n = 16) 
 
 
Age < 75 + Non T2DM 
(n = 27) 
 
 
Age ≥ 75 + T2DM 
(n = 12) 
 
 
Age ≥ 75  + Non T2DM 
(n = 22) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
High shear 
thrombus area, 
µ2/mm 
15579± 
4650 
11338± 
4228 0.024 * 
15629± 
4968 
12422± 
4521 0.000 * 
18217± 
6227 
14332± 
5073 0.027 * 
17069± 
7575 
13537± 
4718 0.011 * 
Low shear 
thrombus area, 
µ2/mm 
9858± 
2259 
7177± 
1577 0.000 * 
9924± 
2821 
7910± 
2304 0.002 * 
9331± 
2087 
7405± 
1005 0.027 * 
9210± 
2546 
8831± 
1677 0.317 
ARU 
445± 
52.8 
422± 
89.5 
0.348 
488± 
79.5 
462± 
86.3 
0.259 
457± 
70.6 
460± 
88.0 
0.564 
475± 
65.6 
486± 
84.8 
0.615 
PRUz 
300± 
31.6 
202± 
37.9 
0.000 * 
302± 
49.8 
164± 
54.4 
0.000 * 
271± 
29.9 
177± 
30.1 
0.000 * 
312± 
75.8 
166± 
41.2 
0.000 * 
Platelet 
inhibition, % 
3.0± 
1.9 
30.9± 
16.3 
0.000 * 
2.6± 
5.0 
41.7± 
22.7 
0.000 * 
3.1± 
4.9 
38.1± 
10.7 
0.000 * 
4.7± 
6.6 
45.2± 
15.1 
0.000 * 
 
Table 4.22 Changes in thrombus area and VerifyNow® indices (good responders to clopidogrel) 
*p<0.05 
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Good responders to clopidogrel 
Age < 75 + 
T2DM (n = 16) 
Age < 75 + Non T2DM 
(n = 27) 
Age ≥ 75 + 
T2DM (n = 12) 
Age ≥ 75  + Non 
T2DM (n = 22) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
High shear thrombus area, µ2/mm 15579± 4650 15629± 4968 18217± 6227 17069± 7575 0.558 
Low shear thrombus area, µ2/mm 9858± 2259 9924± 2821 9331± 2087 9210± 2546 0.758 
ARU 445± 52.8 488± 79.5 457± 70.6 475± 65.6 0.226 
PRUz 300± 31.6 302± 49.8 271± 29.9 312± 75.8 0.230 
Platelet inhibition, % 3.0± 1.9 2.6± 5.0 3.1± 4.9 4.7± 6.6 0.665 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
High shear thrombus area, µ2/mm 11338± 4228 12422± 4521 14332± 5073 13537± 4718 0.337 
Low shear thrombus area, µ2/mm 7177± 1577 7910± 2304 7405± 1005 8831± 1677 0.064 
ARU 422± 89.5 462± 86.3 460± 88.0 486± 84.8 0.183 
PRUz 202± 37.9 164± 54.4 177± 30.1 166± 41.2 0.051 
Platelet inhibition, % 30.9± 16.3 41.7± 22.7 38.1± 10.7 45.2± 15.1 0.107 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 23, -27.4-73.2 27, -20.7-73.7 16, -42.4-73.5 -10, -53.0-32.1 0.630 
Delta PRUz 97, 70.2-124.4 138, 114.2-160.8 96, 74.2-118.5 146, 113.8-178.9 0.084 
Delta Platelet inhibition, % 29.1, 18.7-39.4 39.0, 31.1-46.9 34.7, 28.2-41.3 40.5, 33.9-47.1 0.206 
Table 4.23 Comparison of thrombus area and VerifyNow® indices (good responders to clopidogrel)                                                           
Post hoc analysis (One way ANOVA); *p<0.05 
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Hypo 
responders to 
clopidogrel 
 
Age < 75 + T2DM 
(n = 22) 
 
 
Age < 75 + Non T2DM 
(n = 13) 
 
 
Age ≥ 75 + T2DM 
(n = 21) 
 
 
Age ≥ 75  + Non T2DM 
(n = 20) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
High shear 
thrombus area, 
µ2/mm 
14321± 
5899 
12269± 
4164 
0.063 
 
16113± 
1820 
14809± 
1442 
0.370 
 
15113± 
6561 
12440± 
4637 
0.007 * 
 
17596± 
6101 
14484± 
5024 
0.012 * 
 
Low shear 
thrombus area, 
µ2/mm 
7983± 
2350 
6967± 
1794 
0.047 * 
 
10150± 
2471 
8460± 
2556 
0.047 * 
 
9661± 
2481 
8432± 
1897 
0.016 * 
 
10786± 
2545 
8926± 
2387 
0.007 * 
 
ARU 
472± 
58.0 
438± 
68.2 
0.022 * 
486± 
76.5 
463± 
84.4 
0.274 
492± 
54.6 
488± 
75.9 
0.841 
479± 
52.7 
488± 
81.8 
0.624 
PRUz 
344± 
30.5 
299± 
31.8 
0.000 * 
318± 
32.3 
281± 
36.4 
0.000 
317± 
31.8 
284± 
30.1 
0.000 * 
317± 
36.9 
276± 
27.8 
0.000 * 
Platelet 
inhibition, % 
1.3± 
3.7 
12.2± 
10.1 
0.000 * 
0.9± 
1.6 
11.5± 
8.9 
0.001 
1.9± 
3.6 
11.8± 
1.8 
0.000 * 
3.0± 
4.3 
14.1± 
9.3 
0.000 * 
 
Table 4.24 Changes in thrombus area and VerifyNow® indices (hyporesponders to clopidogrel) 
*p<0.05 
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Hypo responders to clopidogrel Age < 75 + T2DM 
(n = 22) 
Age < 75 + Non T2DM 
(n = 13) 
Age ≥ 75 + T2DM 
(n = 21) 
Age ≥ 75  + Non 
T2DM (n = 20) 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
High shear thrombus area, µ2/mm 14321± 5899 16113± 1820 15113± 6561 17596± 6101 0.390 
Low shear thrombus area, µ2/mm 7983± 2350* 10150± 2471 9661± 2481 10786± 2545* 0.009 * 
ARU 472± 58.0 486± 76.5 492± 54.6 479± 52.7 0.729 
PRUz 344± 30.5 318± 32.3 317± 31.8 317± 36.9 0.061 
Platelet inhibition, % 1.3± 3.7 0.9± 1.6 1.9± 3.6 3.0± 4.3 0.346 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
High shear thrombus area, µ2/mm 12269± 4164 14809± 1442 12440± 4637 14484± 5024 0.241 
Low shear thrombus area, µ2/mm 6967± 1794* 8460± 2556 8432± 1897 8926± 2387* 0.044 * 
ARU 438± 68.2 463± 84.4 488± 75.9 488± 81.8 0.126 
PRUz 299± 31.8 281± 36.4 284± 30.1 276± 27.8 0.135 
Platelet inhibition, % 12.2± 10.1 11.5± 8.9 11.8± 1.8 14.1± 9.3 0.830 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 34, 5.5-61.6 23, -20.8-66.9 4, -34.9-42.5 -9, -44.9-27.6 0.293 
Delta PRUz 48, 31.1-64.2 37, 23.7-50.0 33, 22.7-43.7 40, 26.3-54.5 0.435 
Delta Platelet inhibition, % 10.9, 5.7-16.1 10.7, 5.6-15.8 9.9, 6.3-13.5 11.2, 7.1-15.2 0.977 
Table 4.25 Comparison of thrombus area and VerifyNow® indices (hyporesponders to clopidogrel)                                           
Post hoc analysis (One way ANOVA); *p<0.05
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Correlation with ARU 
Rho (2-tailed p value) 
 
Correlation with PRUz 
Rho (2-tailed p value) 
BMI, Kg/m2 
-0.018 (0.911) 0.292 (0.105) 
Haemoglobin, g/dl 
-0.172 (0.289) -0.684 (0.000) * 
Platelet count x 1000 
cells/mm3 -0.085 (0.604) -0.094 (0.609) 
Fibrinogen, g/ml 
-0.292 (0.072) -0.343 (0.059) 
High shear thrombus 
area, µ2/mm -0.059 (0.449) -0.036 (0.663) 
Low shear thrombus 
area, µ2/mm -0.094 (0.247) 0.127 (0.140) 
R, min 0.081 (0.307) -0.021 (0.804) 
K, min 0.146 (0.066) -0.094 (0.264) 
MA, mm -0.138 (0.081) 0.054 (0.523) 
G Kdynes/sec -0.112 (0.157) 0.088 (0.298) 
CI -0.133 (0.093) 0.053 (0.527) 
MA-AA, mm 0.246 (0.002) * -0.001 (0.988) 
MA-ADP, mm -0.006 (0.940) 0.105 (0.218) 
% aggregation to AA 0.248 (0.002) * -0.055 (0.519) 
% aggregation to ADP 0.032 (0.689) 0.091 (0.287) 
Thrombin generation 
-0.016 (0.842) -0.046 (0.588) 
Maximum rate of 
thrombin generation, 
min 
-0.073 (0.362) -0.005 (0.951) 
Thrombus retraction, L 
parameter mm/min 0.136 (0.183) 0.031 (0.773) 
Maximum rate of 
thrombus retraction, 
min 
-0.067 (0.515) -0.020 (0.853) 
 
Table 4.26 Correlation: VerifyNow® and thrombus area, TEG®, Platelet 
Mapping™, V-curve data at baseline (visit 1) 
*p<0.05  
223 
 
 
  
Correlation with ARU 
Rho (2-tailed p value) 
 
Correlation with PRUz 
Rho (2-tailed p value) 
BMI, Kg/m2 
-0.083 (0.608) 0.025 (0.891) 
Haemoglobin, g/dl 
-0.242 (0.127) -0.649 (0.000) * 
Platelet count x 1000 
cells/mm3 0.144 (0.367) -0.020 (0.914) 
Fibrinogen, g/ml 
-0.028 (0.866) -0.076 (0.685) 
High shear thrombus 
area, µ2/mm -0.81 (0.317) -0.008 (0.916) 
Low shear thrombus 
area, µ2/mm -0.160 (0.053) 0.195 (0.018) * 
R, min 0.035 (0.662) -0.242 (0.002) * 
K, min 0.104 (0.194) -0.094 (0.239) 
MA, mm -0.089 (0.264) 0.030 (0.707) 
G Kdynes/sec -0.089 (0.264) 0.030 (0.710) 
CI -0.076 (0.340) 0.175 (0.027) * 
MA-AA, mm 0.186 (0.020) * 0.084 (0.295) 
MA-ADP, mm 0.090 (0.263) 0.181 (0.024) * 
% aggregation to AA 0.132 (0.101) 0.019 (0.811) 
% aggregation to ADP 0.149 (0.064) 0.225 (0.005) * 
Thrombin generation 
0.004 (0.964) -0.054 (0.521) 
Maximum rate of 
thrombin generation, 
min 
-0.157 (0.048) 0.035 (0.680) 
Thrombus retraction, L 
parameter mm/min 0.046 (0.629) -0.006 (0.950) 
Maximum rate of 
thrombus retraction, 
min 
-0.012 (0.900) -0.001 (0.996) 
 
Table 4.27 Correlation: VerifyNow® and thrombus area, TEG®, Platelet 
Mapping™, V-curve data at visit 2 
*p<0.05 
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Age<75 years vs. Age≥75 years 
I divided the study population as young (age<75 years) and elderly (age≥75 years) to 
assess the effect of age on clopidogrel response and platelet dependent thrombus 
formation.  
Demographic data and baseline characteristics of the patients who had their platelet 
functions measured using VerifyNow® remain the same as discussed in the earlier 
section (Table 4.4). 
Young patients (age<75 years) comprised of 43 good responders to clopidogrel 
(55.1%) compared to only 34 good responders (45.3%) in the elderly group (age≥75 
years). Percentage of hyporesponders to aspirin at baseline and after one week of 
clopidogrel is 26.7% vs. 24.1% in young patients and 36.5% vs. 38.4% in the elderly.  
The absolute mean PRUz value showed a significant reduction in both the groups after 
one week of clopidogrel therapy (age<75: 313±44.8 to 230±72.5, p<0.001; age≥75: 
308±50.6 to 240±70.0, p<0.001). Despite significant reduction in PRUz, the mean 
PRUz in the elderly group remained 240, establishing high platelet reactivity in the 
elderly population. Mean difference in PRUz (Mean, 95%CI) from visit 1 and visit 2 
were similar between the groups; Age≥75: 78.2, 62.6-93.7 and in Age<75: 89, 74.0-
103.0; p=0.952 (Table 4.28, Table 4.29). 
Despite being on long term aspirin therapy, there was a significant reduction in ARU 
from visit 1 to visit 2 in the younger population (mean±SD, 471±70.7 to 444±79.0; 
p=0.015) demonstrating improved platelet inhibition to aspirin after the addition of 
clopidogrel as a second antiplatelet agent. There was no change in ARU value in the 
elderly population after the addition of clopidogrel.  
Good responders to clopidogrel: 
I compared all the good responders to clopidogrel (mean PRUz < 240). There was a 
consistent reduction both in high shear (age<75: 15612± 4803 vs. 12052± 4401, 
p<0.01; age≥75: 17487± 7036 vs. 13826± 4786, p=0.001) and low shear thrombus 
area following one week of clopidogrel therapy. Mean PRUz was similar between the 
groups both at baseline (age<75 vs. age≥75: 301±43.5 vs. 298±66.7, p=0.845) and 
one week after clopidogrel therapy (179±51.8 vs. 169±37.5, p=0.402). Difference in 
PRUz from baseline to one week after clopidogrel (delta PRUz) were also similar 
225 
 
between the groups (mean, 95%CI: 89, 74.0-103.0 vs. 78.2, 62.6-93.7, p=0.952). 
Mean PRUz were much lower than the cut off of 240 in both the groups. There was a 
significant reduction in ARU from baseline to one week after clopidogrel therapy in the 
younger group (mean±SD: 471±70.7 to 444±79.0, p=0.015), but there was no change 
in the elderly group (Table 4.30, Table 4.31). 
Hyporesponders to clopidogrel: 
When hyporesponders to clopidogrel (mean PRUz ≥ 240) were compared, both 
younger (age<75) and elderly (age≥75) patients consistently demonstrated significant 
reduction in both high shear (age<75: 14987± 6120 to 13212± 4669, p=0.040; age≥75: 
16293± 6390 to 13411± 4873, p<0.001) and low shear thrombus area. Mean PRUz at 
baseline was significantly higher in patients with age<75 when compared to the elder 
group (334±33.3 vs. 317±34.0, p=0.032) but one week after clopidogrel therapy this 
difference was not significant (291±33.5 vs. 280±28.9, p=0.116). Difference in PRUz 
from baseline to one week after clopidogrel (delta PRUz) was numerically lower in the 
elderly group but this difference was not statistically significant (mean, 95%CI: 43.5, -
1-107 vs. 36.7, 0-109, p=0.323). Despite demonstrating significant reduction in PRUz, 
the mean PRUz remained ≥ 240 in both the groups indicating high platelet reactivity. 
There was a significant reduction in ARU from baseline to one week after clopidogrel 
therapy in the younger group (mean±SD: 477±65.7 to 448±74.5, p=0.012), but there 
was no change in the elderly group (Table 4.32, Table 4.33).  
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Age < 75 
(n = 87) 
 
 
Age ≥ 75 
(n = 86) 
 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
ARU 
 
471±70.7 444±79.0 0.015 * 476±59.9 476±82.6 0.879 
PRUz 
 
313±44.8 230±72.5 0.000 * 308±50.6 240±70.0 0.000 * 
Platelet 
inhibition, % 
 
2.2±5.2 25.8±21.2 0.000 * 3.2±4.9 
24.6±18.
6 
0.000 * 
 
Table 4.28 Changes in VerifyNow® indices (Age<75 vs. Age≥75) 
*p<0.05  
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Age < 75 
(n = 87) 
 
Age ≥ 75 
(n = 86) 
 
 
    P Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
 
ARU 
 
471±70.7 476±59.9 0.584 
PRUz 
 
313±44.8 308±50.6 0.531 
Platelet inhibition, % 
 
2.2±5.2 3.2±4.9 0.232 
 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
 
ARU 
 
444±79.0 476±82.6 0.016 * 
PRUz 
 
230±72.5 240±70.0 0.592 
Platelet inhibition, % 
 
25.8±21.2 24.6±18.6 0.896 
Good responders, % (n) 
 
55.1 (43) 45.3 (34) 0.259 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 
 
26, 4.9-47.1 -2, -21.9-17.7  0.836 
Delta PRUz 
 
89, 74.0-103.0 78.2, 62.6-93.7 0.952 
Delta Platelet inhibition, % 
 
24.7, 20.0-29.4 23.0, 18.9-27.1  0.532 
 
Table 4.29 Comparison of thrombus area and VerifyNow® indices (Age<75 
vs. Age≥75) 
*p<0.05 
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Figure 4.12 Changes in VerifyNow® indices (Age<75 vs. Age≥75) 
 
Top graph: ARU, aspirin platelet reactivity units 
Bottom graph: PRUz, clopidogrel platelet reactivity units 
* P<0.05 
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Good 
responders 
to clopidogrel 
 
Age < 75 
(n = 43) 
 
 
Age ≥ 75 
(n = 34) 
 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
High shear 
thrombus 
area, µ2/mm 
15612± 
4803 
12052± 
4401 
0.000 
17487± 
7036 
13826± 
4786 
0.001 
Low shear 
thrombus 
area, µ2/mm 
9900± 
2602 
7646± 
2081 
0.000 
9248± 
2379 
8386± 
1628 
0.022 
ARU 
 
472±73.2 447±88.6 0.140 469±66.7 471±80.7 0.912 
PRUz 
 
301±43.5 179±51.8 0.000 298±66.7 169±37.5 0.000 
Platelet 
inhibition, % 
 
2.8±6.0 
38.2±20.
9 
0.000 4.2±6.0 
42.8±14.
2 
0.000 
 
Table 4.30 Changes in thrombus area and VerifyNow® - good responders 
(Age<75 vs. Age≥75) 
*p<0.05 
 
 
 
 
 
 
 
 
  
230 
 
 
 
Good responders to 
clopidogrel 
 
Age < 75 
(n = 43) 
 
Age ≥ 75 
(n = 34) 
 
 
    P Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
15612±4803 17487±7036 0.197 
Low shear thrombus area, 
µ2/mm 
9900±2602 9248±2379 0.274 
ARU 
 
472±73.2 469±66.7 0.852 
PRUz 
 
301±43.5 298±66.7 0.845 
Platelet inhibition, % 
 
2.8±6.0 4.2±6.0 0.314 
 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
12052±4401 13826±4786 0.105 
Low shear thrombus area, 
µ2/mm 
7646±2081 8386±1628 0.098 
ARU 
 
447±88.6 471±80.7 0.145 
PRUz 
 
179±51.8 169±37.5 0.402 
Platelet inhibition, % 
 
38.2±20.9 42.8±14.2 0.213 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 
 
25.2, -206-249 -1.8, -193-201 0.249 
Delta PRUz 
 
122.6, 38-267 129.7, 54-373 0.628 
Delta Platelet inhibition, % 
 
35.5, -12-74 38.6, 10-74 0.426 
 
Table 4.31 Comparison of thrombus area and VerifyNow® - good responders 
(Age<75 vs. Age≥75) 
*p<0.05 
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Hypo 
responders 
to 
clopidogrel 
 
Age < 75 
(n = 35) 
 
 
Age ≥ 75 
(n = 41) 
 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
High shear 
thrombus 
area, µ2/mm 
14987± 
6120 
13212± 
4669 
0.040 
16293± 
6390 
13411± 
4873 
0.000 
Low shear 
thrombus 
area, µ2/mm 
8805± 
2584 
7551± 
2125 
0.004 
10224± 
2544 
8679± 
2141 
0.000 
ARU 
 
477±65.7 448±74.5 0.012 486±53.4 488±77.8 0.857 
PRUz 
 
334±33.3 291±33.5 0.000 317±34.0 280±28.9 0.000 
Platelet 
inhibition, % 
 
1.1±3.1 12.0±9.5 0.000 2.4±4.0 12.9±8.8 0.000 
 
Table 4.32 Thrombus area and VerifyNow® indices - hyporesponders 
(Age<75 vs. Age≥75) 
*p<0.05 
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Hypo responders to 
clopidogrel 
 
Age < 75 
(n = 35) 
 
Age ≥ 75 
(n = 41) 
 
 
    P Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
14987±6120 16293±6390 0.369 
Low shear thrombus area, 
µ2/mm 
8805±2584 10224±2544 0.029 
ARU 
 
477±65.7 486±53.4 0.543 
PRUz 
 
334±33.3 317±34.0 0.032 
Platelet inhibition, % 
 
1.1±3.1 2.4±4.0 0.119 
 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
13212±4669 13411±4873 0.858 
Low shear thrombus area, 
µ2/mm 
7551±2125 8679±2141 0.033 
ARU 
 
448±74.5 488±77.8 0.026 
PRUz 
 
291±33.5 280±28.9 0.116 
Platelet inhibition, % 
 
12.0±9.5 12.9±8.8 0.653 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 
 
29.5, -106-187 -2.3, -162-181 0.063 
Delta PRUz 
 
43.5, -1-107 36.7, 0-109 0.323 
Delta Platelet inhibition, % 
 
-10.8, -30-16 -10.5, -27-0 0.886 
 
Table 4.33 Thrombus area and VerifyNow® indices - hyporesponders 
(Age<75 vs. Age≥75) 
*p<0.05 
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T2DM vs. Non DM 
I divided the study population as T2DM and non DM to assess the effect of T2DM on 
clopidogrel response and platelet dependent thrombus formation.  
Demographic data and baseline characteristics of the patients who had their platelet 
functions measured using VerifyNow® remain the same as discussed in the earlier 
section (Table 4.7). 
T2DM group had only 28 good responders to clopidogrel (36.4%) compared to 49 good 
responders (63.6%) in the non DM group. Percentage of hyporesponders to aspirin at 
baseline and after one week of clopidogrel is 25.9% vs. 24.1% in T2DM patients and 
is 36.7% vs. 37.8% in non-DM patients. 
The absolute mean PRUz value showed a significant reduction in both the groups after 
one week of clopidogrel therapy (T2DM: 314±39.3 to 261±61.8, p<0.001; non DM: 
309±53.2 to 217±72.9, p<0.001). Despite significant reduction in PRUz, the mean 
PRUz in T2DM group remained 240, establishing high platelet reactivity in DM 
population. Mean difference in PRUz (Mean, 95%CI) from visit 1 and visit 2 were 
similar between the groups; T2DM: 63, 51.4-74.0 and in non DM: 100, 84.1-116.3; 
p<0.001 (Table 4.34, Table 4.35, Figure 4.13). 
Despite being on long term aspirin therapy, there was a numerical reduction in ARU 
from visit 1 to visit 2 in T2DM population (mean±SD: 466±60.0 to 448±76.0, p=0.055). 
Though this reduction was not statistically significant, it does demonstrate 
improvement in platelet inhibition by aspirin after the addition of clopidogrel. There was 
no significant change in ARU value in non DM group after the addition of clopidogrel.  
Good responders to clopidogrel: 
I compared all the good responders to clopidogrel (mean PRUz < 240). There was a 
consistent reduction both in high shear (T2DM: 16797± 5487 vs. 12720± 4789, 
p=0.001; non DM: 16259± 6212 vs. 12910± 4592, p<0.001) and low shear thrombus 
area following one week of clopidogrel therapy. Mean PRUz was similar between the 
groups at baseline (T2DM vs. non DM: 288±33.6 vs. 307±62.3, p=0.094) but after one 
week of clopidogrel therapy the PRUz in T2DM group remained significantly higher 
than non DM group (192±36.4 vs. 165±48.4, p=0.008), despite both the values being 
lower than the cut off of 240. Difference in PRUz from baseline to one week after 
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clopidogrel (delta PRUz) was significantly lower in T2DM compared to non DM (mean, 
95%CI: 99, 81-116 in T2DM vs. 141, 123-160 in non DM, p=0.001), suggesting better 
platelet inhibition in non-DM patients compared to T2DM patients despite both the 
groups being good responders to clopidogrel. Though there was a small numerical 
reduction in ARU from baseline to one week after clopidogrel therapy in both the 
groups, this was not significant (Table 4.36, Table 4.37). 
 
Hyporesponders to clopidogrel: 
When hyporesponders to clopidogrel (mean PRUz ≥ 240) were compared, both T2DM 
and non DM patients consistently demonstrated significant reduction in both high shear 
(T2DM: 14708± 6169 to 12352± 4349, p=0.001; non DM: 16994± 6231 to 14616± 
5015; p=0.011) and low shear thrombus area. Mean PRUz was similar at baseline and 
one week after clopidogrel therapy in both the groups.  Difference in PRUz from 
baseline to one week after clopidogrel (delta PRUz) was similar between the groups 
(mean, 95%CI: 40.4, -1-107 vs. 39.0, 0-109.0, p=0.831). Despite demonstrating 
significant reduction in PRUz, the mean PRUz after one week of clopidogrel therapy 
remained ≥ 240 in both the groups indicating high platelet reactivity (T2DM: 331±33.6 
to 290±30.8, p<0.001; non DM: 317±34.6 to 278±31.0, p<0.001). There was a small 
non-significant numerical reduction in ARU from baseline to one week after clopidogrel 
therapy in T2DM group (482±57.3 to 463±75.5, p=0.114) but in non DM group ARU 
remained unchanged (Table 4.38, Table 4.39). 
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T2DM 
(n = 83) 
 
 
Non DM 
(n = 90) 
 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
ARU 
 
466±60.0 448±76.0 0.055 479±68.9 469±84.4 0.351 
PRUz 
 
314±39.3 261±61.8 0.000 309±53.2 217±72.9 0.000 
Platelet 
inhibition, % 
 
2.3±5.1 18.9±15.1 0.000 3.0±5.1 
29.7±21.
9 
0.000 
 
Table 4.34 Changes in VerifyNow® indices (T2DM vs. Non-DM) 
*p<0.05 
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T2DM 
(n = 83) 
 
 
Non DM 
(n = 90) 
 
 
    P Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
 
ARU 
 
466±60.0 479±68.9 0.174 
PRUz 
 
314±39.3 309±53.2 0.594 
Platelet inhibition, % 
 
2.3±5.1 3.0±5.1 0.493 
 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
 
ARU 
 
448±76.0 469±84.4 0.144 
PRUz 
 
261±61.8 217±72.9 0.000 
Platelet inhibition, % 
 
18.9±15.1 29.7±21.9 0.001 
Good responders, % (n) 
 
36.4 (28) 63.6 (49) 0.009 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 
 
18, -1.6-40.0 7, -13.9-28.8  0.027 
Delta PRUz 
 
63, 51.4-74.0 100, 84.1-116.3  0.000 
Delta Platelet inhibition, % 
 
18.7, 14.7-22.6 28.1, 23.7-32.6 0.013 
 
Table 4.35 Comparison of thrombus area and VerifyNow® (T2DM vs. Non-
DM) 
*p<0.05 
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Figure 4.13 Changes in VerifyNow® indices (T2DM vs. Non-DM) 
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Good 
responders 
to 
clopidogrel 
 
T2DM 
(n = 28) 
 
 
Non DM 
(n = 49) 
 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
High shear 
thrombus 
area, µ2/mm 
16797± 
5487 
12720± 
4789 
0.001 
16259± 
6212 
12910± 
4592 
0.000 
Low shear 
thrombus 
area, µ2/mm 
9639± 
2159 
7272± 
1347 
0.000 
9590± 
2691 
8341± 
2067 
0.001 
ARU 
 
450±59.7 438±89.3 0.259 483±73.1 473±85.6 0.531 
PRUz 
 
288±33.6 192±36.4 0.000 307±62.3 165±48.4 0.000 
Platelet 
inhibition, % 
 
3.0±6.5 34.0±14.4 0.000 3.6±5.8 
43.3±19.
6 
0.000 
 
Table 4.36 Thrombus area and VerifyNow® indices - good responders 
(T2DM vs. Non-DM) 
*p<0.05 
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Good responders to 
clopidogrel 
 
T2DM 
(n = 28) 
 
Non DM 
(n = 49) 
 
 
    P Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
16797±5487 16259±6212 0.703 
Low shear thrombus area, 
µ2/mm 
9639±2159 9590±2691 0.934 
ARU 
 
450±59.7 483±73.1 0.041 
PRUz 
 
288±33.6 307±62.3 0.094 
Platelet inhibition, % 
 
3.0±6.5 3.6±5.8 0.728 
 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
12720±4789 12910±4592 0.869 
Low shear thrombus area, 
µ2/mm 
7272±1347 8341±2067 0.011 
ARU 
 
438±89.3 473±85.6 0.105 
PRUz 
 
192±36.4 165±48.4 0.008 
Platelet inhibition, % 
 
34.0±14.4 43.3±19.6 0.020 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 
 
14.2, -21-49 9.9, -22-42 0.670 
Delta PRUz 
 
99, 81-116 141, 123-160 0.001 
Delta Platelet inhibition, % 
 
-32, -37.7- -31.5 -40, -44.8- 34.6 0.042 
 
Table 4.37 Thrombus area and VerifyNow® indices - good responders 
(T2DM vs. Non-DM) 
*p<0.05 
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Hypo 
responders 
to 
clopidogrel 
 
T2DM 
(n = 43) 
 
 
Non DM 
(n = 33) 
 
Mean ± SD Visit 1 Visit 2 P Value Visit 1 Visit 2 P Value 
High shear 
thrombus 
area, µ2/mm 
14708± 
6169 
12352± 
4349 
0.001 
16994± 
6231 
14616± 
5015 
0.011 
Low shear 
thrombus 
area, µ2/mm 
8845± 
2532 
7724± 
1915 
0.001 
10553± 
2495 
8755± 
2417 
0.001 
ARU 
 
482±57.3 463±75.5 0.114 482±62.1 478±82.4 0.773 
PRUz 
 
331±33.6 290±30.8 0.000 317±34.6 278±31.0 0.000 
Platelet 
inhibition, % 
 
1.6±3.6 12.0±9.2 0.000 2.1±3.6 13.1±9.1 0.000 
 
Table 4.38 VerifyNow® indices - hyporesponders (T2DM vs. Non-DM) 
*p<0.05 
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Hypo responders to 
clopidogrel 
 
T2DM 
(n = 43) 
 
Non DM 
(n = 33) 
 
 
    P Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
14708±6169 16994±6231 0.119 
Low shear thrombus area, 
µ2/mm 
8845±2532 10553±2495 0.007 
ARU 
 
482±57.3 482±62.1 0.961 
PRUz 
 
331±33.6 317±34.6 0.097 
Platelet inhibition, % 
 
1.6±3.6 2.1±3.6 0.540 
 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
 
High shear thrombus area, 
µ2/mm 
16994±6231 14616±5015 0.045 
Low shear thrombus area, 
µ2/mm 
10553±2495 8755±2417 0.060 
ARU 
 
463±75.5 478±82.4 0.410 
PRUz 
 
290±30.8 278±31.0 0.073 
Platelet inhibition, % 
 
12.0±9.2 13.1±9.1 0.615 
Difference in variables between Visit 1 and Visit 2 
Mean change, 95% CI 
Delta ARU 
 
18.6, -162-181 3.8, -137-187 0.403 
Delta PRUz 
 
40.4, -1-107 39.0, 0-109.0 0.831 
Delta Platelet inhibition, % 
 
-10.4, -30-16 -11.0, -27.0-0 0.795 
 
Table 4.39 Thrombus area and VerifyNow® - hyporesponders (T2DM vs. 
Non-DM) 
*p<0.05 
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4.3.2 Discussion – platelet reactivity indices 
In my study, baseline (on aspirin alone) PRUz was similar in elderly (age≥75) and 
young patients (age<75), with or without T2DM. My study demonstrated a significant 
reduction in PRUz in elderly and young, again in patients with and without T2DM, after 
one week of clopidogrel (75mg daily) alongside aspirin (75 mg daily). Good response 
to clopidogrel was defined based on PRUz cut off of <240 units. Despite a significant 
reduction, mean PRUz remained significantly higher (≥240 U) both in elderly and young 
patients with T2DM when compared to non-diabetic individuals. This is the first study 
to compare VerifyNow indices with platelet dependent thrombus (PDT) from Badimon 
chamber (mimicking rheological flow conditions in moderately stenosed coronary 
arteries). This comparison of point of care platelet reactivity indices to ex-vivo whole 
blood thrombus generation is novel and will certainly be helpful in further exploring the 
use of these indices in the clinical setting to tailor antiplatelet therapy. 
When comparing elderly and young patients, only 45.3% of elderly patients were good 
responders to clopidogrel versus 55.1% of young patients. PRUz was numerically 
higher in elderly cohort compared to the young. It is not surprising to see that there 
was a significant reduction in thrombus (measured as total thrombus area) among 
good responders to clopidogrel both in elderly and young cohort. Interestingly, my 
study has demonstrated a significant reduction in thrombus even among hypo 
responders to clopidogrel (PRUz ≥240 U), in elderly and young patients, with or without 
T2DM. This demonstrates that clopidogrel reduces thrombus formation despite high 
platelet reactivity as defined by VerifyNow cut off (PRUz ≥ 240 U). 
When patients with T2DM were compared with non-diabetic individuals, only 36.4% 
were good responders in T2DM cohort versus 63.6% among non-diabetic. Mean PRUz 
among T2DM remained well above the cut off 240 U and was less than 240 U among 
non-DM. There was a significant reduction in thrombus area among good responders 
as well as hyporesponders to clopidogrel. Among good responders to clopidogrel, 
PRUz in T2DM remained significantly higher compared to non-diabetic individuals. 
Haemoglobin levels negatively correlated with mean PRUz. This is the first study where 
thrombus area determined by Badimon chamber and TEG® parameters were 
compared to VerifyNow® data. There was a good correlation in the assessment of 
clopidogrel response by both the studies (MA-ADP and PRUz) after a week of 
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clopidogrel therapy. PRUz had a positive correlation with low shear thrombus but did 
not demonstrate any correlation with high shear thrombus. 
Overall, data from my study confirm that on treatment platelet reactivity to clopidogrel 
as measured by PRUz has high variability in elderly patients and in the presence of 
T2DM. Mean PRUz value was numerically higher in elderly when compared to the 
young at 240 U, demonstrating high on-treatment platelet reactivity in the elderly 
cohort. Mean PRUz values were higher in patients with T2DM when compared to non-
diabetic individuals, among both good responders and hypo responders. Even in hypo 
responders, there was a significant reduction in thrombus formation, both in elderly 
and young patients, with or without TDM. Antiplatelet response measured using TEG® 
(MA-ADP) correlated with the corresponding measures using VerifyNow (PRUz). 
Haemoglobin had a negative correlation with mean PRUz. VerifyNow® has been 
shown to be more reliable than TEG® in measuring responsiveness to antiplatelet 
therapy (Madsen et al., 2010). Blais et al measured platelet reactivity using five 
different platelet function testing methods, before and one week after aspirin therapy. 
In this study TEG-PM showed higher prevalence of aspirin resistance compared to 
VerifyNow (Blais et al., 2009).    
The routine use of VerifyNow in clinical practice to guide the choice and monitoring of 
antiplatelet therapy in patients with CAD has been evaluated in a number of studies. 
The work of Silvain et al, SENIOR-PLATELET study conducted in patients who 
underwent coronary stent insertion, supported “age” as a factor independently 
influencing platelet reactivity during clopidogrel therapy alongside aspirin for ≥14 days. 
They also reported that the elderly patients had significantly higher platelet reactivity 
compared to young. In addition, the prevalence of high on-treatment platelet reactivity 
(HPR) was higher in the elderly whilst on clopidogrel and aspirin. In patients treated 
with 150 mg clopidogrel or 10 mg prasugrel, there was a trend towards higher platelet 
reactivity in the elderly compared to the young but this was not statistically significant 
(Silvain et al., 2012). The discrepancy between the frequency of HPR reported in this 
study and others during prasugrel therapy may be related to the difference in treatment 
cohort - all ST-elevation myocardial infarction (STEMI) patients (see below). SENIOR-
PLATELET study supports previous observations of the limited effectiveness of high-
dose clopidogrel in overcoming high platelet reactivity (HPR) and the continued 
presence of high activity in acute coronary syndrome (ACS) patients treated with 
prasugrel (Michelson et al., 2009; Price et al., 2011a). The authors suggested that age 
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integrates several factors affecting clopidogrel metabolism, resulting in a higher 
prevalence of HPR. In their multivariate analysis, age was an independent predictor of 
HPR. 
The report of Silvain et al is not the first evidence that platelet physiology is influenced 
by age during clopidogrel therapy. In a genome-wide association study in healthy 
subjects, increasing age was a significant factor for clopidogrel response (3.8% of 
variance, p=0.001) (Shuldiner et al., 2009). In recent large translational studies, old 
age (defined as ≥65 or 75 years) was associated with high on-treatment platelet 
reactivity to ADP and also adverse ischaemic outcomes (Breet et al., 2010; Price et 
al., 2011a). However, the latter studies were not specifically designed to explore the 
influence of age on platelet reactivity.  
Higher baseline pre-treatment platelet reactivity has been associated with higher post-
treatment reactivity especially in the elderly (Gurbel et al., 2003). However, no actual 
baseline platelet function measurements were made and the authors acknowledged 
this limitation. P2Y12 modulates the response to all agonists including TRAP that 
degranulate the platelet. Hence including baseline TRAP measurement as pre-
treatment assessment of platelet function is not entirely correct. Therefore, the 
response to clopidogrel was not truly measured in this study. Therefore, the conclusion 
that elderly patients demonstrate an impaired ‘response’ to clopidogrel cannot be 
substantiated, although is implied by the data.  
In large-scale ACS trials, the elderly patients have high ischaemic events despite 
treatment with more potent P2Y12 inhibitors. In the TRITON trial, patients aged ≥75 
years (13% of the total population) had a 17.3% vs. 18.3% primary end-point compared 
with 8.1% vs. 10.6% in those < 65 years old during prasugrel vs. clopidogrel therapy, 
respectively (Wiviott et al., 2007a). In Silvain’s study, prasugrel (10 mg) was only 
administered to STEMI patients or diabetic patients presenting with non-STEMI. The 
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients 
with Unstable Angina/Non-STEMI states that prasugrel therapy may be considered in 
patients’ ≥75 years of age who have ‘high risk’ situations: diabetes or prior myocardial 
infarction (Wright et al., 2011).  
STEMI, diabetes, and prior infarction are considered ‘high risk’ situations possibly due 
to HPR. Now we have further evidence that age is another ‘high risk’ component partly 
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due to a high prevalence of HPR. In this situation, it would be expected that the most 
pharmacodynamically effective agent would be associated with the greatest reduction 
in primary efficacy endpoint occurrence. However, this hypothesis is not supported by 
the data: in ACS setting ≥75 years of age (15% of the total population) had a 16.8% 
vs. 18.3% primary endpoint compared with 8.6% vs.10.4% in those < 75 years of age 
during ticagrelor vs. clopidogrel therapy, respectively (Wallentin et al., 2009). 
The majority of studies have shown adequate platelet inhibition post clopidogrel 
therapy in 20-25% of cohort, both in ACS and stable CAD setting. My study has 
demonstrated variable platelet inhibition with adequate inhibition in 36-64% among the 
stable CAD cohort. Difficulty in comparing data from various studies arises due to the 
differences in study design, varying dosage regimens, different baseline characteristics 
and clinical settings. Emerging data also suggest the association between low PRU 
and the risk of bleeding. International cardiac societies have therefore not included 
VerifyNow or other platelet reactivity indices as a routine standard of care in patients 
with CAD, except in high risk setting like post PCI stent thrombosis (ST) or recurrent 
ischaemic events following PCI despite DAPT (Bonello et al., 2010; Tantry et al., 2013). 
In addition to the occurrence of a greater number of ischaemic events, the elderly also 
have more frequent serious bleeding. Personalized antiplatelet therapy may have a 
significant clinical impact in the elderly given their overall high prevalence of treatment 
failure (ischaemia + bleeding). An interesting observation in Silvain’s study was the low 
prevalence of low PRUz (<30) in elderly patients treated with thienopyridines.  
Numerous studies have demonstrated an association between platelet reactivity on 
clopidogrel and cardiovascular events after coronary intervention and stent insertion. 
VerifyNow has been used to measure on-treatment platelet reactivity and several 
prospective observational studies have proposed optimal cut offs to identify high-risk 
patients. Migliorini et al identified PRUz value ≥240 as the only independent predictor 
of cardiac death (HR, 3.29; 95% CI, 1.16 to 9.37; p=0.025) and ST (HR, 3.44; 95% CI, 
1.01 to 11.80; P=0.049) (Migliorini et al., 2009). In the Gauging Responsiveness with 
A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 
patients with PRU ≥230 U after PCI were treated with high-dose clopidogrel (150mg) 
instead of 75mg once daily. At 6 months, high-dose clopidogrel demonstrated a 
variable and modest pharmacodynamic effect but did not reduce the risk of CV death, 
MI and ST compared with standard-dose clopidogrel. After adjustment for other risk 
factors and significant predictors associated with adverse outcomes, PRUz <208 units 
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was significantly and independently associated with a markedly lower risk of the 
primary end point at 60-day follow-up (adjusted HR, 0.23; 95% CI, 0.05 to 0.98; 
P=0.047) and at 6 months (HR, 0.53; 95% CI, 0.28 to 1.04; P=0.06). It was also 
observed that, PRU <230 units was not significantly associated with the risk of the 
primary end point and this was consistent with the primary results of the trial. The 
analysis incorporated the dynamic characteristics of platelet reactivity by evaluating 
on-treatment reactivity as a time-varying covariate and supported the independent 
prognostic value of serial platelet function test post coronary intervention (Price et al., 
2009; Price et al., 2011a).  
These observations have important implications regarding the prognostic utility of 
platelet function testing and the identification of clinically effective strategies for 
individualized P2Y12 antagonist therapy. The attenuation in the association between 
reactivity and clinical outcome over longer-term follow-up could be due to ongoing 
variability in reactivity that weakened the relationship between the reactivity measured 
at 30-day follow-up and the actual reactivity at later time points. In addition, it has been 
suggested that platelet inhibition has greatest influence on cardiovascular events in 
the early post-PCI period. The influence of other clinical characteristics associated with 
longer-term outcome on the risk related to on-treatment reactivity also cannot be 
excluded. 
A randomized pharmacodynamic study, SWitching Anti Platelet (SWAP) study 
demonstrated that switching patients with HPR after an ACS from clopidogrel to 
prasugrel resulted in earlier and better platelet inhibition (Angiolillo et al., 2010). Similar 
effects were demonstrate with ticagrelor in patients who had HPR whilst on clopidogrel. 
Ticagrelor reduced PRU levels to <235 units among both good and hyporesponders to 
clopidogrel (Gurbel et al., 2010a). 
Assessment with a double Randomization of (1) a fixed dose versus a monitoring-
guided dose of aspirin and Clopidogrel after DES implantation, and (2) Treatment 
Interruption versus Continuation, 1 year after stenting (ARCTIC) trial, studied the role 
of routine platelet function testing and dose adjustment of clopidogrel in those with 
HPR. In this trial 2440 patients scheduled for elective coronary stenting were randomly 
assigned to a strategy of VerifyNow P2Y12 and aspirin point-of-care platelet-function 
monitoring, with drug adjustment in patients who had a poor response to antiplatelet 
therapy, or to a conventional strategy without monitoring and drug adjustment. In the 
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monitoring group, HPR in patients taking clopidogrel (34.5% of patients, using a cut off 
of PRUz 208) or aspirin (7.6% of patients, using a cut off of ARU 550) led to the 
administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with gp 
IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the 
patients in the monitoring group, as compared with 31.1% of those in the conventional-
treatment group (hazard ratio, 1.13; 95% CI, 0.98 to 1.29; P=0.10). The main 
secondary end point, stent thrombosis or any urgent revascularization, occurred in 
4.9% of the patients in the monitoring group and 4.6% of those in the conventional-
treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major 
bleeding events did not differ significantly between groups. This study did not 
demonstrate any significant improvement in clinical outcomes with platelet-function 
monitoring and treatment adjustment for coronary stenting, as compared with standard 
antiplatelet therapy without monitoring (Collet et al., 2011). 
Assessment of Dual AntiPlatelet Therapy with Drug Eluting Stents) ADAPT-DES study, 
demonstrated that among 8582 patients who entered the study, 42.7% patients had 
HPR (PRU >208). Rate of ST was higher in patients with HPR after clopidogrel therapy 
(1.3% vs. 0.5%; HR, 2.54; 95% CI, 1.55-4.16; p=0.0002) but clinically relevant bleeding 
events were lower (5.6% vs. 6.7%; HR, 0.73; 95% CI, 0.61-0.89; p=0.002). Incidence 
of acute MI was higher in these patients (3.9% vs. 2.7%; p=0.01).  One year mortality 
was again higher in patients with HPR after clopidogrel therapy (2.4% vs. 1.5%; 
p=0.002). By multivariable analysis, ST, MI, and clinically relevant bleeding were all 
strongly associated with all-cause mortality through 1-year follow-up but HPR was not 
independently related to mortality (Stone et al., 2013). 
Brar et al performed a meta-analysis of 6 studies and demonstrated that on a 
continuous scale, every 10 U increase in PRU was associated with a significantly 
higher rate of the primary endpoint death, MI or ST (HR: 1.04; 95% CI: 1.03-1.06; p < 
0.0001). A PRU value ≥230 was associated with a higher rate of the composite primary 
endpoint (HR: 2.10; 95% CI: 1.62-2.73; p < 0.0001), as well as the individual endpoints 
of death (HR: 1.66; 95% CI: 1.04-2.68; p = 0.04), MI (HR: 2.04; 95% CI: 1.51-2.76; p 
< 0.001), and stent thrombosis (HR: 3.11; 95% CI: 1.50-6.46; p = 0.002). These 
findings suggest that VerifyNow might help in predicting short or medium CAD risk up 
to 1 year in patients undergoing coronary intervention, but not after 2 years (Brar et al., 
2011).   
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Park et al demonstrated a substantial interaction between platelet reactivity on 
clopidogrel and clinical presentations on cardiovascular events after PCI. The major 
findings of this study are that (1) in patients undergoing PCI for ACS, HPR on 
clopidogrel was independently associated with increased risks of primary end point 
(HR, 2.03; 95% CI, 1.30-3.18; p=0.002) and mortality (HR, 3.46; 95% CI, 1.18-10.18; 
p=0.02), whereas in patients with stable CAD, HPR did not significantly affect clinical 
outcomes, and (2) a significant interaction was present between HPR status and 
clinical presentations on the adjusted risks of the primary end point (p=0.02) mortality 
(p=0.04) (Park et al., 2012). 
In contrast to clopidogrel, aspirin induced platelet inhibition as measured by ARU units 
demonstrated less variability in young patients and in patients with T2DM. In my study, 
baseline (on aspirin alone) ARU were similar in elderly (age≥75) and young patients 
(age<75), with or without T2DM. ARU was numerically higher in the elderly cohort 
compared to the young. In young patients, there was a significant reduction in ARU 
after the addition of clopidogrel both among good and hyporesponders, a finding 
similar to the results from TEG®. This enhanced response to aspirin was not seen in 
the elderly cohort. In patients with T2DM there was a numerical reduction in ARU after 
adding clopidogrel to aspirin but this reduction was not statistically significant. This 
enhanced aspirin response was not seen in non-DM cohort. This non-significant 
reduction in ARU was also present among the cohort of patients who were 
hyporesponders with T2DM. Antiplatelet response to aspirin measured using TEG® 
(MA-AA) demonstrated a good correlation with the corresponding measures using 
VerifyNow (ARU). Nielson et al performed a small study with healthy volunteers and 
stable CAD in which all the patients were found to be good responders to aspirin using 
an ARU cut off of ≥550 (Nielsen et al., 2008). In a small study with 201 stable CAD 
patients, platelet function tests varied significantly in measuring aspirin's antiplatelet 
effect and they correlated poorly amongst themselves (Lordkipanidzé et al., 2007). In 
a large cohort of patients with stable CAD, age was independently correlated with 
reduced on-treatment aspirin responsiveness, determined using the VerifyNow Aspirin 
assay. Furthermore, patients aged ≥75 years exhibited higher mean ARU (450 ± 54 
vs. 434 ± 53; p = 0.0007) and higher rates of aspirin resistance (19% vs 11%; p = 
0.009) using an ARU cut off of ≥500 than patients aged <75 years. Older patients also 
consistently demonstrated higher platelet aggregation values than younger patients 
(Vaturi et al., 2013).  
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Early prospective studies have suggested age as a potential risk factor in increasing 
incidence of aspirin resistance. There are several potential mechanisms by which age 
may modulate responsiveness to aspirin. First, it has been proposed that the high co-
morbid disease burden in older patients may play a role. It has been demonstrated 
already that metabolic risk factors may be related to aspirin resistance in healthy 
subjects (Vaduganathan et al., 2008). Second, platelet-level changes may occur in 
older patients that may predispose them to aspirin resistance. In addition, older 
patients may have enhanced basal platelet reactivity before aspirin exposure, which 
has been shown to be an important determinant of on-treatment platelet reactivity 
(Frelinger et al., 2006). Significant microvascular dysfunction may also occur in these 
patients, with reductions in nitric oxide synthesis, impaired platelet responsiveness to 
vasoactive agents, and increased formation of platelet-monocyte aggregates 
(Goubareva et al., 2007). Finally, increased platelet turnover in this population, 
possibly related to advanced atherosclerotic disease, may contribute to impaired 
responses to aspirin (Cesari et al., 2008). 
Stable CAD patients with T2DM, treated with low dose aspirin (81mg daily) exhibited 
higher aspirin resistance (ARU levels), higher ADP- and collagen-induced platelet 
aggregation and serum thromboxane levels than nondiabetic patients. Increased 
aspirin dosing resulted in similar reductions in resistance and platelet function levels 
between groups. These findings indicate that patients with T2DM exhibit a global high 
platelet reactivity phenotype that may be partially overcome by higher aspirin doses 
(DiChiara et al., 2007).  
Grove et al performed a comprehensive comparison of light transmission 
aggregometry (LTA), multiple electrode aggregometry (MEA), VerifyNow® Aspirin and 
urinary and serum thromboxane metabolites. Each of these tests were performed 8–
10 times in healthy individuals and patients with CAD to evaluate the repeatability and 
concordance between these tests. This study demonstrated VerifyNow® Aspirin assay 
as the most reproducible test, and which had the strongest correlation with LTA. 
Furthermore, VerifyNow also demonstrated significant positive correlation with serum 
thromboxane levels, which is the most specific way to evaluate the pharmacological 
effect of aspirin on platelets (Grove et al., 2010). However, my study did not show any 
correlation between ARU and thrombus area implying that ARU levels are a poor 
marker of thrombogenicity in those on aspirin. Except for a positive correlation between 
PRUz and low shear thrombus no significant association between PRUz or ARU and 
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thrombus has been demonstrated. This highlights the point that platelet reactivity 
indices using VerifyNow® is not useful in predicting thrombogenicity or future 
atherothrombotic risk in patients with stable CAD.  
We desperately need a better understanding of how on-treatment platelet reactivity is 
related to thrombotic and bleeding events especially in the elderly population. Platelet 
function studies of adequate number have never been conducted in large-scale ACS 
trials to provide this answer. At this time, dedicated pharmacodynamic and clinical 
endpoint trials in the elderly specifically to address the issue of antiplatelet therapy are 
warranted. An individualized antiplatelet strategy based on serial platelet function 
testing merits investigation.
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4.4 Multiplate® (Impedance aggregometry) - Elderly stable CAD study  
4.4.1 Results – platelet reactivity indices 
Baseline characteristics of the patients in all the four groups who had their platelet 
reactivity indices measured remain the same as discussed in the earlier section (Table 
4.40). Published ADP AU cut-off value of 460 AU was used to classify patients as on 
treatment high platelet reactivity (hyporesponders). Patients with ADP AU<460 were 
classified as good responders to clopidogrel. Elderly T2DM group had the least number 
of good responders to clopidogrel, 17 patients (45.9%) and elderly non-diabetic group 
had the highest number of good responders, 29 patients (64.4%). 
The absolute mean ADP AU was significantly lower in all the four groups after one 
week of clopidogrel therapy [median (IQR); young T2DM: 672 (552-941) to 452 (291-
676), p=0.002; young non-diabetic: 822 (726-989) to 461 (268-626), p<0.001; elderly 
T2DM: 769 (653-974) to 488 (310-638), p<0.001; elderly non-diabetic: 762 (589-1012) 
to 386 (271-559), p<0.001]. Despite significant reduction in ADP AU, the mean AU in 
elderly T2DM group [488 (310-638)] still remained ≥460, establishing high platelet 
reactivity in the elderly diabetic population. In contrast, ADP AU was lowest in elderly 
non-diabetic group [386 (271-559)] after one week of clopidogrel treatment. Similar 
trends were seen with ASP AU, collagen AU and TRAP AU in young non-diabetics and 
older group (both T2DM and non-diabetic). These reductions were not demonstrated 
in the young T2DM group (Table 4.41, Table 4.42, Figure 4.14). 
Despite being on long term aspirin therapy, it is interesting to note a significant 
reduction in ASP AU from visit 1 to visit 2 in the older population both in T2DM and non 
DM group and in younger non-diabetic group. This demonstrates improved platelet 
inhibition to aspirin after the addition of clopidogrel as a second antiplatelet agent. With 
VerifyNow this improved platelet inhibition was demonstrated in the younger group 
(both T2DM and non DM group), but Multiplate has demonstrated improved platelet 
inhibition in the elderly group (both T2DM and non DM group) and the young non DM 
group after the addition of clopidogrel. The percentage of good responders to aspirin 
increased after addition of clopidogrel in all four groups (young T2DM: 60% to 86.7%; 
young non-diabetic: 53.3% to 88.6%; old T2DM: 64.9% to 89.5%; old non-diabetic: 
74.6% to 86.7%). 
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Good responders to clopidogrel: 
I compared all the good responders to clopidogrel (mean ADP AU < 460) from all the 
four groups. There was a consistent reduction both in high shear [median (IQR); 
age<75+T2DM: 13910 (8699-15594) to 10489 (7884-12106), p=0.022; age<75+non 
DM: 133323 (11210-18031) to 10942 (9373-13024), p=0.001; age≥75+T2DM: 15727 
(9033-20021) to 11639 (8885-15453), p=0.041; age≥75+non DM: 17119 (11616-
20464) to 13007 (8997-16029), p<0.001] and low shear thrombus area following one 
week of clopidogrel therapy. There was a significant reduction in ASP AU, Collagen 
AU and TRAP AU in young non DM group and in the elderly group (both T2DM and 
non DM) as shown in Table. Young T2DM group did not demonstrate these reductions 
(Table 4.43, Table 4.44, Table 4.45). 
Hyporesponders to clopidogrel: 
When hyporesponders to clopidogrel (mean PRUz ≥ 460) were compared, elderly non 
DM group demonstrated a numerical reduction in high shear thrombus area but this 
was not statistically significant [20387 (9947-27810) to 17565 (10728-21318), 
p=0.064]. All the other groups demonstrated significant reduction in thrombus area 
after one week of clopidogrel therapy [median (IQR); age<75+T2DM: 17451 (14577-
18868) to 12295 (10272-16639), p=0.045; age<75+non DM: 16723 (11295-20299) to 
12953 (11031-18355), p=0.021; age≥75+T2DM: 16411 (10454-19644) to 14069 
(8705-15999), p=0.002]. All the four groups demonstrated significant reduction in 
PRUz but the mean ADP AU remained well above the cut off 460 (Table 4.46, Table 
4.47, Table 4.48). 
At baseline when patients were on aspirin alone, high shear thrombus area 
demonstrated a significant positive correlation with ADP AU (rho=0.191; p=0.025) and 
TRAP AU (rho=0.199; p=0.019). The parameters which measured aspirin induced 
platelet inhibition using TEG®, MA-AA and percentage aggregation to AA, correlated 
positively with ASP AU (aspirin induced platelet inhibition measurement using 
Multiplate®) (rho=0.452; p<0.001 and rho=0.425; p<0.001 respectively). MA-ADP 
correlated positively with ADP AU and Collagen AU. ARU and PRUz measured using 
VerifyNow correlated positively with ASU AU and ADP AU respectively (rho=0.309; 
p<0.001 and rho=0.183; p=0.040 respectively). Thrombin generation (TG) and 
maximum rate of thrombin generation (MRTG) demonstrated significant positive 
correlation with ADP AU, Collagen AU and TRAP AU (Table). Standard TEG 
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parameters R and K, demonstrated negative correlation with ADP AU, Collagen AU 
and TRAP AU whereas MA, G and CI demonstrated positive correlation with Multiplate 
indices (Figure 4.15). 
After a week of clopidogrel therapy, high shear thrombus area continued to 
demonstrate a positive correlation with ADP AU (rho=0.170; p=0.046) and TRAP AU 
(rho=0.216; p=0.011). MA-AA correlated positively with ASP AU (rho=0.508; p<0.001), 
ADP AU (rho=0.180; p=0.033) and Collagen AU (rho=0.207; p=0.013) and percentage 
aggregation to AA correlated with ASP AU. MA-ADP correlated positively with ADP 
AU, Collagen AU and TRAP AU. ARU and PRUz measured using VerifyNow correlated 
positively with ASU AU and ADP AU respectively (rho=0.193; p=0.022 and rho=0.438; 
p<0.001 respectively). TG and MRTG demonstrated significant positive correlation 
with ADP AU and TRAP AU (Table). Correlation between standard TEG parameters 
with Multiplate indices (ADP AU, Collagen AU and TRAP AU) remained significant after 
the addition of clopidogrel (Figure 4.16, Figure 4.17).
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Age < 75 + T2DM 
(n = 15) 
 
Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 64.1 ± 7.6 63 ± 7.3 78.6 ± 3.2 79.0 ± 3.7  
Male gender, % ( n ) 86.7 (13) 68.9 (31) 80.5 (33) 71.1 (32) 0.361 
Body mass index, kg/m2 33.0 ± 4.5 29.6 ± 3.7 29.1 ± 5.0 27.8 ± 3.6 0.001 
Waist to hip ratio 1.0 ± 0.1* 1.0 ± 0.2 1.0 ± 0.1 0.9 ± 0.1* 0.030* 
Heart rate, beats  per minute 72 ± 11* 62 ± 11* 68 ± 14 64 ± 10 0.010* 
Systolic BP, mmHg 135 ± 19.2 137 ± 17 156 ± 22.5 152 ± 22.4 0.000 
Diastolic BP, mmHg 76 ± 13.2 77 ± 7.8 76 ± 10 75± 9.0 0.756 
Risk profile: % ( n ) 
Angina 80 (12) 77.8 (35) 80.5 (33) 60 (27) 0.101 
Previous MI 40 (6) 48.9 (22) 46.3 (19) 66.7 (30) 0.187 
Previous PCI 20 (3) 40 (18) 34.1 (14) 28.9 (13) 0.441 
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Previous CABG 26.7 (4) 11.1 (5) 39.0 (16) 26.7 (12) 0.016 
H/o Hypertension 33.3 (5) 51.1 (21) 68.3 (28) 66.7 (30) 0.021 
H/o CKD 0 (0) 0 (0) 14.6 (6) 2.2 (1) 0.014 
H/o PVD 26.7 (4) 0 (0) 26.8 (11) 11.1 (5) 0.002 
H/o CVA 15.4 (2) 4.4 (2) 14.6 (6) 8.9 (4) 0.519 
Medications: % ( n ) 
Sulphonylurea 26.7 (4)  19.5 (8)   
Metformin 34.6 (9)  47.5 (19)   
Insulin 22.2 (6)  48.8 (20)   
Beta-blocker 73.3 (11) 82.2 (37) 68.3 (28) 66.7 (30) 0.462 
ACE inhibitor / ARB 80 (12) 73.3 (33) 87.8 (36) 84.4 (38) 0.271 
Statin 100 (15) 93.3 (42) 92.7 (38) 95.6 (43) 0.687 
Laboratory data: Mean ± SD 
Haemoglobin, g/dl 13.7 ± 0.8 13.6 ± 1.2 12.6 ± 1.3 12.9 ± 1.2 0.000 
Platelets x 1000 cells/mm3 219 ± 40.0 238 ± 63.6 211 ± 48.8 232 ± 66.2 0.150 
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Fibrinogen, g/ml 3.2 ± 0.5 3.2 ± 0.6 3.4 ± 0.7 3.3 ± 0.6 0.554 
HbA1c, mmol/mol 57.5 ± 15.3 39.3 ± 7.0 61.2 ± 15.1 41.3 ± 3.4  
Fasting plasma glucose, 
mmol/L 
8.3 ± 3.4 5.2 ± 0.6 8.3 ± 4.3 5.2 ± 0.7  
Creatinine, micromol/L 87 ± 16.2 83 ± 25.2* 110 ± 53.5* 100 ± 27.7 0.004* 
Total cholesterol, mmol/L 3.3 ± 0.6 4.2 ± 1.0 4.0 ± 0.9 4.2 ± 0.8 0.024 
LDLc, mmol/L 1.7 ± 0.5 2.2 ± 0.9 2.1 ± 0.9 2.1 ± 0.7 0.310 
HDLc, mmol/L 1.0 ± 0.2 1.3 ± 0.3 1.2 ± 0.3 1.4 ± 0.3 0.000 
Triglyceride, mmol/L 1.6 ± 0.5 1.4 ± 0.8 1.5 ± 0.7 1.3 ± 0.6 0.489 
HsCRP, mg/L 2.6 ± 2.2 1.8 ± 1.8 4.3 ± 6.6 4.4 ± 7.7  0.137 
 
Table 4.40 Baseline characteristics - Multiplate® sub study. 
Body mass index, kg/m2: Age<75+T2DM vs Age<75+non DM, p=0.042; Age<75+T2DM vs Age≥75+T2DM, p=0.015; Age<75+T2DM vs 
Age≥75+non DM, p<0.001 
Systolic BP, mmHg: Age<75+T2DM vs Age≥75+T2DM, p=0.004; Age<75+T2DM vs Age≥75+non DM, p=0.042; Age<75+non DM vs 
Age≥75+T2DM, p<0.001; Age<75+non DM vs Age≥75+non DM, p=0.004 
Total cholesterol, mmol/L: Age<75+T2DM vs Age<75+non DM, p=0.026; Age<75+T2DM vs Age≥75+non DM, p=0.041 
HDLc, mmol/L: Age<75+T2DM vs Age<75+non DM, p=0.018; Age<75+T2DM vs Age≥75+non DM, p<0.001 
*p<0.05
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Age < 75 + T2DM 
(n = 15) 
 
 
Age < 75 + Non T2DM 
(n = 45) 
 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
 
Median 
(IQR) 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
High shear 
thrombus 
area, 
µ2/mm 
14941 
(11821-
17778) 
 
11450 
(8554-
13000) 
 
0.011 
 
 
15633 
(11257-
19736) 
 
12918 
(9516-
15667) 
 
0.000 
 
 
15706 
(9379-
19977) 
 
12593 
(8793-
15450) 
 
0.000 
 
 
17726 
(11021-
21806) 
 
14128 
(10354-
18012) 
 
0.000 
 
 
Low shear 
thrombus 
area, 
µ2/mm 
9391 
(7854-
10095) 
 
7139  
(6517- 
7702) 
 
0.938 
 
 
9831 
(7786-
11809) 
 
8010 (6127-
9666) 
 
0.004 
 
 
9635 
(7984-
11373) 
 
8260 (7224-
9701) 
 
0.000 
 
 
10039 
(8380-
11947) 
 
8967 (7509-
10372) 
 
0.000 
 
 
ASP AU 
356  
(222-499) 
264 
(176-300) 
0.143 
385 
(249-516) 
198  
(160-286) 
0.000 
312 
(210-466) 
220 
(142-278) 
0.004 
298 
(234-384) 
196 
(127-270) 
0.000 
ADP AU 
672  
(552-941) 
452 
(291-676) 
0.002 
822 
(726-989) 
461 
(268-626) 
0.000 
769 
(653-974) 
488 
(310-638) 
0.000 
762 
(589-1012) 
386 
(271-559) 
0.000 
Collagen  
AU 
547 
(383-686) 
497  
(409-619) 
0.653 
702  
(556-824) 
571 
(448-742) 
0.000 
711 
(493-856) 
601 
(423-754) 
0.034 
623 
(496-831) 
531 
(394-672) 
0.001 
TRAP AU 
994 (656-
1141) 
1018 (883-
1151) 
0.468 
1172 
(1010-
1252) 
1065  
(941-1276) 
0.011 
1140 
(845-
1405) 
1015 
(775-1250) 
0.007 
1128 (914-
1319) 
1052 
(834-1282) 
0.002 
 
Table 4.41 Thrombus area and platelet reactivity indices - Multiplate® substudy. 
*p<0.05 
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Age < 75 + T2DM 
(n = 15) 
 
Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) Mean (IQR) 
ASP AU 356 (222-499) 385 (249-516) 312 (210-466) 298 (234-384) 0.772 
ADP AU 672 (552-941) 822 (726-989) 769 (653-974) 762 (589-1012) 0.757 
Collagen AU 547 (383-686) 702 (556-824) 711 (493-856) 623 (496-831) 0.091 
TRAP AU 994 (656-1141) 1172 (1010-1252) 1140 (845-1405) 1128 (914-1319) 0.142 
Aspirin good responders, % (n) 60 (9) 53.3 (24) 64.9 (24) 75.6 (34) 0.175 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) Mean (IQR) 
ASP AU 264 (176-300) 198 (160-286) 220 (142-278) 196 (127-270) 0.898 
ADP AU 452 (291-676) 461 (268-626) 488 (310-638) 386 (271-559) 0.685 
Collagen AU 497 (409-619) 571 (448-742) 601 (423-754) 531 (394-672) 0.180 
TRAP AU 1018 (883-1151) 1065 (941-1276) 1015 (775-1250) 1052 (834-1282) 0.739 
Aspirin good responders,% (n) 86.7 (13) 88.6 (39) 89.5 (34) 86.7 (13.3) 0.978 
Clopidogrel Good responders, % (n) 60 (9) 50 (22) 45.9 (17) 64.4 (29) 0.330 
Difference in variables between Visit 1 and Visit 2 Mean change, IQR 
Delta ASP AU 69 (-63-236) 125 (42-234) 85 (11-237) 101 (6-201) 0.786 
Delta ADP AU 237 (143-443) 355 (157-530) 300 (190-428) 336 (210-336) 0.868 
Delta Collagen AU -39 (-145-104) 107 (-10-210) 38 (-68.5-207) 118 (3-273) 0.367 
Delta TRAP AU 44 (-234-191) 80 (-2170 88 (-48-284) 100 (0-208) 0.056 
Table 4.42 Comparison of Multiplate® indices; Post hoc analysis (One way ANOVA); *p<0.05 
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Good 
responders to 
clopidogrel 
 
Age < 75 + T2DM 
(n = 9) 
 
 
Age < 75 + Non T2DM 
(n = 22) 
 
 
Age ≥ 75 + T2DM 
(n = 17) 
 
 
Age ≥ 75  + Non T2DM 
(n = 29) 
 
Mean (IQR) 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
High shear 
thrombus area, 
µ2/mm 
13910 
(8699-
15594) 
10489 
(7884-
12106) 
0.022 
 
133323 
(11210-
18031) 
10942 
(9373-
13024) 
 
0.001 
 
15727 
(9033-
20021) 
11639 
(8885-
15453) 
0.041 
 
17119 
(11616-
20464) 
13007 
(8997-
16029) 
0.000 
 
Low shear 
thrombus area, 
µ2/mm 
8922 
(7548-
9658) 
6600 
(6341-
7649) 
0.011 
 
9524 
(7526-
11809) 
7438 
(5782-
8992) 
0.004 
 
8826 
(7104-
11387) 
7523 
(7127-
9320) 
0.051 
 
9018 
(7960-
11086) 
8341 
(7243-
9747) 
0.005 
 
ASP AU 
356 
(244-
473) 
241 
(204-292) 
0.293 
311 
(233-553) 
175 
(140-
226) 
0.000 
236 
(173-424) 
151 
(107-243) 
0.002 
285 
(229-352) 
191 
(116-244) 
0.001 
 
ADP AU 
598 
(417-
692) 
307 
(187-378) 
0.026 
776 
(630-931) 
269 
(217-
388) 
0.000 
670 
(527-799) 
302 
(250-384) 
0.000 
647 
(575-797) 
314 
(237-383) 
0.000 
Collagen AU 
472 
(246-
647) 
488 
(362-581) 
0.804 
679 
(554-728) 
510 
(416-
583) 
0.000 
577 
(408-713) 
426 
(315-581) 
0.050 
569 
(487-724) 
424 
(355-535) 
0.002 
TRAP AU 
856 
(486-
1080) 
931 
(819-
1024) 
0.370 
1085 
(958-1248) 
975 
(816-
1151) 
0.013 
899 
(735-
1167) 
779 
(673-977) 
0.004 
1046 
(843-1293) 
915 
(752-
1197) 
0.000 
 
Table 4.43 Thrombus area and Multiplate® indices - good responders 
*p<0.05 
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Good responders to clopidogrel 
 
Age < 75 + T2DM 
(n = 9) 
 
Age < 75 + Non T2DM 
(n = 22) 
 
Age ≥ 75 + T2DM 
(n = 17) 
 
Age ≥ 75  + Non 
T2DM (n = 29) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Median (IQR) 
High shear thrombus area, µ2/mm 13910  
(8699-15594) 
133323 
(11210-18031) 
15727 
(9033-20021) 
17119 
(11616-20464) 
0.166 
Low shear thrombus area, µ2/mm 8922 
(7548-9658) 
9524 
(7526-11809) 
8826 
(7104-11387) 
9018 
(7960-11086) 
0.625 
ASP AU 356 (244-473) 311 (233-553) 236 (173-424) 285 (229-352) 0.361 
ADP AU 598 (417-692) 776 (630-931) 670 (527-799) 647 (575-797) 0.630 
Collagen AU 472 (246-647) 679 (554-728) 577 (408-713) 569 (487-724) 0.145 
TRAP AU 856 (486-1080) 1085 (958-1248) 899 (735-1167) 1046 (843-1293) 0.061 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Median (IQR) 
High shear thrombus area, µ2/mm 10489 
(7884-12106) 
10942 
(9373-13024) 
11639 
(8885-15453) 
13007 
(8997-16029) 
0.281 
Low shear thrombus area, µ2/mm 6600 
(6341-7649) 
7438 
(5782-8992) 
7523 
(7127-9320) 
8341 
(7243-9747) 
0.120 
ASP AU 241 (204-292) 175 (140-226) 151 (107-243) 191 (116-244) 0.189 
ADP AU 307 (187-378) 269 (217-388) 302 (250-384) 314 (237-383) 0.784 
Collagen AU 488 (362-581) 510 (416-583) 426 (315-581) 424 (355-535) 0.652 
TRAP AU 931 (819-1024) 975 (816-1151) 779 (673-977) 915 (752-1197) 0.116 
 
Table 4.44 Thrombus area and Multiplate® indices - good responders; Post hoc analysis (One way ANOVA); *p<0.05  
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Good responders to clopidogrel 
 
Age < 75 + T2DM 
(n = 9) 
 
Age < 75 + Non T2DM 
(n = 22) 
 
Age ≥ 75 + T2DM 
(n = 17) 
 
Age ≥ 75  + Non 
T2DM (n = 29) 
 
P Value 
Difference in variables between Visit 1 and Visit 2 
Median (IQR) 
Delta ASP AU 120 (-45-218) 135 (52-238) 63 (15-222) 91 (14-157) 0.677 
Delta ADP AU 227 (134-491) 512 (338-640) 331 (211-474) 365 (263-509) 0.486 
Delta Collagen AU -68 (-183-73) 127 (48-224) 70(-60-247) 118 (21-231) 0.175 
Delta TRAP AU 16 (-333-140) 93 (3-228) 98 (-30-281) 127 (10-223) 0.019 
 
Table 4.45 Comparison of change in Multiplate® indices - good responders 
Post hoc analysis (One way ANOVA); *p<0.05 
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Hypo 
responders 
to 
clopidogrel 
 
Age < 75 + T2DM 
(n = 6) 
 
 
Age < 75 + Non T2DM 
(n = 22) 
 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
 
Age ≥ 75  + Non T2DM 
(n = 16) 
 
Median (IQR) 
 
Visit 1 
 
Visit 2 
 
P  
Value 
 
Visit 1 
 
Visit 2 
 
P  
Value 
 
Visit 1 
 
Visit 2 
 
P  
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
High shear 
thrombus 
area, µ2/mm 
17451 
(14577-
18868) 
12295 
(10272-
16639) 0.045 
16723 
(11295-
20299) 
12953 
(11031-
18355) 
0.021 
 
16411 
(10454-
19644) 
14069 
(8705-
15999) 
0.002 
 
20387 
(9947-
27810) 
17565 
(10728-
21318) 
0.064 
 
Low shear 
thrombus 
area, µ2/mm 
10246 
(7854-
13165) 
7654 
(7370-
8250) 0.158 
9335 
(8543-
10521) 
8797 
(6729-
9795) 
0.009 
 
10000 
(8315-
11816) 
8493 
(7184-
10467) 
0.004 
 
11090 
(8555-
13287) 
10180 
(8011-
12247) 
0.269 
 
ASP AU 
354 
(203-
554) 
191 
(159-
392) 
0.327 
412 
(301-
515) 
233 
(176-
351) 
0.017 
380 
(271-
564) 
259 
(207-
323) 
0.145 
356 
(263-
664) 
256 
(146-
485) 
0.160 
ADP AU 
905 
(774-
1171) 
706 
(512-
867) 
0.005 
861 
(774-
997) 
621 
(550-
812) 
0.000 
922 
(729-
1129) 
628 
(522-
752) 
0.000 
1012 
(747-
1117) 
670 
(525-
894) 
0.015 
Collagen AU 
643 
(517-
687) 
574 
(339-
640) 
0.334 
729 
(608-
900) 
656 
(549-
808) 
0.120 
817 
(615-
952) 
698 
(599-
891) 
0.439 
831 
(595-
1003) 
694 
(622-
761) 
0.114 
TRAP AU 
1093 
(897-
1597) 
1169 
(1028-
1348) 
0.999 
1183 
(1059-
1261) 
1234 
(1004-
1311) 
0.431 
1376 
(1135-
1444) 
1218 
(1037-
1370) 
0.307 
1246 
(1133-
1319) 
1231 
(1025-
1462) 
0.770 
 
Table 4.46 Thrombus area and Multiplate® indices - hyporesponders  
*p<0.05 
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Hypo responders to 
clopidogrel 
 
Age < 75 + T2DM 
(n = 9) 
 
Age < 75 + Non 
T2DM (n = 22) 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
Age ≥ 75  + Non 
T2DM (n = 16) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Median (IQR) 
High shear thrombus area, 
µ2/mm 
17451 (14577-
18868) 
16723 (11295-
20299) 
16411 (10454-
19644) 20387 (9947-27810) 
0.708 
Low shear thrombus area, 
µ2/mm 10246 (7854-13165) 9335 (8543-10521) 10000 (8315-11816) 11090 (8555-13287) 
0.576 
ASP AU 354 (203-554) 412 (301-515) 380 (271-564) 356 (263-664) 0.913 
ADP AU 905 (774-1171) 861 (774-997) 922 (729-1129) 1012 (747-1117) 0.936 
Collagen AU 643 (517-687) 729 (608-900) 817 (615-952) 831 (595-1003) 0.454 
TRAP AU 1093 (897-1597) 1183 (1059-1261) 1376 (1135-1444) 1246 (1133-1319) 0.321 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Median (IQR) 
High shear thrombus area, 
µ2/mm 
12295 (10272-
16639) 
12953 (11031-
18355) 14069 (8705-15999) 17565 (10728-21318) 
0.345 
Low shear thrombus area, 
µ2/mm 7654 (7370-8250) 8797 (6729-9795) 8493 (7184-10467) 10180 (8011-12247) 
0.042 
ASP AU 191 (159-392) 233 (176-351) 259 (207-323) 256 (146-485) 0.903 
ADP AU 706 (512-867) 621 (550-812) 628 (522-752) 670 (525-894) 0.873 
Collagen AU 574 (339-640) 656 (549-808) 698 (599-891) 694 (622-761) 0.135 
TRAP AU 1169 (1028-1348) 1234 (1004-1311) 1218 (1037-1370) 1231 (1025-1462) 0.548 
Table 4.47 Thrombus area and Multiplate® indices – hyporesponders; Post hoc analysis (One way ANOVA); *p<0.05 
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Hypo responders to clopidogrel 
 
Age < 75 + T2DM 
(n = 9) 
 
Age < 75 + Non T2DM 
(n = 22) 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
Age ≥ 75  + Non 
T2DM (n = 16) 
 
P Value 
Difference in variables between Visit 1 and Visit 2 
Median (IQR) 
Delta ASP AU -4 (-69-337) 122 (42-212) 92 (2-277) 169 (-44-262) 0.901 
Delta ADP AU 311 (182-412) 193 (104-372) 230 (122-409) 213 (39-441) 0.860 
Delta Collagen AU 26 (-41-335) 79 (-55-202) 24 (-85-98) 141 (-22-341) 0.779 
Delta TRAP AU 103 (-281-248) 27 (-88-135) 34 (-134-276) 20 (-125-110) 0.876 
 
Table 4.48 Comparison of change in thrombus area and Multiplate® indices - hyporesponders 
Post hoc analysis (One way ANOVA)  
*p<0.05 
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Figure 4.14 Changes in Multiplate® indices 
*p<0.05 
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Figure 4.15 Correlation: ADP AU with thrombus area, PRUz, MA and MA-
ADP (baseline) 
 
ADP AU positively correlated with the following parameters 
i. Thrombus area (rho= 0.191, p=0.025).  
ii. PRUz (rho= 0.183, p=0.040) 
iii. MA (rho= 0.316, p<0.001) 
iv. MA-ADP (rho=0.274, p=0.001) 
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Figure 4.16 Correlation: ADP AU with thrombus, PRUz, MA & MA-ADP (after 
clopidogrel) 
 
ADP AU positively correlated with the following parameters 
i. Thrombus area (rho= 0.170, p=0.046)  
ii. PRUz (rho= 0.438, p<0.001) 
iii. MA (rho= 0.269, p=0.001) 
iv. MA-ADP (rho=0.336, p<0.001) 
v. Percentage aggregation to ADP (rho=0.204, p=0.016)  
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Figure 4.17 Correlation: ASP AU with ARU, MA and MA-AA 
At baseline ASP AU positively correlated with the following parameters: ARU (rho= 
0.183, p=0.040); MA-AA (rho= 0.452, p<0.001); % aggregation to AA (rho=0.425, 
p<0.001) (figures in column A). After a week of clopidogrel therapy positive correlation 
persisted with the following parameters: ARU (rho= 0.193, p=0.022); MA-AA (rho= 
0.508, p<0.001); % aggregation to AA (rho=0.425, p<0.001) (figures in column B). 
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Age<75 years vs. Age≥75 years 
I divided the study population as young (age<75 years) and elderly (age≥75 years) to 
assess the effect of age on clopidogrel response and platelet dependent thrombus 
formation.  
Demographic data between these two groups are shown in Table 4.49. The elderly 
group had a significantly higher number of participants with a history of hypertension, 
PVD, DM, previous CABG and CKD. Mean systolic BP was higher in the elderly 
population. Laboratory data demonstrated significantly higher serum creatinine, 
hsCRP and HbA1c levels and lower haemoglobin level in the elderly group. 
Significantly higher number of patients in the elderly group were prescribed insulin 
(Table 4.49). 
Young patients (age<75 years) had 31 good responders to clopidogrel (52.5%) 
compared to 46 good responders (56.1%) in the elderly group (age≥75 years). The 
absolute mean ADP AU showed a significant reduction in both the groups after one 
week of clopidogrel therapy (mean, IQR, age<75: 801, 669-987 to 443, 269-630, 
p<0.001; age≥75: 765, 598-995 to 428, 298-624, p<0.001). Mean difference in PRUz 
(Mean, IQR) from visit 1 and visit 2 were similar between the groups; Age≥75: 333, 
152-506 and in Age<75: 325, 208-446; p=0.532 (Table 4.50, Table 4.51). 
Despite being on long term aspirin therapy, there was a significant reduction in ASP 
AU from visit 1 to visit 2 in the younger population (mean, IQR: 359, 237-510 to 205, 
166-288; p<0.001) demonstrating improved platelet inhibition to aspirin after the 
addition of clopidogrel as a second antiplatelet agent. There was a similar reduction in 
ASP AU in the elderly cohort as well from visit 1 and visit 2 (mean, IQR: 302, 225-440 
to 212, 133-274; p<0.001). The percentage of good responders to aspirin increased 
after addition of clopidogrel in both the groups (young: 55% to 88.1% and elderly: 
70.7% to 88%). 
Good responders to clopidogrel: 
I compared all the good responders to clopidogrel (mean ADP AU < 460). There was 
a consistent reduction both in high shear (age<75: 13642, 10984-16405 vs. 10942, 
8933-12455, p<0.001; age≥75: 16508, 10134-20021 vs. 12878, 9042-15679, p<0.001) 
and low shear thrombus area following one week of clopidogrel therapy. Mean ADP 
AU was numerically lower in the elderly group at baseline (age<75 vs. age≥75: 741, 
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535-835 vs. 659, 562-790; p=0.554) but was numerically higher one week after 
clopidogrel therapy (277, 220-378 vs. 311, 248-382, p=0.369), but this difference was 
not statistically significant. Difference in ADP AU from baseline to one week after 
clopidogrel (delta ADP AU) was low in the elderly cohort but was not significant (mean, 
IQR: 468, 222-571 vs. 339, 238-491, p=0.371). Mean ADP AU were much lower than 
the cut off of 460 in both the groups. There was a significant reduction in ASP AU from 
baseline to one week after clopidogrel therapy both in young (332, 237-499 vs. 196, 
151-258, p<0.001) and elderly cohort (283, 203-364 vs. 176, 116-243, p<0.001) (Table 
4.52, Table 4.53). 
Hyporesponders to clopidogrel: 
When hyporesponders to clopidogrel (mean ADP AU ≥ 460) were compared, both 
younger (age<75) and elderly (age≥75) patients consistently demonstrated significant 
reduction in both high shear (age<75: 17300, 12178-20093 vs. 12584, 11169-17002, 
p=0.002; age≥75: 16813, 9947-22867 vs. 14532, 9241-18753, p<0.001) and low shear 
thrombus area. The younger cohort of patients demonstrated a numerically lower 
mean ADP AU when compared to the elderly (863, 777-1016 vs. 957, 729-1124, 
p=0.682) but one week after clopidogrel therapy mean ADP AU were similar (631, 549-
826 vs. 628, 522-837, p=0.696). The difference in ADP AU from baseline to one week 
after clopidogrel (delta ADP AU) was numerically lower in the elderly group but this 
difference was not statistically significant (mean, IQR: 221, 122-392 vs. 230, 100-409, 
p=0.935). Despite demonstrating significant reduction, the mean ADP AU remained ≥ 
460 in both the groups indicating high platelet reactivity. There was a significant 
reduction in ASP AU from baseline to one week after clopidogrel therapy in both young 
(mean, IQR: 412, 261-518 to 219, 169-333, p=0.008 and elderly cohort (361, 265-567 
to 256, 194-447, p=0.039) (Table 4.54, Table 4.55). 
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Age < 75 
(n = 60) 
 
Age ≥ 75  
(n = 83) 
 
 
    P Value 
Demographic data: Mean ± SD or % (n) 
 
Age, years 
 
63±7.3 79±3.4  
Male gender, % ( n ) 
 
73.3 (44) 75.9 (63) 0.727 
Body mass index, kg/m2 
 
30.5±4.1 28.4±4.4 0.004 * 
Waist to hip ratio 
 
1.0±0.1 0.9±0.1 0.121 
Heart rate, beats  per minute 
 
64±11.9 66±12.2 0.546 
Systolic BP, mmHg 
 
137±18.0 155±22.6 0.000 * 
Diastolic BP, mmHg 
 
77±9.3 75±9.5 0.348 
Risk profile: % ( n ) 
 
Angina 
 
78.3 (47) 69.9 (58) 0.259 
Previous MI 
 
46.7 (28) 59.0 (49) 0.143 
Previous PCI 
 
35.0 (21) 32.5 (27) 0.758 
Previous CABG 
 
15 (9) 33.7 (28) 0.012 * 
Diabetes Mellitus 
 
25 (15) 38 (45.8) 0.011 * 
Hypertension 
 
46.7 (28) 69.9 (58) 0.005 * 
Heart failure 
 
1.7 (1) 10.8 (9) 0.034 
CKD 
 
0 (0) 7.2 (6) 0.033 * 
PVD 
 
6.7 (4) 19.3 (16) 0.032 * 
CVA 
 
6.7 (4) 10.8 (9) 0.391 
Medications: % ( n ) 
 
Sulphonylurea 
 
6.7 (4) 9.6 (8) 0.527 
Metformin 
 
15 (9) 20.5 (17) 0.402 
Insulin 
 
10 (6) 25.3 (21) 0.021 * 
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Beta-blocker 80 (48) 68.7 (57) 0.258 
ACE inhibitor / ARB 
 
75 (45) 86.7 (72) 0.072 
Statin 
 
95 (57) 94 (78) 0.793 
Laboratory data: Mean ± SD 
 
Haemoglobin, g/dl 
 
13.6±1.1 12.7±1.2 0.000 * 
Platelets x 1000 cells/mm3 
 
234±59.9 222±59.8 0.218 
Fibrinogen, g/ml 
 
3.2±0.6 3.3±0.6 0.309 
HbA1c, mmol/mol 
 
43.4±12.0 50.7±14.8 0.002 * 
Fasting plasma glucose, mmol/L 
 
5.9±2.1 6.6±3.4 0.121 
Creatinine, micromol/L 
 
84±23.3 105±42.6 0.000 * 
Total cholesterol, mmol/L 
 
4.0±1.0 4.0±0.9 0.860 
LDLc, mmol/L 
 
2.1±0.9 2.1±0.8 0.644 
HDLc, mmol/L 
 
1.3±0.3 1.3±0.3 0.285 
Triglyceride, mmol/L 
 
1.5±0.8 1.4±0.7 0.662 
HsCRP, mg/L 
 
2.0±1.9 4.2±7.2 0.009 * 
 
Table 4.49 Baseline characteristics – Multiplate® sub study (Age<75 vs. 
Age≥75) 
*p<0.05 
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Age < 75 
(n = 60) 
 
 
Age ≥ 75 
(n = 83) 
 
Median 
(IQR) Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
High shear 
thrombus 
area, µ2/mm 
14796 
(11298-
19461) 
120101 
(9503-
15110) 
0.000 
 
16545 
(10134-
20547) 
13069 
(9312-
16759) 
0.000 
 
Low shear 
thrombus 
area, µ2/mm 
9302 
(7830-
11291) 
7680 
(6461-
8912) 
0.000 
 
9585 
(8290-
11571) 
8513 
(7407-
9881) 
0.000 
 
ASP AU 
359 
(237-510) 
205 
(166-288) 
0.000 
302 
(225-440) 
212 
(133-274) 
0.000 
ADP AU 
801 
(669-987) 
443 
(269-630) 
0.000 
765 
(598-995) 
428 
(298-624) 
0.000 
Collagen AU 
685 
(542-787) 
559 
(440-679) 
0.001 
677 
(497-834) 
539 
(395-715) 
0.000 
TRAP AU 
1126 
(983-1246) 
1060 
(921-1237) 
0.179 
1135 
(904-1365) 
1027 
(824-1257) 
0.000 
 
Table 4.50 Thrombus area and Multiplate® indices (Age<75 vs. Age≥75) 
*p<0.05 
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 Age < 75 
(n = 60) 
Age ≥ 75 
(n = 83) 
 
P 
Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Median (IQR) 
High shear thrombus 
area, µ2/mm 
14796 (11298-19461) 16545 (10134-20547) 0.178 
Low shear thrombus 
area, µ2/mm 
9302 (7830-11291) 9585 (8290-11571) 0.764 
ASP AU 359 (237-510) 302 (225-440) 0.332 
ADP AU 801 (669-987) 765 (598-995) 0.653 
Collagen AU 685 (542-787) 677 (497-834) 0.786 
TRAP AU 1126 (983-1246) 1135 (904-1365) 0.418 
Aspirin  
good responders, % (n) 
55 (33) 70.7 (58) 0.040 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Median (IQR) 
High shear thrombus 
area, µ2/mm 120101 (9503-15110) 13069 (9312-16759) 
0.273 
Low shear thrombus 
area, µ2/mm 7680 (6461-8912) 8513 (7407-9881) 
0.016 
ASP AU 205 (166-288) 212 (133-274) 0.695 
ADP AU 443 (269-630) 428 (298-624) 0.897 
Collagen AU 559 (440-679) 539 (395-715) 0.933 
TRAP AU 1060 (921-1237) 1027 (824-1257) 0.571 
Aspirin  
good responders, % (n) 
88.1 (52) 88 (73) 0.594 
Clopidogrel  
Good responders, % (n) 
52.5 (31) 56.1 (46) 0.406 
Difference in variables between Visit 1 and Visit 2 
Median (IQR) 
Delta ASP AU 120 (29-236) 90 (10-219) 0.568 
Delta ADP AU 333 (152-506) 325 (208-446) 0.532 
Delta Collagen AU 76 (-35-196) 90 (-55-222) 0.893 
Delta TRAP AU 79 (-37-173) 93 (-28-252) 0.070 
 
Table 4.51 Comparison of thrombus area and Multiplate® indices (Age<75 
vs. Age≥75)      
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Good 
responders 
to 
clopidogrel 
 
Age < 75 
(n = 31) 
 
 
Age ≥ 75 
(n = 46) 
 
Median (IQR) 
Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
High shear 
thrombus 
area, µ2/mm 
13642 
(10984-
16405) 
10942 
(8933-
12455) 
0.000 
 
16508 
(10134-
20021) 
12878 
(9042-
15679) 
0.000 
Low shear 
thrombus 
area, µ2/mm 
9152 
(7526-
11062) 
7410 
(5965-
8504) 
0.000 
 
9018 
(7585-
11204) 
7841 
(7234-
9621) 
0.001 
ASP AU 
332 
(237-499) 
196 
(151-258) 
0.000 
283 
(203-364) 
176 
(116-243) 
0.000 
ADP AU 
741 
(535-835) 
277 
(220-378) 
0.000 
659 
(562-790) 
311 
(248-382) 
0.000 
Collagen AU 
575 
(472-723) 
490 
(421-574) 
0.009 
570 
(440-715) 
425 
(338-534) 
0.000 
TRAP AU 
1037 
(856-
1203) 
968 
(819-968) 
0.233 
998 
(789-1259) 
861 
(712-
1116) 
0.000 
 
Table 4.52 Thrombus area and Multiplate® indices - good responders 
(Age<75 vs. Age≥75)   
*p<0.05 
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Good responders to 
clopidogrel 
Age < 75 
(n = 31) 
Age ≥ 75 
(n = 46) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
High shear thrombus area, 
µ2/mm 
13642 (10984-
16405) 
16508 (10134-20021) 0.118 
Low shear thrombus area, 
µ2/mm 
9152 (7526-11062) 9018 (7585-11204) 0.907 
ASP AU 332 (237-499) 283 (203-364) 0.118 
ADP AU 741 (535-835) 659 (562-790) 0.554 
Collagen AU 575 (472-723) 570 (440-715) 0.636 
TRAP AU 1037 (856-1203) 998 (789-1259) 0.833 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
High shear thrombus area, 
µ2/mm 
10942 (8933-12455) 12878 (9042-15679) 0.094 
Low shear thrombus area, 
µ2/mm 
7410 (5965-8504) 7841 (7234-9621) 0.071 
ASP AU 196 (151-258) 176 (116-243) 0.218 
ADP AU 277 (220-378) 311 (248-382) 0.369 
Collagen AU 490 (421-574) 425 (338-534) 0.201 
TRAP AU 968 (819-968) 861 (712-1116) 0.196 
Difference in variables between Visit 1 and Visit 2 
Median, IQR 
Delta ASP AU 128 (49-236) 83 (14-186) 0.457 
Delta ADP AU 468 (222-571) 339 (238-491) 0.371 
Delta Collagen AU 73 (-42-172) 103 (9-231) 0.585 
Delta TRAP AU 80 (-34-223) 124 (6-251) 0.118 
 
Table 4.53 Comparison of thrombus area and Multiplate® - good responders 
(Age<75 vs. Age≥75) 
  
277 
 
 
Hypo 
responders 
to 
clopidogrel 
 
Age < 75 
(n = 28) 
 
 
Age ≥ 75 
(n = 36) 
 
Median (IQR) 
Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
High shear 
thrombus 
area, µ2/mm 
17300 
(12178-
20093) 
12584 
(11169-
17002) 
0.002 
 
16813 
(9947-
22867) 
14532 
(9241-
18753) 
0.000 
Low shear 
thrombus 
area, µ2/mm 
9385 
(8248-
11283) 
8026 
(6976-
9281) 
0.003 
 
10168 
(8388-
12313) 
9281 
(7484-
10743) 
0.003 
ASP AU 
412 
(261-518) 
219 
(169-333) 
0.008 
361 
(265-567) 
256 
(194-447) 
0.039 
ADP AU 
863 
(777-1016) 
631 
(549-826) 
0.000 
957 
(729-1124) 
628 
(522-837) 
0.000 
Collagen AU 
703 
(598-850) 
619 
(540-768) 
0.057 
819 
(615-952) 
696 
(607-790) 
0.082 
TRAP AU 
1177 
(1051-
1278) 
1186 
(1014-
1320) 
0.579 
1299 
(1135-
1411) 
1231 
(1025-
1373) 
0.293 
 
Table 4.54 Thrombus area and Multiplate® indices - hyporesponders 
(Age<75 vs. Age≥75) 
*p<0.05 
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Hypo responders to 
clopidogrel 
 
Age < 75 
(n = 28) 
 
Age ≥ 75 
(n = 36) 
 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
High shear thrombus 
area, µ2/mm 
17300 (12178-20093) 16813 (9947-22867) 0.496 
Low shear thrombus 
area, µ2/mm 
9385 (8248-11283) 10168 (8388-12313) 0.336 
ASP AU 412 (261-518) 361 (265-567) 0.861 
ADP AU 863 (777-1016) 957 (729-1124) 0.682 
Collagen AU 703 (598-850) 819 (615-952) 0.207 
TRAP AU 1177 (1051-1278) 1299 (1135-1411) 0.065 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
High shear thrombus 
area, µ2/mm 
12584 (11169-17002) 14532 (9241-18753) 0.661 
Low shear thrombus 
area, µ2/mm 
8026 (6976-9281) 9281 (7484-10743) 0.058 
ASP AU 219 (169-333) 256 (194-447) 0.508 
ADP AU 631 (549-826) 628 (522-837) 0.696 
Collagen AU 619 (540-768) 696 (607-790) 0.190 
TRAP AU 1186 (1014-1320) 1231 (1025-1373) 0.145 
Difference in variables between Visit 1 and Visit 2 
Median, IQR 
Delta ASP AU 116 (23-216) 151 (-15-277) 0.517 
Delta ADP AU 221 (122-392) 230 (100-409) 0.935 
Delta Collagen AU 59 (-40-197) 38 (-71-194) 0.748 
Delta TRAP AU 68 (-108-140) 20 (-122-240) 0.664 
 
Table 4.55 Multiplate® indices - hyporesponders (Age<75 vs. Age≥75) 
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T2DM vs. Non DM 
I divided the study population as patients with T2DM and non DM to assess the effect 
of T2DM on clopidogrel response and platelet dependent thrombus formation.  
Demographic data between these two groups are shown in Table 4.56. Patients with 
T2DM had significantly higher number of participants with history of PVD, previous 
CABG and CKD. Heart rate and waist-hip ratio were higher in T2DM cohort. Laboratory 
data demonstrated significantly lower platelet count, total cholesterol and HDLc level 
in T2DM group (Table 4.56). 
T2DM had 26 good responders to clopidogrel (50%) compared to 51 good responders 
(57.3%) in the non DM cohort. The absolute mean ADP AU showed a significant 
reduction in both the groups after one week of clopidogrel therapy (mean, IQR, T2DM: 
737, 607-973 to 474, 303-643, p<0.001; non DM: 790, 658-994 to 425, 269-611, 
p<0.001). Mean difference in ADP AU (Mean, IQR) from visit 1 and visit 2 were similar 
between the groups; T2DM: 283, 174-433 and in non DM: 342, 193-511; p=0.496. 
Despite being on long term aspirin therapy, there was a significant reduction in ASP 
AU from visit 1 to visit 2 in T2DM (mean, IQR: 342, 216-470 to 220, 157-283; p=0.002) 
and non DM (314, 238-484 to 196, 144-273, p<0.001) demonstrating improved platelet 
inhibition to aspirin after the addition of clopidogrel as a second antiplatelet agent. A 
similar reduction was also seen with collagen AU and TRAP AU in non DM patients 
but not in patients with T2DM. The percentage of good responders to aspirin increased 
after addition of clopidogrel in both the groups (T2DM: 63.5% to 88.7% and non DM: 
63.7% to 87.6%) (Table 4.57, Table 4.58).   
Good responders to clopidogrel: 
I compared all the good responders to clopidogrel (mean ADP AU < 460). There was 
a consistent reduction both in high shear (T2DM: 16788, 13144-18871 vs. 13031, 
8793-16262, p<0.001; non DM: 15301, 11210-19623 vs. 12076, 9373-14753, p<0.001) 
and low shear thrombus area following one week of clopidogrel therapy. Mean ADP 
AU was numerically lower in the non DM at baseline (T2DM vs. non DM: 914, 739-
1109 vs. 732, 577-823; p=0.265) and there was a much greater reduction in mean ADP 
AU among non DM when compared to T2DM one week after clopidogrel therapy (638, 
517-770 vs. 289, 221-380; p=0.683), but this difference was not statistically significant. 
Difference in ADP AU from baseline to one week after clopidogrel (delta ADP AU) in 
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T2DM cohort was not significant (mean, IQR: 266, 159-405 vs. 384, 301-551; 
p=0.212). Mean ADP AU were much lower than the cut off of 460 in both the groups. 
There was a significant reduction in ASP AU from baseline to one week after 
clopidogrel therapy both in T2DM (380, 233-555 vs. 239, 199-315, p=0.070) and non 
DM (287, 230-400 vs. 180, 129-236, p<0.001). There was a significant reduction in 
Collagen Au and TRAP AU in non DM cohort of good responders but this was not 
demonstrated in T2DM group (Table 4.59, Table 4.60). 
Hyporesponders to clopidogrel: 
When hyporesponders to clopidogrel (mean ADP AU ≥ 460) were compared, again 
both T2DM and non DM patients’ consistently demonstrated significant reduction in 
both high shear (T2DM: 16788, 13144-18871 vs. 13030, 8793-16262, p=0.002; non 
DM: 17964, 10793-23227 vs. 14794, 11188-19172, p<0.001) and low shear thrombus 
area. At baseline, mean ADP AU was similar among T2DM and non DM patients (914, 
739-1109 vs. 917, 774-1059, p=0.538) and one week after clopidogrel therapy mean 
ADP AU still remained similar between the groups (638, 517-770 vs. 629, 548-845, 
p=0.860). Despite demonstrating significant reduction, the mean ADP AU remained ≥ 
460 in both the groups indicating high platelet reactivity. There was a reduction in ASP 
AU from baseline to one week after clopidogrel therapy in both T2DM (mean, IQR: 380, 
233-555 to 239, 199-315; p=0.070 and non DM cohort (397, 266-521 to 242, 165-418; 
p=0.006). The hyporesponders in the non DM group demonstrated a reduction in 
Collagen AU but not in TRAP AU. T2DM group did not demonstrate any significant 
reduction in Collagen AU and TRAP AU (Table 4.61, Table 4.62). 
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T2DM 
(n = 53) 
 
Non DM 
(n = 90) 
 
 
    P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 
 
75±8.2 71±9.9 0.019 * 
Male gender, % ( n ) 
 
83 (44) 70 (63) 0.083 
Body mass index, kg/m2 
 
30.2±5.2 28.7±3.7 0.065 
Waist to hip ratio 
 
1.0±0.1 0.9±0.1 0.033 * 
Heart rate, beats  per minute 
 
69±13.5 63±10.5 0.005 * 
Systolic BP, mmHg 
 
151±24.4 145±21.3 0.104 
Diastolic BP, mmHg 
 
76±10.9 76±8.4 0.945 
Risk profile: % ( n ) 
Angina 
 
81.1 (43) 68.9 (62) 0.109 
Previous MI 
 
47.2 (25) 57.8 (52) 0.219 
PCI 
 
32.1 (17) 34.4 (31) 0.772 
CABG 
 
37.7 (20) 18.9 (17) 0.013 * 
Hypertension 
 
62.3 (33) 58.9 (53) 0.691 
Heart failure 
 
11.3 (6) 4.4 (4) 0.119 
CKD 
 
9.4 (5) 1.1 (1) 0.017 * 
PVD 
 
28.3 (15) 14 (20) 0.000 * 
CVA 
 
13.2 (7) 6.7 (6) 0.189 
Medications: % ( n ) 
Sulphonylurea 
 
22.6 (12) 0  
Metformin 
 
49.1 (26) 0  
Insulin 
 
49.1 (26) 0  
Beta-blocker 
71.7 (38) 74.4 (67) 0.419 
ACE inhibitor / ARB 
 
86.8 (46) 78.9 (71) 0.237 
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Statin 
 
94.3 (50) 94.4 (85) 0.979 
Laboratory data: Mean ± SD 
Haemoglobin, g/dl 
 
12.8±1.1 13.2±1.2 0.069 
Platelets x 1000 cells/mm3 
 
212±47.2 235±64.6 0.016 * 
Fibrinogen, g/ml 
 
3.4±0.6 3.2±0.6 0.295 
HbA1c, mmol/mol 
 
60.6±15.3 40.3±5.5  
Fasting plasma glucose, mmol/L 
 
8.3±4.2 5.2±0.6  
Creatinine, micromol/L 
 
104±48.5 91±27.7 0.083 
Total cholesterol, mmol/L 
 
3.8±0.9 4.2±0.9 0.017 * 
LDLc, mmol/L 
 
2.0±0.8 2.2±0.8 0.208 
HDLc, mmol/L 
 
1.1±0.3 1.4±0.3 0.000 * 
Triglyceride, mmol/L 
 
1.5±0.7 1.4±0.7 0.171 
HsCRP, mg/L 
 
3.7±5.7 3.1±5.7 0.551 
 
Table 4.56 Baseline characteristics – Multiplate® sub study (T2DM vs. Non-
DM) 
*p<0.05 
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T2DM 
(n = 53) 
 
Non DM 
(n = 90) 
 
Median 
(IQR) Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
ASP AU 
342 
(216-470) 
220 
(157-283) 
0.002 
314 
(238-484) 
196 
(144-273) 
0.000 
ADP AU 
737 
(607-973) 
474 
(303-643) 
0.000 
790 
(658-994) 
425 
(269-611) 
0.000 
Collagen AU 
662 
(442-811) 
559 
(419-709) 
0.047 
681 
(525-824) 
555 
(416-693) 
0.000 
TRAP AU 
1107 
(799-1390) 
1000 
(830-1189) 
0.068 
1147 
(988-1308) 
1065 
(914-1276) 
0.000 
 
Table 4.57 Thrombus area and Multiplate® indices (T2DM vs. Non DM) 
*p<0.05 
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T2DM 
(n = 53) 
 
Non DM 
(n = 90) 
 
 
    P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
ASP AU 342 (216-470) 314 (238-484) 0.551 
ADP AU 737 (607-973) 790 (658-994) 0.792 
Collagen AU 662 (442-811) 681 (525-824) 0.299 
TRAP AU 1107 (799-1390) 
1147 (988-
1308) 
0.335 
Aspirin good responders, % (n) 63.5 (33) 63.7 (58) 0.524 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
ASP AU 220 (157-283) 196 (144-273) 0.681 
ADP AU 474 (303-643) 425 (269-611) 0.483 
Collagen AU 559 (419-709) 555 (416-693) 0.763 
TRAP AU 1000 (830-1189) 
1065 (914-
1276) 
0.320 
Aspirin good responders, % (n) 88.7 (47) 87.6 (78) 0.540 
Clopidogrel  
Good responders, % (n) 
50 (26) 57.3 (51) 0.401 
Difference in variables between Visit 1 and Visit 2 
Median, IQR 
Delta ASP AU 81 (4-234) 114 (27.5-221) 0.348 
Delta ADP AU 283 (174-433) 342 (193-511) 0.496 
Delta Collagen AU 32 (-71-114) 118 (2-222) 0.097 
Delta TRAP AU 68 (-56-254) 80 (-10-80) 0.898 
 
Table 4.58 Comparison of Multiplate® indices (T2DM vs. Non-DM) 
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Good 
responders 
to 
clopidogrel 
 
T2DM 
(n = 26) 
 
 
Non DM 
(n = 51) 
 
Median (IQR) 
Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
High shear 
thrombus 
area, µ2/mm 
14549 
(9033-
18768) 
11314 
(8462-
14236) 
0.004 
 
15301 
(11210-
19623) 
12076 
(9373-
14753) 
0.000 
Low shear 
thrombus 
area, µ2/mm 
8922 
(7263-
10237) 
7505 
(6517-
8494) 
0.002 
 
9140 
(7670-
11291) 
7828 
(6921-
9546) 
0.000 
ASP AU 
322  
(173-450) 
204  
(129-253) 
0.011 
287 
(230-400) 
180 
(129-236) 
0.000 
ADP AU 
612 
(497-745) 
305 
(246-377) 
0.000 
732 
(577-823) 
289 
(221-380) 
0.000 
Collagen AU 
509  
(381-712) 
445  
(318-544) 
0.180 
575 
(498-723) 
472 
(386-559) 
0.000 
TRAP AU 
878  
(725-
1123) 
854  
(692-991) 
0.210 
1053 
(880-1257) 
958 
(797-
1165) 
0.000 
 
Table 4.59 Thrombus area and Multiplate® indices - good responders (T2DM 
vs. Non-DM) 
*p<0.05 
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Good responders to 
clopidogrel 
 
T2DM 
(n = 26) 
 
Non DM 
(n = 51) 
 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
High shear thrombus area, 
µ2/mm 
14549 (9033-18768) 15301 (11210-19623) 0.138 
Low shear thrombus area, 
µ2/mm 
8922 (7263-10237) 9140 (7670-11291) 0.166 
ASP AU 322 (173-450) 287 (230-400) 0.507 
ADP AU 612 (497-745) 732 (577-823) 0.265 
Collagen AU 509 (381-712) 575 (498-723) 0.087 
TRAP AU 878 (725-1123) 1053 (880-1257) 0.018 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
High shear thrombus area, 
µ2/mm 
11314 (8462-14236) 12076 (9373-14753) 0.334 
Low shear thrombus area, 
µ2/mm 
7505 (6517-8494) 7828 (6921-9546) 0.120 
ASP AU 204 (129-253) 180 (129-236) 0.491 
ADP AU 305 (246-377) 289 (221-380) 0.683 
Collagen AU 445 (318-544) 472 (386-559) 0.923 
TRAP AU 854 (692-991) 958 (797-1165) 0.033 
Difference in variables between Visit 1 and Visit 2 
Median, IQR 
Delta ASP AU 79 (17-219) 101 (30-233) 0.347 
Delta ADP AU 283 (174-479) 384 (301-551) 0.240 
Delta Collagen AU 38 (-87-135) 122 (39-209) 0.076 
Delta TRAP AU 78 (-51-256) 111 (11-227) 0.285 
 
Table 4.60 Comparison of Multiplate® indices - good responders (T2DM vs. 
Non-DM)  
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Hypo 
responders 
to 
clopidogrel 
 
T2DM 
(n = 28) 
 
 
Non DM 
(n = 38) 
 
Median 
(IQR) Visit 1 Visit 2 
P 
Value Visit 1 Visit 2 
P 
Value 
High shear 
thrombus 
area, µ2/mm 
16788 
(13144-
18871) 
13030 
(8793-
16262) 
0.000 
 
17964 
(10793-
23227) 
14794 
(11188-
19172) 
0.003 
Low shear 
thrombus 
area, µ2/mm 
10168 
(8220-
11750) 
8183 
(7333-
9746) 
0.001 
 
9638 
(8552-
12428) 
8951 
(7539-
10796) 
0.007 
ASP AU 
380 
(233-555) 
239 
(199-315) 
0.070 
397 
(266-521) 
242 
(165-418) 
0.006 
ADP AU 
914 
(739-1109) 
638 
(517-770) 
0.000 
917 
(774-
1059) 
629 
(548-845) 
0.000 
Collagen AU 
767 
(602-914) 
653 
(570-785) 
0.214 
767 
(614-932) 
677 
(574-771) 
0.023 
TRAP AU 
1295 
(1075-
1456) 
1189 
(1050-
1365) 
0.374 
1191 
(1105-
1315) 
1233 
(1018-
1333) 
0.435 
 
Table 4.61 Thrombus area and Multiplate® indices - hyporesponders (T2DM 
vs. Non-DM)  
*p<0.05 
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Hypo responders to 
clopidogrel 
 
T2DM 
(n = 28) 
 
Non DM 
(n = 36) 
 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
High shear thrombus 
area, µ2/mm 16788 (13144-18871) 
17964 (10793-23227) 0.681 
Low shear thrombus 
area, µ2/mm 10168 (8220-11750) 
9638 (8552-12428) 0.924 
ASP AU 380 (233-555) 397 (266-521) 0.701 
ADP AU 914 (739-1109) 917 (774-1059) 0.538 
Collagen AU 767 (602-914) 767 (614-932) 0.948 
TRAP AU 1295 (1075-1456) 1191 (1105-1315) 0.417 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel (Visit 2) 
Mean ± SD 
High shear thrombus 
area, µ2/mm 13030 (8793-16262) 
14794 (11188-19172) 0.148 
Low shear thrombus 
area, µ2/mm 8183 (7333-9746) 
8951 (7539-10796) 0.204 
ASP AU 239 (199-315) 242 (165-418) 0.929 
ADP AU 638 (517-770) 629 (548-845) 0.860 
Collagen AU 653 (570-785) 677 (574-771) 0.952 
TRAP AU 1189 (1050-1365) 1233 (1018-1333) 0.405 
Difference in variables between Visit 1 and Visit 2 
Median, IQR 
Delta ASP AU 85 (-47-278) 131 (6-213) 0.547 
Delta ADP AU 266 (159-405) 194 (90-394) 0.406 
Delta Collagen AU 25 (-70-110) 80 (-32-222) 0.533 
Delta TRAP AU 52 (-172-252) 27 (-108-130) 0.646 
 
Table 4.62 Comparison of Multiplate® indices - hyporesponders (T2DM vs. 
Non-DM) 
Post hoc analysis (One way ANOVA); *p<0.05 
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4.4.2 Discussion – platelet reactivity indices 
I report the findings of Multiplate® parameters from my study. Baseline (on aspirin 
alone) ADP AU was similar in elderly (age≥75) and young patients (age<75), with or 
without T2DM. One week of clopidogrel therapy led to a significant reduction in ADP 
AU in elderly and young, again in patients with and without T2DM. An ADP AU cut off 
of 460 was used to define hyporesponders to clopidogrel. Despite a significant 
reduction, mean ADU AU remained greater than 460 in elderly diabetic patients. This 
is the first study to compare Multiplate® indices with platelet dependent thrombus. 
Similar to VerifyNow®, comparing Multiplate® derived platelet reactivity indices to ex-
vivo whole blood thrombus generation is also novel and will certainly be helpful in 
further exploring the use of these indices in clinical setting to tailor antiplatelet therapy. 
In elderly and young patients, 56.1% and 52.5% were good responders to clopidogrel 
respectively. Mean ADP AU were similar in both the elderly and the young cohorts. 
There was a significant reduction in thrombus (measured as total thrombus area) 
among good responders to clopidogrel both in the elderly and the young cohorts. 
Interestingly, similar to VerifyNow data there was a significant reduction in thrombus 
even among hyporesponders to clopidogrel (ADP AU ≥460), in elderly and young 
patients, with or without T2DM. This again demonstrates that clopidogrel reduces 
thrombus formation despite high platelet reactivity as defined by Multiplate cut off (ADP 
AU ≥ 460). These findings are novel and can potentially be explained by 
i) additional pleiotropic anti-atherosclerotic roles of clopidogrel such as 
modulation of vascular tone, improvement of nitric oxide bioavailability as 
well as inhibition of inflammation and oxidative stress (Ostad et al., 2011) 
ii) reconstituted in-vitro thrombus in test cells involves different mechanism 
when compared to real time thrombus generated from ex-vivo Badimon 
chamber 
iii) factors other than platelets involved in thrombogenesis e.g. fibrin cannot be 
assessed by Multiplate®  
ASP AU cut off of 400 was used to define hyporesponders to aspirin. A significantly 
higher percentage of elderly patients were good responders to aspirin (70.7%) 
compared to young patients (55%) at baseline. After one week of clopidogrel this 
percentage increased to 88% and 88.1% in elderly and young respectively. 
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In patients with T2DM and non DM, 50% and 57.3% were good responders to 
clopidogrel. Mean ADP AU among T2DM remained well above the cut off 460 U but 
was <460 in non-DM cohort. There was a significant reduction in thrombus area among 
good responders as well as hyporesponders to clopidogrel. Among good responders 
to clopidogrel, ADP AU in patients with T2DM remained significantly higher compared 
to patients without diabetes. Percentage of good responders to aspirin increased with 
addition of clopidogrel to aspirin in T2DM (63.5% to 88.7%) and non DM patients (63.7 
to 87.6%). 
This is the first study where thrombus area was determined by Badimon chamber, and 
TEG® parameters and VerifyNow® indices were compared with Multiplate® data. High 
shear and low shear thrombus area correlated significantly with ADP AU both at 
baseline and one week after clopidogrel therapy. This possibly is due to the fact that 
platelets play a significant role in thrombus formation. There was a good correlation in 
the assessment of clopidogrel response by TEG® and Multiplate® (MA-ADP and ADP 
AU respectively) after a week of clopidogrel therapy. Assessment of aspirin response 
by TEG® and Multiplate® (MA-AA and ASP AU) also demonstrate significant 
correlation. VerifyNow® indices ARU and PRUz positively correlated with ASP AU and 
ADP AU respectively both at baseline and one week after clopidogrel therapy. These 
results suggest the usefulness of Multiplate® alongside other point of care tests in the 
assessment of thrombogenicity and platelet inhibition by various antiplatelet agents.  
Overall, data from my study confirm high variability in on-treatment platelet reactivity 
as measured by ADP AU among elderly patients and in the presence of T2DM. Both 
elderly and young patients demonstrated significant reduction in ADP AU following 
clopidogrel therapy. Mean ADP AU value as a measure of platelet reactivity was similar 
in elderly and young, contrary to what was demonstrated by VerifyNow indices. Mean 
ADP AU value remained higher than 460 in patients with T2DM when compared to 
non-diabetics, among both good responders and hyporesponders. Even in 
hyporesponders, there was a significant reduction in thrombus formation, both in 
elderly and young patients, with or without TDM. Antiplatelet response for both aspirin 
and clopidogrel measured using TEG® (MA-AA and MA-ADP) and VerifyNow® (ARU 
and PRUz) correlated well with the corresponding measures using Multiplate® (ASP 
AU and ADP AU). 
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Multiplate has been shown to be useful in monitoring clopidogrel responsiveness in my 
study, both in younger group and in the elderly, in the presence and absence of T2DM. 
Multiplate was used to quantify platelet aggregation in a large prospective study of over 
1000 patients who underwent successful coronary stenting after 600mg loading dose 
of clopidogrel. In this study, 11.7% demonstrated low response to clopidogrel. 
Independent predictors for low response were acute coronary syndrome (OR = 6.54), 
diabetes mellitus (OR = 2.07) and male gender (OR = 1.83). Age was not found to be 
a predictor (OR = 1.02, p=0.06) (Behr et al., 2011). In a small study conducted on 
healthy volunteers, Multiplate® was shown to consistently and reliably detect the 
antiplatelet effect of aspirin and AA-induced platelet aggregation (Jámbor et al., 2009). 
Light transmission aggregometry (LTA) is considered to be the gold standard for 
assessing the platelet response to agonists such as adenosine diphosphate (ADP) and 
has been used to assess the drug response to clopidogrel in the initial dose-finding 
studies. In a study with 149 patients who had 600mg of clopidogrel loading dose prior 
to coronary stent insertion, Multiplate strongly correlated with LTA (rho = 0.7; 
p<0.0001) (Sibbing et al., 2010b). Similar correlation was demonstrated in other large 
scale studies as well (Siller-Matula et al., 2012).  
Multiplate was also used to predict the risk of bleeding in patients taking clopidogrel. 
ADP AU cut off of 188 was found to be the optimal cut off to predict the occurrence of 
in-hospital major bleeding. The incidence of major bleeding was significantly higher in 
enhanced clopidogrel responders (very low ADP AU <188) as compared to the 
remaining patients (2.2% vs. 0.8%; OR 2.6; p=0.005) (Sibbing et al., 2010b).  
Karon et al performed a study on 40 healthy volunteers and 10 volunteers on aspirin 
and/or clopidogrel and assessed arachidonic acid–induced platelet function by LTA, 
Multiplate®, VerifyNow®, and TEG-PM®. ADP-induced platelet function was also 
measured using the same methods and flow cytometry. From this study, Multiplate® 
was the only method to demonstrate an acceptable reliability coefficient among healthy 
volunteers and those on both aspirin and clopidogrel therapy. TEG-PM® was found to 
be the least suited point of care test in monitoring the effects of antiplatelet agents 
(Karon et al., 2014). In a meta-analysis, Multiplate® ADP AU significantly predicted 
acute MI (OR 4.03, 95% CI [1.16-14.00], P = 0.03) and stent thrombosis (OR 13.89, 
95% CI [2.63-73.45], P = 0.002), but only a trend was observed regarding CV death 
(3.21 [0.86-12.00], P = .08). 
292 
 
In a study conducted by Mueller et al in patients with stable CAD, 57% of patients were 
hyporesponders to clopidogrel using a cut off of 460 AU. There was also a trend 
towards improved aspirin induced platelet inhibition after the addition of clopidogrel, 
which is in keeping with my findings (Mueller et al., 2007). In my study, approximately 
45 % of the whole cohort were hyporesponders to clopidogrel, with a higher proportion 
of good responders in the elderly and the non DM cohort. Awidi et al demonstrated that 
26% of patients on aspirin 75 to 100mg daily for secondary prevention were 
hyporesponders (Awidi et al., 2010). In my study 25-45% were hyporesponders to 
aspirin at baseline which reduced, falling to 10-15% after the addition of clopidogrel. 
This improvement could be due to two reasons:  
i) enhanced aspirin induced platelet inhibition after the addition of clopidogrel  
ii) improved compliance to aspirin along with clopidogrel during study period  
Verdoia et al analysed HPR on 195 post-ACS patients who underwent coronary 
stenting and were on dual antiplatelet therapy with aspirin and ticagrelor. In this study 
the prevalence of HPR was significantly higher in elderly patients (age≥70 years) when 
compared to the young (21.5% vs. 5.2% respectively, p=0.002).Though patients with 
DM had numerically higher prevalence of HPR compared to the non DM cohort this 
was not statistically significant (14.6% vs. 11.5% respectively, p=0.61). Age ≥ 70 years 
was found to be an independent predictor of HPR with ticagrelor (OR [95%CI] = 4.6 
[1.55–13.8], p=0.006) (Verdoia et al., 2016). 
In Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity 
and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE) 
study, 810 ACS patients and 739 stable CAD patients were recruited and platelet 
reactivity analysed. From this study, age was a significant predictor of HPR (OR 2.11, 
95%CI [1.26–3.53], p=0.005) (Droppa et al., 2015). In another small study, Multiplate 
ADP AU platelet reactivity was measured in 45 elderly (age ≥ 75 years) patients with 
NSTE-ACS undergoing coronary stenting. Almost half (49%) had low platelet reactivity 
(< 188 AU) consistent with increased risk of bleeding. Interestingly, platelet reactivity 
did not correlate with age or with diabetes status (Batty et al., 2015). 
In my study, very low platelet reactivity was identified in only a very small percentage 
of patients in the elderly cohort compared to the young (3.7% vs. 10.2% respectively) 
and this was not statistically significant (P=0.114). Among patients with T2DM and non 
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DM, percentage of participants with very low platelet reactivity were similar (5.8% vs. 
6.7% respectively, p=0.562). 
Over all, it is clear that the Multiplate® assay has demonstrated consistency, good 
reproducibility, low coefficient of variation and high probability of predicting adverse 
events, making it a suitable point of care assay to monitor pharmacodynamics of newer 
antiplatelet / antithrombotic agents in developmental trials. 
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4.5 Coagulation biomarkers - Elderly stable CAD study 
4.5.1 Results 
In patients with established CAD, three groups were analysed: age<75+non DM; 
age≥75+T2DM and age≥75+non DM. 
Demographic data and baseline characteristics of the patients remains the same as 
discussed in the earlier section (Table 4.1). Plasma levels of fibrinogen, P selectin, 
CD40 ligand and PAI-1 were similar between the groups at baseline. Post chamber 
effluent blood levels of P selectin, CD40 ligand and PAI-1 were measured and 
compared with venous blood levels. A significant increase in levels of P selectin, CD40 
ligand and PAI-1 was demonstrated in the post chamber effluent blood in all three 
groups (Table 4.64, Figure 4.18, Figure 4.19). 
P selectin (ng/ml): age<75+non DM: 62.7±18.5 vs. 85.6±20.5, p<0.001; 
age≥75+T2DM: 62.8±19.3 vs. 80.4±23.1, p<0.001; age≥75+non DM: 65.5±19.3 vs. 
86.1±24.2, p<0.001.  
CD40 ligand (pg/ml): age<75+non DM: 2730±1683 vs. 5506±2044, p<0.001; 
age≥75+T2DM: 2447±2051 vs. 3818±2445, p<0.001; age≥75+non DM: 2471±2101 vs. 
4457±1906, p<0.001. 
PAI-1 (ng/ml): age<75+non DM: 24.8±25.3 vs. 42.1±30.0, p<0.001; age≥75+T2DM: 
20.2±26.6 vs. 32.4±32.9, p<0.001; age≥75+non DM: 16.1±27.2 vs. 30.1±23.4, 
p<0.001. 
Following one week of clopidogrel therapy, there was a significant reduction in levels 
of CD40 ligand in non DM group, both young (pg/ml, mean±SD: 2730±1683 vs. 
2121±1368; p=0.05) and elderly (2471±2101 vs. 1733±1119; p=0.006). In the elderly 
T2DM cohort there was a numerical reduction in CD40 ligand but this reduction was 
not statistically significant (2447±2051 vs. 2075±1644; p=0.195). There was no 
significant change in the levels of fibrinogen, P selectin, and PAI-1 compared to 
baseline (Table 4.63, Table 4.65, Table 4.66).  
There was a significant increase in post chamber effluent blood levels of P selectin, 
CD40 ligand and PAI-1 when compared with venous blood levels, similar to that 
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demonstrated at baseline. This increase was similar with and without clopidogrel 
treatment.  
There were no significant correlations seen between thrombus area and levels of 
soluble P selectin and PAI-1both from venous blood samples and post chamber 
effluent blood samples. After one week of clopidogrel therapy, venous CD40 ligand 
and post chamber CD40 ligand correlated positively with low shear thrombus area 
(rho=0.190, p=0.018 and rho=0.178, p=0.028). Delta values of P selectin, CD40L and 
PAI-1 (pre and post chamber levels) showed no correlation to thrombus area.
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Age < 75 + Non T2DM 
(n = 45) 
 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Visit 1 
 
Visit 2 
 
P 
Value 
 
Fibrinogen, g/l 3.2±0.6 3.2±0.7 0.814 3.5±0.7 3.5±0.7 0.685 3.3±0.6 3.3±0.8 0.555 
Venous P 
selectin, ng/ml 62.7±18.5 63.7±15.1 0.613 62.8±19.3 59.9±26.6 0.462 65.5±19.3 60.3±21.9 0.038 
Post chamber P 
selectin, ng/ml 85.6±20.5 73.7±24.1 0.000 80.4±23.1 78.6±26.4 0.618 86.1±24.2 85.2±31.0 0.819 
Venous CD40 
ligand, pg/ml 2730±1683 2121±1368 0.050 2447±2051 2075±1644 0.195 2471±2101 1733±1119 0.006 
Post chamber 
CD40 ligand, 
Pg/ml 
5506±2044 5827±2168 0.326 3818±2445 4071±2488 0.474 4457±1906 4096±1503 0.210 
Venous  
PAI-1, ng/ml 24.8±25.3 25.5±32.8 0.776 20.2±26.6 18.4±23.0 0.422 16.1±27.2 12.1±14.2 0.221 
Post chamber 
PAI-1, ng/ml 42.1±30.0 32.8±24.0 0.014 32.4±32.9 26.2±25.5 0.057 30.1±23.4 29.2±29.7 0.738 
 
Table 4.63 Coagulation biomarkers – Elderly stable CAD study  
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Age < 75 + Non T2DM 
(n = 45) 
 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
 
Age ≥ 75  + Non T2DM 
(n = 45) 
 
Mean ± SD 
 
Venous 
sample 
Post 
chamber 
sample 
P 
Value 
 
Venous 
sample 
Post 
chamber 
sample 
P 
Value 
 
Venous 
sample 
Post 
chamber 
sample 
P 
Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
P selectin, 
ng/ml 62.7±18.5 85.6±20.5 0.000 * 62.8±19.3 80.4±23.1 0.000 * 65.5±19.3 86.1±24.2 
0.000 
* 
CD40 ligand, 
pg/ml 2730±1683 5506±2044 0.000 * 2447±2051 3818±2445 0.000 * 2471±2101 4457±1906 
0.000 
* 
PAI-1, ng/ml 24.8±25.3 42.1±30.0 0.000 * 20.2±26.6 32.4±32.9 0.000 * 16.1±27.2 30.1±23.4 
0.000 
* 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
P selectin, 
ng/ml 63.7±15.1 73.7±24.1 0.002 * 59.9±26.6 78.6±26.4 0.001 * 60.3±21.9 85.2±31.0 
0.000 
* 
CD40 ligand, 
Pg/ml 2121±1368 5827±2168 0.000 * 2075±1644 4071±2488 0.000 * 1733±1119 4096±1503 
0.000 
* 
PAI-1, ng/ml 
25.5±32.8 32.8±24.0 0.024 * 18.4±23.0 26.2±25.5 0.001 * 12.1±14.2 29.2±29.7 
0.000 
* 
 
Table 4.64 Change in coagulation markers pre and post chamber; *p<0.05 
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Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
Median (IQR) 
Fibrinogen, g/l 3.2±0.6 3.5±0.7 3.3±0.6 
0.283 
Venous P selectin, ng/ml 
62.7± 18.5 
60.4 (50.9-73.2) 
62.8± 19.3 
60.1 (48.9-75.6) 
65.5± 19.3 
68.5 (49.3-77.9) 
0.736 
Post chamber P selectin, 
ng/ml 
85.6± 20.5 
86.1 (73.7-99.6) 
80.4± 23.1 
78.4 (62.5-98.7) 
86.1± 24.2 
85.2 (69.7-102.4) 
0.439 
Venous CD40 ligand, pg/ml 
2730± 1683 
2151 (1527-3734) 
2447± 2051 
1697 (1223-2997) 
2471± 2101 
1762 (1122-2929) 
0.753 
Post chamber CD40 ligand, 
pg/ml 
5506± 2044 
5296 (4135-6803) *Ɨ 
3818± 2445 
3289 (2021-5216) * 
4457± 1906 
4288 (2839-5558) Ɨ 
0.001 * 
Venous PAI-1, ng/ml 
24.8± 25.3 
16.6 (6.04-35.9) 
20.2± 26.6 
9.5 (3.6-25.9) 
16.1± 27.2 
8.5 (1.9-18.6) 
0.298 
Post chamber PAI-1, ng/ml 
42.1± 30.0 
40.0 (18.8-52.1) 
32.9± 32.6 
24.8 (12.9-38.7) 
30.1± 23.4 
23.7 (11.3-49.7) 
0.123 
 
Table 4.65 Comparison of coagulation biomarkers at baseline 
*Ɨ p<0.05 
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Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
 
P Value 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
Median (IQR) 
Fibrinogen, g/l 3.2±0.7 3.5±0.7 3.3±0.8 
 
0.193 
Venous P selectin, ng/ml 
63.7± 15.1 
65.8 (52.0-71.2) 
59.9± 26.6 
54.0 (39.6-74.7) 
60.3± 21.9 
57.2 (44.7-68.9) 
0.666 
Post chamber P selectin, 
ng/ml 
73.7± 24.1 
71.1 (59.3-82.0) 
78.6± 26.4 
80.6 (59.3-93.8) 
85.2± 31.0 
80.0 (65.2-100.6) 
0.138 
Venous CD40 ligand, pg/ml 
2121± 1368 
1595 (1337-2204) 
2075± 1644 
1410 (946-2737) 
1733± 1119 
1251 (1050-2341) 
0.355 
Post chamber CD40 ligand, 
pg/ml 
5827± 2168 
5791 (4072-7265) *Ɨ 
4071± 2488 
3466 (2080-5611) * 
4096± 1503 
3816 (2860-5093) Ɨ 
0.001 
Venous PAI-1, ng/ml 
25.5± 32.8 
15.3 (3.8-35.0) * 
18.4± 23.0 
10.6 (3.3-24.4) 
12.1± 14.2 
5.3 (2.2-17.6) * 
0.037 
Post chamber PAI-1, ng/ml 
32.8± 24.0 
27.2 (12.2-44.4) 
26.2± 25.5 
16.8 (6.3-35.6) 
29.2± 29.7 
20.3 (6.2-37.9) 
0.519 
 
Table 4.66 Comparison of coagulation biomarkers after clopidogrel 
  *Ɨ p<0.05 
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Table 4.67 Change in coagulation biomarkers (delta) 
   
* p<0.05
 
 
 
Age < 75 + Non T2DM  
(n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non T2DM  
(n = 45) 
 
 
P Value 
Difference in variables between Visit 1 and Visit 2 
Mean ± SD 
Median (IQR) 
Delta Venous P 
selectin, ng/ml 
-0.98±12.85 
-4.04 (-8.09-6.67) 
2.83±24.39 
8.92 (-2.49-16.64) 
5.16±16.18 
7.4 (-2.23-16.68) 
0.277 
 
Delta Post chamber 
P selectin, ng/ml 
11.85±16.46 
13.48 (5.51-22.55) * 
1.73±22.09 
-0.74 (-9.43-15.68) 
0.86±25.05 
1.92 (-15.37-16.42) * 
0.030 * 
 
Delta Venous CD40 
ligand, pg/ml 
608.41±2025.52 
326.43(-107.49-
1766.44) 
372.33±1809.95 
187.97 (-266.62-938.27) 
738.47±1702.45 
336.58 (-388.51-1183.35) 
0.653 
 
Delta Post chamber 
CD40 ligand, pg/ml 
-320.98±2166.57 
-206.71 (-1469.91-
757.19) 
-253.41±2243.12 
-202.66 (-1833.92-
986.33) 
360.88±1859.45 
142.54 (-822.35-1440) 
0.253 
 
Delta Venous PAI-1,  
ng/ml 
-0.75±17.62 
-0.04 (-6.57-7.28) 
1.80±14.23 
0.02 (-3.03-6.35) 
4.02±21.73 
0.13 (-1.12-2.63) 
0.465 
 
Delta Post chamber 
PAI-1, ng/ml 
9.27±24.29 
7.39 (-6.22-28.79) 
6.21±19.77 
2.86 (-3.54-18.46) 
1.52±30.18 
3.78 (-5.98-12.54) 
0.350 
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Figure 4.18 P Selectin, CD40 ligand & PAI-1 levels – pre- vs. post-chamber 
at baseline 
*p<0.05 
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Figure 4.19 P Selectin, CD40 ligand & PAI-1 levels – pre- vs. post-chamber 
after clopidogrel  
*p<0.05 
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4.5.2 Discussion 
To explore the mechanisms involved in platelet dependent thrombus formation in 
elderly individuals and also to determine the effects of antiplatelet therapy on other 
markers of thrombus formation, I measured the levels of coagulation markers namely 
fibrinogen, P selectin and CD40. The levels of these biomarkers were similar between 
the young and the elderly cohort and also between patients with T2DM and without 
DM in the elderly cohort. One week of clopidogrel therapy did not affect the levels of 
fibrinogen, P selectin or PAI-1 but CD40 levels demonstrated a significant reduction in 
the non-diabetic cohort, both the elderly and the young. 
P selectin, earlier known as α-granule membrane protein-140 (GMP-140) is now a well-
studied biomarker of atherothrombosis, especially in patients with established coronary 
artery disease or T2DM. One of the first studies performed by Wu et al demonstrated 
significantly raised levels of GMP-140 in patients after acute MI or cerebral thrombosis 
(Wu et al., 1993). Following this study, numerous studies were conducted in various 
subsets of patients and soluble P selectin levels were found to be raised in patients 
with unstable angina (Ikeda et al., 1995; Aoki and Tomoda, 1998), acute coronary 
syndrome (Ikeda et al., 1994), stable CAD and peripheral arterial disease (Blann et al., 
1995). Blann et al also demonstrated that increased soluble P-selectin is also a marker 
of disease progression in patients who have survived a myocardial infarction (Blann et 
al., 1997). Levels of soluble P selectin were higher in patients with stable CAD 
compared to healthy volunteers (Furman et al., 1998).  
P-selectin is stored in the α-granules of platelets and the Weibel Palade bodies of 
endothelial cells and is rapidly translocated to the cell surface upon activation by a 
variety of mediators including thrombin and histamine (Bevilacqua and Nelson; 
Kansas, 1996). A number of studies have confirmed higher plasma levels of P selectin 
in patients with T2DM and hyperglycemia is an independent predictor of P selectin in 
patients with T2DM (Yngen et al., 2001). A significant reduction in P selectin following 
improved glycemic control has suggested a direct impact of hyperglycemia on platelet 
activation (Santilli et al., 2010). In a study of 667 patients with symptomatic CAD who 
underwent coronary intervention, Stellos et al reported high levels of platelet derived 
P selectin in ACS patients especially in those with STEMI. P selectin levels correlated 
with myocardial necrosis markers troponin I and creatinine kinase (CK-MB) (Stellos et 
al., 2010). New recombinant monoclonal antibodies against P-selectin such as 
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Inclacumab are being tested in clinical trials and have shown promising results by 
reducing myocardial damage after PCI in patients with non–ST-segment elevation 
myocardial infarction (Tardif et al., 2013). 
There are very few published studies in the literature regarding the effect of increasing 
age on P selectin levels. The few studies that do exist provide conflicting data. Although 
the underlying mechanism of ageing is poorly understood, the oxidative stress 
hypothesis, an imbalance due to increased oxidative stress and a weakened anti-
oxidative defense system, is the most accepted theory behind the ageing process. 
Endothelium tops the list of tissues vulnerable to stress and hence it was proposed 
that endothelial derived soluble adhesion molecules (SAMs) levels increase as a result 
of oxidative stress due to ageing. Zou and colleagues demonstrated a 2.45-fold higher 
level of P selectin in older rats (24 months of age; equivalent to human age of 70 – 75 
years) compared to the younger ones (6 months of age) confirming age related 
alterations to sAMs as a result of endothelial activation / dysfunction (Zou et al., 2004). 
On the contrary, Blann et al could only demonstrate a significant correlation between 
vascular cell adhesion molecule-1 (VCAM-1) and ageing. P selectin levels did not 
correlate with ageing (Blann et al., 1996). In another study in patients with atrial 
fibrillation, plasma von Willebrand factor (vWF, a marker of endothelial damage / 
dysfunction) levels were associated with four recognized risk factors for thrombotic 
events which included advancing age, prior stroke, previous heart failure and DM, but 
soluble P selectin (a marker of platelet activation) was associated only with DM and 
not advancing age (Conway et al., 2002). 
The role of CD40 ligand (CD40L) in atherosclerosis and coronary artery disease has 
been well established (Tousoulis et al., 2010). It has been demonstrated that CD40L 
is expressed on the surface of platelets within seconds of platelet activation (Henn et 
al., 1998). It is stored in platelet granules and is responsible for 95% of circulating 
sCD40 levels. Following platelet activation, the granules are translocated rapidly to the 
platelets’ surface where they are activated then cleaved and shed from the surface as 
sCD40L (Schonbeck and Libby, 2001). Increased levels of CD40L have been found in 
patients with asymptomatic hypercholesterolemia, unstable angina, and acute MI. 
Elevated levels of sCD40L in patients with unstable CAD, indicates an increased risk 
of major cardiovascular events, including AMI, sudden death, and recurrent angina 
(Heeschen et al., 2003; Yan et al., 2004b). In patients with ACS, elevated levels of 
sCD40L levels have also been shown to be associated with higher risk of major 
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adverse cardiovascular events (Vishnevetsky et al., 2004; Antoniades et al., 2009). In 
vivo studies have demonstrated the role of sCD40L in destabilization of atheromatous 
plaque (Erbel et al., 2007) and hence sCD40L may be used as a valuable marker for 
predicting the severity of ACS (Aukrust et al., 1999; Yan et al., 2002; Wang et al., 
2007). Diabetes mellitus and smoking were independently associated with elevated 
sCD40L levels (Tousoulis et al., 2007a). 
At a clinical level, elevated levels of sCD40L identify patients at high risk of UA and 
ACS. Patients with ACS have higher levels of sCD40L when compared to patients with 
stable CAD and controls (Tousoulis et al., 2007b). Levels of sCD40L were much higher 
following coronary stent insertion in ACS patients with high ADP induced platelet 
aggregation (Obradovic et al., 2009). Levels of sCD40L have also been correlated with 
complex coronary stenosis (r = 0.60, P < 0.01) in ACS patients undergoing coronary 
intervention (Yan et al., 2004a). In these patients, intracoronary CD40L measured from 
the blood sample drawn from the culprit artery were higher when compared with that 
from the peripheral circulation (Aggarwal et al., 2004; Tousoulis et al., 2007b). Elevated 
levels of sCD40L 1 month after PCI also predict angiographic restenosis (L'Allier et al., 
2005). 
Despite these findings, there is a growing body of evidence questioning the clinical 
significance of circulating sCD40L in the ACS setting. Hence measuring sCD40L levels 
routinely still remains controversial. In a large population-based study, 1524 patients 
treated with a GPIIb/IIIa receptor inhibitor, higher sCD40L levels were not associated 
with higher risk of nonfatal MI or re-hospitalization for ACS (Morrow et al., 2008). In 
another study on patients presenting with ST-elevation MI (STEMI), elevated levels of 
sCD40L at admission were not associated with the onset of STEMI and did not provide 
any prognostic information regarding future mortality (Tan et al., 2008). In the Dallas 
Heart Study, a large and representative multiethnic population study, sCD40L was not 
associated with established atherosclerotic risk factors suggesting that sCD40L 
measurement cannot be used as a screening tool (de Lemos et al., 2005). Adding to 
this, studies have also found that in non-ACS patients, higher sCD40L levels are 
associated with a reduction in the risk of developing CAD (Rondina et al., 2008), but in 
ACS cohort, no significant association was demonstrated between sCD40L and 
cardiovascular outcomes (Olenchock et al., 2008). All these results have raised 
questions regarding the role of sCD40L in the development of CAD (Zirlik et al., 2007). 
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Literature on sCD40L in elderly individuals (age≥75 years) is minimal. There is no 
published literature on sCD40L in elderly population with stable CAD or in ACS setting 
either. Hence my study findings are important in that respect. Deterioration of immune 
function in old age is a common finding (Lio et al., 1998). This progressive decline of 
the immune system, defined `immunosenescence' (Pawelec et al., 1997), is one of the 
several physiological changes thought to occur with increasing age. It has been 
demonstrated that CD40–CD40L pathways become dysfunctional with ageing (Effros, 
2000; Weiskopf et al., 2009). Levels of CD40, and CD40L decline with increasing age 
(Fernandez-Gutierrez et al., 1999).  
Levels of sCD40L are higher in both T1DM and T2DM than in non-diabetic individuals 
(Santilli et al., 2007). Significantly increased co-expression of CD40 and CD40L on 
diabetic platelets has also been documented (Santilli et al., 2007). In patients with 
T2DM, CD40L levels correlated significantly with urinary excretion rate of 11-dehydro-
thromboxane B2, which is a marker of in vivo platelet activation (Santilli et al., 2006). 
In my study there was no difference in the levels of sCD40L between the elderly and 
young cohort or between T2DM and non DM. In the non DM cohort, addition of 
clopidogrel for 7 days resulted in a significant reduction in sCD40L levels. This finding 
is in keeping with the previous published data where administration of clopidogrel for 
one week in an ACS setting reduced platelet monocyte interaction and sCD40L levels 
(Xiao and Theroux, 2004). Quinn et al demonstrated low serum CD40L levels with 
clopidogrel pre-treatment with 300-600mg in patients who underwent PCI and these 
changes were more marked in flow cytometry assay after stimulation with ADP (Quinn 
et al., 2004). In the PROCLAIM study (Pilot Study to Examine the Effects of Clopidogrel 
on Inflammatory Markers in Patients with Metabolic Syndrome Receiving Low-Dose 
Aspirin), the effect of 9 week treatment with dual antiplatelet therapy (aspirin and 
clopidogrel) was compared with aspirin and placebo, in participants with metabolic 
syndrome and who were clinically stable on appropriate medications. A significant 
reduction in CD40L was demonstrated after 9 weeks without changes in P selectin and 
other inflammatory markers (Willerson et al., 2009).  
PAI-1 is an independent risk factor in the development of cardiovascular disease and 
insulin resistance (Thögersen et al., 1998). Serum PAI-1 levels are associated with 
cardiovascular morbidity and mortality in both men and women in prospective studies 
(Speiser et al., 1988). In vivo, PAI-1 is synthesized by endothelial cells and 
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megakaryocytes (Sawdey and Loskutoff, 1991; Konkle et al., 1993). PAI-1 is then 
sequestered in platelets and stored in the α-granules (Erickson et al., 1984). Platelets 
form the main reservoir of PAI-1 in blood and the concentration of PAI-1 is extremely 
low in plasma (Kruithof et al., 1986). From these data, it can be deduced that activation 
of platelets and release of the contents of the a-granules would result in a high local 
PAI-1 concentration in thrombi (Stringer et al., 1994). 
The age-associated increased risk of atherothrombotic disease may be related to 
reduced fibrinolytic potential as evidenced by reduction in tPA activity and/or increase 
in PAI-1 (Hashimoto et al., 1987; Abbate et al., 1993; Gleerup and Winther, 1995; 
Yamamoto et al., 2005). PAI-1 levels are elevated in patients with T2DM (Mcgill et al., 
1994; Sobel et al., 1998). In the IRAS (Insulin Resistance Atherosclerosis Study) study, 
PAI-1 predicted the incidence of T2DM and insulin resistance (Festa et al., 2006). In 
poorly controlled T2DM patients, higher levels of PAI-1 have been reported (Lemkes 
et al., 2010). In patients with acute coronary syndrome, levels of PAI-1 were increased 
(Yazici et al., 2005). PAI-1 has also been demonstrated to play a significant role in 
evolution and outcomes in patients with T2DM following ACS (Sobel et al., 1998; 
Sobel, 1999; Schneider and Sobel, 2012).  
Long term dual antiplatelet therapy with aspirin and clopidogrel reduces PAI-1 levels 
(Sakata and Kario., 2011). Other strategies which successfully demonstrated a 
significant reduction in PAI-1 levels include improved glycaemic control, weight 
reduction and use of insulin sensitising agents (Schneider and Sobel, 2012). Statins 
increase the expression of tissue-type plasminogen activator and inhibit the expression 
of PAI-1 (Essig et al., 1998). This inhibitory effect of statins on PAI-1 expression is 
mediated through the Phosphatidylinositol 3-kinase/protein kinase Akt pathway (Mukai 
et al., 2007).   
In my study, PAI-1 levels at baseline in the elderly cohort was similar to the young 
cohort. Within the elderly cohort, T2DM patients had similar PAI-1 levels when 
compared to patients without DM. All participants in my study were on good secondary 
prevention therapy including statin and this could be the reason for low PAI-1 levels 
over all.  
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Post chamber “effluent blood” (activated blood) from the Badimon chamber 
When the blood flows through the chamber, it is subjected to high shear force and is 
exposed to tunica media, where contact activation of platelets with collagen occurs. 
Hence this effluent blood represents “activated blood” and should theoretically have 
increased levels of biomarkers that are released during platelet activation and involved 
in platelet dependent thrombus formation. Since the flow conditions within the chamber 
mimic the rheological flow conditions in a moderately stenosed coronary artery with a 
plaque rupture, the post chamber effluent blood may be equivalent to the blood sample 
from coronary sinus in patients with established CAD and acute plaque rupture. For P 
selectin, sCL40L and PAI-1 the gradient between pre and post chamber blood sample 
might be useful to quantify the amount of these biomarkers released by the activated 
platelets inside the chamber.  
My study has demonstrated a significant increase in levels of P selectin, sCD40L and 
PAI-1 in the effluent blood both in the elderly and the young and in patients with T2DM 
and non DM. This may represent the amount of these biomarkers released from 
activated platelets inside the chamber. This increase was demonstrated at baseline 
and at one week after clopidogrel therapy. Addition of clopidogrel did not result in any 
significant reduction in release of these biomarkers from activated platelets as 
measured by the delta values of these biomarkers (pre and post chamber difference). 
However, I could not demonstrate any correlation between the venous levels, post 
chamber levels or the delta values (pre and post chamber difference) of P selectin, 
CD40L, PAI-1 and the thrombus area. This might be due to the small sample size in 
my study. The ELISA method used in my study has previously demonstrated more 
heterogeneous spread of P selectin measurements when compared to results from 
flow cytometry (Ritchie et al., 2000). A better correlation could potentially have been 
demonstrated between thrombus area and levels of P selectin and CD40 ligand if the 
sample size was much higher and if flow cytometric methods were used in this study. 
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4.6 Inflammatory biomarkers - Elderly stable CAD study 
4.6.1 Results 
In patients with established CAD, three groups were analysed: age<75+non DM; 
age≥75+T2DM and age≥75+non DM. 
Demographic data and baseline characteristics of the patients remains the same as 
discussed in the earlier section (Table 4.1). At baseline, venous blood levels of IFNγ, 
IL-6 and IL-1 were similar between the groups. Venous TNFα levels were higher in 
elderly diabetic group compared to the young non diabetic group (mean±SD, ng/ml: 
3.99±1.12 vs. 4.96±1.42, p=0.002). Post chamber effluent blood levels of IFNγ, IL-6, 
IL-1 and TNFα were measured and compared with venous blood levels. This 
demonstrated significant reduction in IL-6 levels in patients with age<75+non DM 
(3.84±3.71 vs. 3.0±2.68, p<0.01) and age≥75+DM (6.21±6.27 vs. 4.82±4.47, p=0.014). 
Patients with age≥75+non DM also demonstrated a numerical reduction in IL-6 level 
but this was not statistically significant (5.27±5.92 vs. 4.88±5.34, p=0.182) (Table 4.69, 
Table 4.70).  
Following one week of clopidogrel therapy, the elderly diabetic population interestingly 
demonstrated a slight but significant increase in venous blood levels of IFNγ and TNFα. 
The elderly non diabetic population also demonstrated a slight but significant increase 
in levels of TNFα. Post chamber effluent blood again demonstrated significant 
reduction in IL-6 levels in patients with age<75+non DM (4.82±5.21 vs. 4.22±4.68, 
p<0.01). Patients with age≥75+DM and age≥75+non DM also demonstrated a 
numerical reduction in IL-6 level but this was not statistically significant (Table). Venous 
TNFα levels remained higher in elderly diabetic group compared to young non diabetic 
group (5.66±1.80 vs. 3.97±0.96, p<0.01) (Figure 4.20, Table 4.68, Table 4.71). 
There were modest but significant correlations between hsCRP and thrombus area 
(rho=0.158, p=0.05) at baseline and IL-6 levels and thrombus area (rho=0.191, 
p=0.017), 1 week after clopidogrel therapy.   The difference in IL-6 levels between 
baseline and after 1 week of clopidogrel therapy (delta IL-6) also demonstrated a 
modest but significant correlation with thrombus area (rho=0.281, p=0.019) (Table 
4.73). 
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Age < 75 + Non T2DM 
(n = 45) 
Age ≥ 75 + T2DM 
(n = 41) 
Age ≥ 75  + Non T2DM 
(n = 45) 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Venous IFNγ, 
ng/ml 
1.55±1.96 4.35±11.75 0.113 1.16±0.92 1.86±1.06 0.000 * 1.49±1.74 3.43±10.4 0.219 
Post chamber 
IFNγ, ng/ml 
1.56±1.83 4.80±13.66 0.116 1.33±0.81 1.76±0.91 0.001 * 1.54±1.75 3.7±11.72 0.241 
Venous IL-1, 
ng/ml 
0.20±0.33 0.23±1.54 0.880 0.11±0.28 0.23±1.32 0.607 0.26±0.79 0.03±0.13 0.072 
Post chamber  
IL-1, ng/ml 
0.84±2.92 0.04±0.13 0.075 0.36±1.22 0.17±0.30 0.330 0.22±0.43 1.0±5.47 0.339 
Venous IL-6, 
ng/ml 
3.84±3.71 4.82±5.21 0.106 6.21±6.27 6.22±5.55 0.978 5.27±5.92 4.84±4.86 0.653 
Post chamber    
IL-6, ng/ml 
3.0±2.68 4.22±4.68 0.032 * 4.82±4.47 5.63±4.63 0.188 4.88±5.34 4.77±4.56 0.909 
Venous TNFα, 
ng/ml 
3.99±1.12 3.97±0.96 0.910 4.96±1.42 5.66±1.80 0.011 * 4.41±1.30 4.89±1.65 0.003 * 
Post chamber 
TNFα, ng/ml 
3.71±1.37 4.07±1.13 0.070 4.75±2.72 5.30±1.67 0.185 5.17±7.58 4.7±1.45 0.693 
Table 4.68 Inflammation biomarkers – Elderly stable CAD study; 
 * p<0.05 
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Age < 75 + Non T2DM 
(n = 45) 
Age ≥ 75 + T2DM 
(n = 41) 
Age ≥ 75  + Non T2DM 
(n = 45) 
Mean ± SD 
 
Venous 
sample 
Post 
chamber 
sample 
P 
Value 
 
Venous 
sample 
Post 
chamber 
sample 
P 
Value 
 
Venous 
sample 
Post 
chamber 
sample 
P 
Value 
 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
IFNγ, ng/ml 1.55±1.96 1.56±1.83 0.908 1.16±0.92 1.33±0.81 0.062 1.49±1.74 1.54±1.75 0.513 
IL-1, ng/ml 0.20±0.33 0.84±2.92 0.152 0.11±0.28 0.36±1.22 0.196 0.26±0.79 0.22±0.43 0.849 
IL-6, ng/ml 3.84±3.71 3.0±2.68 0.000 * 6.21±6.27 4.82±4.47 0.014 * 5.27±5.92 4.88±5.34 0.182 
TNFα, ng/ml 3.99±1.12 3.71±1.37 0.114 4.96±1.42 4.75±2.72 0.572 4.41±1.30 5.17±7.58 0.534 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
IFNγ, ng/ml 4.35±11.75 4.80±13.66 0.201 1.86±1.06 1.76±0.91 0.282 3.43±10.4 3.7±11.72 0.323 
IL-1, ng/ml 0.23±1.54 0.04±0.13 0.403 0.23±1.32 0.17±0.30 0.789 0.03±0.13 1.0±5.47 0.252 
IL-6, ng/ml 4.82±5.21 4.22±4.68 0.000 * 6.22±5.55 5.63±4.63 0.071 4.84±4.86 4.77±4.56 0.160 
TNFα, ng/ml 3.97±0.96 4.07±1.13 0.002 * 5.66±1.80 5.30±1.67 0.192 4.89±1.65 4.7±1.45 0.383 
Table 4.69 Change in inflammation markers pre and post chamber 
* p<0.05 
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Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + 
T2DM (n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
Median (IQR) 
Hs CRP mg/l 
1.8± 1.8 
1.2 (0.6-2.6) 
4.3±6.6 
2.0 (1.0-4.8) 
4.4±7.7 
1.5 (0.7-3.9) 
0.075 
Venous IFNγ, ng/ml 
1.55± 1.96 
1.13 (0.47-2.1) 
1.16± 0.92 
0.93 (0.46-1.87) 
1.49± 1.74 
1.13 (0.58-1.60) 
0.494 
Post chamber IFNγ, ng/ml 
1.56± 1.83 
1.11 (0.89-1.50) 
1.33± 0.81 
1.18 (0.64-1.94) 
1.54± 1.75 
1.08 (0.66-1.6) 
0.747 
Venous IL-1, ng/ml 
0.20± 0.33 
0 (0-0.26) 
0.11± 0.28 
0 
0.26± 0.79 
0 
0.465 
Post chamber IL-1, ng/ml 
0.84± 2.92 
0 (0-0.34) 
0.36± 1.22 
0 (0-0.22) 
0.23± 0.43 
0 (0-0.26) 
0.269 
Venous IL-6, ng/ml 
3.84± 3.71 
3.21 (1.86-4.21) 
6.21± 6.27 
4.39 (2.4-6.23) 
5.27± 5.92 
3.06 (2.49-5.17) 
0.126 
Post chamber IL-6, ng/ml 
3.0± 2.68 
2.12 (1.54-3.39) 
4.82± 4.47 
3.34 (2.04-4.75) 
4.88± 5.34 
2.94 (2.09-4.41) 
0.081 
Venous TNFα, ng/ml 
3.99± 1.12 
3.73 (3.26-4.66) * 
4.96± 1.42 
4.85 (4.18-5.6) * 
4.41± 1.30 
4.26 (3.46-4.86) 
0.003 * 
Post chamber TNFα, ng/ml 
3.71± 1.37 
3.32 (2.96-4.38) 
4.75± 2.72 
4.22 (3.42-4.88) 
5.17± 7.58 
3.9 (3.12-4.5) 
0.349 
 
Table 4.70 Comparison of inflammation biomarkers at baseline  
* p<0.05 
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Age < 75 + Non T2DM 
(n = 45) 
 
Age ≥ 75 + T2DM 
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
P Value 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
Median (IQR) 
Venous IFNγ, ng/ml 
4.35± 11.75 
1.15 (0.74-2.13) 
1.86± 1.06 
1.7 (1.09-2.47) 
3.43± 10.4 
1.41 (0.94-2.41) 
0.454 
Post chamber IFNγ, ng/ml 
4.80± 13.66 
1.21 (0.94-2.0) 
1.76± 0.91 
1.62 (1.09-2.2) 
3.7± 11.72 
1.62 (1.09-2.4) 
0.406 
Venous IL-1, ng/ml 
0.23± 1.54 
0 
0.23± 1.32 
0 
0.03± 0.13 
0 
0.660 
Post chamber IL-1, ng/ml 
0.04± 0.13 
0 
0.17± 0.30 
0 (0-0.24) 
1.0± 5.47 
0 (0-0.21) 
0.312 
Venous IL-6, ng/ml 
4.82± 5.21 
3.46 (2.11-4.87) 
6.22± 5.55 
4.79 (2.73-8.07) 
4.84± 4.86 
3.45 (2.32-5.59) 
0.368 
Post chamber IL-6, ng/ml 
4.22± 4.68 
2.96 (1.77-4.72) 
5.63± 4.63 
4.43 (2.57-7.54) 
4.77± 4.56 
3.48 (2.22-5.38) 
0.367 
Venous TNFα, ng/ml 
3.97± 0.96 
3.89 (3.26-4.53) *Ɨ 
5.66± 1.80 
5.22 (4.41-6.8) * 
4.89± 1.65 
4.62 (3.8-5.63) Ɨ 
0.000* 
Post chamber TNFα, ng/ml 
4.07± 1.13 
3.83 (3.36-4.46) * 
5.30± 1.67 
4.98 (3.99-6.06) * 
4.7± 1.45 
4.27 (3.75-5.11)  
0.001 
 
Table 4.71 Comparison of inflammation biomarkers one week after clopidogrel therapy  
*Ɨ p<0.05 
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Age < 75 + Non 
T2DM (n = 45) 
 
Age ≥ 75 + T2DM  
(n = 41) 
 
Age ≥ 75  + Non 
T2DM (n = 45) 
 
 
P Value 
Difference in variables between Visit 1 and Visit 2 
Mean ± SD 
Median (IQR) 
Delta Venous IFNγ, ng/ml 
 
-2.8±11.61 
-0.03 (-0.82-0.22) 
-0.70±1.01 
-0.54 (-1.06- -0.04) 
-1.94±10.46 
-0.42 (-0.89-0.15) 
0.570 
 
Delta Post chamber IFNγ, 
ng/ml 
 
-3.24±13.56 
-0.14 (-0.84-0.22) 
-0.43±0.79 
-0.36 (-1.41-0.19) 
-2.14±11.81 
-0.45 (-0.97- -0.10) 
0.464 
 
Delta Venous IL-1, ng/ml 
 
-0.04±1.61 
0 (0-0.26) 
-0.11±1.37 
0 
0.22±0.81 
0 
0.456 
 
Delta Post chamber IL-1, 
ng/ml 
0.80±2.94 
0 (0-0.34) 
0.19±1.25 
0 (-0.15-0.17) 
-0.78±5.32 
0 (-0.08-0.05) 
0.120 
 
Delta Venous IL-6, ng/ml 
 
-0.98±3.96 
-0.40 (-1.07-0.56) 
-0.016±3.73 
-0.25 (-1.64-1.18) 
0.43±6.38 
-0.004 (-1.08-0.91) 
0.380 
 
Delta Post chamber IL-6, 
ng/ml 
-1.22±3.69 
-0.61 (-1.28-0.09) 
-0.81±3.89 
-0.48 (-1.73-0.25) 
0.11±6.03 
-0.31 (-0.84-0.30) 
0.400 
 
Delta Venous TNFα, ng/ml 
 
0.01±0.85 
0.06 (-0.63-0.73) 
-0.70±1.68 
-0.37 (-1.41-0.19) 
-0.48±1.01 
-0.34 (-1.10-0.21) 
0.021* 
 
Delta Post chamber TNFα, 
ng/ml 
-0.36±1.29 
-0.41 (-0.96-0.15) 
-0.54±2.58 
-0.81 (-1.55- -0.11) 
0.46±7.66 
-0.58 (-1.23- -0.08) 
0.578 
 
 
Table 4.72 Change in inflammatory biomarkers (delta) 
* p<0.05
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Correlation with high 
shear thrombus area 
Rho (2-tailed p value) 
 
Correlation with low 
shear thrombus area 
Rho (2-tailed p value) 
Stable CAD Patients on Aspirin alone 
Venous IFNγ, ng/ml 
-0.157 (0.043) * -0.050 (0.539) 
Hs CRP, mg/l 
0.033 (0.674) 0.158 (0.050) * 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel 
Post chamber IFNγ, ng/ml 
-0.178 (0.022) * -0.092 (0.257) 
Venous IL-1, ng/ml 
0.014 (0.858) -0.270 (0.001) * 
Venous IL-6, ng/ml 
-0.002 (0.983) 0.191 (0.017) * 
Delta IL-6, ng/ml 
0.108 (0.368) 0.281 (0.019) * 
Post chamber TNFα, 
ng/ml -0.104 (0.183) -0.213 (0.008) * 
 
Table 4.73 Correlation between inflammatory biomarkers and thrombus area 
* p<0.05 
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Figure 4.20 Change in venous TNFα levels with clopidogrel therapy 
*p<0.05 
At baseline: significantly higher TNFα levels in patients with age≥75+T2DM compared 
to age<75+non DM (4.96± 1.42 vs. 3.99± 1.12, p=0.003) 
In patients with age≥75+T2DM there was a significant increase in TNFα one week after 
clopidogrel therapy compared to baseline (5.66±1.80 vs. 4.96±1.42, p=0.011) 
In patients with age≥75+non DM there was a significant increase in TNFα one week 
after clopidogrel therapy compared to baseline (4.89±1.65 vs. 4.41±1.30, p=0.003) 
After 1 week of clopidogrel therapy: significantly higher levels of TNFα were measured 
in patients with age≥75+T2DM (5.66±1.80 vs. 3.97±0.96, p<0.01) and age≥75+non-
DM (4.89±1.65 vs. 3.97±0.96, p<0.01), when compared with age<75+non DM.  
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4.6.2 Discussion 
Ageing has been associated with chronic low grade inflammation which in turn has 
been hypothesized to play a significant role in the pathogenesis of atherosclerosis and 
T2DM in the elderly. T2DM is also associated with inflammation and thrombotic events. 
I wanted to explore the role of inflammation in thrombus formation in elderly and CAD 
patients, with and without T2DM. Tumour necrosis factor-α (TNFα) levels were 
significantly higher in the elderly cohort compared to the young at baseline (whilst on 
aspirin alone) and continued to be high in the elderly cohort after addition of clopidogrel 
for one week. High sensitivity CRP (hs CRP) and interleukin-6 (IL-6) levels were 
numerically higher in the elderly cohort but were not statistically significant at baseline. 
IL-6 levels continued to remain high in the elderly compared to the young after the 
addition of clopidogrel but this again was not statistically significant. Levels of TNFα 
and IL-6 were highest among elderly diabetic patients. 
Increasing age has been associated with increased circulating levels of inflammatory 
markers, including proinflammatory and anti-inflammatory cytokines, cytokine 
antagonists and acute phase proteins (Bruunsgaard et al., 2001). Elevated levels of 
proinflammatory cytokines such as TNF-α (Paolisso et al., 1998; Bruunsgaard et al., 
1999) and IL-6 (Wei et al., 1992; Cohen et al., 1997) are particularly important as they 
are associated with increased morbidity and mortality in the elderly (Brüünsgaard and 
Pedersen, 2003). Plasma TNF-α concentration also predicts impaired insulin action 
with advancing age (Paolisso et al., 1998). Various reports have indicated that 
inflammatory markers might predict future cardiovascular events, especially in the 
elderly population (De Martinis et al., 2006). Harris et al demonstrated that high 
circulating levels of IL-6 and CRP were associated with increased cardiovascular 
mortality in the elderly population (Harris et al., 1999). High levels of IL-6 and CRP 
were also noted in patients with unstable angina and depending on the fall or raise of 
their levels in the blood the outcome of the patients was good or bad respectively 
(Biasucci et al., 1996).  
An increase in tissue factor expression caused by inflammation tends to shift the 
hemostatic balance in favour of thrombogenicity. Prothrombotic effect of TNFα and IL-
6 are due to their ability to induce tissue factor expression, primarily on monocytes and 
macrophages (Walsh, 1987; Edgington et al., 1991). TNFα also increases the 
production of ultra-large von Willebrand factor (vWF) multimers and fibrinogen, thereby 
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shifting haemostasis towards thrombus formation (Bernardo et al., 2004). Normally 
these multimers of vWF are processed into smaller forms which are less thrombogenic. 
IL-6 prevents this process, thereby maintaining a thrombogenic milieu (Bernardo et al., 
2004). Increased levels of IL-6 have been associated with increased platelet 
production. The newly formed platelets appear to be more thrombogenic as they can 
be activated at lower concentrations of thrombin. Thus both platelet count and platelet 
reactivity are increased, thereby increasing their thrombogenic potential (Burstein, 
1997). TNFα and IL-1 down regulate natural anticoagulant pathways involving protein 
C and thrombomodulin (Conway and Rosenberg, 1988; Fukudome and Esmon, 1994). 
Substantial experimental evidence suggests the association of TNFα and IL-6 with 
hyperglycaemia, insulin resistance and T2DM (Sandler et al., 1990; Grau et al., 1996; 
Pickup et al., 1997; Tsigos et al., 1997; Festa et al., 2000). In another study conducted 
by Pradhan et al, CRP and IL-6, were determinants of risk for T2DM. CRP was a 
powerful independent predictor of T2DM after adjustment for obesity, clinical risk 
factors, and fasting insulin levels (Dovio and Angeli, 2001; Pradhan et al., 2001). 
Inflammatory cytokines and hsCRP levels appear to fall after treatment with aspirin 
and clopidogrel in a number of studies (Mehta et al., 2001; Yusuf et al., 2001a; 
Steinhubl et al., 2002; Chen et al., 2005b; Sabatine et al., 2005b; Sabatine et al., 
2005c). Clopidogrel does not have any direct anti-inflammatory actions, hence its 
clinical benefits may be due to indirect anti-inflammatory effect in addition to its well 
characterised antiplatelet effect. Interestingly in my study, contrary to what was 
expected, after one week of clopidogrel there was a modest but significant increase in 
TNFα levels in elderly cohort (both in T2DM and non DM). Failure of clopidogrel to 
demonstrate any significant reduction in inflammatory biomarkers is probably due to 
the fact that 75 mg daily dose of clopidogrel for 7 days is not adequate enough to 
suppress inflammation. 
Failure of DAPT to reduce inflammatory biomarkers was seen in Evaluation of Long-
term clopidogrel AntiPlatelet and Systemic anti-inflammatory Effects (ELAPSE) study, 
a prospective study involving 26 patients who received DAPT for 12 months following 
coronary stent insertion. Levels of hsCRP, IL-10 and IL-18 initially increased for a few 
days but remained unchanged at 12 months but the contradictory finding was an 
increase in sP selectin level at 12 month follow up (Saw et al., 2008). 
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I found that the levels of hsCRP and IL-6 demonstrated significant positive correlation 
with thrombus area (hsCRP: rho=0.158, p=0.05; IL-6: rho=0.191, p=0.017). Delta IL-6 
also demonstrated a positive correlation with thrombus area (rho=0.281, p0.019). 
These findings further emphasise the potential role of these inflammatory markers in 
thrombus generation. 
Post chamber “effluent blood” (activated blood) from the Badimon chamber 
I compared the levels of inflammatory biomarkers from venous blood sample and from 
post chamber “effluent” blood. As explained before, post chamber blood may be 
equivalent to the blood sample from coronary sinus in patients with established CAD 
and acute plaque rupture. Cytokines are neither synthesised nor released from the 
blood that is flowing through the chamber. Hence any change in the levels of 
biomarkers pre and post chamber would represent the usage / consumption of these 
cytokines in the formation of thrombus within the chamber.  
From my study, I observed a reduction in IL-6 in post chamber blood compared to 
venous blood sample (pre-chamber blood) both at baseline (when on aspirin alone) 
and after one week of clopidogrel alongside aspirin. This reduction was seen in the 
elderly and the young cohort, both in patients with T2DM and non DM. Levels of TNFα, 
IL-1 and IFNy remain unchanged in elderly and young patients both in the presence 
and absence of T2DM. This negative observation could be due to average low levels 
of inflammatory markers in my cohort of patients with stable CAD, as they all were on 
appropriate secondary prevention therapy including statins. 
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4.7 Scanning electron microscopy (SEM) – Elderly stable CAD study 
4.7.1 Results - Ultrastructural analysis of thrombus 
To explore the differences in ultrastructural characteristics of the formed thrombus, I 
performed a sub-study using scanning electron microscopy (SEM), in all three groups 
of patients: age<75+non DM, age≥75+T2DM and age≥75+non DM. 
I randomly chose 20 patients from each group (n=20 in each group). Demographic 
profiles, metabolic profiles and cardiovascular risk factors are shown in Table 4.74. 
Overall, baseline characteristics are similar between the groups except for significantly 
higher systolic blood pressure and lower haemoglobin in the elderly cohort compared 
to the young. The elderly non DM cohort demonstrated a modest but significantly 
higher HDLc level compared to the elderly T2DM group. 
SEM image analysis of high shear thrombus was performed to quantify the platelet 
content of thrombus and this was measured as proportion of platelet rich areas to fibrin 
rich areas at 60X magnification. At baseline, percentage of platelet rich areas were 
similar between the three groups (Table 4.76). After a week of clopidogrel therapy, a 
significant reduction in platelet rich area was demonstrated in all the groups 
(age<75+non T2DM: 75.9% to 66.7%, mean difference [MD]: 9.2%; 95%CI: 6.9-11.5; 
p<0.001; age≥75+T2DM: 77.6% to 69.3%; MD: 8.3%; 95%CI: 7.11-9.46; p<0.001; 
age≥75+Non T2DM: 77.7 % to 69.6%; MD: 8.1%; 95%CI: 5.8-10.3; p<0.001). The 
mean difference in reduction in platelet rich area of thrombus was similar in all the 
three groups. 
Quantitative assessment of fibrin was performed by measuring the following 
parameters: fibrin diameter (µm), fibrin fibre density (n/µ2), fibrin spokes (n/µ2), fibrin 
hubs (n/µ2). Platelet diameter was also measured (Table 4.75, Table 4.76, Table 4.77, 
Figure 4.24). 
Fibrin diameter increased in all the three groups following one week of clopidogrel 
therapy (µm, mean±SD; age<75+T2DM: 218.1±20.2 to 243.4±16.6, p<0.001; 
age≥75+T2DM: 198.9± 70.2 to 245.0± 32.9, p=0.038; age≥75+non DM: 204.8± 22.9 
to 233.2±27.9, p<0.001). There was no significant difference in fibrin diameter 
between the groups at baseline or at one week after clopidogrel therapy. Platelet 
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diameter was similar between the groups at baseline and remained unchanged after 
one week of clopidogrel therapy. 
Fibrin fibre density (n/µ2) increased in all three groups following one week of 
clopidogrel therapy (n/µ2, mean±SD; age<75+T2DM: 38.5±4.3 to 43.2±7.1, p=0.026; 
age≥75+T2DM: 40.5±2.9 to 44.7±8.7, p=0.039; age≥75+non DM: 37.4±3.3 to 
42.8±7.6, p=0.035) 
Spokes of fibrin (n/µ2 of thrombus), increased in all three groups following one week 
of clopidogrel therapy (mean±SD; age<75+T2DM: 26.3± 3.1 to 31.2±6.7, p=0.031; 
age≥75+T2DM: 25.3±3.8 to 29.1±6.4, p=0.023; age≥+non DM: 24.8±3.1 to 30.7±7.3, 
p=0.041) (Figure 4.25) 
Hubs of fibrin (n/µ2 of thrombus), increased in all three groups following one week of 
clopidogrel therapy (mean±SD; age<75+T2DM: 16.4±1.6 to 18.7±2.8, p=0.039; 
age≥75+T2DM: 17.4±2.3 to 19.4±2.6, p=0.014; age≥+non DM: 16.3±1.5 to 18.2±3.1, 
p=0.009) 
In this cohort of patients, there was a significant reduction in platelet dependent 
thrombus (PDT) in both young non-diabetic and elderly diabetic group. In the elderly 
non-diabetic group there was a numerical reduction in thrombus area, but because of 
small number of patients in this substudy the reduction in thrombus did not reach 
statistical significance. At baseline, the number of spokes per µ2 of thrombus 
demonstrated a strong negative correlation with low shear thrombus area (rho= -
0.374, p=0.005) and high shear thrombus area (rho= -0.327, p=0.013). After a week 
of clopidogrel therapy percentage platelet rich area from SEM correlated significantly 
with high shear thrombus area (rho=0.408, p=0.002) (Figure 4.26). 
Thromboelastography (TEG®) data demonstrated minimal numerical reduction in 
maximum strength of the thrombus (MA) and clot index (CI) with a trend towards 
increased clot lysis. These changes again were not statistically significant due to small 
sample size. The maximum amplitude of viscoelastic force of thrombus upon 
stimulation with ADP (MA-ADP) was significantly lower after one week of clopidogrel 
therapy (Table 4.78). At baseline, fibrin fibre density demonstrated a significant 
negative correlation with MA (rho= -0.459, p=0.048), G (rho= -0.469, p=0.043) and 
rate of thrombin generation (TG) (rho= -0.458, p=0.049).  
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VerifyNow® PRUz and percentage platelet inhibition demonstrated significant 
reduction after a week of clopidogrel therapy. ARU demonstrated a trend towards 
reduction but this was not statistically significant (Table 4.79). VerifyNow® indices did 
not show any correlation with SEM data both at baseline and after clopidogrel therapy. 
Multiplate® ADP AU demonstrated a significant reduction after clopidogrel therapy. 
ASP AU demonstrated a significant reduction in the young non-diabetic cohort. In the 
elderly cohort there was a trend towards reduction but this was not statistically 
significant. At baseline, percentage platelet rich area with SEM demonstrated a strong 
positive correlation with ADP AU (rho=0.499, p=0.030).
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 Age < 75 + Non T2DM 
(n = 19) 
Age ≥ 75 + T2DM  
(n = 20) 
Age ≥ 75  + Non T2DM  
(n = 19) 
P Value 
Demographic data: Mean ± SD or % (n) 
Age, years 56.4 ± 5.4 80.2 ± 2.6 82.0 ± 2.9  
Male gender, % ( n ) 84.2 (16) 80 (16) 89.5 (17) 0.716 
Body mass index, kg/m2 30.1 ± 3.5 28.7 ± 4.7 27.7 ± 2.8 0.158 
Waist to hip ratio 1.0 ± 0.1 1.0 ± 0.08 0.9 ± 0.06 0.628 
Heart rate, beats  per minute 64 ± 13 71 ± 18 62 ± 10 0.117 
Systolic BP, mmHg 131 ± 17 *Ɨ 158 ± 21 * 154 ± 25 Ɨ 0.000 * 
Diastolic BP, mmHg 78 ± 7 78 ± 11 73 ± 10 0.268 
Risk profile: % ( n ) 
Angina 26.3 (5) 15 (3) 26.3 (5) 0.617 
Previous MI 57.9 (11) 50 (10) 63.2 (12) 0.423 
Previous PCI 36.8 (7) 30 (6) 31.6 (6) 0.894 
Previous CABG 5.3 (1) 35 (7) 31.6 (6) 0.062 
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H/o Hypertension 47.4 (9) 75 (15) 68.4 (13) 0.175 
H/o CKD 0 (0) 15 (3) 5.3 (1) 0.171 
H/o PVD 0 (0) 30 (6) 21.1 (4) 0.040 
H/o CVA 10.5 (2) 0 (0) 5.3 (1) 0.333 
Medications: % ( n ) 
Sulphonylurea 0 (0) 10 (2) 0 (0) 0.140 
Metformin 0 (0) 40 (8) 0 (0)  
Insulin 0 (0) 40 (8) 0 (0)  
Beta-blocker 84.2 (16) 70 (14) 68.4 (13) 0.512 
ACE inhibitor / ARB 68.4 (13) 95 (19) 89.5 (17) 0.055 
Statin 94.7 (18) 95 (19) 94.7 (18) 0.999 
Laboratory data: Mean ± SD 
Haemoglobin, g/dl 14.1 ± 0.8 *Ɨ 12.5 ± 1.0 * 12.8 ± 0.9 Ɨ 0.000 * 
Platelets x 1000 cells/mm3 240 ± 66 195 ± 49 219 ± 52 0.055 
Fibrinogen, g/ml 3.2 ± 0.8 3.3 ± 0.6 3.3 ± 0.5 0.732 
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HbA1c, mmol/mol 40 ± 3.6 58.5 ± 15.6 41.4 ± 3.5  
Fasting plasma glucose, 
mmol/L 
5.5 ± 0.7 8.8 ± 5.4 5.1 ± 0.6  
Creatinine, micromol/L 89 ± 14.9 101 ± 27.1 107 ± 36.7 0.139 
Total cholesterol, mmol/L 4.1 ± 1.0 3.9 ± 1.1 4.0 ± 0.6 0.865 
LDLc, mmol/L 2.2 ± 0.8 2.0  ± 0.9 2.0 ± 0.6 0.553 
HDLc, mmol/L 1.3 ± 0.4 1.2 ± 0.3 * 1.5 ± 0.3 * 0.035 * 
Triglyceride, mmol/L 1.3 ± 0.9 1.6 ± 0.7 1.2 ± 0.5 0.090 
HsCRP, mg/L 1.5  ± 1.0 3.0 ± 3.3 2.7 ± 3.3 0.187 
 
Table 4.74 Baseline characteristics – SEM substudy 
*p<0.05 
LDLc – Low density lipoprotein cholesterol; HDLc – High density lipoprotein cholesterol; HsCRP – high-sensitive C-reactive protein; H/o – 
History of 
Systolic BP: Age<75+Non DM vs. Age≥75+T2DM, p=0.001; Age<75+Non DM vs. Age≥75+Non DM, p=0.003 
Haemoglobin: Age<75+Non DM vs. Age≥75+T2DM, p<0.001; Age<75+Non DM vs. Age≥75+Non DM, p<0.001 
HDLc: Age≥75+Non DM vs. Age≥75+T2DM, p=0.040 
329 
 
 
 
Age < 75 + Non T2DM 
(n = 19) 
 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
 
Age ≥ 75  + Non T2DM 
(n = 19) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
High shear 
thrombus 
area, µ2/mm 
16697± 
5134 
12712± 
4991 
0.000 * 
15625± 
7805 
12711± 
4683 
0.020 * 
16108± 
6407 
14143± 
5131 
0.094 
Low shear 
thrombus 
area, µ2/mm 
9414± 
2667 
8250± 
2249 
0.044 * 
9036±  
2410 
8059± 
1706 
0.076 
9883± 
2380 
9081±  
1690 
0.068 
Fibrin 
diameter, nm 
218.1± 
20.2 
243.4± 
16.6 
0.000 * 
198.9± 
70.2 
245.0± 
32.9 
0.038 * 
204.8± 
22.9 
233.2± 
27.9 
0.000 * 
Platelet 
diameter, µm 
1.87± 0.15 
1.82±  
0.18 
0.198 
1.85±  
0.11 
1.84±  
0.08 
0.743 
1.86± 
0.08 
1.86±  
0.1 
0.954 
Fibrin fibre 
density, n/µ2 
of thrombus 
38.5± 4.3 43.2±7.1 0.026 * 40.5±2.9 44.7±8.7 0.039 * 37.4±3.3 42.8±7.6 0.035 * 
Spokes of 
fibrin, n/µ2 of 
thrombus 
26.3± 3.1 31.2±6.7 0.031 * 25.3±3.8 29.1±6.4 0.023 * 24.8±3.1 30.7±7.3 0.041 * 
Hubs of fibrin, 
n/µ2 of 
thrombus 
16.4± 1.6 18.7±2.8 0.039 * 17.4±2.3 19.4±2.6 0.014 * 16.3±1.5 18.2±3.1 0.009 * 
 
Table 4.75 Thrombus area and fibrin ultrastructure parameters 
* p<0.05 
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Age < 75 + Non T2DM 
(n = 19) 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
Age ≥ 75  + Non 
T2DM (n = 19) 
 
P Value 
Stable CAD Patients on Aspirin alone (Visit 1) 
Mean ± SD 
Fibrin diameter, nm 218.1±20.2 198.9±70.2 204.8±22.9 
0.401 
Platelet diameter, µm 1.87±0.15 1.85±0.11 1.86±0.08 
0.829 
Fibrin fibre density, n/µ2 of 
thrombus 
38.5±4.3 40.5±2.9 37.4±3.3 
0.458 
Spokes of fibrin, n/µ2 of thrombus 26.3±3.1 25.3±3.8 24.8±3.1 
0.718 
Hubs of fibrin, n/µ2 of thrombus 16.4±1.6 17.4±2.3 16.3±1.5 
0.351 
Platelet rich area, % 75.9±7.1 77.6±8.6 77.7±7.8 
0.302 
 
Table 4.76 Comparison of fibrin and platelet parameters at baseline 
* p<0.05 
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Age < 75 + Non T2DM 
(n = 19) 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
Age ≥ 75  + Non 
T2DM (n = 19) 
 
P Value 
Stable CAD Patients on Aspirin + 7 days of Clopidogrel  (Visit 2) 
Mean ± SD 
Fibrin diameter, nm 243.4±16.6 245.0±32.9 233.2±27.9 
0.341 
Platelet diameter, µm 1.82±0.18 1.84±0.08 1.86±0.1 
0.421 
Fibrin fibre density, n/µ2 of 
thrombus 
43.2±7.1 44.7±8.7 42.8±7.6 
0.562 
Spokes of fibrin, n/µ2 of thrombus 31.2±6.7 29.1±6.4 30.7±7.3 
0.201 
Hubs of fibrin, n/µ2 of thrombus 18.7±2.8 19.4±2.6 18.2±3.1 
0.694 
Platelet rich area, % 66.7±8.2 69.3±9.2 69.6±9.8 
0.587 
 
Table 4.77 Comparison of fibrin and platelet parameters one week after clopidogrel therapy 
* p<0.05 
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Age < 75 + Non T2DM 
(n = 19) 
 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
 
Age ≥ 75  + Non T2DM 
(n = 19) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Thromboelastography data 
R, minutes 6.8±2.0 7.1±1.3 0.504 6.9±2.1 6.4±1.6 0.149 6.2±1.4 6.6±.1.8 0.233 
MA, mm 62.7±5.6 62.7±5.2 0.994 63.4±3.3 63.0±5.3 0.745 64.6±3.6 63.7±3.9 0.190 
MA-AA, mm 36.8±21.2 24.8±16.6 0.010 * 27.5±14.6 26.4±16.8 0.740 27.2±17.2 20.8±12.5 0.164 
MA-ADP, mm 57.4±12.8 51.7±9.4 0.124 59.2±5.6 56.4±7.6 0.017 * 62.3±6.2 56.6±8.8 0.001 * 
G, Kdynes/sec 8.7±1.9 8.6±1.8 0.884 8.7±1.2 8.8±2.3 0.834 9.3±1.5 8.9±1.2 0.139 
CI -0.57±2.6 -0.66±1.7 0.841 -0.30±1.8 0.12±1.6 0.220 0.58±1.1 0.04±1.4 0.126 
L Parameter, 
mm/min 
78.6±14.2 84.4±17.1 0.166 87.3±26.4 107.6±43.2 0.115 85.6±21.2 81.7±22.1 0.339 
 
Table 4.78 TEG® and Platelet Mapping™ - SEM substudy 
* p<0.05  
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Age < 75 + Non T2DM 
(n = 19) 
 
 
Age ≥ 75 + T2DM 
(n = 20) 
 
 
Age ≥ 75  + Non T2DM 
(n = 19) 
 
Mean ± SD 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
Visit 1 
 
Visit 2 
 
P Value 
 
VerifyNow® data 
ARU 489±94.2 453±84.2 0.157 480±56.2 476±82.5 0.853 489±64 500±79 0.631 
PRUz 299±39.9 178±72.0 0.000 * 306±29.8 258±51.7 0.000 * 309±49 220±78 0.000 * 
Platelet 
inhibition, % 
4.2±6.9 33±27.4 0.000 * 2.7±4.2 16.3±12.4 0.000 * 3.6±5.3 29±23.3 0.000 * 
Multiplate® data 
Arachidonic 
acid, AU 
465±249 307±252 0.013 * 349±243 289±240 0.090 359±195 245±163 0.070 
ADP, AU 831±180 493±272 0.000 * 843±315 530±254 0.000 * 748±194 453±230 0.000 * 
 
Table 4.79 VerifyNow® and Multiplate® indices - SEM substudy 
  * p<0.05 
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Figure 4.21 Platelet and fibrin content of thrombus - scanning electron 
microscopy  
SEM image of platelet and fibrin content of thrombus at baseline (left) and one week 
(right) after clopidogrel therapy (60x magnifications). Solid white arrow in first picture 
is platelet rich area. A reduction in platelet rich area can be seen after one week of 
clopidogrel therapy. 
 
 
Figure 4.22 Ultrastructure of platelet at baseline and one week after 
clopidogrel therapy 
Platelet ultrastructure at 3.4x103 to 3.6x103 magnification. Solid arrows represent 
activated “angry” platelets with pseudopodia and membrane granules. Platelet 
diameter remained unchanged after clopidogrel therapy.   
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Figure 4.23 Fibrin ultrastructure at baseline and one week after clopidogrel 
therapy 
Fibrin architecture at 10.5 x103 to 14.0x103 magnifications. Solid arrows represent 
fibrin fibres. After one week of clopidogrel therapy, there was an overall increase in 
fibrin fibre diameter, density, number of hubs and spokes and overall susceptibility to 
fibrinolysis.  
336 
 
 
Figure 4.24 Change in platelet content of thrombus, fibrin diameter and fibrin 
fibre density 
There was a significant reduction in percentage platelet content and increase in fibrin 
diameter and fibrin fibre density after a week of clopidogrel therapy. (Table 4.78) 
*p<0.05  
337 
 
 
Figure 4.25 Changes to number of hubs and spokes per square micron of 
thrombus 
There was a significant increase in fibrin hubs and spokes per square micron of 
thrombus after a week of clopidogrel therapy. (Table 4.78) 
*p<0.05  
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Figure 4.26 Correlation: SEM measured parameters and thrombus area 
At baseline, number of spokes negatively correlated with high shear thrombus area 
(rho= -0.327, p=0.013) and low shear thrombus area (rho= -0.374, p=0.005); fibrin 
fibre density also correlated negatively with thrombus area (rho= -0.356, p=0.008). 
After one week of clopidogrel therapy, negative correlation between fibrin fibre density 
and thrombus area persisted (rho= -0.309, p=0.022); percentage platelet content 
correlated positively with thrombus area (rho=0.408, p=0.008).
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4.7.2 Discussion - Ultrastructural analysis of thrombus 
I report the ultrastructural characteristics of platelet dependent thrombus formed in 
Badimon chamber from elderly patients (age≥75 years) with and without T2DM. My 
study has shown a significant reduction in platelet content of thrombus following 
addition of clopidogrel in addition to aspirin for one week. There was a significant 
increase in fibrin fibre diameter, fibrin fibre density and increase in number of spokes 
and hubs per square micron of thrombus following one week of clopidogrel therapy. 
These changes in fibrin architecture were seen consistently in both elderly and young 
population, with and without T2DM. These assessment methods were novel and hence 
full internal validation was performed at every step. Our previous work in young T2DM 
patients also demonstrated a similar result in patients treated with clopidogrel 
(Viswanathan et al., 2013). 
After one week of clopidogrel therapy, the percentage platelet content in the thrombus 
reduced significantly in all the groups, similar to the reduction in platelet dependent 
thrombus formation observed in my main study. As explained before, Badimon 
chamber simulates rheological flow conditions in a moderately stenosed coronary 
artery (high shear) and hence the thrombus formed inside the chamber is platelet rich, 
similar to the “white thrombus” or platelet rich thrombus as described by Davies et al 
in patients after an acute MI (Davies and Thomas, 1984). This result suggests that one 
of the ways of achieving a reduction in the quantity of thrombus is by altering the 
cellular contents of the thrombus. Numerous studies have revealed that, antiplatelet 
therapy resulted in a reduction of platelet activation, smaller mean platelet volume and 
low platelet counts, thereby altering the ultrastructure of the thrombus (Standeven et 
al., 2005; Undas and Ariëns, 2011).  
An important step in clot formation is thrombin production. This in turn stimulates the 
conversion of fibrinogen into a 3-dimensional fibrin fibre network. Further cross-linking 
and stabilisation of fibrin is mediated by thrombin-activated factor (F XIII). Clot structure 
has a role in atherothrombotic disease. Alterations in clot structures in coronary artery 
disease (CAD) was first demonstrated by Fatah et al in 1992 (Fatah et al., 1992). In 
my study fibrin fibre architecture was altered by clopidogrel therapy in elderly and 
young, with and without T2DM. Individual fibrin fibre diameter increased following one 
week of clopidogrel therapy. It is already well established from previous studies that 
increase in fibrin fibre diameter favours fibrinolysis and reduces the stability of the 
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thrombus. Clots with thin fibers, small pores, and compact structure are associated 
with the development of premature and more severe coronary artery disease, which 
may be related to slower lysis of clots (Williams et al., 1995; Collet et al., 2000). Aspirin 
treatment has been demonstrated to promote  an increase in fibrin fibre diameter (Ajjan 
et al., 2009). Progressive fragmentation of the fibrin fibre as a result of lateral 
transection initially led to an increase in fibre diameter. This then resulted in 
progressive bending of the fibre, sometimes splaying of the edges, and finally 
disaggregation into small chunks (Collet et al., 2000). Polymerisation of fibrin fibres 
results in a network of fibrins with stretching, twisting, branching and lateral 
aggregation. This has already been demonstrated by SEM and TEM (Weisel and 
Litvinov, 2013). The point where twisting of fibrin fibre occurs around an axis is termed 
as “hub”. The viscoelastic force in the fibrin strand is reduced at “hub” points as it limits 
the elastic recoiling of the fibres. With increasing hubs and branching points, the 
number of binding sites for fibrinolytic agonists such as tissue plasminogen activator 
(tPA) and plasmin increases, thereby reducing the threshold for fibrinolysis (Ajjan et 
al., 2009). In my study, addition of clopidogrel to aspirin resulted in increased number 
of hubs and branches (“spokes”), thereby allowing the thrombus to respond well to 
fibrinolysis. 
With increasing age there is heightened coagulation enzyme activity, accompanied by 
enhanced fibrin formation. The impaired fibrinolytic potential in old age has been 
described as a state of ‘‘thrombotic preparedness’’ (Gharacholou and Becker, 2009). 
Pretorius et al studied fibrin ultrastructure in healthy individuals with age > 75 years 
and compared it to healthy individuals < 25 years of age. They concluded that with 
age, major fibres become sparse and thinner and minor, thin fibres dominate forming 
a fine mesh-like structure. Thicker, fibrin fibres were also identified at irregular intervals. 
This is possibly due to enhanced fibrin formation and heightened coagulation enzyme 
activity (Pretorius et al., 2010). In people with diabetes, non-enzymatic glycation of 
fibrinogen resulted in increased fibrin polymerisation, reduction in binding of tPA and 
plasminogen and slowing the conversion of plasminogen to plasmin, thereby 
increasing overall blood thrombogenicity (Dunn et al., 2005). 
My study has demonstrated a significant positive correlation between percentage 
platelet content and thrombus area from Badimon perfusion chamber. A significant 
negative correlation between fibrin fibre density and thrombus area was demonstrated 
at baseline and one week after clopidogrel therapy. At baseline, number of spokes per 
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square micron of thrombus demonstrated significant negative correlation with 
thrombus area. These findings suggest that reduction in platelet content reduces 
thrombus area. Increase in fibrin fibre density and number of spokes results in a 
reduction in thrombus possibly due to increased susceptibility to fibrinolysis as 
discussed below. 
The viscoelastic properties of thrombus are some of the most sensitive measures that 
reflect small changes in clot structure (Weisel, 2007). I measured viscoelastic 
properties using thromboelastography (TEG®) and Platelet Mapping™. At baseline 
when patients were on aspirin alone, I demonstrated a significant negative correlation 
between fibrin fibre density and maximum strength of thrombus after stimulation with 
kaolin (MA), viscoelastic force of the thrombus (G) and rate of thrombin generation 
(TG). Increase in fibrin fibre density indirectly reflects increase in fibrin thickness and 
increase in total number of “hubs” and “spokes”, with overall increase in binding sites 
to fibrinolytic agonists. This reduced the overall viscoelasticity of the formed thrombus 
as published in previous studies (Collet et al., 2005; Gersh et al., 2009). VerifyNow® 
PRUz showed a significant reduction in PRU after the addition of clopidogrel for one 
week. However, no significant associations were noted between VerifyNow® indices 
and SEM parameters. 
Multiplate® results demonstrated significant reduction in ADP AU and a trend towards 
reduction in ASP AU. I was able to demonstrate a significant positive correlation 
between percentage platelet rich area on the thrombus and ADP AU. This is not 
surprising, because the platelet inhibitory effect of clopidogrel reduces platelet 
aggregation and hence a reduction in platelet rich area. No significant associations 
were noted between Multiplate® indices and fibrin measurements based on SEM were 
noted. This could possibly be due to no impact or minimal impact of alterations in fibrin 
architecture on electrical impedance aggregometry. 
Platelet diameter remained unchanged after a week of clopidogrel therapy both in 
elderly and young patients, in patients with T2DM and non DM cohorts. Mean platelet 
volume increases with increasing age and in the presence of T2DM (Lippi et al., 2012). 
Higher MPV indicates larger platelet size, which in turn is deemed to suggest increased 
platelet activation. Little is known about effect of various antiplatelet agents on platelet 
size and mean platelet volume (MPV). Previous in vitro studies found no effect of 
aspirin on platelet size (Sharpe et al., 1994; Jagroop et al., 2003). However, it has been 
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demonstrated that clopidogrel significantly inhibits the ADP-induced increase in MPV 
in vitro (Jagroop and Mikhailidis, 2003), similar to the findings in my study. One 
previous study demonstrated that platelet diameter decreases with clopidogrel therapy 
in non-diabetic healthy volunteers (Papanas et al., 2004). The possible explanations 
for unchanged platelet diameter in my study could be because in the elderly and T2DM 
populations, platelets are under constant stimulation by a number of naturally 
circulating agonists alongside low grade inflammation (Bruunsgaard et al., 2001) and 
one week of maintenance dose clopidogrel may not be sufficient to cause any 
significant reduction in platelet size. 
Platelet function tests such as TEG, VerifyNow and Multiplate are being used widely 
in clinical research and also in some specific clinical settings. My SEM substudy has 
demonstrated some correlation between ultrastructure characteristics of thrombus and 
some platelet reactivity indices.  
My findings from this substudy are novel and the findings may be helpful to develop 
future studies. The main limitation in my study is that the sample size is very small and 
the patient cohort is carefully chosen with strict inclusion and exclusion criteria. For 
these reasons the findings from this study cannot be generalised. Experiments with 
newer antiplatelet agents (Ticagrelor and Prasugrel) need to be performed to assess 
their effect on fibrin architecture. 
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4.8 Rafigrelide study – Platelet dependant thrombosis and viscoelastic 
properties 
4.8.1 Results 
Rafigrelide, a novel, highly selective and potent platelet-lowering agent was used to 
reduce the platelet count. Baseline demographic data of participants in treatment 
period 1 and 2, panel A and panel B are shown in Table 4.80. 
Platelet count: 
Following administration of rafigrelide in Period 1, participants in Panel A 
demonstrated a reduction in platelet count (mean±SD) from 283±17 x109/L at baseline 
to 125±47 x109/L at Day 14. Rafigrelide was not administered after Day 14, and by 
Day 21 the platelet count had partially recovered to 206±48 x109/L, but remained 
significantly lower than at baseline. A similar pattern was seen in Panel A when the 
drug was co-administered with aspirin (Period 2); platelet count decreased from 
280±36 x109/L at baseline to 134±27 x109/L at Day 14, and recovered to 239±41 
x109/L after treatment cessation, at Day 21. 
There was also a reduction in platelet count in treatment Period 1, in Panel B, from 
250±25 x109/L at baseline to 160±51 x109/L at Day 14, when treatment was stopped. 
Platelet counts were taken until Day 18 for volunteers in Panel B, and no recovery was 
seen at this time point. Similar results were seen in Period 2, after co-treatment with 
rafigrelide and aspirin (Table 4.81, Figure 4.27and Figure 4.29).  
Mean platelet volume: 
Mean platelet volume (MPV) was assessed along with platelet count during all the 
visits (Table 4.81). In treatment period 1, following administration of rafigrelide, 
participants in panel A demonstrated an increase in MPV (mean±SD, fL) from 10.7±0.9 
fL at baseline to 12.2±0.8 fL at day 14. Rafigrelide was no longer administered after 
day 14, and by day 21 mean MPV was 12±0.9 fL, higher than at baseline. A similar 
pattern was seen in panel A when the drug was co-administered with aspirin (period 
2); mean MPV increased from 10.7±0.6 fL at baseline to 12.2±0.9 fL at day 14, and 
reduced to 11.8±0.8 fL after treatment cessation, at day 21. 
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There was also an increase in mean MPV in treatment period 1, in panel B, from 
10.1±0.6 fL at baseline to 11.5±1.1 fL at day 14. MPVs were taken until day 18 for 
volunteers in panel B, and no recovery was seen after treatment cessation at day 14.  
Similar results were seen in period 2, after co-treatment of rafigrelide and aspirin. 
Platelet-dependent thrombus formation: 
Under both high and low shear stress conditions, treatment with rafigrelide generally 
led to reductions in thrombus area (Table 4.82, Table 4.83). These reductions tended 
to occur in conjunction with reductions in platelet count under both high and low shear 
conditions, with moderate correlations between the parameters (Figure 4.31).  
Under high shear conditions, there was a reduction from baseline in mean thrombus 
area at Day 14 in Panel A after administration of rafigrelide alone (thrombus area in 
μ2/mm, mean±SD: 22613 ± 12221 on Day 1 vs. 11930 ± 5348 on Day 14). Although 
there was a slight increase in thrombus area from Day 1 to Day 4 in Panel B 
(15894±10052 on Day 1 to 19414± 7870 on Day 4), by Day 10 a reduction was seen 
(14618±6312 on Day 10). When aspirin was added to rafigrelide in treatment period 
2, a similar pattern of reduction in thrombus area was observed: Panel A: 
25656±14324 on Day 1 to 14696±2446 on Day 14; Panel B: 24593±9401 on Day 1 to 
14675±7331 on Day 10.There was no clear difference in high shear thrombus area 
between rafigrelide administered alone or in combination with aspirin in either panel 
(Figure 4.28, Figure 4.30).  
Under low shear conditions, there were generally small reductions in mean thrombus 
area after rafigrelide treatment with or without aspirin in both panels but these 
reductions were not statistically significant. 
There was a significant correlation between platelet count and high shear thrombus 
area (Figure 4.31). 
Viscoelastic properties of thrombus assessed using Thromboelastography® 
(TEG) and Platelet Mapping™: 
Administration of rafigrelide alone in Panel A increased time to initiate clot formation - 
R time (measured in min, mean±SD). In this group, the R time increased from 5.17 ± 
0.80 min at baseline to 8.25 ± 2.33 min on Day 14. In Panel B, R time increased from 
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6.35 ± 1.29 min at baseline to 7.05 ± 2.09 min on Day 10. This increase was not 
statistically significant.  After drug withdrawal, R time returned towards baseline to 6.07 
± 1.93 min on Day 21 for Panel A, but remained constant until Day 18 in Panel B (7.10 
± 2.24 min). A similar pattern was seen for Panel A when rafigrelide was co-
administered with aspirin; R time increased from baseline to Day 14 and decreased 
after drug withdrawal. In Panel B, treatment with a combination of aspirin and 
rafigrelide had little effect on mean R time between Days 1 and 10 (8.48 ± 1.09 min 
on Day 1; 8.20 ± 1.78 min on Day 10) but there was a small reduction in R time by 
Day 18 in these participants (7.02 ± 2.65 min). Similar patterns were seen for K time.   
On assessment of the effects of rafigrelide on MA (a measure of clot strength), in Panel 
A, MA decreased with time after initiation of treatment in Period 1 (mm, mean±SD, 
68.8±2.3 on Day 1 to 63.4±5.8 on Day 14, p<0.05) and Period 2 (67.4±2.6 on Day 1 
to 61.6±0.8 on Day 14, p<0.05) and increased again after treatment cessation 
indicating a reduction in clot strength with drug treatment that recovers after drug 
withdrawal. In Panel B, treatment with rafigrelide, both alone (Period 1) and when co-
administered with aspirin (Period 2), demonstrated a similar effect on MA up to Day 
18 of the study. Other parameters such as G Kdynes/sec (shear elastic force of the 
thrombus) and Clot index (CI) also demonstrated a similar trend like MA, when treated 
with rafigrelide, both alone and when co-administered with aspirin. 
Rafigrelide with or without aspirin had no discernible effect on lysis as measured by 
clot lysis 30, clot lysis 60 and estimated plasma lysis. 
Platelet mapping™ tests were performed alongside baseline TEG®. Maximum 
viscoelastic strength of thrombus as measured by maximum amplitude upon 
stimulation with 10µl of arachidonic acid (MA-AA, in mm) demonstrated a numerical 
reduction when rafigrelide was co-administered with aspirin (Period 2). Panel A: 
56.8±7.5 on Day 1 to 47.2±6.3 on Day 14; Panel B: 62.5±3.7 on Day 1 to 38.4±17.8 
on Day 10, p<0.01. Percentage inhibition to arachidonic acid (% inhibition to AA, %) 
also increased proportionately when aspirin was co-administered with rafigrelide 
(Table 4.84, Table 4.85). No significant change in MA-AA or percentage inhibition to 
AA was observed when rafigrelide was administered alone (Figure 4.32, Figure 4.33, 
Figure 4.34 and Figure 4.35).  
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Pharmacokinetics: 
Plasma concentrations of rafigrelide were generally similar in both panels when 
administered alone (Period 1) or in combination with aspirin (Period 2) (Table 4.86). 
Tolerability, adverse events and safety: 
Most of the AEs during both treatment periods were mild to moderate in severity, and 
were considered to be related to the IMP (rafigrelide), but rarely led to drug withdrawal. 
Although the overall incidence and number of AEs was slightly higher when rafigrelide 
was administered in combination with aspirin, this was primarily due to single event 
instances, in different volunteers, of palpitations, nasopharyngitis, contusion, migraine, 
cough, nasal congestion and four instances (in one participant) of mild photophobia. 
The most common AEs (occurring in at least three individuals during any period) for 
rafigrelide both as monotherapy and in combination with aspirin were 
thrombocytopenia (defined as a platelet count <150x109/L; 9 events and 10 events, 
respectively) and headache (11 events and 14 events, respectively). 
One participant developed severe thrombocytopenia with platelet count falling to 
82x109/L on Day 14 (last dosing day).The platelet count continued to fall to below the 
clinically important level (75x109/L) to 50x109/L on Day 17 and to 39x109/L on Day 18. 
This was reported as a serious AE although the participant remained asymptomatic. 
Without intervention his platelet count increased to 43x109/L on Day 19, 76x109/L on 
Day 20, 144x109/L on Day 21 and 410x109/L on Day 27. In another participant, 
rafigrelide was withdrawn on Day 10 because his reduced platelet count (140x109/L) 
met the protocol-defined level for cessation of the IMP (platelet count below 150x109/L 
or reduction of ≥60x109/L over 3 days). Subsequently, his platelet count recovered to 
baseline levels without intervention.  
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Demographic data 
Mean ± SD 
Treatment  
period 1 
Panel A (n=6) 
Treatment  
period 2 
Panel A (n=7) 
 
Panel B 
(n=6) 
 
Age (years) 
 
34.2 ± 5.4 30.9 ± 4.8 34.3 ± 7.7 
Body Mass Index (Kg / m2) 
 
25.7 ± 2.7 25.2 ± 7.4 25.3 ± 2.4 
Systolic B.P. (mmHg) 
 
126 ± 7.7 125 ± 7.4 125 ±12.3 
Diastolic B.P. (mmHg) 
 
80 ± 4.5 78 ± 5.3 82 ± 9.4 
Platelet count (109/L) 
 
283 ± 16.8 271 ± 27.2 250 ± 24.6 
Mean platelet volume (fL) 
 
10.7 ± 0.9 11.7 ± 0.7 10.1 ± 0.6 
Glucose (mmol/L) 
 
4.8 ± 0.5 4.9 ± 0.6 4.6 ± 0.7 
Creatinine (µmol/L) 
 
85 ± 9.0 85 ± 6.2 83 ± 13.2 
 
Table 4.80 Baseline characteristics of healthy volunteers in Rafigrelide study 
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Mean±SD 
 
Day 1 
 
Day 4 
 
Day 7 
 
Day 10 
 
Day 14 
 
Day 18 
 
Day 21 
Treatment Period 1 – Rafigrelide alone 
Panel A 
Platelet count x  
109/L 
283±16.8  276±32.1 244±14.5 * 183±16.5 * 125±46.9 *  206±47.8 * 
MPV, fL 10.7±0.9 10.6±1.1 10.7±0.8 11.3±0.7 * 12.2±0.8 *  12.0±0.9 * 
Panel B 
Platelet count x  
109/L 
250±24.6 252±27.4 226±18.3 * 196±37.4 * 160±50.6 * 160±57.5 *  
MPV, fL 10.1±0.6 10.2±0.7 10.3±0.7 10.8±0.9 * 11.5±1.1 * 11.6±1.0 *  
Treatment Period 2 – Rafigrelide and aspirin 
Panel A 
Platelet count x  
109/L 
280±35.9 275±52.1 254±45.6 191±32.5 134±27.0  239±41.1 
MPV, fL 10.5±0.5 10.4±0.6 10.9±0.5 11.1±0.5 12.2±0.9  11.5±0.9 
Panel B 
Platelet count x  
109/L 
244±16.2 248±28.4 235±29.7 198±29.6 166±46.9 171±48.9  
MPV, fL 10.1±0.8 10.4±0.9 10.3±1.0 10.7±0.8 11.3±1.0 11.6±1.2  
Table 4.81 Effect of Rafigrelide on platelet count and MPV - treatment period 1 and 2; *p<0.05 
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Mean±SD 
 
Day 1 
 
Day 7 
 
Day 14 
 
Day 21 
Treatment Period 1 – Rafigrelide alone 
Panel A 
High shear thrombus area, µ2/mm 22613± 12221 17784± 11045 * 11930± 5348 15518± 3728 
Low shear thrombus area, µ2/mm 8233± 1471 7444±  1018 6997±  2586 6821±  1683 
Treatment Period 2 – Rafigrelide and aspirin 
Panel A 
High shear thrombus area, µ2/mm 25656± 14324 16321± 6598 14696± 2446 17785± 7707 
Low shear thrombus area, µ2/mm 8188± 2555 8286±  1398 7670±  1353 7504±  3013 
 
Table 4.82 Effect of Rafigrelide on thrombus area - treatment period 1 and 2 in panel A 
*p<0.05 
 
 
350 
 
 
 
Mean±SD 
 
Day 1 
 
Day 4 
 
Day 10 
 
Day 18 
Treatment Period 1 – Rafigrelide alone 
Panel B 
High shear thrombus area, 
µ2/mm 
15894± 10052 19414± 7870 14618± 6312 12526± 5590 
Low shear thrombus area, 
µ2/mm 
7268± 2727 7658±  3143 6040±  1991 6192±  1733 
Treatment Period 2 – Rafigrelide and aspirin 
Panel B 
High shear thrombus area, 
µ2/mm 
24593± 9401 18834± 7738 14675± 7331 * 12850± 4239 * 
Low shear thrombus area, 
µ2/mm 
9438± 2286 8324± 2183 7733±  1309 7980±  2074 
 
Table 4.83 Effect of Rafigrelide on thrombus area - treatment period 1 and 2 in panel B 
*p<0.05 
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Figure 4.27 Effect of rafigrelide on platelet count and MPV - treatment period 
1. Panel A and B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Panel A (top left and bottom left graphs) and B (top right and bottom right graphs) 
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Figure 4.28 Effect of rafigrelide on high and low shear thrombus - treatment 
period 1. Panel A & B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Panel A (top left and bottom left graphs) and B (top right and bottom right graphs) 
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Figure 4.29 Effect of rafigrelide + aspirin on platelet count & MPV - treatment 
period 2. Panel A & B 
Treatment with rafigrelide was stopped on Day 14 in both the panels 
Aspirin administration was stopped on Day 20 for Panel A and Day 17 for Panel B 
during treatment period 2 
Panel A (top left and bottom left graphs) and B (top right and bottom right graphs) 
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Figure 4.30 Effect of rafigrelide on high and low shear thrombus - treatment 
period 2. Panel A and B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Aspirin administration was stopped on Day 20 for Panel A and Day 17 for Panel B 
during treatment period 2 
Panel A (top left and bottom left graphs) and B (top right and bottom right graphs) 
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Figure 4.31 Correlation between thrombus area and platelet count  
Relationship between the total thrombus area and platelet count under high shear (A) 
and low shear (B) conditions when platelet levels were lowered with rafigrelide (Period 
1) and rafigrelide in combination with aspirin (Period 2) 
Data shown are measurements provided by all participants at each time point in their 
respective panels (Panel A: Days 1, 7, 14 and 21; Panel B: Days 1, 4, 10 and 18).  
Regression lines are shown with correlation coefficients (r, r2) and p-values   
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Mean±SD Day 1 Day 7 Day 14 Day 21 
Treatment Period 1 – Rafigrelide alone; Panel A 
R, min 5.2±0.8 6.5±2.1 8.2±2.3 * 6.1±1.9 
K, min 1.7±0.3 2.2±0.7 2.8±1.0 1.8±0.6 
MA, mm 68.8±2.3 66.3±4.2 63.4±5.8 * 69.3±3.4 
G Kdynes/sec 11.1±1.2 10.1±2.1 9.0±2.3 * 11.4±1.8 
CI 1.2±1.1 -0.2±2.5 -2.3±3.2 * 1.0±2.0 
MA-A, mm 5.0±1.6 5.8±3.5 10.8±13.9 7.8±5.8 
MA-AA, mm 61.0±6.4 57.3±9.8 54.0±8.9 * 60.6±8.5 
MA-ADP, mm 56.9±9.7 55.2±11.5 50.2±11.7* 60.2±3.9 
% inhibition to AA 12.3±7.3 16.0±13.0 15.3±8.8 13.9±8.9 
% inhibition to ADP 18.8±12.5 18.3±4.8 23.6±12.9 14.9±4.5 
Treatment Period 2 – Rafigrelide and aspirin; Panel A 
R, min 6.0±1.7 6.7±2.0 7.8±1.5 7.0±1.6 
K, min 2.2±0.4 2.7±1.0 3.1±0.4 2.5±0.6 
MA, mm 67.4±2.6 64.4±5.8 61.6±0.8 66.1±4.6 
G Kdynes/sec 10.4±1.3 9.3±2.1 8.0±0.3 10.0±2.4 
CI 0.3±1.5 -1.1±1.7 -2.6±1.4 -0.8±2.0 
MA-A, mm 8.3±8.8 4.6±1.5 10.1±13.8 13.2±13.9 
MA-AA, mm 56.8±7.5 43.3±8.9 47.2±6.3 54.3±14.6 
MA-ADP, mm 59.0±9.5 57.4±5.7 55.1±6.4 62.2±5.0 
% inhibition to AA 14.6±12.9 11.6±4.4 9.4±9.8 7.6±4.5 
% inhibition to ADP 18.5±9.9 34.6±17.8 27.6±8.5 22.8±20.2 
Table 4.84 Changes to TEG-PM parameters - Panel A, treatment   
period 1 & 2 
*p<0.05 
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Mean±SD Day 1 Day 4 Day 10 Day 18 
Treatment Period 1 – Rafigrelide alone; Panel B 
R, min 6.4±1.3 6.4±2.0 7.1±2.1 7.1±2.2 
K, min 1.9±0.4 1.9±0.4 2.3±0.8 2.3±0.8 
MA, mm 67.4±3.6 68.5±2.9 65.9±4.2 66.6±2.9 
G Kdynes/sec 10.5±1.7 11.0±1.5 9.8±1.8 10.1±1.3 
CI 0.4±1.7 0.4±1.8 -0.7±2.7 -0.9±2.7 
MA-A, mm 6.7±3.2 6.2±1.9 8.3±6.9 9.0±5.9 
MA-AA, mm 60.1±5.6 58.7±4.0 58.3±6.2 60.8±5.1 
MA-ADP, mm 58.5±4.4 58.8±5.1 56.3±7.9 58.2±6.7 
% inhibition to AA 12.4±8.3 15.7±6.7 14.2±9.3 10.1±9.1 
% inhibition to ADP 14.7±6.3 15.5±6.9 17.1±9.5 14.5±9.4 
Treatment Period 2 – Rafigrelide and aspirin; Panel B 
R, min 8.5±1.1 8.6±2.0 8.2±1.8 7.0±2.6 
K, min 2.6±0.5 2.7±0.6 2.5±0.7 2.8±1.0 
MA, mm 66.6±3.1 66.3±2.4 66.5±2.3 66.0±3.3 
G Kdynes/sec 10.1±1.3 9.9±1.1 9.9±1.0 9.8±1.3 
CI -1.9±1.5 -2.0±2.1 -1.6±2.1 -1.2±2.9 
MA-A, mm 6.5±2.4 7.3±2.7 8.1±5.1 10.9±12.8 
MA-AA, mm 62.5±3.7 45.6±19.3 38.4±17.8 
* 
41.5±20.0 
MA-ADP, mm 60.5±2.3 59.4±.3.2 57.3±4.3 57.8±4.0 
% inhibition to AA 8.3±6.4 37.8±27.4 48.0±27.1 
* 
42.0±29.4 
% inhibition to ADP 9.8±5.3 11.6±6.1 15.8±7.6 15.0±6.8 
Table 4.85 Changes to TEG-PM parameters - Panel B, treatment 
period 1 & 2 
*p<0.05 
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Figure 4.32 Effect of rafigrelide alone on TEG® parameters in panel A & B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Panel A (all graphs on the left) and B (all graphs on the right) 
359 
 
 
Figure 4.33 Effect of rafigrelide alone on TEG®-PM™ indices in panel A & B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Panel A (all graphs on the left) and B (all graphs on the right) 
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Figure 4.34 Effect of rafigrelide and aspirin on TEG® parameters in panel A 
& B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Aspirin administration was stopped on Day 20 for Panel A and Day 17 for Panel B 
during treatment period 2. Panel A (all graphs on the left) and B (all graphs on the 
right) 
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Figure 4.35 Effect of rafigrelide and aspirin on TEG®-PM™ indices in panel 
A & B 
Treatment with rafigrelide was stopped on Day 14 for both panels 
Aspirin administration was stopped on Day 20 for Panel A and Day 17 for Panel B 
during treatment period 2. Panel A (all graphs on the left) and B (all graphs on the 
right) 
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Figure 4.36 Reduction in high shear thrombus area with rafigrelide (Period 1, 
Panel A). 
There is a stepwise reduction in thrombus formation with Rafigrelide administration 
until day 14. After stopping the IMP on day 14, thrombus formation increased on day 
21 but was still less than baseline. These are sample images from one of the 
volunteers in the study.
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Plasma rafigrelide concentration (mean±SD, in 
ng/mL) 
  
Treatment day 
    1 7 14 21 
Panel A 
n 6 6 6 6 
Period 1 0.00±0.00 64.83±20.91 67.02±20.01 3.08±2.05 
n 8 8 7 7 
Period 2 6.21±17.57 56.01±19.81 44.21±22.42 1.79±1.94 
  Treatment day 
   1 4 10 18 
 n 6 6 6 6 
Panel B 
Period 1 0.00±0.00 36.05±12.72 40.47±17.32 5.85±4.29 
n 6 6 6 6 
Period 2 0.00±0.00 26.90±16.59 41.35±13.74 5.57±4.95 
 
Table 4.86 Pharmacokinetics of rafigrelide 
Plasma concentrations of rafigrelide throughout the study 
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4.8.2 Discussion 
In this early phase study of rafigrelide, a novel platelet lowering agent, we report a 
reduction in circulating platelets and thrombus size together with delayed initiation 
of clot formation and reduced clot strength. The addition of aspirin to rafigrelide did 
not affect thrombus area or standard TEG parameters. Platelet mapping 
demonstrated a reduction in MA-AA and percentage inhibition to AA in Panel B 
from Day 1 to Day 10. But these parameters did not change in Panel A despite 
addition of aspirin in treatment period 2 (Balasubramaniam et al., 2014).  
The Badimon perfusion chamber system is a validated ex vivo model of vessel 
injury and thrombosis as explained before (Badimon et al., 1986; Badimon et al., 
1987) and has been used to evaluate the effects of novel antithrombotic agents in 
human participants in different disease states (Lev et al., 2001; Osende et al., 
2001; Sarich et al., 2003). The model enables the measurement of thrombus 
formation in native (non-anticoagulated) whole blood triggered by exposure to 
physiologically relevant substrate (collagen in tunica media), and under different 
rheological conditions mimicking flow in stenosed coronary arteries. 
Thromboelastography is a point of care assay that assesses visco-elastic forces in 
whole blood under low shear conditions during coagulation in vitro. It measures the 
strength of the thrombus (fibrin-platelet binding) as it forms and is widely used in 
different clinical areas (Kang et al., 1985; Gorbet and Sefton, 2004; Reikvam et al., 
2009). 
The role of platelets in thrombus formation is well established and has been 
explained in detail earlier. Briefly, platelets become activated when they come into 
contact with a thrombogenic surface such as injured endothelium or an artificial 
surface such as a stent, vascular graft, or cardiopulmonary or haemodialysis 
equipment (Gorbet and Sefton, 2004). This in turn triggers a complex cascade 
involving cellular and non-cellular components leading to thrombus formation at 
the site of injury (Blockmans et al., 1995). Platelet count has been associated with 
thrombosis and the role of platelets as mediators and regulators of inflammation in 
thrombotic events has been well established (Hamad et al., 2012). The contribution 
of P-selectin-mediated platelet-leukocyte aggregates and tissue-factor-positive 
platelet-derived microparticles in atherothrombosis, has also been studied 
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extensively (Zarbock et al., 2007; Morel et al., 2008). 
Successful antithrombotic therapy balances improvements in ischaemic outcomes 
whilst minimising bleeding risk. Aspirin and clopidogrel exert significant but 
relatively weak antiplatelet effects when compared to other P2Y12 inhibitors 
(ticagrelor and prasugrel) and GP IIb/IIIa inhibitors like abciximab. However, this 
weak antiplatelet effect is balanced with an acceptable bleeding risk and this is 
partly the reason behind their success as standard antiplatelet agents (Jernberg et 
al., 2006; Wiviott et al., 2007b). Despite optimal therapy with modern antiplatelet 
and antithrombotic agents, patients presenting with atherothrombotic disease 
typically continue to have high rates of recurrent events up to one year after 
initiating therapy. Hence there is a need for improvement in the currently available 
antithrombotic therapies. Newer therapies such as factor Xa inhibitors, direct 
thrombin inhibitors, nitric oxide donors, and collagen- and ristocetin-mediated 
platelet aggregation inhibitors are in various stages of development (Cannon et al., 
2007; Zafar et al., 2007a; Zafar et al., 2007b; Buller et al., 2008; Zafar et al., 2010). 
Our data show rafigrelide to have platelet-lowering properties and that these 
translate into a reduction in platelet-dependent thrombosis. Although mean platelet 
counts were similar to baseline at Day 4, steady reductions were observed 
thereafter until treatment cessation. Following abrupt cessation of rafigrelide 
treatment on Day 14, the platelet count remained low for 3 to 4 days before 
increasing toward baseline levels.  Platelet counts had generally returned to 
baseline levels at the final follow-up visit.  
The reduction in platelet count was associated with a reduction in mean thrombus 
area in both low and high shear environments, mimicking rheologies of arterial and 
venous flow conditions, respectively. Under high shear conditions, the reduction in 
thrombus area was more pronounced and there was a moderate correlation 
between platelet count and thrombus area, as would be expected given the greater 
role of platelets in arterial thrombosis (platelet rich) compared with thrombus 
formation in veins (fibrin rich) under low shear conditions. 
Seven days after the last dose of rafigrelide, reversal of the antithrombotic effect 
was evident. With the addition of aspirin, there were no discernible additional 
366 
 
effects on platelet count or TTA beyond that seen with rafigrelide alone. Rafigrelide 
delayed initiation of clot formation (R time), time taken to form a firm thrombus (K 
time) and provided small reductions in MA (a measure of clot strength), G (shear 
elastic force) and CI (over all measure of thrombus strength).  
The adverse events reported with rafigrelide over each 2-week treatment period 
were mild to moderate in nature, although one serious case of thrombocytopenia 
was observed, which resolved after IMP cessation and without any additional 
intervention. The platelet count fell below the protocol-defined threshold for study 
termination in only two individuals. There were no bleeding complications in any of 
the participants during the treatment or follow-up periods. The occurrence of 
photophobia, reported in one individual in this study, is another AE that may be of 
interest in future studies. Overall, in this early phase study of the pharmacodynamic 
and pharmacokinetic effects of rafigrelide on healthy volunteers, the product was 
found to be well tolerated. 
In conclusion, this new platelet-lowering agent rafigrelide showed antithrombotic 
properties during a 2-week treatment period in healthy male volunteers. 
Importantly, the reductions in thrombus formation were seen in surrogate models 
of both high and low shear rates suggesting drug efficacy in different arterial 
conditions. The antithrombotic effect of rafigrelide in this early phase study 
suggests that further clinical studies involving different doses of rafigrelide, longer 
therapy duration and measuring other elements of coagulation system to confirm 
its mechanism of action are warranted. Lowering platelet count, especially in 
patients with thrombocytosis or platelet counts in the higher end of normal might 
be an option to further reduce future adverse thrombotic events following acute 
coronary syndrome alongside antiplatelet therapy. Possible adverse reaction such 
as thrombocytopenia and bleeding should be regularly checked for.   
Limitations 
In addition to platelets, a number of cellular and non-cellular components of the 
coagulation system are also involved in thrombus formation and these were not 
measured in our study. Though we measured platelet numbers and MPV, neither 
platelet reactivity nor fibrinogen were measured.   
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Chapter 5 Conclusion 
5.1 General discussion 
The main objective of my first study was to determine the effect of age and age 
plus T2DM on platelet-dependent thrombus (PDT) formation in patients with stable 
CAD and to compare the effects of dual antiplatelet therapy on PDT. My hypothesis 
was that dual antiplatelet therapy (DAPT) with aspirin and clopidogrel inhibits PDT 
formation more powerfully in subjects aged ≥75 years than in younger individuals 
but in the presence of T2DM, the effect of age is reduced. 
 My study did not demonstrate any difference in thrombus area between elderly 
and young and between patients with and without T2DM at baseline (on aspirin 
monotherapy). After one week of DAPT, there was a significant reduction in PDT 
formation in both elderly and young, and in those with and without T2DM. 
Thrombus area was again similar between the groups after one week of DAPT, as 
was the change in thrombus area with DAPT. Thus my hypothesis was disproved. 
The VerifyNow® point of care assay demonstrated a higher proportion of 
hyporesponders (high platelet reactivity) to aspirin in the elderly cohort and in those 
with T2DM at baseline. After one week of DAPT, the mean platelet reactivity to 
clopidogrel remained high (≥240 cut-off) in the elderly and in those with T2DM 
suggesting platelet hyporesponsiveness to clopidogrel. An interesting observation 
was that even among these hyporesponders there was a significant reduction in 
PDT after one week of DAPT. Addition of clopidogrel appeared to potentiate the 
antiplatelet effect of aspirin in the young cohort but this effect was not 
demonstrated in the elderly patients.  
Standard thromboelastography (TEG®) parameters were similar between the 
groups both at baseline and after one week of DAPT.  The elderly non-diabetic 
cohort took longer to initiate clot formation and they demonstrated less over-all clot 
strength after the addition of clopidogrel. Platelet Mapping™ data demonstrated 
much better platelet inhibition to aspirin at baseline in the elderly cohort, a finding 
different to that from VerifyNow® data. The antiplatelet response to clopidogrel was 
similar between the groups using platelet mapping indices. 
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The Multiplate® point of care assay demonstrated that the highest percentage of 
clopidogrel hyporesponders was in the elderly T2DM cohort. After addition of 
clopidogrel, significant platelet inhibition occurred to a similar degree in all the 
groups but the mean ADP AU remained ≥460 in the elderly T2DM cohort. 
All three above mentioned point of care assays are platelet centric, mainly 
assessing platelet response to various agonists, whereas the Badimon chamber 
thrombus area gives a composite measure of all cellular and non-cellular 
components involved in thrombus formation and thus forms a more holistic 
assessment of blood thrombogenicity. This might be one reason why I was not able 
to demonstrate a significant difference in thrombus area between the groups, 
despite high platelet reactivity in the elderly and T2DM patients. A sample size of 
around forty stable CAD patients on appropriate secondary prevention therapy in 
each of the four groups might not be adequate enough to demonstrate effects of 
age or T2DM on thrombus area. However, this sample size was adequate to 
demonstrate a significant reduction in thrombus area with one week of DAPT when 
compared to aspirin monotherapy, suggesting that platelet reactivity is one of the 
major contributing factors to blood thrombogenicity.  
Despite reduction in thrombus area, platelet reactivity remained high after one 
week of DAPT in elderly and T2DM patients in the stable CAD setting. This high 
residual platelet activity due to constant platelet activation, might be one of the 
reasons for increased atherothrombotic events in these high risk population 
groups. A significant reduction in PDT after one week of DAPT even among 
hyporesponders, highlights the fact that platelet reactivity indices do not exactly 
correlate with thrombus burden and might not be useful in predicting future 
thrombotic events, at least in patients with stable CAD. 
Coagulation biomarkers (P selectin, CD40L and PAI-1) were similar between 
elderly and young cohort, both with and without T2DM. CD40 ligand levels were 
reduced in elderly, young and in non-diabetic patients after addition of clopidogrel. 
This reduction was not seen in T2DM cohort. An interesting finding in my study 
was a significant increase in these biomarkers measured from post chamber 
“effluent” blood in all the groups, suggesting the release of these biomarkers from 
platelets granules within seconds after platelet activation within the chamber. 
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Inflammatory biomarkers (IFNy and IL-1) were similar between the groups. TNFα 
levels and IL-6 levels were higher in elderly T2DM compared to young and non DM 
individuals. These levels remained elevated in elderly T2DM cohort after DAPT for 
one week. Post chamber “effluent” blood demonstrated a reduction in IL-6 levels, 
possibly due to its consumption in the process of thrombus formation. 
Scanning electron microscopic analysis of fibrin architecture demonstrated a 
reduction in platelet content of thrombus following one week of clopidogrel therapy. 
Significant increase in fibrin diameter, fibrin fibre density, number of hubs and 
spokes per square micron of thrombus were demonstrated following one week of 
clopidogrel. These changes favour fibrinolysis. Though not significant, the elderly 
cohort had thinner fibrin fibres than younger patients. This is the first study to 
assess fibrin ultrastructure in whole blood thrombus from elderly patients with 
stable CAD. Prospective, long term outcome and follow up studies are necessary 
to see if fibrin fibre parameters can assess the response to antiplatelet therapy and 
predict future adverse cardiovascular outcomes in elderly and T2DM. The 
association between viscoelastic properties of thrombus and fibrin fibre parameters 
should be studied further to explore opportunities for new therapeutic target in high 
risk populations (elderly and T2DM). 
Overall, elderly patients compared to young have demonstrated similar thrombus 
area but high platelet reactivity using VerifyNow® and Multiplate® and more 
hyporesponders to aspirin and clopidogrel. Significant release of coagulation 
markers from platelet granules after activation were demonstrated in both elderly 
and young patients with and without T2DM. DAPT demonstrated a significant but 
similar reduction in PDT in all the four groups. Addition of clopidogrel for 7 days, 
resulted in similar changes to fibrin architecture in all the four groups. These 
changes included increase in fibrin diameter, fibrin fibre density and number of 
hubs and spokes, all favouring fibrinolysis. The reduction in thrombus formation 
was not associated with any increase in bleeding complications during and one 
week after the study period. 
The elderly population with CAD has never been extensively studied as far as 
thrombus formation, platelet reactivity indices and antiplatelet therapies are 
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concerned. The findings from this elderly stable CAD study are important for the 
following reasons: 
iv. This is the first study assessing and comparing platelet dependent 
thrombus formation using the Badimon chamber, in stable CAD patients 
with age<75 years and age≥75 years, with and without T2DM 
 
v. All participants were on appropriate secondary prevention therapy including 
maintenance dose aspirin; clopidogrel was added for 1 week as dual 
antiplatelet therapy (DAPT) 
 
vi. Participants were carefully chosen for the study with strict inclusion and 
exclusion criteria to try to minimise confounding variables 
 
vii. To achieve a significant reduction of thrombus area with DAPT in all the 4 
groups of patients with stable CAD and good secondary prevention therapy 
(good lipid control, good hypertension control and good glycaemic control) 
is clinically very important 
 
viii. The data describe the effect of dual antiplatelet therapy on thrombus 
formation and platelet function in stable CAD patients with age≥75 years 
and age˂75 years, with and without T2DM 
 
With increasing age, patients are at increased risk of atherothrombosis and CAD. 
Those with established CAD are at increased risk of future adverse cardiovascular 
events. However, these patients also encounter an increased bleeding risk 
associated with antiplatelet therapy. Thus, we face a challenging treatment 
dilemma in these patients. Multiple factors contribute to higher blood 
thrombogenicity in elderly patients. Platelets in elderly are constantly kept activated 
by background chronic low grade inflammation. Increased platelet reactivity and 
endothelial dysfunction play a significant role in this increase thrombotic milieu. 
This platelet hyperactivation was demonstrated in my study by high platelet 
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reactivity indices and higher thrombus formation. Similar to in the elderly, platelets 
in patients with T2DM are also in a constant state of activation. Platelet dysfunction, 
inflammation, hyperglycaemic state and activation of coagulation markers all 
contribute to increased blood thrombogenicity in T2DM.  
The role of inflammation in thrombogenicity has become a great area of interest 
since this area is not yet fully evaluated. My findings from post chamber “effluent” 
blood demonstrated the release of coagulation markers (P selectin, CD40 ligand 
and PAI-1) from platelet granules immediately after platelet activation. Elderly 
patients also demonstrated higher levels of TNFα and IL-6. Mediators of 
inflammation such as hsCRP and IL-6 were associated with PDT in elderly diabetic 
patients. All these data suggest that inflammation has a direct role in increased 
thrombogenicity in both the elderly and the T2DM population. This causal link 
needs confirmation from large scale studies, following which opportunities for 
newer therapeutic targets will arise. In ACS setting, along with dual antiplatelet and 
antithrombotic agents, there might be a role for anti-inflammatory agents (e.g. anti 
-TNFα antibodies). 
In patients with stable CAD, the CHARISMA trial demonstrated a small but 
significant benefit in the subgroup of patients with known atherothrombosis, 
demonstrating a potential role for intensification of antithrombotic therapy beyond 
aspirin alone (long-term dual antiplatelet therapy) in certain high-risk groups such 
as elderly and T2DM. The recently published DAPT and PEGASUS trials, favour 
long-term use of DAPT following coronary stent insertion. The DAPT study 
demonstrated that patients taking DAPT at 30 months had lower risk of stent 
thrombosis, myocardial infarction (MI) and major ischaemic adverse events 
compared to those who stopped DAPT at 12 months, while patients with long-term 
DAPT had an increased risk of moderate or severe bleeding (Mauri et al., 2014). 
The PEGASUS trial enrolled patients with acute coronary syndromes (STEMI and 
NSTEMI). Major findings of this study were that 3 years of DAPT (ticagrelor plus 
aspirin) after DES implantation was associated with significant less incidence of 
cardiac death, MI and stroke and a higher incidence of bleeding (Murphy et al., 
2015). However, fatal bleedings, or intracranial haemorrhage or haemorrhagic 
stroke was not significantly different in the 2 study arms. These studies indirectly 
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suggest, DAPT could be beneficial long-term atleast in high risk population such 
as elderly and T2DM (Elmariah et al.). 
Clopidogrel has the least bleeding risk when compared to prasugrel or ticagrelor 
and is much more cost effective. With more and more data suggesting the need 
for extended DAPT following an acute coronary event and revascularisation as 
discussed above, this study reinforces the potential usage of clopidogrel in certain 
high risk groups, especially in the elderly and T2DM. My findings strengthen the 
argument that dual antiplatelet therapy might be able to provide better platelet 
inhibition without overtly increasing the bleeding risk in stable CAD patients in 
elderly and T2DM who are at high risk of future thrombotic events. Large scale 
studies are needed to further validate the role of long term dual antiplatelet therapy 
in providing clinical benefits with reduction in future thrombotic events without 
significant increase in bleeding in this population. 
Change in platelet content of thrombus was associated with a reduction in 
thrombus area, suggesting the possibility that reducing the platelet count might 
reduce thrombus quantity. The hypothesis of my second study was that reduction 
in the platelet count will reduce platelet dependent thrombus formation and alter 
thrombus characteristics. Rafigrelide was the novel pharmacological agent which 
reduced the platelet count. This reduction in platelet count was associated with a 
reduction in both high shear and low shear thrombus area. Under high shear 
conditions, the reduction in thrombus area was more pronounced and there was a 
moderate correlation between platelet count and thrombus area, as would be 
expected given the greater role of platelets in arterial thrombosis (platelet rich) 
compared with thrombus formation in veins (fibrin rich) under low shear conditions. 
This study demonstrates that modification of platelet synthesis and reduction of 
platelet count might be a possible therapeutic option in patients with high normal 
platelet count and high risk factors such as elderly or T2DM. 
5.2 Limitations 
My study was a single centre study on a small cohort of patients (131 patients in 
three groups recruited by myself and data from 41 young T2DM patients used from 
a previous study from our group). The fact that all the patients in my study were 
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strictly selected with pre-defined inclusion / exclusion criteria suggests that these 
patients might not represent the “real world” population. All my study participants 
were Caucasians and hence the results cannot be extrapolated to global elderly / 
diabetic population. I used clopidogrel in my study for dual antiplatelet therapy 
alongside aspirin as it is the most widely used antiplatelet agent after aspirin 
especially in elderly population and in T2DM patients. Newer antiplatelet agents 
(P2Y12 inhibitors) such as prasugrel and ticagrelor which are superior to 
clopidogrel in platelet inhibition have been licensed for use in the UK, in acute 
coronary syndrome setting and in patients undergoing coronary intervention. Use 
of these newer agents has increased significantly in recent years, with a significant 
reduction in clopidogrel usage especially in the diabetic population. This is not a 
major limitation as far as elderly patients are concerned since my study suggests 
that clopidogrel still has a significant role at least in elderly cohort and in stable 
CAD setting. My study participants received clopidogrel at maintenance dose only 
for a week and hence my study does not address the effects of long term dual 
antiplatelet therapy. Various point of care platelet function assays were used to 
assess effect of antiplatelet agents and various serum and plasma assays were 
used to measure coagulation and inflammatory biomarkers. Flow cytometry 
methods would have been more accurate but much more time consuming. My 
study involved only two visits, day 1 and day 8 (after 7 days of clopidogrel), I did 
not record any long term clinical outcomes of my participants. 
My second study recruited only healthy volunteers with very small sample size of 
12 volunteers. In this study, platelet count, mean platelet volume, platelet-
dependent thrombus and TEG® and Platelet Mapping™ were studied. Other than 
platelets, a number of cellular and non-cellular components of the coagulation 
system are involved in thrombus formation but these were not measured in our 
study. Other established point of care platelet function tests such as VerifyNow® 
and Multiplate® were not used in this study. The mechanism of rafigrelide is to 
reduce the platelet count and 14 days of rafigrelide demonstrated significant 
reduction in platelet count to pre-defined adverse event range in 2 healthy 
volunteers. IMP was stopped after 14 days and hence long term effect of this IMP 
on platelet count, thrombus formation and risk of bleeding secondary to significant 
thrombocytopenia were not addressed since this was not the aim of the study. 
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5.3 Future directions 
My study has demonstrated a trend towards higher blood thrombogenicity in elderly 
and T2DM patients with stable CAD. Ageing is a well establish independent risk 
factor for future cardiovascular events especially in people with established CAD. 
T2DM is another most important risk factor for atherosclerosis, thrombosis and 
future adverse cardiovascular events in patients with established CAD. 
In patients with STEMI, NSTE-ACS and those undergoing coronary intervention, 
newer and more potent antiplatelet agents have shown promising results by 
demonstrating significant reduction in adverse cardiac events compared to 
clopidogrel. Hence international societies have included these agents in their 
guidelines. However, in elderly population (age≥75 years), severe bleeding risk 
associated with prasugrel compensated for any improvement in adverse 
atherothrombotic events and the overall outcome was worse compared to 
clopidogrel. Hence prasugrel is not used in elderly patients (age≥75 years). A 
lowered maintenance dose of prasugrel (5mg daily) was tested in the elderly 
population. This study demonstrated similar outcome and bleeding risk compared 
to clopidogrel, without any additional benefit from prasugrel (Roe et al., 2013). 
Hence it is cost-effective to use clopidogrel 75mg daily instead of prasugrel 5mg 
daily. Ticagrelor has shown improved benefits over clopidogrel without any 
substantial bleeding risk and hence is currently the recommended antiplatelet 
therapy of choice alongside aspirin. Patients with T2DM still have poor outcomes 
compared to non DM population despite the introduction of these newer more 
potent antiplatelet agents. 
My thesis, to some extent has helped in understanding the complex 
pathophysiology of atherothrombosis in elderly population and in T2DM. My study 
has demonstrated heightened blood thrombogenicity and high platelet reactivity in 
elderly population alongside some unique information on coagulation and 
inflammation in this high risk population.  
The following studies might be helpful in carrying forward this research further so 
as to understand pathophysiology and treatment options in the elderly in detail: 
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i. Study to assess the effect of long term dual antiplatelet therapy in elderly 
stable CAD patients in terms of adverse cardiovascular events, bleeding 
risk and overall long term benefits. 
ii. Study evaluating platelet dependent thrombus and platelet reactivity 
comparing newer antiplatelet agents such as ticagrelor with clopidogrel 
in elderly patients with stable CAD. 
iii. Study evaluating PDT, platelet reactivity, inflammation and coagulation 
biomarkers, viscoelastic properties and ultrastructural assessment of 
thrombus in elderly patients presenting with ACS. 
iv. Study evaluating PDT, platelet reactivity, viscoelastic properties and 
ultrastructural assessment of thrombus in elderly patients presenting 
with ACS comparing the effects of clopidogrel vs. ticagrelor. 
v. Interventional studies to assess the role of novel therapeutic agents such 
as anti-inflammatory agents (anti-TNFα antibodies), agents that reduce 
the platelet count by inhibiting platelet synthesis, fibrin antagonists and 
direct thrombin inhibitors in high risk patient groups such as elderly and 
T2DM using Badimon perfusion chamber     
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Appendices 
 
Appendix 1: Publications 
Peer reviewed original research article 
Balasubramaniam K, Viswanathan G, Dragone J, Grose-Hodge R, Martin P, Troy 
S, Preston P, Zaman AG. (2014) 'Antithrombotic properties of rafigrelide: a phase 
1, open-label, non-randomised, single-sequence, crossover study', Thromb 
Haemost, 112(1), pp. 205-15. 
 
Review article 
Karthik Balasubramaniam, Girish N. Viswanathan, Sally M. Marshall, and Azfar G. 
Zaman, “Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and 
Acute Coronary Syndrome: A Review of Antiplatelet Therapy,” Cardiology 
Research and Practice, vol. 2012, Article ID 909154, 18 pages, 2012. 
doi:10.1155/2012/909154 
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